

# **Exhibit 12**

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA**

IN RE: ROUNDUP PRODUCTS  
LIABILITY LITIGATION

MDL No. 2741

Case No. 16-md-02741-VC

This document relates to:  
ALL ACTIONS

**EXPERT REPORT OF DR. DENNIS WEISENBURGER, M.D.  
IN SUPPORT OF GENERAL CAUSATION  
ON BEHALF OF PLAINTIFFS**

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

IN RE: ROUNDUP PRODUCTS  
LIABILITY LITIGATION

MDL No. 2741

Case No. 16-md-02741-VC

This document relates to:

ALL ACTIONS

R. 26 EXPERT REPORT OF DENNIS D. WEISENBURGER, M.D.

I am a physician and pathologist specializing in the study of diseases of the hematopoietic and immune systems, with a special interest in non-Hodgkin lymphoma (NHL). My background, qualifications, academic accomplishments, and publications are fully detailed in my curriculum vitae. Briefly, I received a BA degree from the University of North Dakota in 1970 and an MD degree from the University of Minnesota in 1974. After a one-year internship in internal medicine (1974-1975) at Ohio State University, I pursued and completed training in anatomic and clinical pathology at the University of Iowa Hospitals (1975-78). Then, I completed a two-year hematopathology fellowship (1979-1981) with Dr. Henry Rappaport and colleagues at the City of Hope National Medical Center.

From 1984 to 2012, I was a faculty member in the Department of Pathology and Microbiology at the University Nebraska Medical Center (UNMC), and I was promoted to full professor in 1988. During the last 40 years, I have been actively engaged in the study of diseases of the hematopoietic and immune systems, including the pathology, genetics, epidemiology and clinical features of NHL. During this time, I was the chief pathologist for the Nebraska Lymphoma Study Group, and I directed the training program for hematopathology fellows at UNMC. I was also a member of the UNMC Eppley Institute for Research in Cancer and Allied Disease from 1988 to 2012, and the Center for Environmental Health and Toxicology from 1998 to 2012. I have served as a consulting hematopathologist for national lymphoma

clinical trials and research studies performed by the Cancer and Leukemia Study Group B (CALGB). In 2001, I served on the National Cancer Institute (NCI) Peer Review Group which assessed the future research needs for hematopoietic cancers including NHL.

During the last 40 years, I have been particularly interested in the pathobiological mechanisms of how leukemia and NHL develop in humans and the environmental exposures that may play a role in causing these cancers. When I first moved to Nebraska, I was told that there appeared to be an increased incidence of NHL in some counties of Nebraska. Therefore, I began an investigation of this observation and found that the incidence of NHL was increased in over one-half of the counties in eastern Nebraska, and that this increase appeared to correlate with the heavy use of pesticides and fertilizers in agriculture in those counties (1, 2). To study this further, in the mid 1980's, I organized and directed a large epidemiologic case-control study of NHL and related disorders in eastern Nebraska in collaboration with epidemiologists from the NCI. I then collaborated with the same NCI group in a large epidemiologic case-control study of cancers of the brain, stomach and lower esophagus in Nebraska. Later, I participated in a second large epidemiologic case-control study of NHL in Nebraska, and I am currently collaborating with an international consortium of investigators working on lymphoma epidemiologic studies (InterLymph).

In 2012, I became the Chairman of the Department of Pathology at the City of Hope National Medical Center in Duarte, CA. The City of Hope is an NCI-designated comprehensive cancer center, and a major center for the research study and treatment of hematopoietic cancers including NHL. I am also a member of the Beckman Research Institute at City of Hope. During my career, I have published over 300 papers on NHL in peer-reviewed journals, and over 50 papers on the epidemiology of NHL. Therefore, based on my extensive experience and research in the area of NHL, and my knowledge and review of the published scientific literature, I will render an expert opinion on whether the herbicide glyphosate and/or glyphosate-based formulations (GBFs), including Roundup, are a cause of NHL in humans exposed to these chemicals in the workplace or environment. A copy of my current Curriculum Vitae is attached as Exhibit A, a list of my testimony for the past four years and my billing rate is attached as Exhibit B, and a list of the additional materials I have reviewed is attached as Exhibit C.



**Background**

Glyphosate is a broad-spectrum organophosphate herbicide that is widely used to kill unwanted plants, both in agriculture and in non-agricultural landscapes. Glyphosate is the most heavily used herbicide in the world. Most GBFs, such as Roundup, are either made or used with a surfactant which helps glyphosate penetrate plant cells. A common surfactant used in Roundup is polyethyloxyated tallowamine (POEA), and this GBF was found to be more acutely toxic in animal studies than glyphosate alone (3). Users of GBFs including, but not limited to, farmers, nursery and forestry workers, landscapers and bystanders may be heavily exposed to GBFs during application, mainly by skin and inhalation exposures (4). Glyphosate biomonitoring of farmers has shown that 60% had low levels of glyphosate in their urine on the day of application (5). In another study (6), high concentrations of glyphosate were found in the urine of exposed individuals (average, 7.6 mg/L; range, 0-130 g/L), and there was a significant relationship between the manual application of glyphosate and urine concentrations. In California (1984-1990), glyphosate was the most commonly reported cause of pesticide illness among landscape maintenance workers, and the third most common cause among agriculture workers (3). Thus, people who apply or are otherwise exposed to GBFs can have significant biological exposures to the chemicals in these formulations including glyphosate.

In 2015, the International Agency for Research on Cancer (IARC), a part of the World Health Organization (WHO) and an authoritative body for the evaluation of carcinogenic hazards to humans (7), published its assessment of the carcinogenicity of glyphosate (4, 8). The IARC concluded that glyphosate and GBFs are probably carcinogenic to humans (Group 2A) based on limited epidemiological evidence in humans, mainly for NHL, and significant evidence of carcinogenicity in animals. The IARC also found strong evidence that glyphosate and GBFs can operate through two key characteristics of known human carcinogens, specifically genotoxicity to cells and the induction of oxidative stress. The IARC assessment of glyphosate has led to intense opposition from the pesticide industry, resulting in a series of industry-sponsored articles and reviews on this subject (9-15). Recently, the European Food Safety Authority (EFSA) and the US Environmental Protection Agency (EPA) found that glyphosate is not likely to be carcinogenic in humans (16-18).

### Epidemiology in Humans

Numerous epidemiologic studies of the relationship of glyphosate exposure to cancer in humans have been reported, and these are summarized in the IARC and EPA reports (4, 18). These studies have been negative for most of the cancers studied including soft tissue sarcoma, leukemia, multiple myeloma, Hodgkin lymphoma, and cancers of the brain, stomach and esophagus, and prostate. However, most of the studies of NHL have shown a positive association with glyphosate exposure. Therefore, I will focus on the epidemiological studies of NHL in this report.

Six case-control studies of NHL and glyphosate exposure have been published (19-24) and the results of these studies are summarized in Table 1. Of these six case-control studies, five (19-22, 24) showed elevated odds ratios for NHL in workers exposed to glyphosate, whereas only one study (23) with limited statistical power showed no increase. Four of the five positive studies (19-22) showed statistically-significant increases in the risk for NHL (see bolded risk estimates), and the two studies (19, 22) in which a dose-response effect was evaluated showed significantly increased risks of NHL with an increased number of days that glyphosate was used (22) or days per year used (19). In all five positive studies, odds ratios of greater than 2.0 were demonstrated and these were statistically-significant in four of the studies. The only study with a non-significant increase had limited statistical power (24). In three of the five positive studies (20-23), the risk estimates for glyphosate were adjusted for the use of other pesticides but remained elevated. The results of these studies provide evidence for an etiological link between NHL and glyphosate exposure.



Table 1. Case-control studies of NHL and Glyphosate

Reference Location Time	Population Studied	Exposure Category	Exposed Cases	Risk Estimates (95% CI)	Covariants Controlled	Comments
1. McDuffie et al. (19) Canada 1991-1994	517 cases 1506 controls	Exposed ≤ 2 days/yr > 2 days/yr	51 28 23	1.2 (0.83-1.74)* 1.0 (0.63-1.57) <b>2.12 (1.2 -3.73)</b>	Age, province	Cross-Canada study; *adjusted for significant medical variables
2. Hardell et al. (20) Sweden 1987-1992	515 cases 1411 controls	Exposed Univariate Multivariate	8  8	<b>3.04 (1.08-8.52)</b>  1.85 (0.55-6.20)*	Age, county, study site, vital status	*Adjusted for other pesticides; limited statistical power
3. De Roos et al. (21) Midwest USA 1979-1986	650 cases 1933 controls	Exposed	36	<b>2.1 (1.1 -4.0)*</b>	Age, study site	*Adjusted for other pesticides
4. Eriksson et al. (22) Sweden 1999-2002	910 cases 1016 controls	Exposed  ≤ 10 days > 10 days	29 29 12 17	<b>2.02 (1.1 -3.71)</b> <b>1.51 (0.77-2.94)*</b> <b>1.69 (0.7 -4.07)</b> <b>2.36 (1.04-5.37)</b>	Age, sex, year of enrollment	*Adjusted for other pesticides; odds ratios also increased for all NHL subtypes
5. Orsi et al. (23) France 2000-2004	244 cases 454 controls	Exposed	12	1.0 (0.5 -2.20)	Age, site, socioeconomic category	Limited statistical power; odds ratios increased for some NHL subtypes
6. Cocco et al. (24) Europe 1998-2004	2348 cases 2462 controls	Exposed	4	3.1 (0.6 -17.1)*	Age, sex, site, education	Six countries; *B-cell NHL; limited statistical power

Only one large cohort study of licensed pesticide applicators, the Agricultural Health Study (25), has reported on the risk of NHL associated with glyphosate exposure. This study did not find a significantly elevated risk for cancer overall, or for most of the cancer types including NHL. The NHL risk estimate was 1.1 (0.7-1.9) for glyphosate with 92 exposed cases, and risk did not increase with the number of days glyphosate was used. However, the median follow-up time in this study was only 6.7 years, too short a time to detect a meaningful increase in NHL or other cancers associated with glyphosate. The average latency period for the development of NHL due to long-term exposure to carcinogenic chemicals, such as organic solvents for example, is about 20 years with a range of 10 to 30 years or more (26). However, short-term, high-dose exposures could result in a shorter latency period (26). In one pesticide study of NHL (22), a latency period of greater than 10 years was required to find excess cases of NHL. For glyphosate exposures of less than 10 years, the risk estimate was only 1.11 (0.24 -5.08), whereas it was significantly increased to 2.26 (1.16-4.40) for cases with a latency period of greater than 10 years (22).

Three meta-analyses of the six older epidemiological studies (19-23, 25) were also positive for an association between NHL risk and use of glyphosate. One study (27) showed a significantly increased meta-risk ratio of 1.5 (1.1-2.0), whereas reanalysis by the IARC Working

Group found a significant ratio of 1.3 (1.03-1.65) using fully adjusted risk estimates (4). An industry-sponsored study (9) also found the same risk ratio of 1.3 (1.0-1.9). Additional meta-analyses of two studies (21, 24) for an association of glyphosate use and risk for B-cell NHL were also significantly positive with a meta-risk ratio of 2.0 (1.1-3.6) in two separate analyses (9, 27). These findings provide additional evidence for an etiological link between NHL and glyphosate exposure.

Two industry-sponsored reviews (9, 13) and the EPA report (18) on these same epidemiological studies of NHL have suggested that the positive results are due to various methodologic issues such as study design, selection bias, recall bias, exposure misclassification, confounding and other issues. However, these case-control studies were performed by experienced epidemiologists using widely-accepted study designs and methods, were published in peer-reviewed journals, and I find them acceptable for review and consideration. The industry-sponsored and EPA reviews have given undue weight to the Agricultural Health Study (25) in their assessments, although admitting that the study duration was "relatively short". Taken together, the case-control studies provide evidence for a relationship between glyphosate exposure and risk of NHL, and this evidence cannot be simply dismissed due to the suggestion of possible methodologic issues or the negative results of the immature Agricultural Health Study.

### **Animal Studies**

Glyphosate has also been tested for carcinogenicity in mice and rats in multiple studies (4, 17, 18, 28), and some studies have been positive for the development of tumors. The IARC Working Group (4) found a significant positive and dose-related trend in the incidence of renal tubule carcinoma ( $p = 0.037$ ), and in renal tubule adenoma and carcinoma combined ( $p = 0.034$ ), in males in a feeding study of CD1 mice. Renal tubule carcinoma is a rare tumor in this strain of mice. However, there was no increase in these tumors in female mice in that study. In another feeding study of CD-1 mice, IARC found a significant positive and dose-related trend in the incidence of hemangiosarcoma ( $p < 0.001$ ) in males but not in females. Also, in a feeding study of Sprague-Dawley rats, IARC found an increase in the incidence of pancreatic islet cell adenoma at all doses of glyphosate in males, with a significant increase in the low dose group



( $p < 0.05$ ), but no significant dose-related trend and no increase in females. In another feeding study of Sprague-Dawley rats, IARC again found an increase in the incidence of pancreatic islet cell adenoma at all doses of glyphosate in males, with significant increases in the low-dose group ( $p = 0.018$ ) and the high dose group ( $p = 0.042$ ) but no significant dose-related trend, and no increase in females. In the same study, IARC also found a significant positive and dose-related trend in the incidence of hepatocellular adenoma in males ( $p = 0.016$ ), and in thyroid follicular C-cell adenoma in females ( $p = 0.031$ ).

In an industry-sponsored review (28) of industry studies in rodents, which were not available for review by IARC but were reviewed by EPA, the authors also found a significant increase in hepatocellular adenoma in male Wistar rats ( $p = 0.028$ ) at the highest feeding dose in one study (study 7), and a significant dose-related trend in the incidence of these tumors ( $p = 0.01$ ). In this same review, the authors also reported increases in malignant lymphoma (NHL), the same cancer seen in the human epidemiologic studies, in four mouse feeding studies. In study 13, they found a significant increase in lymphoma in the high-dose groups in both male and female Swiss albino mice compared to controls ( $p < 0.05$ ). In study 14, a dose-related increase ( $p = 0.01$ ) was seen in male but not female CD1 mice, whereas increases were seen in female CD1 mice (study 10) and in male ICD-CD-1 mice (study 12) at the highest feeding doses in the other two studies ( $p$  values not given).

In the EPA review of unpublished industry studies (18), the EPA found a significant increase in testicular interstitial cell tumors in male Sprague-Dawley rats at the highest dose ( $p = 0.013$ ) in one study (study 1), with a significant dose-related trend ( $p = 0.001$ ). In another study (study 8), they reported a significant increase ( $p = 0.046$ ) in mammary gland tumors (adenoma and adenocarcinoma combined) at the highest dose in female Wistar rats, with a significant dose-related trend ( $p = 0.01$ ). In a study of male CD1 mice (study 14), the EPA found an increase in lung adenocarcinoma with a significant dose-related trend ( $p = 0.05$ ). In another study of SPF-ICR-CD-1 mice (study 12), they also reported a significant increase in hemangiomas in females at the highest dose ( $p = 0.028$ ), with a dose-related trend ( $p = 0.01$ ). I have read the three animal studies that were made available to me, and I concur with the above findings.

Despite these positive findings of carcinogenicity for glyphosate in multiple animal studies, industry and the EPA have continued to argue that glyphosate has no carcinogenic

potential based on other negative studies, and various methodologic, statistical and other issues (11, 14, 18, 28). However, the positive studies listed above cannot be dismissed, and provide sufficient evidence for the carcinogenicity of glyphosate in experimental animals despite these arguments.

### **Mechanisms of Carcinogenesis**

The IARC Working Group (4) concluded that glyphosate and GBFs were genotoxic in various systems. They found that the mechanistic data overall provided strong evidence for genotoxicity and for oxidative stress induced by glyphosate, with evidence that these effects can also operate in humans.

Two studies of individuals living or working in areas sprayed with GBFs (29, 30) are particularly informative with regard to the genotoxicity of these chemicals in humans. In the first study (29), the authors used the comet assay to evaluate DNA damage in 24 persons exposed to aerial spray of a GBF, some of whom had symptoms of toxicity after several exposures, but who did not use other pesticides. The comet assay is a rapid and sensitive method for the detection of DNA damage induced in blood leukocytes *in vivo*. They found that the exposed group had a significant increase in DNA damage (DNA strand breaks) in blood leukocytes collected two weeks to two months after exposure compared to the unexposed controls ( $p < 0.001$ ). In the other study (30), the authors used the blood lymphocyte micronucleus test as an index of chromosomal damage in 274 persons living in five regions of Columbia. This test is an appropriate biomarker for monitoring the effects of cumulative exposures to genotoxic agents. In the three regions with exposures to GBFs from aerial spraying, blood samples were taken from the same individuals at three time-points, before spraying (baseline), up to five days after spraying, and four months after spraying. The baseline frequency of binucleated cells with micronuclei was significantly higher in subjects from the three regions where there had been aerial spraying of GBFs, and in a fourth region with exposures due only to manual spraying of multiple pesticides, compared to the reference region without the use of pesticides ( $p \leq 0.05$ ). The frequency of micronucleus formation in blood lymphocytes was further increased in the same individuals shortly after the aerial spraying of GBFs compared with the baseline levels in the same individuals ( $p < 0.001$ ), and



remained significantly elevated in individuals from one of the three regions four months later. These two studies provide compelling evidence of genotoxic damage to blood cells (lymphocytes) in individuals exposed to GBFs in the immediate environment due to aerial spraying. These same assays have been used by others to monitor genetic damage in persons exposed to pesticides (31-33).

*In vitro* studies demonstrating the genotoxicity of glyphosate and GBFs in human blood lymphocytes using various assays have also been reported (34-40). Lioi et al (34) showed a significant dose-dependent increase in aberrant cells ( $p < 0.05$ ) and chromosome aberrations ( $p < 0.01$ ), as well as sister chromatid exchange frequencies per cell ( $p < 0.05$ ), compared to controls, most likely due to oxidative stress and the generation of reactive oxygen species. In two studies, Mladinic et al (35, 36) demonstrated a significant increase in DNA strand breaks ( $p < 0.01$ ) and chromosomal damage ( $p < 0.01$ ), respectively, at the higher doses tested. Alvarez-Moya et al (37) also demonstrated a significant increase in DNA strand breaks ( $p < 0.01$ ), even at very low concentrations. Manas et al (38) have also shown a significant increase in chromosomal aberrations ( $p < 0.05$ ) with exposure to AMPA, an environmental metabolite of glyphosate. A significant increase in sister chromatid exchange frequency was also demonstrated for glyphosate and for Roundup ( $p < 0.05$ ) by Bolognesi et al (39), with a dose-response effect seen for glyphosate, and 10-fold greater genotoxicity of Roundup compared to glyphosate. Vigfusson and Vyse (40) also found a significant increase in sister chromatid exchange frequency in human lymphocytes upon exposure to high concentrations of Roundup ( $p < 0.001$ ).

Similar genotoxic effects have also been reported in other types of human cells tested *in vitro* with glyphosate, AMPA, or GBFs (4, 18). Genotoxic effects have also been reported in numerous studies of these chemicals in non-human mammalian cells *in vivo* and *in vitro*, including mouse bone marrow cells and bovine lymphocytes, as well as non-mammalian systems *in vivo* and *in vitro* (reviewed in 4, 18, 41). Thus, there is extensive evidence that glyphosate and GBFs are genotoxic to human and animal cells in numerous studies. IARC concluded that glyphosate and GBFs are genotoxic (4), and I concur with the IARC findings. However, industry-sponsored reviews (11, 15, 42, 43) and the EPA (18) have concluded that glyphosate and GBFs do not pose a genotoxic hazard, and explain away the positive findings in

the IARC assessment and their own analyses as due to technical or methodologic issues, or cytotoxicity rather than genotoxicity. The EPA and industry-sponsored studies also place undue weight on assays performed in bacteria, and on industry studies that were not available for review by IARC. I have placed greater weight on the two human biomonitoring studies (29, 30) and the many positive studies performed in mammalian systems, particularly human blood lymphocytes which are the cells from which NHL arises as a result of genetic damage.

Recent studies have shown that glyphosate and GBFs can have toxic effects on cells at doses below the regulatory limits (44, 45). For example, glyphosate provokes oxidative stress and cell damage in rat liver and kidneys by disrupting mitochondrial metabolism at exposure levels currently considered safe and acceptable by regulatory agencies (44, 45). Glyphosate and GBFs can also disrupt endocrine signaling in cells at low doses (44-46), induce human breast cancer cells to grow via estrogen receptors *in vitro* (47), and also induce breast tumors in female rats (48). GBFs can also alter the levels of xenobiotic-metabolizing enzymes (49) and affect cell cycle regulation (50, 51) at low doses, which are effects that can also contribute to carcinogenesis. Thus, these findings indicate that even low doses of these chemicals can have significant biological effects on living cells.

### General Causation

In the evaluation of whether a specific exposure (glyphosate and GBFs in this case) is a cause of a specific disease (NHL in this case), experts follow a scientific method in the review and evaluation of evidence, and consider and weigh this evidence based on the guidelines set forth by Bradford Hill (52, 53). These guidelines or criteria for the evaluation of general causation are listed below along with my comments concerning this case.

1. **Temporal Relationship.** If an exposure causes a disease, the exposure must occur before the disease develops. This criteria was met by all of the epidemiologic and animal studies cited in this report.
2. **Strength of Association.** Relative risk is one of the cornerstones of causal inference. The higher the relative risk, the greater the likelihood that an exposure is causal. In the



epidemiologic case-control studies, relative risks of greater than 2.0 were seen in five of the six studies and were statistically significant in four of these studies (Table 1).

3. **Dose-response Relationship.** Generally, higher exposures should increase the frequency of disease, and a dose-response effect is considered strong evidence for a causal relationship. The two case-control studies in which a dose-response effect was evaluated (19, 22) showed significantly increased risks with an increased number of days that glyphosate was used. A dose-response effect was also seen in most of the positive animal studies.
4. **Replication of Results.** It is important that epidemiologic study results be replicated in different populations and by different investigators. Consistency of the findings in different studies is an important factor in making a judgement about causation. Five of the six case-control studies had positive findings for NHL, and these were performed by different investigators in the USA, Canada, Sweden, and six other countries in Europe. Only one study (23) with limited statistical power was negative. Animal studies have also replicated the findings for pancreatic islet cell adenoma, hepatocellular adenoma, hemangioma/hemangiosarcoma, and for malignant lymphoma (NHL).
5. **Biological Plausibility.** The association of an exposure with a disease should be consistent with existing knowledge and be biologically plausible. Human NHL is a disease characterized by genetic abnormalities. The occurrence of NHL in people exposed to GBFs is consistent with the genotoxic effects of these chemicals observed in exposed individuals, as well as in human and animal lymphocytes (the precursor cells of NHL), and in other animal and cell models. The fact that mice exposed to glyphosate also develop malignant lymphoma (NHL) contributes to biological plausibility.
6. **Alternative Explanations.** In assessing causation, experts should also consider alternative explanations for an association, such as bias or confounding factors in epidemiologic studies. However, the case-control studies of NHL were performed by experienced epidemiologists using widely-accepted study designs and methods, were published in peer-reviewed journals, and were found acceptable for review and consideration by IARC and the EPA. In three of the five positive studies (20-22), the risk estimates for glyphosate were adjusted for the use of other pesticides but remained

elevated, suggesting that confounding due to the use of other pesticides does not fully explain the increased risk estimates for glyphosate. Also, in general, case-response bias tends to bias risk estimates toward the null and not create false-positive findings (54, 55). Thus, taken together, the case-control studies provide evidence for a relationship between glyphosate exposure and risk of NHL, and this evidence cannot be simply dismissed due to possible methodological issues or the negative results of the immature Agricultural Health Study.

7. **Disease Specificity.** The only disease linked to glyphosate exposure to date is NHL, with negative findings for other hematopoietic malignancies including Hodgkin lymphoma, leukemia, and multiple myeloma, as well as negative findings for multiple other cancer types. Thus, glyphosate exposure causes a specific disease, namely NHL.
8. **Coherence.** The evidence described above is consistent with other relevant knowledge concerning similar pesticides as a cause of NHL. Glyphosate is an organophosphate herbicide, and other organophosphate pesticides have also been implicated as causes of NHL by similar mechanisms (8, 27, 56).

In summary, based on my expertise, and my review and evaluation of the literature on this subject, I conclude with a reasonable degree of medical certainty that glyphosate and GBFs (including Roundup) can cause NHL in humans exposed to these chemicals in the workplace or environment.



Dennis D. Weisenburger, M.D.  
Professor and Chairman  
Department of Pathology

Date: 4/21/17

## References

1. Weisenburger, D.D., *Lymphoid Malignancies in Nebraska: A Hypothesis*. Nebr Med J, 1985. 70(8): p. 300-305.
2. Weisenburger, D.D., *Environmental Epidemiology of Non-Hodgkin's Lymphoma in Eastern Nebraska*. Am J Ind Med, 1990. 18(3): p. 303-305.
3. Cox, C., *Glyphosate Fact Sheets: Part 1, Toxicology; Part 2, Human Exposure and Ecological Effects*. J Pesticide Reform, 1995a. 15(3 and 4): p. 1-27.
4. IARC Working Group, *Glyphosate. In: Some Organophosphate Insecticides and Herbicides: Diazinon, Glyphosate, Malathion, Parathion, and Tetrachlorvinphos*. IARC Monogr Prog, 2015. Vol 112: p. 1-92.
5. Acquavella, J.F., Alexander, B.H., Mandel, J.S., Gustin, C., Baker, B., Chapman, P., and Bleeke, M., *Glyphosate Biomonitoring for Farmers and Their Families: Results from the Farm Family Exposure Study*. Environ Health Perspect, 2004. 112(3): p. 321-326.
6. Varona, M., Henao, G.L., Diaz, S., Lancheros, A., Murcia, A., Rodriguez, N., and Alvarez, V.H., *Effects of Aerial Applications of the Herbicide Glyphosate and Insecticides on Human Health*. Biomedica, 2009. 29(3): p. 456-475.
7. Pearce, N., Blair, A., Vineis, P., Ahrens, W., Andersen, A., Anto, J.M., Armstrong, B.K., Baccarelli, A.A., Beland, F.A., Berrington, A., Bertazzi, P.A., Birnbaum, L.S., Brownson, R.C., Bucher, J.R., Cantor, K.P., Cardis, E., Cherrie, J.W., Christiani, D.C., Cocco, P., Coggon, D., Comba, P., Demers, P.A., Dement, J.M., Douwes, J., Eisen, E.A., Engel, L.S., Fenske, R.A., Fleming, L.E., Fletcher, T., Fontham, E., Forastiere, F., Frentzel-Beyme, R., Fritschi, L., Gerin, M., Goldberg, M., Grandjean, P., Grimsrud, T.K., Gustavsson, P., Haines, A., Hartge, P., Hansen, J., Hauptmann, M., Heederik, D., Hemminki, K., Hemon, D., Hertz-Picciotto, I., Hoppin, J.A., Huff, J., Jarvholm, B., Kang, D., Karagas, M.R., Kjaerheim, K., Kjuus, H., Kogevinas, M., Kriebel, D., Kristensen, P., Kromhout, H., Laden, F., Lebailly, P., LeMasters, G., Lubin, J.H., Lynch, C.F., Lynge, E., t Mannelje, A., McMichael, A.J., McLaughlin, J.R., Marrett, L., Martuzzi, M., Merchant, J.A., Merler, E., Merletti, F., Miller, A., Mirer, F.E., Monson, R., Nordby, K.C., Olshan, A.F., Parent, M.E., Perera, F.P., Perry, M.J., Pesatori, A.C., Pirastu, R., Porta, M., Pukkala, E., Rice, C., Richardson, D.B., Ritter, L., Ritz, B., Ronckers, C.M., Rushton, L., Rusiecki, J.A., Rusyni, I.,



- Samet, J.M., Sandler, D.P., de Sanjose, S., Schernhammer, E., Costantini, A.S., Seixas, N., Shy, C., Siemiatycki, J., Silverman, D.T., Simonato, L., Smith, A.H., Smith, M.T., Spinelli, J.J., Spitz, M.R., Stallones, L., Stayner, L.T., Steenland, K., Stenzel, M., Stewart, B.W., Stewart, P.A., Symanski, E., Terracini, B., Tolbert, P.E., Vainio, H., Vena, J., Vermeulen, R., Victora, C.G., Ward, E.M., Weinberg, C.R., Weisenburger, D., Wesseling, C., Weiderpass, E. and Zahm, S.H., *IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans*. Environ Health Perspect, 2015. 123(6): p. 507-514.
8. Guyton, K.Z., Loomis, D., Grosse, Y., El Ghissassi, F., Benbrahim-Tallaa, L., Guha, N., Scoccianti, C., Mattock, H., Straif, K., and International Agency for Research on Cancer Monograph Working Group, *Carcinogenicity of Tetrachlorvinphos, Parathion, Malathion, Diazinon, and Glyphosate*. Lancet Oncol, 2015. 16(5): p. 490-491.
  9. Chang, E.T. and Delzell, E., *Systematic Review and Meta-Analysis of Glyphosate Exposure and Risk of Lymphohematopoietic Cancers*. J Environ Sci Health B, 2016. 51(6): p. 402-434.
  10. Tarone, R.E., *On the International Agency for Research on Cancer Classification of Glyphosate as a Probable Human Carcinogen*. Eur J Cancer Prev, 2016.
  11. Williams, G.M., Aardema, M., Acquavella, J., Berry, S.C., Brusick, D., Burns, M.M., de Camargo, J.L., Garabrant, D., Greim, H.A., Kier, L.D., Kirkland, D.J., Marsh, G., Solomon, K.R., Sorahan, T., Roberts, A., and Weed, D.L., *A Review of the Carcinogenic Potential of Glyphosate by Four Independent Expert Panels and Comparison to the IARC Assessment*. Crit Rev Toxicol, 2016. 46(sup1): p. 3-20.
  12. Solomon, K.R., *Glyphosate in the General Population and in Applicators: A Critical Review of Studies on Exposures*. Crit Rev Toxicol, 2016. 46(sup1): p. 21-27.
  13. Acquavella, J., Garabrant, D., Marsh, G., Sorahan, T., and Weed, D.L., *Glyphosate Epidemiology Expert Panel Review: A Weight of Evidence Systematic Review of the Relationship between Glyphosate Exposure and Non-Hodgkin's Lymphoma or Multiple Myeloma*. Crit Rev Toxicol, 2016. 46(sup1): p. 28-43.
  14. Williams, G.M., Berry, C., Burns, M., de Camargo, J.L., and Greim, H., *Glyphosate Rodent Carcinogenicity Bioassay Expert Panel Review*. Crit Rev Toxicol, 2016. 46(sup1): p. 44-55.



15. Brusick, D., Aardema, M., Kier, L., Kirkland, D., and Williams, G., *Genotoxicity Expert Panel Review: Weight of Evidence Evaluation of the Genotoxicity of Glyphosate, Glyphosate-Based Formulations, and Aminomethylphosphonic Acid*. Crit Rev Toxicol, 2016. 46(sup1): p. 56-74.
16. European Food Safety Authority (EFSA). *Conclusion on the Peer Review of the Pesticide Risk Assessment of the Active Substance Glyphosate*. EFSA Journal, 2015. 13(11): 4302, p. 1-107.
17. Rapporteur Member State (Germany). *Assessment of the IARC Monographs Volume 112 (2015): Glyphosate. Glyphosate Addendum I to Renewal Assessment Reprint, August 31, 2015*.
18. *Glyphosate Issue Paper: Evaluation of Carcinogenic Potential*, Environmental Protection Agency Office of Pesticide Programs, Editor September 12, 2016.
19. McDuffie, H.H., Pahwa, P., McLaughlin, J.R., Spinelli, J.J., Fincham, S., Dosman, J.A., Robson, D., Skinnider, L.F., and Choi, N.W., *Non-Hodgkin's Lymphoma and Specific Pesticide Exposures in Men: Cross-Canada Study of Pesticides and Health*. Cancer Epidemiol Biomarkers Prev, 2001. 10(11): p. 1155-1163.
20. Hardell, L., Eriksson, M., and Nordstrom, M., *Exposure to Pesticides as Risk Factor for Non-Hodgkin's Lymphoma and Hairy Cell Leukemia: Pooled Analysis of Two Swedish Case-Control Studies*. Leuk Lymphoma, 2002. 43(5): p. 1043-1049.
21. De Roos, A.J., Zahm, S.H., Cantor, K.P., Weisenburger, D.D., Holmes, F.F., Burmeister, L.F., and Blair, A., *Integrative Assessment of Multiple Pesticides as Risk Factors for Non-Hodgkin's Lymphoma among Men*. Occup Environ Med, 2003. 60(9): p. E11.
22. Eriksson, M., Hardell, L., Carlberg, M., and Akerman, M., *Pesticide Exposure as Risk Factor for Non-Hodgkin Lymphoma Including Histopathological Subgroup Analysis*. Int J Cancer, 2008. 123(7): p. 1657-1663.
23. Orsi, L., Delabre, L., Monnereau, A., Delval, P., Berthou, C., Fenaux, P., Marit, G., Soubeyran, P., Huguet, F., Milpied, N., Leporrier, M., Hemon, D., Troussard, X., and Clavel, J., *Occupational Exposure to Pesticides and Lymphoid Neoplasms among Men: Results of a French Case-Control Study*. Occup Environ Med, 2009. 66(5): p. 291-298.

24. Cocco, P., Satta, G., Dubois, S., Pili, C., Pilleri, M., Zucca, M., t Mannetje, A.M., Becker, N., Benavente, Y., de Sanjose, S., Foretova, L., Staines, A., Maynadie, M., Nieters, A., Brennan, P., Miligi, L., Ennas, M.G., and Boffetta, P., *Lymphoma Risk and Occupational Exposure to Pesticides: Results of the Epilymph Study*. *Occup Environ Med*, 2013. 70(2): p. 91-98.
25. De Roos, A.J., Blair, A., Rusiecki, J.A., Hoppin, J.A., Svec, M., Dosemeci, M., Sandler, D.P., and Alavanja, M.C., *Cancer Incidence among Glyphosate-Exposed Pesticide Applicators in the Agricultural Health Study*. *Environ Health Perspect*, 2005. 113(1): p. 49-54.
26. Weisenburger, D.D., *Pathological Classification of Non-Hodgkin's Lymphoma for Epidemiological Studies*. *Cancer Res*, 1992. 52(19 Suppl): p. 5456s-5462s; discussion 5462s-5464s.
27. Schinasi, L. and Leon, M.E., *Non-Hodgkin Lymphoma and Occupational Exposure to Agricultural Pesticide Chemical Groups and Active Ingredients: A Systematic Review and Meta-Analysis*. *Int J Environ Res Public Health*, 2014. 11(4): p. 4449-4527.
28. Greim, H., Saltmiras, D., Mostert, V., and Strupp, C., *Evaluation of Carcinogenic Potential of the Herbicide Glyphosate, Drawing on Tumor Incidence Data from Fourteen Chronic/Carcinogenicity Rodent Studies*. *Crit Rev Toxicol*, 2015. 45(3): p. 185-208.
29. Paz-y-Miño, C., Sánchez, M.E., Arévalo, M., Muñoz, M.J., Witte, T., De-la-Carrera, G.O., and Leone, P.E., *Evaluation of DNA Damage in an Ecuadorian Population Exposed to Glyphosate*. *Genetics and Molecular Biology*, 2007. 30(2): p. 456-460.
30. Bolognesi, C., Carrasquilla, G., Volpi, S., Solomon, K.R., and Marshall, E.J., *Biomonitoring of Genotoxic Risk in Agricultural Workers from Five Colombian Regions: Association to Occupational Exposure to Glyphosate*. *J Toxicol Environ Health A*, 2009. 72(15-16): p. 986-997.
31. Bolognesi, C., *Genotoxicity of Pesticides: A Review of Human Biomonitoring Studies*. *Mutat Res*, 2003. 543(3): p. 251-272.
32. Benedetti, D., Nunes, E., Sarmiento, M., Porto, C., Dos Santos, C.E., Dias, J.F., and da Silva, J., *Genetic Damage in Soybean Workers Exposed to Pesticides: Evaluation with the Comet and Buccal Micronucleus Cytome Assays*. *Mutat Res*, 2013. 752(1-2): p. 28-33.



33. Bolognesi, C. and Holland, N., *The Use of the Lymphocyte Cytokinesis-Block Micronucleus Assay for Monitoring Pesticide-Exposed Populations*. *Mutat Res*, 2016. 770(Pt A): p. 183-203.
34. Lioi, M.B., Scarfi, M.R., Santoro, A., Barbieri, R., Zeni, O., Salvemini, F., Di Berardino, D., and Ursini, M.V., *Cytogenetic Damage and Induction of Pro-Oxidant State in Human Lymphocytes Exposed in Vitro to Glyphosate, Vinclozolin, Atrazine, and Dpx-E9636*. *Environ Mol Mutagen*, 1998. 32(1): p. 39-46.
35. Mladinic, M., Berend, S., Vrdoljak, A.L., Kopjar, N., Radic, B., and Zeljezic, D., *Evaluation of Genome Damage and Its Relation to Oxidative Stress Induced by Glyphosate in Human Lymphocytes in Vitro*. *Environ Mol Mutagen*, 2009. 50(9): p. 800-807.
36. Mladinic, M., Perkovic, P., and Zeljezic, D., *Characterization of Chromatin Instabilities Induced by Glyphosate, Terbutylazine and Carbofuran Using Cytome Fish Assay*. *Toxicol Lett*, 2009. 189(2): p. 130-137.
37. Alvarez-Moya, C., Silva, M.R., Ramirez, C.V., Gallardo, D.G., Sanchez, R.L., Aguirre, A.C., and Velasco, A.F., *Comparison of the in Vivo and in Vitro Genotoxicity of Glyphosate Isopropylamine Salt in Three Different Organisms*. *Genet Mol Biol*, 2014. 37(1): p. 105-110.
38. Manas, F., Peralta, L., Raviolo, J., Garcia Ovando, H., Weyers, A., Ugnia, L., Gonzalez Cid, M., Larripa, I., and Gorla, N., *Genotoxicity of Ampa, the Environmental Metabolite of Glyphosate, Assessed by the Comet Assay and Cytogenetic Tests*. *Ecotoxicol Environ Saf*, 2009. 72(3): p. 834-837.
39. Bolognesi, C., Bonatti, S., Degan, P., Gallerani, E., Peluso, M., Rabboni, R., Roggieri, P., and Abbondandolo, A., *Genotoxic Activity of Glyphosate and Its Technical Formulation Roundup*. *Journal of Agricultural and Food Chemistry*, 1997. 45(5): p. 1957-1962.
40. Vigfusson, N.V. and Vyse, E.R., *The Effect of the Pesticides, Dexon, Captan and Roundup, on Sister-Chromatid Exchanges in Human Lymphocytes in Vitro*. *Mutat Res*, 1980. 79(1): p. 53-57.
41. Ghisi, N.d.C., Oliveira, E.C.d., and Prioli, A.J., *Does Exposure to Glyphosate Lead to an Increase in the Micronuclei Frequency? A Systematic and Meta-Analytic Review*. *Chemosphere*, 2016. 145: p. 42-54.

42. Kier, L.D. and Kirkland, D.J., *Review of Genotoxicity Studies of Glyphosate and Glyphosate-Based Formulations*. Crit Rev Toxicol, 2013. 43(4): p. 283-315.
43. Kier, L.D., *Review of Genotoxicity Biomonitoring Studies of Glyphosate-Based Formulations*. Crit Rev Toxicol, 2015. 45(3): p. 209-218.
44. Mesnage, R., Defarge, N., Spiroux de Vendomois, J., and Seralini, G.E., *Potential Toxic Effects of Glyphosate and Its Commercial Formulations Below Regulatory Limits*. Food Chem Toxicol, 2015. 84: p. 133-153.
45. Myers, J.P., Antoniou, M.N., Blumberg, B., Carroll, L., Colborn, T., Everett, L.G., Hansen, M., Landrigan, P.J., Lanphear, B.P., Mesnage, R., Vandenberg, L.N., Vom Saal, F.S., Welshons, W.V., and Benbrook, C.M., *Concerns over Use of Glyphosate-Based Herbicides and Risks Associated with Exposures: A Consensus Statement*. Environ Health, 2016. 15: p. 19.
46. Gasnier, C., Dumont, C., Benachour, N., Clair, E., Chagnon, M.C., and Seralini, G.E., *Glyphosate-Based Herbicides Are Toxic and Endocrine Disruptors in Human Cell Lines*. Toxicology, 2009. 262(3): p. 184-191.
47. Thongprakaisang, S., Thiantanawat, A., Rangkadilok, N., Suriyo, T., and Satayavivad, J., *Glyphosate Induces Human Breast Cancer Cells Growth Via Estrogen Receptors*. Food Chem Toxicol, 2013. 59(1): p. 129-136.
48. Seralini, G.E., Clair, E., Mesnage, R., Gress, S., Defarge, N., Malatesta, M., Hennequin, D., and de Vendomois, J.S., *Republished Study: Long-Term Toxicity of a Roundup Herbicide and a Roundup-Tolerant Genetically Modified Maize*. Environ Sci Eur, 2014. 26(1): p. 14.
49. Larsen, K., Najle, R., Lifschitz, A., Mate, M.L., Lanusse, C., and Virkel, G.L., *Effects of Sublethal Exposure to a Glyphosate-Based Herbicide Formulation on Metabolic Activities of Different Xenobiotic-Metabolizing Enzymes in Rats*. Int J Toxicol, 2014. 33(4): p. 307-318.
50. Marc, J., Mulner-Lorillon, O., and Belle, R., *Glyphosate-Based Pesticides Affect Cell Cycle Regulation*. Biol Cell, 2004. 96(3): p. 245-249.
51. Marc, J., Belle, R., Morales, J., Cormier, P., and Mulner-Lorillon, O., *Formulated Glyphosate Activates the DNA-Response Checkpoint of the Cell Cycle Leading to the Prevention of G2/M Transition*. Toxicol Sci, 2004. 82(2): p. 436-442.



52. Hill, A.B., *The Environment and Disease: Association or Causation?* Proceedings of the Royal Society of Medicine, 1965. 58(5): p. 295-300.
53. Green, M.D., Freedman, D.M., and Gordis, L., *Reference Guide on Epidemiology In: Reference Manual on Scientific Evidence: Third Edition*. The National Academies Press, 2011: p. 597-606.
54. Blair, A. and Zahm, S.H., *Patterns of Pesticide Use among Farmers: Implications for Epidemiologic Research*. Epidemiology, 1993. 4(1): p. 55-62.
55. Blair, A., Tarone, R., Sandler, D., Lynch, C.F., Rowland, A., Wintersteen, W., Steen, W.C., Samanic, C., Dosemeci, M., and Alavanja, M.C., *Reliability of Reporting on Life-Style and Agricultural Factors by a Sample of Participants in the Agricultural Health Study from Iowa*. Epidemiology, 2002. 13(1): p. 94-99.
56. Lukaszewicz-Hussain, A., *Role of Oxidative Stress in Organophosphate Insecticide Toxicity – Short Review*. Pesticide Biochemistry and Physiology, 2010. 98(2): p. 145-150.

# EXHIBIT A

Dennis Weisenburger, MD - MC

## **CURRICULUM VITAE**

DENNIS D. WEISENBURGER, MD

Professor and Chairman, Department of Pathology  
City of Hope National Medical Center

[REDACTED]  
[REDACTED]  
[REDACTED]  
Date Prepared: April 2017

### **I. EDUCATION**

**University** University of North Dakota, Grand Forks, ND, BA (General), Honors, 1970

**University** University of North Dakota, Grand Forks, ND, BS (Medicine), Honor, 1972

**Medical School** University of Minnesota, Minneapolis, MN, MD, 1974

### **II. POST GRADUATE EDUCATION AND TRAINING**

**Internship** Ohio State University Hospitals (Internal Medicine), Columbus, OH, 07/74-06/75

**Residency** University of Iowa Hospitals (Anatomic and Clinical Pathology), Iowa City, IA, 07/75-12/78

**Fellowship** City of Hope National Medical Center (Hematopathology), Duarte, CA, 01/79-12/80

### **CERTIFICATIONS**

- National Board of Medical Examiners, 1977
- Anatomic and Clinical Pathology, American Board of Pathology, 1979

### **MEDICAL LICENSURES**

- [REDACTED] Iowa, 1977, Active
- [REDACTED] Nebraska, 1984, Active
- [REDACTED] California, 2012, Active

**III. PROFESSIONAL EXPERIENCE, POSITIONS & EMPLOYMENT** Separate faculty appointments from other administrative, hospital or industry appointments and program affiliations

#### **Hospital Appointments**

Assistant Pathologist, City of Hope National Medical Center, Duarte, CA, 1981

Staff Pathologist, Mercy San Juan and American River Hospitals, Carmichael, CA, 1981-1984

#### **Academic Appointments**

Assistant Clinical Professor of Pathology, University of California at Davis Medical Center, 1981-1984



Dennis Weisenburger, MD - MC

Associate Professor of Pathology & Microbiology, University of Nebraska Medical Center, 1984-1988

Director of Hematopathology

Chief Pathologist, Nebraska Lymphoma Study Group

Director of Hematopathology Fellowship Program, 1984-1988

Director of University Hospital Clinical Laboratories, 1986-1988

Director of Bone Marrow Culture Laboratory, 1984-1989

Director of University Hospital Regional Reference Laboratory, 1984-1987

Professor of Pathology & Microbiology, University of Nebraska Medical Center, 1988-2012

Director of Hematopathology

Chief Pathologist, Nebraska Lymphoma Study Group

Director of Hematopathology Fellowship Program, 1988-2011

Director of University Hospital Clinical Laboratories, 1988-1996

Professor and Chairman, Department of Pathology, City of Hope National Medical Center, 2012-present

Program Member, Hematologic Malignancies, City of Hope Comprehensive Cancer Center

#### **Clinical Administrative Appointments**

- See above

#### **Other Professional Activities**

Associate Professor Courtesy, Eppley Institute for Research in Cancer and Allied Diseases, 1985-1988

Graduate College Faculty Fellow, University of Nebraska Medical Center, 1985-2012

Consulting Pathologist, Omaha Veterans Administration Hospital, 1985-1993, 1997-2000

Consulting Pathologist, Nebraska Department of Health Laboratory, 1987-1989

Professor Courtesy, Eppley Institute for Research in Cancer and Allied Diseases, 1988-2012

Consulting Pathologist, North American Autologous Blood and Bone Marrow Transplant Registry, 1994-2012

Consulting Pathologist, Cancer and Leukemia Study Group B, 1996-1999

Member, Lymphoma and Pathology Core Committees, 1996-1999

Co-chair, Correlative Sciences Core Committee for Leukemia/Lymphoma, 1997-1998

Member, Center for Environmental Health and Toxicology, University of Nebraska, 1998-2012

NCI Leukemia, Lymphoma, and Myeloma Progress Review Group, 2000

NCI AIDS-related Malignancy Tissue Bank Review Group, 2000-2010

Lymphoma Foundation of America Scientific Review Panel, 2000-present

International Consortium of Investigators Working on Lymphoma Epidemiologic Studies, 2001-present

(InterLymph); Chair, Pathology Working Group, 2001-2014

Member, Center for Research in Leukemia and Lymphoma, University of Nebraska, 2004-2012

Member, Center for Molecular Genetics and Genomics, University of Nebraska, 2007-2012

Advisory Board, Lugano International Conference on Malignant Lymphoma, 2009-2013

#### **IV. National Honors, Scholarships and Awards Honors and Awards**

1970 Phi Beta Kappa, University of North Dakota

1970 Grey Gown Award, University of North Dakota

1972 Pathology Award, University of North Dakota Medical School

1985 Alexander von Humboldt Fellowship

1994 Groundwater Foundation Special Recognition Award for Research

1996-1998 Best Doctors in America, Central Region

2000-present America's Top Doctors/Medical Specialists

2001-present Best Doctors in America

2004 Alpha Omega Alpha, University of Nebraska

Dennis Weisenburger, MD - MC

2005-2008	Visiting Professor, China Three Gorges University
2005-2008	Visiting Professor, Hubei Province Cancer Hospital
2006	Milton R. Hales Lecture in Pathology, West Virginia University School of Medicine
2006-present	Who's Who in Science and Engineering
2006-present	American Men and Women of Science
2008	UNeMED Research Innovation Award
2008	UNMC Distinguished Scientist
2011	John J. Kepes Lectures in Pathology, Kansas City Society of Pathologists
2012, 2016	UNMC Innovation Award for Patent
2016	Distinguished Lecturer, Sylvester Comprehensive Cancer Center, University of Miami

## **V. CLINICAL ACTIVITIES**

- See above

## **VI. SERVICE TO INSTITUTION**

### **Administrative Service**

#### **Committee Assignments at University of Nebraska Medical Center:**

1984-1985	Departmental Education Committee
1985-1987	Departmental Laboratory Computer Committee
1985-1987	University Hospital Computer Committee
1985-1998	Departmental Administrative Committee
1986-1996	Chairman, Clinical Laboratory Quality Assurance Committee
1985-1989	Deans Scholastic Evaluation Committee
1986	Deans Ad Hoc Committee on Tenure
1986-1987	Deans Ad Hoc Committee for selection of Obstetrics/Gynecology Chairman
1988-1989	Deans Ad Hoc Committee for selection of Biostatistics/Epidemiology Chairman
1988-1990	Intercampus Water Quality Advisory Committee for Governor's Research Initiatives
1988-1992	Chairman (1989), Departmental Promotion and Tenure Committee
1988-1989	Chancellors Ad Hoc Committee for selection of Director of Eppley Institute
1989-1990	Nursing Staffing Patterns Task Force
1988-1996	University Medical Associates (UMA) Ambulatory Affairs Committee
1988-1992	Chairman, UMA Ancillary Diagnostic Standards Committee
1989-1991	UMA Clinic Policies and Procedures Committee
1989-1992	Board of Directors, Professional Fees Office, Nebraska Clinicians Group
1990-1993	Chairman, Clinical Laboratory Service Excellence Committee
1991	Chancellor's Ad Hoc Subcommittee on Total Quality Management
1991	Chairman, Deans Ad Hoc Committee for selection of Water Center Toxicologist
1991-1992	American Board of Pathology, Hematology Committee
1991-1999	A. Ross McIntyre Awards Selection Committee
1992-1996	Chairman, Hospital Quality Assurance Committee for Ancillary Laboratory Testing
1993-1996	Hospital Quality Assurance and Improvement Committee
1993-1994	Clinical Laboratory Quality Monitoring Team
1994	University of Nebraska Medical Center Leadership Institute
1994-1995	University Hospital Consortium Laboratory Strategic Benchmarking Committee



Dennis Weisenburger, MD - MC

1996-1997	Chairman, Departmental Promotion and Tenure Committee
1996-1997	Campus Committee for Selection of Director of Molecular Genetics
1997-2003	Cancer Center Membership Committee
1997-2012	Associate Director, Cancer Center Tissue Procurement Core Facility Committee
2002-2003	Campus Comprehensive Space Planning and Analysis Group
2002-2003	Campus Research Development Board
2002-2004	Departmental Promotion and Tenure Committee, Chairman 2002-2003,
2003-2011	College of Medicine Graduate Medical Education Committee
2004-2007	Chairman, Departmental Grand Rounds Committee
2004-2012	Executive Committee, Center for Research in Leukemia and Lymphoma
2008	Chairman, Departmental Workload Committee

#### **Committee Assignments at City of Hope Medical Center:**

2012-present	Committee of Chairs
2012-present	Medical Group Board of Directors
2012-present	Cancer Center Leadership Council
2012-2013	Chairman, Tissue Biorepository Initiative
2013-present	Chairman, City of Hope Biorepository Committee
2014-present	Director, Cancer Center Pathology Core Cluster Shared Resource
2015	Committee for Selection of Chair of Medical Oncology
2015-2016	Laboratory Information System Steering Committee
2015-present	Lymphoma Clinical Database Committee
2015-present	Lymphoma Center Investigator Committee
2015-present	ORIEN Steering Committee
2016-present	Clinical Laboratory Test Utilization Committee
2016-present	Precision Medicine Working Group

#### **Teaching Service**

- Director of Hematopathology Fellowship Program, University of Nebraska Medical Center, 1984-2011
- Hematopathology and general pathology for medical students, residents, and fellows, University of Nebraska Medical Center, 1984-2011

#### **Other Research Mentoring Activities/Committees**

- N/A

### **VII. SERVICE TO PROFESSION**

#### **Professional Organizations**

National/International	American Association for Cancer Research, 1984-present
	American Society of Clinical Pathologists, 1984-present
	Member, Council on Hematology, 1994-2000
	American Society for Hematology, 1984-present
	College of American Pathologists, 1984-present
	European Association for Haematopathology, 1984-present
	Society for Hematopathology, 1984-present



Dennis Weisenburger, MD - MC

	Member, Executive Committee, 1995-1999
	United States and Canadian Academy of Pathology, 1984-present
Regional/Local	Los Angeles Society of Pathologists, 2012-present
<b>Government Activities</b>	N/A
<b>NIH Study Section</b>	N/A
<b>Editorships</b>	N/A
<b>Editorial Boards</b>	Modern Pathology, 1990-2007 Clinical Lymphoma, Myeloma, and Leukemia, 2000-present Journal of Oncology 2008-2009 The European Journal of Clinical and Medical Oncology, 2009-present World Journal of Clinical Oncology, 2010-present Blood and Lymphatic Cancer: Targets and Therapy, 2010- present Journal of Epidemiology and Public Health, 2016-present Clinics in Oncology, 2016-present
<b>Journal Reviews</b>	American Journal of Clinical Pathology; American Journal of Gastroenterology; American Journal of Hematology; American Journal of Pathology; Annals of Hematology; Annals of Internal Medicine; Annals of Oncology; Blood; Bone Marrow Transplantation; Cancer; Cancer Causes and Control; Digestive Diseases; Environmental Health Perspectives; European Journal of Cancer; Human Pathology; International Journal of Cancer; Journal of Clinical Oncology; Laboratory Investigation; Leukemia; Leukemia and Lymphoma; Leukemia Research; New England Journal of Medicine.
<b>Grant Reviews</b>	N/A
<b>Community Service</b>	Nebraska Environmental Control Council (Governor's appointment), 1987-1989 Professional Education Committee, American Cancer Society, Nebraska Division, 1986- 1989 Advisory Committee on Cancer Prevention and Control, Nebraska Department of Health, 1987-1995 Nebraska Cancer Registry Advisory Committee, Nebraska Department of Health, 1989- 2011 Board of Directors, American Cancer Society, Nebraska Division, 1990-1992 Board of Directors, AAA Center for Pregnancy Counseling, 2004-2012
<b>Other:</b>	
<b>Symposia</b>	N/A
<b>Sessions Chaired</b>	N/A
<b>Consultantships</b>	N/A

**VIII. Grants/Research Support****ACTIVE GRANTS**

- N/A

**PENDING GRANTS/RESEARCH SUPPORT**

- N/A

Dennis Weisenburger, MD - MC

## COMPLETED GRANTS/RESEARCH SUPPORT

- N/A

## IX. Publications

### Publications (peer-reviewed), 425 Total

1. Weisenburger, D.D., O'Conner, M.L., and Hart, M.N., Thrombotic Thrombocytopenic Purpura with C'3 Vascular Deposits: Report of a Case. *Am J Clin Pathol*, 1977. 67(1): p. 61-63.
2. Rankin, W.E., Hart, M.N., and Weisenburger, D.D., Thrombotic Thrombocytopenic Purpura in a Child with Alexander's Disease. *Arch Pathol Lab Med*, 1977. 101(12): p. 655-657.
3. Weisenburger, D., Armitage, J., and Dick, F., Immunoblastic Lymphadenopathy with Pulmonary Infiltrates, Hypocomplementemia and Vasculitis. A Hyperimmune Syndrome. *Am J Med*, 1977. 63(6): p. 849-854.
4. Weisenburger, D.D., Interstitial Pneumonitis Associated with Azathioprine Therapy. *Am J Clin Pathol*, 1978. 69(2): p. 181-185.
5. Weisenburger, D.D., Immunoblastic Lymphadenopathy Associated with Methyldopa Therapy: A Case Report. *Cancer*, 1978. 42(5): p. 2322-2327.
6. Seibert JJ, Seibert RW, Weisenburger DD, Alsbrook W. Multiple Congenital Hemangiopericytomas of the Head and Neck. *Laryngoscope* 88:1006-1011, 1978.
7. Helms, C.M., Sturm, R.H., Viner, J.P., Weisenburger, D., Renner, E., and Rose, E., Legionnaires' Disease: A Case from Iowa. *J Iowa Med Soc*, 1978. 68(9): p. 311-317.
8. Weisenburger, D.D., DeGowin, R.L., Gibson, P., and Armitage, J.O., Remission of Giant Lymph Node Hyperplasia with Anemia after Radiotherapy. *Cancer*, 1979. 44(2): p. 457-462.
9. Weisenburger, D.D., Membranous Nephropathy. Its Association with Multicentric Angiofollicular Lymph Node Hyperplasia. *Arch Pathol Lab Med*, 1979. 103(11): p. 591-594.
10. Hunsicker, L.G., Shearer, T.P., Plattner, S.B., and Weisenburger, D., The Role of Monocytes in Serum Sickness Nephritis. *J Exp Med*, 1979. 150(3): p. 413-425.
11. Weisenburger, D.D., Acute Myelofibrosis Terminating as Acute Myeloblastic Leukemia. *Am J Clin Pathol*, 1980. 73(1): p. 128-132.
12. Weisenburger, D.D., Rappaport, H., Ahluwalia, M.S., Melvani, R., and Renner, E.D., Legionnaires' Disease. *Am J Med*, 1980. 69(3): p. 476-482.
13. Diamond, L.W., Bearman, R.M., Berry, P.K., Mills, B.J., Nathwani, B.N., Weisenburger, D.D., Winberg, C.D., Teplitz, R.L., and Rappaport, H., Prolymphocytic Leukemia: Flow Microfluorometric, Immunologic, and Cytogenetic Observations. *Am J Hematol*, 1980. 9(3): p. 319-330.
14. Helms, C.M., Viner, J.P., Renner, E.D., Chiu, L.C., and Weisenburger, D.D., Legionnaires' Disease among Pneumonias in Iowa (Fy 1972-1978). Epidemiologic and Clinical Features of 30 Sporadic Cases of *L. Pneumophila* Infection. *Am J Med Sci*, 1981. 281(1): p. 2-13.



Dennis Weisenburger, MD - MC

15. Weisenburger, D.D., Helms, C.M., and Renner, E.D., Sporadic Legionnaires' Disease. A Pathologic Study of 23 Fatal Cases. *Arch Pathol Lab Med*, 1981. 105(3): p. 130-137.
16. Weisenburger, D.D., Nathwani, B.N., Diamond, L.W., Winberg, C.D., and Rappaport, H., Malignant Lymphoma, Intermediate Lymphocytic Type: A Clinicopathologic Study of 42 Cases. *Cancer*, 1981. 48(6): p. 1415-1425.
17. Diamond, L.W., Weisenburger, D.D., and Rappaport, H., The Relationship between Lymphocyte Nuclear Morphology and Cell Cycle Stage in Lymphoid Neoplasia. *Am J Hematol*, 1981. 11(2): p. 165-173.
18. Weisenburger, D.D., Kim, H., and Rappaport, H., Mantle-Zone Lymphoma: A Follicular Variant of Intermediate Lymphocytic Lymphoma. *Cancer*, 1982. 49(7): p. 1429-1438.
19. Weisenburger, D.D., Nathwani, B.N., Forman, S.J., and Rappaport, H., Noncutaneous Peripheral T-Cell Lymphoma Histologically Resembling Mycosis Fungoides. *Cancer*, 1982. 49(9): p. 1839-1847.
20. Weisenburger, D.D., Mantle-Zone Lymphoma. An Immunohistologic Study. *Cancer*, 1984. 53(5): p. 1073-1080.
21. Helms, C.M., Viner, J.P., Weisenburger, D.D., Chiu, L.C., Renner, E.D., and Johnson, W., Sporadic Legionnaires' Disease: Clinical Observations on 87 Nosocomial and Community-Acquired Cases. *Am J Med Sci*, 1984. 288(1): p. 2-12.
22. Weisenburger, D.D., Nathwani, B.N., Winberg, C.D., and Rappaport, H., Multicentric Angiofollicular Lymph Node Hyperplasia: A Clinicopathologic Study of 16 Cases. *Hum Pathol*, 1985. 16(2): p. 162-172.
23. Weisenburger, D.D., Astorino, R.N., Glassy, F.J., Miller, C.H., MacKenzie, M.R., and Caggiano, V., Peripheral T-Cell Lymphoma. A Clinicopathologic Study of a Morphologically Diverse Entity. *Cancer*, 1985. 56(8): p. 2061-2068.
24. Weisenburger, D.D., Vinh, T.N., and Levinson, B., Malakoplakia of Bone. An Unusual Cause of Pathologic Fracture in an Immunosuppressed Patient. *Clin Orthop Relat Res*, 1985(201): p. 106-110.
25. Weisenburger, D.D., Lymphoid Malignancies in Nebraska: A Hypothesis. *Nebr Med J*, 1985. 70(8): p. 300-305.
26. Armitage, J.O., Weisenburger, D.D., Hutchins, M., Moravec, D.F., Dowling, M., Sorensen, S., Mailliard, J., Okerbloom, J., Johnson, P.S., Howe, D., and et al., Chemotherapy for Diffuse Large-Cell Lymphoma—Rapidly Responding Patients Have More Durable Remissions. *J Clin Oncol*, 1986. 4(2): p. 160-164.
27. Berg, A.R., Weisenburger, D.D., Linder, J., and Armitage, J.O., Lymphoplasmacytic Lymphoma. Report of a Case with Three Monoclonal Proteins Derived from a Single Neoplastic Clone. *Cancer*, 1986. 57(9): p. 1794-1797.
28. Homler, H.J., Goetz, C.S., and Weisenburger, D.D., Lymphangitic Cutaneous Metastases from Lung Cancer Mimicking Cellulitis. *Carcinoma Erysipeloides*. *West J Med*, 1986. 144(5): p. 610-612.



Dennis Weisenburger, MD - MC

29. Armitage, J.O., Gingrich, R.D., Klassen, L.W., Bierman, P.J., Kumar, P.P., Weisenburger, D.D., and Smith, D.M., Trial of High-Dose Cytarabine, Cyclophosphamide, Total-Body Irradiation, and Autologous Marrow Transplantation for Refractory Lymphoma. *Cancer Treat Rep*, 1986. 70(7): p. 871-875.
30. Kessinger, A., Armitage, J.O., Landmark, J.D., and Weisenburger, D.D., Reconstitution of Human Hematopoietic Function with Autologous Cryopreserved Circulating Stem Cells. *Exp Hematol*, 1986. 14(3): p. 192-196.
31. Sanger, W.G., Weisenburger, D.D., Armitage, J.O., and Purtilo, D.T., Cytogenetic Abnormalities in Noncutaneous Peripheral T-Cell Lymphoma. *Cancer Genet Cytogenet*, 1986. 23(1): p. 53-59.
32. Mirvish, S.S., Weisenburger, D.D., Salmasi, S., and Kaplan, P.A., Carcinogenicity of 1-(2-Hydroxyethyl)-1-Nitrosourea and 3-Nitroso-2-Oxazolidinone Administered in Drinking Water to Male Mrc-Wistar Rats: Induction of Bone, Hematopoietic, Intestinal, and Liver Tumors. *J Natl Cancer Inst*, 1987. 78(2): p. 387-393.
33. Joshi, S.S., Kessinger, A., Mann, S.L., Stevenson, M., Weisenburger, D.D., Vaughan, W.P., Armitage, J.O., and Sharp, J.G., Detection of Malignant Cells in Histologically Normal Bone Marrow Using Culture Techniques. *Bone Marrow Transplant*, 1987. 1(3): p. 303-310.
34. Harrington, D.S., Weisenburger, D.D., and Purtilo, D.T., Malignant Lymphoma in the X-Linked Lymphoproliferative Syndrome. *Cancer*, 1987. 59(8): p. 1419-1429.
35. Weisenburger, D.D., Linder, J., Daley, D.T., and Armitage, J.O., Intermediate Lymphocytic Lymphoma: An Immunohistologic Study with Comparison to Other Lymphocytic Lymphomas. *Hum Pathol*, 1987. 18(8): p. 781-790.
36. Mroczek, E.C., Weisenburger, D.D., Grierson, H.L., Markin, R., and Purtilo, D.T., Fatal Infectious Mononucleosis and Virus-Associated Hemophagocytic Syndrome. *Arch Pathol Lab Med*, 1987. 111(6): p. 530-535.
37. Weisenburger, D.D., Sanger, W.G., Armitage, J.O., and Purtilo, D.T., Intermediate Lymphocytic Lymphoma: Immunophenotypic and Cytogenetic Findings. *Blood*, 1987. 69(6): p. 1617-1621.
38. Smith, D.M., Weisenburger, D.D., Bierman, P., Kessinger, A., Vaughan, W.P., and Armitage, J.O., Acute Renal Failure Associated with Autologous Bone Marrow Transplantation. *Bone Marrow Transplant*, 1987. 2(2): p. 195-201.
39. Linder, J., Ye, Y.L., Harrington, D.S., Armitage, J.O., and Weisenburger, D.D., Monoclonal Antibodies Marking T Lymphocytes in Paraffin-Embedded Tissue. *Am J Pathol*, 1987. 127(1): p. 1-8.
40. Vaughan, W.P., Weisenburger, D.D., Sanger, W., Gale, R.P., and Armitage, J.O., Early Leukemic Recurrence of Non-Hodgkin Lymphoma after High-Dose Anti-Neoplastic Therapy with Autologous Marrow Rescue. *Bone Marrow Transplant*, 1987. 1(4): p. 373-378.
41. Harrington, D.S., Ye, Y.L., Weisenburger, D.D., Armitage, J.O., Pierson, J., Bast, M., and Purtilo, D.T., Malignant Lymphoma in Nebraska and Guangzhou, China: A Comparative Study. *Hum Pathol*, 1987. 18(9): p. 924-928.

Dennis Weisenburger, MD - MC

42. Speaks, S.L., Sanger, W.G., Linder, J., Johnson, D.R., Armitage, J.O., Weisenburger, D., and Purtilo, D., Chromosomal Abnormalities in Indolent Lymphoma. *Cancer Genet Cytogenet*, 1987. 27(2): p. 335-344.
43. Weisenburger, D.D., Linder, J., and Armitage, J.O., Peripheral T-Cell Lymphoma: A Clinicopathologic Study of 42 Cases. *Hematol Oncol*, 1987. 5(3): p. 175-187.
44. Vago, J.F. and Weisenburger, D.D., Acute Megakaryocytic Leukemia with Myeloid/Monocytic Differentiation. *Am J Surg Pathol*, 1987. 11(11): p. 883-889.
45. Sanger, W.G., Armitage, J.O., Bridge, J., Weisenburger, D.D., Fordyce, R., and Purtilo, D.T., Initial and Subsequent Cytogenetic Studies in Malignant Lymphoma. *Cancer*, 1987. 60(12): p. 3014-3019.
46. Vago, J.F., Weisenburger, D.D., and Armitage, J.O., Do Pathologic Features Predict Prognosis in Diffuse Large B-Cell Lymphoma? *Hematol Pathol*, 1987. 1(4): p. 217-225.
47. Linder, J., Ye, Y., Armitage, J.O., and Weisenburger, D.D., Monoclonal Antibodies Marking B-Cell Non-Hodgkin's Lymphoma in Paraffin-Embedded Tissue. *Mod Pathol*, 1988. 1(1): p. 29-34.
48. Weisenburger, D.D., Multicentric Angiofollicular Lymph Node Hyperplasia. *Pathology of the Spleen. Am J Surg Pathol*, 1988. 12(3): p. 176-181.
49. Kessinger, A., Armitage, J.O., Landmark, J.D., Smith, D.M., and Weisenburger, D.D., Autologous Peripheral Hematopoietic Stem Cell Transplantation Restores Hematopoietic Function Following Marrow Ablative Therapy. *Blood*, 1988. 71(3): p. 723-727.
50. Harrington, D.S., Patil, K., Lai, P.K., Yasuda, N.N., Armitage, J.O., Ip, S.H., Weisenburger, D.D., Linder, J., and Purtilo, D.T., Soluble Interleukin 2 Receptors in Patients with Malignant Lymphoma. *Arch Pathol Lab Med*, 1988. 112(6): p. 597-601.
51. Glenn L, Armitage JO, Goldsmith JC, Sorenson S, Howe D, Weisenburger DD. Pulmonary Emboli in Patient's Receiving Chemotherapy for Non-Hodgkin's Lymphoma. *Chest* 94:589-594, 1988.
52. Joshi, S.S., Glenn, L.D., Vaughan, W.P., Stevenson, M., Sanger, W.G., Sharp, J.G., and Weisenburger, D.D., Preferential in-Vitro Growth and Expansion of Leukemic T Lymphoblasts. *Leuk Res*, 1988. 12(2): p. 103-108.
53. Severson, G.S., Harrington, D.S., Weisenburger, D.D., McComb, R.D., Casey, J.H., Gelber, B.R., Varet, B., Abelanet, R., and Rappaport, H.H., Castleman's Disease of the Leptomeninges. Report of Three Cases. *J Neurosurg*, 1988. 69(2): p. 283-286.
54. Armitage, J.O., Sanger, W.G., Weisenburger, D.D., Harrington, D.S., Linder, J., Bierman, P.J., Vose, J.M., and Purtilo, D.T., Correlation of Secondary Cytogenetic Abnormalities with Histologic Appearance in Non-Hodgkin's Lymphomas Bearing t(14;18)(q32;q21). *J Natl Cancer Inst*, 1988. 80(8): p. 576-580.
55. Vose, J.M., Armitage, J.O., Weisenburger, D.D., Bierman, P.J., Sorensen, S., Hutchins, M., Moravec, D.F., Howe, D., Dowling, M.D., Mailliard, J., and et al., The Importance of Age in Survival of Patients Treated with Chemotherapy for Aggressive Non-Hodgkin's Lymphoma. *J Clin Oncol*, 1988. 6(12): p. 1838-1844.



Dennis Weisenburger, MD - MC

56. Wooldridge, T.N., Grierson, H.L., Weisenburger, D.D., Armitage, J.O., Sanger, W.G., Collins, M.M., Pierson, J.L., Pauza, M.E., Fordyce, R., and Purtilo, D.T., Association of DNA Content and Proliferative Activity with Clinical Outcome in Patients with Diffuse Mixed Cell and Large Cell Non-Hodgkin's Lymphoma. *Cancer Res*, 1988. 48(22): p. 6608-6613.
57. Vose, J., Armitage, J., Weisenburger, D., Moravec, D., Hutchins, M., Howe, D., Sorensen, S., Dowling, M., Okerbloom, J., Pevnick, W., and et al., CHLVPP--an Effective and Well-Tolerated Alternative to MOPP Therapy for Hodgkin's Disease. *Am J Clin Oncol*, 1988. 11(4): p. 423-426.
58. Vaughan, W.P., Civin, C.I., Weisenburger, D.D., Karp, J.E., Graham, M.L., Sanger, W.G., Grierson, H.L., Joshi, S.S., and Burke, P.J., Acute Leukemia Expressing the Normal Human Hematopoietic Stem Cell Membrane Glycoprotein CD34 (My10). *Leukemia*, 1988. 2(10): p. 661-666.
59. Armitage, J.O., Greer, J.P., Levine, A.M., Weisenburger, D.D., Formenti, S.C., Bast, M., Conley, S., Pierson, J., Linder, J., Cousar, J.B., and et al., Peripheral T-Cell Lymphoma. *Cancer*, 1989. 63(1): p. 158-163.
60. Schouten, H.C., Armitage, J.O., Klassen, L.W., Vaughan, W.P., Bierman, P.J., Weisenburger, D., and Kessinger, A., Allogeneic Bone Marrow Transplantation in Patients with Lymphoma Relapsing after Autologous Marrow Transplantation. *Bone Marrow Transplant*, 1989. 4(1): p. 119-121.
61. Lynch, H.T., Marcus, J.N., Weisenburger, D.D., Watson, P., Fitzsimmons, M.L., Grierson, H., Smith, D.M., Lynch, J., and Purtilo, D., Genetic and Immunopathological Findings in a Lymphoma Family. *Br J Cancer*, 1989. 59(4): p. 622-626.
62. Harrington, D.S., Braddock, S.W., Blocher, K.S., Weisenburger, D.D., Sanger, W., and Armitage, J.O., Lymphomatoid Papulosis and Progression to T Cell Lymphoma: An Immunophenotypic and Genotypic Analysis. *J Am Acad Dermatol*, 1989. 21(5 Pt 1): p. 951-957.
63. Schouten, H.C., Sanger, W.G., Duggan, M., Weisenburger, D.D., MacLennan, K.A., and Armitage, J.O., Chromosomal Abnormalities in Hodgkin's Disease. *Blood*, 1989. 73(8): p. 2149-2154.
64. Kessinger, A., Armitage, J.O., Smith, D.M., Landmark, J.D., Bierman, P.J., and Weisenburger, D.D., High-Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation for Patients with Lymphoma. *Blood*, 1989. 74(4): p. 1260-1265.
65. Schouten, H.C., Bierman, P.J., Vaughan, W.P., Kessinger, A., Vose, J.M., Weisenburger, D.D., and Armitage, J.O., Autologous Bone Marrow Transplantation in Follicular Non-Hodgkin's Lymphoma before and after Histologic Transformation. *Blood*, 1989. 74(7): p. 2579-2584.
66. Armitage, J.O., Vose, J.M., Linder, J., Weisenburger, D., Harrington, D., Casey, J., Bierman, P., Sorensen, S., Hutchins, M., Moravec, D.F., and et al., Clinical Significance of Immunophenotype in Diffuse Aggressive Non-Hodgkin's Lymphoma. *J Clin Oncol*, 1989. 7(12): p. 1783-1790.
67. Vose, J.M., Armitage, J.O., Bierman, P.J., Weisenburger, D.D., Hutchins, M., Dowling, M.D., Moravec, D.F., Sorensen, S., Okerbloom, J., Bascom, G., and et al., Salvage Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma Utilizing Autologous Bone Marrow Transplantation. *Am J Med*, 1989. 87(3): p. 285-288.



Dennis Weisenburger, MD - MC

68. Kessinger, A., Smith, D.M., Strandjord, S.E., Landmark, J.D., Dooley, D.C., Law, P., Coccia, P.F., Warkentin, P.I., Weisenburger, D.D., and Armitage, J.O., Allogeneic Transplantation of Blood-Derived, T Cell-Depleted Hemopoietic Stem Cells after Myeloablative Treatment in a Patient with Acute Lymphoblastic Leukemia. *Bone Marrow Transplant*, 1989. 4(6): p. 643-646.
69. Vose, J.M., Peterson, C., Bierman, P.J., Weisenburger, D.D., Linder, J., Harrington, D., Vaughan, W.P., Kessinger, A., and Armitage, J.O., Comparison of High-Dose Therapy and Autologous Bone Marrow Transplantation for T-Cell and B-Cell Non-Hodgkin's Lymphomas. *Blood*, 1990. 76(2): p. 424-431.
70. Conlan, M.G., Bast, M., Armitage, J.O., and Weisenburger, D.D., Bone Marrow Involvement by Non-Hodgkin's Lymphoma: The Clinical Significance of Morphologic Discordance between the Lymph Node and Bone Marrow. *Nebraska Lymphoma Study Group. J Clin Oncol*, 1990. 8(7): p. 1163-1172.
71. Alter, R., Joshi, S.S., Verdirame, J.D., and Weisenburger, D.D., Pure Red Cell Aplasia Associated with B Cell Lymphoma: Demonstration of Bone Marrow Colony Inhibition by Serum Immunoglobulin. *Leuk Res*, 1990. 14(3): p. 279-286.
72. Duggan, M.J., Weisenburger, D.D., Ye, Y.L., Bast, M.A., Pierson, J.L., Linder, J., and Armitage, J.O., Mantle Zone Lymphoma. A Clinicopathologic Study of 22 Cases. *Cancer*, 1990. 66(3): p. 522-529.
73. Schouten, H.C., Sanger, W.G., Weisenburger, D.D., Anderson, J., and Armitage, J.O., Chromosomal Abnormalities in Untreated Patients with Non-Hodgkin's Lymphoma: Associations with Histology, Clinical Characteristics, and Treatment Outcome. *The Nebraska Lymphoma Study Group. Blood*, 1990. 75(9): p. 1841-1847.
74. Zahm, S.H., Weisenburger, D.D., Babbitt, P.A., Saal, R.C., Vaught, J.B., Cantor, K.P., and Blair, A., A Case-Control Study of Non-Hodgkin's Lymphoma and the Herbicide 2,4-Dichlorophenoxyacetic Acid (2,4-D) in Eastern Nebraska. *Epidemiology*, 1990. 1(5): p. 349-356.
75. Joshi, S.S., Novak, D.J., Messbarger, L., Maitreya, V., Weisenburger, D.D., and Sharp, J.G., Levels of Detection of Tumor Cells in Human Bone Marrow with or without Prior Culture. *Bone Marrow Transplant*, 1990. 6(3): p. 179-183.
76. Schouten, H.C., Sanger, W.G., Weisenburger, D.D., and Armitage, J.O., Abnormalities Involving Chromosome 6 in Newly Diagnosed Patients with Non-Hodgkin's Lymphoma. *Nebraska Lymphoma Study Group. Cancer Genet Cytogenet*, 1990. 47(1): p. 73-82.
77. Schouten, H.C., Sanger, W.G., Weisenburger, D.D., and Armitage, J.O., Chromosomal Abnormalities in Patients with Non-Cutaneous T-Cell Non-Hodgkin's Lymphoma. *The Nebraska Lymphoma Study Group. Eur J Cancer*, 1990. 26(5): p. 618-622.
78. Grierson, H.L., Wooldridge, T.N., Purtilo, D.T., Pierson, J., Bast, M., Wooldridge, L., Armitage, J.O., and Weisenburger, D.D., Low Proliferative Activity Is Associated with a Favorable Prognosis in Peripheral T-Cell Lymphoma. *Cancer Res*, 1990. 50(16): p. 4845-4848.
79. Weisenburger, D.D., Environmental Epidemiology of Non-Hodgkin's Lymphoma in Eastern Nebraska. *Am J Ind Med*, 1990. 18(3): p. 303-305.

Dennis Weisenburger, MD - MC

80. Schouten, H.C., Kessinger, A., Smith, D.M., Landmark, J.D., Wigton, R.S., Weisenburger, D.D., and Armitage, J.O., Counterflow Centrifugation Apheresis for the Collection of Autologous Peripheral Blood Stem Cells from Patients with Malignancies: A Comparison with a Standard Centrifugation Apheresis Procedure. *J Clin Apher*, 1990. 5(3): p. 140-144.
81. Perry, D.A., Bast, M.A., Armitage, J.O., and Weisenburger, D.D., Diffuse Intermediate Lymphocytic Lymphoma. A Clinicopathologic Study and Comparison with Small Lymphocytic Lymphoma and Diffuse Small Cleaved Cell Lymphoma. *Cancer*, 1990. 66(9): p. 1995-2000.
82. Mirvish, S.S., Weisenburger, D.D., Joshi, S.S., and Nickols, J., 2-Hydroxyethylnitrosourea Induction of B Cell Lymphoma in Female Swiss Mice. *Cancer Lett*, 1990. 54(1-2): p. 101-106.
83. Mirvish, S.S., Nickols, J., Weisenburger, D.D., Johnson, D., Joshi, S.S., Kaplan, P., Gross, M., and Tong, H.Y., Effects of 2,4,5-Trichlorophenoxyacetic Acid, Pentachlorophenol, Methylprednisolone, and Freund's Adjuvant on 2-Hydroxyethylnitrosourea Carcinogenesis in Mrc-Wistar Rats. *J Toxicol Environ Health*, 1991. 32(1): p. 59-74.
84. Conlan, M.G., Armitage, J.O., Bast, M., and Weisenburger, D.D., Clinical Significance of Hematologic Parameters in Non-Hodgkin's Lymphoma at Diagnosis. *Cancer*, 1991. 67(5): p. 1389-1395.
85. Maennle, D.L., Grierson, H.L., Gnarr, D.G., and Weisenburger, D.D., Sinus Histiocytosis with Massive Lymphadenopathy: A Spectrum of Disease Associated with Immune Dysfunction. *Pediatr Pathol*, 1991. 11(3): p. 399-412.
86. Philip, T., Chauvin, F., Armitage, J., Bron, D., Hagenbeek, A., Biron, P., Spitzer, G., Velasquez, W., Weisenburger, D.D., Fernandez-Ranada, J., and et al., Parma International Protocol: Pilot Study of DHAP Followed by Involved-Field Radiotherapy and BEAC with Autologous Bone Marrow Transplantation. *Blood*, 1991. 77(7): p. 1587-1592.
87. Joshi, S.S., DeBoer, J.M., Strandjord, S.J., Pirruccello, S.J., Sanger, W.G., Weisenburger, D.D., and Sharp, J.G., Characterization of a Newly Established Human Burkitt's Lymphoma Cell Line, Oma-B1-1. *Int J Cancer*, 1991. 47(5): p. 643-648.
88. Strobach, R.S., Nakamine, H., Masih, A.S., Linder, J., and Weisenburger, D.D., Nerve Growth Factor Receptor Expression on Dendritic Reticulum Cells in Follicular Lymphoid Proliferations. *Hum Pathol*, 1991. 22(5): p. 481-485.
89. Joshi, S.S., O'Connor, S.J., Weisenburger, D.D., Sharp, J.G., Gharpure, H.M., and Brunson, K.W., Enhanced Antiproliferative Activity by Metastatic Raw117 Lymphoma Cells. *Clin Exp Metastasis*, 1991. 9(1): p. 27-37.
90. Mirvish SS, Gannett P, Babcook DM, Williamson D, Chen SC, Weisenburger DD, N-Nitrosoatrazine: Synthesis, Kinetics of Formation, and Nuclear Magnetic Resonance Spectra and Other Properties. *J Agric Food Chem*, 1991. 39:1205-1210.
91. Nakamine, H., Masih, A.S., Strobach, R.S., Duggan, M.J., Bast, M.A., Armitage, J.O., and Weisenburger, D.D., Immunoblastic Lymphoma with Abundant Clear Cytoplasm. A Comparative Study of B- and T-Cell Types. *Am J Clin Pathol*, 1991. 96(2): p. 177-183.



Dennis Weisenburger, MD - MC

92. Vose, J.M., Bierman, P.J., Anderson, J.R., Weisenburger, D., Moravec, D.F., Sorensen, S., Hutchins, M., Dowling, M.D., Howe, D., Okerbloom, J., and et al., CHLVPP Chemotherapy with Involved-Field Irradiation for Hodgkin's Disease: Favorable Results with Acceptable Toxicity. *J Clin Oncol*, 1991. 9(8): p. 1421-1425.
93. Masih, A., Weisenburger, D., Duggan, M., Armitage, J., Bashir, R., Mitchell, D., Wickert, R., and Purtilo, D.T., Epstein-Barr Viral Genome in Lymph Nodes from Patients with Hodgkin's Disease May Not Be Specific to Reed-Sternberg Cells. *Am J Pathol*, 1991. 139(1): p. 37-43.
94. Bashir, R.M., Bierman, P.J., Vose, J.M., Weisenburger, D.D., and Armitage, J.O., Central Nervous System Involvement in Patients with Diffuse Aggressive Non-Hodgkin's Lymphoma. *Am J Clin Oncol*, 1991. 14(6): p. 478-482.
95. Armitage, J.O., Bierman, P.J., Vose, J.M., Anderson, J.R., Weisenburger, D.D., Kessinger, A., Reed, E.C., Vaughan, W.P., Coccia, P.F., and Purtilo, D.T., Autologous Bone Marrow Transplantation for Patients with Relapsed Hodgkin's Disease. *Am J Med*, 1991. 91(6): p. 605-611.
96. Lobo, F., Kessinger, A., Landmark, J.D., Smith, D.M., Weisenburger, D.D., Wigton, R.S., and Armitage, J.O., Addition of Peripheral Blood Stem Cells Collected without Mobilization Techniques to Transplanted Autologous Bone Marrow Did Not Hasten Marrow Recovery Following Myeloablative Therapy. *Bone Marrow Transplant*, 1991. 8(5): p. 389-392.
97. Masih, A.S., Weisenburger, D.D., Vose, J.M., Bast, M.A., and Armitage, J.O., Histologic Grade Does Not Predict Prognosis in Optimally Treated, Advanced-Stage Nodular Sclerosing Hodgkin's Disease. *Cancer*, 1992. 69(1): p. 228-232.
98. Sharp, J.G., Joshi, S.S., Armitage, J.O., Bierman, P., Coccia, P.F., Harrington, D.S., Kessinger, A., Crouse, D.A., Mann, S.L., and Weisenburger, D.D., Significance of Detection of Occult Non-Hodgkin's Lymphoma in Histologically Uninvolved Bone Marrow by a Culture Technique. *Blood*, 1992. 79(4): p. 1074-1080.
99. Sharp JG, Kessinger A, Vaughan WP, Mann S, Crouse DA, Dicke K, Masih A, Weisenburger DD. Detection and Clinical Significance of Minimal Tumor Cell Contamination of Peripheral Stem Cell Harvests. *Int J Cell Cloning (Suppl. 1)* 10:92-94, 1992.
100. Zahm, S.H., Weisenburger, D.D., Babbitt, P.A., Saal, R.C., Vaught, J.B., and Blair, A., Use of Hair Coloring Products and the Risk of Lymphoma, Multiple Myeloma, and Chronic Lymphocytic Leukemia. *Am J Public Health*, 1992. 82(7): p. 990-997.
101. Parks, J.D., Synovec, M.S., Masih, A.S., Braddock, S.W., Nakamine, H., Sanger, W.G., Harrington, D.S., and Weisenburger, D.D., Immunophenotypic and Genotypic Characterization of Lymphomatoid Papulosis. *J Am Acad Dermatol*, 1992. 26(6): p. 968-975.
102. Nakamine, H., Masih, A.S., Sanger, W.G., Wickert, R.S., Mitchell, D.W., Armitage, J.O., and Weisenburger, D.D., Richter's Syndrome with Different Immunoglobulin Light Chain Types. Molecular and Cytogenetic Features Indicate a Common Clonal Origin. *Am J Clin Pathol*, 1992. 97(5): p. 656-663.
103. Poje, E.J., Soori, G.S., and Weisenburger, D.D., Systemic Polyclonal B-Immunoblastic Proliferation with Marked Peripheral Blood and Bone Marrow Plasmacytosis. *Am J Clin Pathol*, 1992. 98(2): p. 222-226.



Dennis Weisenburger, MD - MC

104. Vose, J.M., Bierman, P.J., Anderson, J.R., Kessinger, A., Pierson, J., Nelson, J., Frappier, B., Schmit-Pokorny, K., Weisenburger, D.D., and Armitage, J.O., Progressive Disease after High-Dose Therapy and Autologous Transplantation for Lymphoid Malignancy: Clinical Course and Patient Follow-Up. *Blood*, 1992. 80(8): p. 2142-2148.
105. Gordon, B.G., Warkentin, P.I., Weisenburger, D.D., Vose, J.M., Sanger, W.G., Strandjord, S.E., Anderson, J.R., Verdirame, J.D., Bierman, P.J., Armitage, J.O., and et al., Bone Marrow Transplantation for Peripheral T-Cell Lymphoma in Children and Adolescents. *Blood*, 1992. 80(11): p. 2938-2942.
106. Gordon, B.G., Weisenburger, D.D., Warkentin, P.I., Anderson, J., Sanger, W.G., Bast, M., Gnarr, D., Vose, J.M., Bierman, P.J., Armitage, J.O., and et al., Peripheral T-Cell Lymphoma in Childhood and Adolescence. A Clinicopathologic Study of 22 Patients. *Cancer*, 1993. 71(1): p. 257-263.
107. Hoar Zahm, S., Weisenburger, D.D., Cantor, K.P., Holmes, F.F., and Blair, A., Role of the Herbicide Atrazine in the Development of Non-Hodgkin's Lymphoma. *Scand J Work Environ Health*, 1993. 19(2): p. 108-114.
108. Anderson, J.R., Vose, J.M., Bierman, P.J., Weisenburger, D.D., Sanger, W.G., Pierson, J., Bast, M., and Armitage, J.O., Clinical Features and Prognosis of Follicular Large-Cell Lymphoma: A Report from the Nebraska Lymphoma Study Group. *J Clin Oncol*, 1993. 11(2): p. 218-224.
109. Nakamine, H., Bagin, R.G., Vose, J.M., Bast, M.A., Bierman, P.J., Armitage, J.O., and Weisenburger, D.D., Prognostic Significance of Clinical and Pathologic Features in Diffuse Large B-Cell Lymphoma. *Cancer*, 1993. 71(10): p. 3130-3137.
110. Nakamine, H., Masih, A.S., Chan, W.C., Sanger, W.G., Armitage, J.O., and Weisenburger, D.D., Oncogene Rearrangement in Non-Hodgkin's Lymphoma with a 14q+ Chromosome of Unknown Origin. *Leuk Lymphoma*, 1993. 10(1-2): p. 79-88.
111. Zahm, S.H., Weisenburger, D.D., Saal, R.C., Vaught, J.B., Babbitt, P.A., and Blair, A., The Role of Agricultural Pesticide Use in the Development of Non-Hodgkin's Lymphoma in Women. *Arch Environ Health*, 1993. 48(5): p. 353-358.
112. Chan, W.C., Hooper, C., Wickert, R., Benson, J.M., Vardiman, J., Hinrichs, S., and Weisenburger, D., HTLV-I Sequence in Lymphoproliferative Disorders. *Diagn Mol Pathol*, 1993. 2(3): p. 192-199.
113. O'Reilly, P.E., Jr., Joshi, V.V., Holbrook, C.T., and Weisenburger, D.D., Multicentric Castleman's Disease in a Child with Prominent Thymic Involvement: A Case Report and Brief Review of the Literature. *Mod Pathol*, 1993. 6(6): p. 776-780.
114. Seemayer, T.A., Grierson, H., Pirruccello, S.J., Gross, T.G., Weisenburger, D.D., Davis, J., Spiegel, K., Brichacek, B., and Sumegi, J., X-Linked Lymphoproliferative Disease. *Am J Dis Child*, 1993. 147(11): p. 1242-1245.
115. Mirvish, S.S., Weisenburger, D.D., Hinrichs, S.H., Nickols, J., and Hinman, C., Effect of Catechol and Ethanol with and without Methylamyl nitrosamine on Esophageal Carcinogenesis in the Rat. *Carcinogenesis*, 1994. 15(5): p. 883-887.

Dennis Weisenburger, MD - MC

116. Gordon, B.G., Weisenburger, D.D., Sanger, W.G., Armitage, J.O., and Coccia, P.F., Peripheral T-Cell Lymphoma in Children and Adolescents: Role of Bone Marrow Transplantation. *Leuk Lymphoma*, 1994. 14(1-2): p. 1-10.
117. Bashir, R., McManus, B., Cunningham, C., Weisenburger, D., and Hochberg, F., Detection of EBER-1 RNA in Primary Brain Lymphomas in Immunocompetent and Immunocompromised Patients. *J Neurooncol*, 1994. 20(1): p. 47-53.
118. Nashelsky, M.B., Hess, M.M., Weisenburger, D.D., Pierson, J.L., Bast, M.A., Armitage, J.O., and Sanger, W.G., Cytogenetic Abnormalities in B-Immunoblastic Lymphoma. *Leuk Lymphoma*, 1994. 14(5-6): p. 415-420.
119. Ward, M.H., Zahm, S.H., Weisenburger, D.D., Gridley, G., Cantor, K.P., Saal, R.C., and Blair, A., Dietary Factors and Non-Hodgkin's Lymphoma in Nebraska (United States). *Cancer Causes Control*, 1994. 5(5): p. 422-432.
120. Delabie, J., Tierens, A., Wu, G., Weisenburger, D.D., and Chan, W.C., Lymphocyte Predominance Hodgkin's Disease: Lineage and Clonality Determination Using a Single-Cell Assay. *Blood*, 1994. 84(10): p. 3291-3298.
121. Darrington, D.L., Vose, J.M., Anderson, J.R., Bierman, P.J., Bishop, M.R., Chan, W.C., Morris, M.E., Reed, E.C., Sanger, W.G., Tarantolo, S.R., and et al., Incidence and Characterization of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia Following High-Dose Chemoradiotherapy and Autologous Stem-Cell Transplantation for Lymphoid Malignancies. *J Clin Oncol*, 1994. 12(12): p. 2527-2534.
122. Baddoura, F.K., Chan, W.C., Masih, A.S., Mitchell, D., Sun, N.C., and Weisenburger, D.D., T-Cell-Rich B-Cell Lymphoma. A Clinicopathologic Study of Eight Cases. *Am J Clin Pathol*, 1995. 103(1): p. 65-75.
123. Cabanillas, F., Armitage, J., Pugh, W.C., Weisenburger, D., and Duvic, M., Lymphomatoid Papulosis: A T-Cell Dyscrasia with a Propensity to Transform into Malignant Lymphoma. *Ann Intern Med*, 1995. 122(3): p. 210-217.
124. Stewart, D.A., Vose, J.M., Weisenburger, D.D., Anderson, J.R., Ruby, E.I., Bast, M.A., Bierman, P.J., Kessinger, A., and Armitage, J.O., The Role of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma. *Ann Oncol*, 1995. 6(3): p. 263-266.
125. Downing, J.R., Shurtleff, S.A., Zielenska, M., Curcio-Brint, A.M., Behm, F.G., Head, D.R., Sandlund, J.T., Weisenburger, D.D., Kossakowska, A.E., Thorner, P., and et al., Molecular Detection of the (2;5) Translocation of Non-Hodgkin's Lymphoma by Reverse Transcriptase-Polymerase Chain Reaction. *Blood*, 1995. 85(12): p. 3416-3422.
126. Grierson, H.L., Wooldridge, T.N., Hess, M., Wooldridge, L., Ratashak, A., Bast, M., Armitage, J.O., Weisenburger, D.D., and Sanger, W.G., Comparison of DNA Content in Non-Hodgkin's Lymphoma as Measured by Flow Cytometry and Cytogenetics. *Cancer Genet Cytogenet*, 1995. 80(2): p. 124-128.
127. Martin, A.R., Chan, W.C., Perry, D.A., Greiner, T.C., and Weisenburger, D.D., Aggressive Natural Killer Cell Lymphoma of the Small Intestine. *Mod Pathol*, 1995. 8(5): p. 467-472.



Dennis Weisenburger, MD - MC

128. Martin, A.R., Weisenburger, D.D., Chan, W.C., Ruby, E.I., Anderson, J.R., Vose, J.M., Bierman, P.J., Bast, M.A., Daley, D.T., and Armitage, J.O., Prognostic Value of Cellular Proliferation and Histologic Grade in Follicular Lymphoma. *Blood*, 1995. 85(12): p. 3671-3678.
129. Yan, Y., Chan, W.C., Weisenburger, D.D., Anderson, J.R., Bast, M.A., Vose, J.M., Bierman, P.J., and Armitage, J.O., Clinical and Prognostic Significance of Bone Marrow Involvement in Patients with Diffuse Aggressive B-Cell Lymphoma. *J Clin Oncol*, 1995. 13(6): p. 1336-1342.
130. Wickert, R.S., Weisenburger, D.D., Tierens, A., Greiner, T.C., and Chan, W.C., Clonal Relationship between Lymphocytic Predominance Hodgkin's Disease and Concurrent or Subsequent Large-Cell Lymphoma of B Lineage. *Blood*, 1995. 86(6): p. 2312-2320.
131. Elmberger, P.G., Lozano, M.D., Weisenburger, D.D., Sanger, W., and Chan, W.C., Transcripts of the NPM-ALK Fusion Gene in Anaplastic Large Cell Lymphoma, Hodgkin's Disease, and Reactive Lymphoid Lesions. *Blood*, 1995. 86(9): p. 3517-3521.
132. Grierson, H.L., Wooldridge, T.N., Hess, M., Ratashak, A., Wooldridge, L., Fordyce-Boyer, R., Bast, M., Armitage, J.O., Weisenburger, D.D., and Sanger, W.G., Proliferative Fraction and DNA Content Are Lower in B-Cell Non-Hodgkin's Lymphomas with the t(14;18). *Leuk Lymphoma*, 1995. 19(3-4): p. 253-257.
133. d'Amore, F., Johansen, P., Houmand, A., Weisenburger, D.D., and Mortensen, L.S., Epstein-Barr Virus Genome in Non-Hodgkin's Lymphomas Occurring in Immunocompetent Patients: Highest Prevalence in Nonlymphoblastic T-Cell Lymphoma and Correlation with a Poor Prognosis. Danish Lymphoma Study Group, Lyfo. *Blood*, 1996. 87(3): p. 1045-1055.
134. Sharp, J.G., Kessinger, A., Mann, S., Crouse, D.A., Armitage, J.O., Bierman, P., and Weisenburger, D.D., Outcome of High-Dose Therapy and Autologous Transplantation in Non-Hodgkin's Lymphoma Based on the Presence of Tumor in the Marrow or Infused Hematopoietic Harvest. *J Clin Oncol*, 1996. 14(1): p. 214-219.
135. Delabie, J., Greiner, T.C., Chan, W.C., and Weisenburger, D.D., Concurrent Lymphocyte Predominance Hodgkin's Disease and T-Cell Lymphoma. A Report of Three Cases. *Am J Surg Pathol*, 1996. 20(3): p. 355-362.
136. Lozano, M.D., Tierens, A., Greiner, T.C., Wickert, R.S., Weisenburger, D.D., and Chan, W.C., Clonality Analysis of B-Lymphoid Proliferations Using the Polymerase Chain Reaction. *Cancer*, 1996. 77(7): p. 1349-1355.
137. Moynihan, M.J., Bast, M.A., Chan, W.C., Delabie, J., Wickert, R.S., Wu, G., and Weisenburger, D.D., Lymphomatous Polyposis. A Neoplasm of Either Follicular Mantle or Germinal Center Cell Origin. *Am J Surg Pathol*, 1996. 20(4): p. 442-452.
138. Weisenburger, D.D., Gordon, B.G., Vose, J.M., Bast, M.A., Chan, W.C., Greiner, T.C., Anderson, J.R., and Sanger, W.G., Occurrence of the t(2;5)(p23;q35) in Non-Hodgkin's Lymphoma. *Blood*, 1996. 87(9): p. 3860-3868.
139. Greiner, T.C., Moynihan, M.J., Chan, W.C., Lytle, D.M., Pedersen, A., Anderson, J.R., and Weisenburger, D.D., P53 Mutations in Mantle Cell Lymphoma Are Associated with Variant Cytology and Predict a Poor Prognosis. *Blood*, 1996. 87(10): p. 4302-4310.



Dennis Weisenburger, MD – MC

140. Delabie, J., Tierens, A., Gavril, T., Wu, G., Weisenburger, D.D., and Chan, W.C., Phenotype, Genotype and Clonality of Reed-Sternberg Cells in Nodular Sclerosis Hodgkin's Disease: Results of a Single-Cell Study. *Br J Haematol*, 1996. 94(1): p. 198-205.
141. Ward, M.H., Mark, S.D., Cantor, K.P., Weisenburger, D.D., Correa-Villasenor, A., and Zahm, S.H., Drinking Water Nitrate and the Risk of Non-Hodgkin's Lymphoma. *Epidemiology*, 1996. 7(5): p. 465-471.
142. Smir, B.N., Greiner, T.C., and Weisenburger, D.D., Multicentric Angiofollicular Lymph Node Hyperplasia in Children: A Clinicopathologic Study of Eight Patients. *Mod Pathol*, 1996. 9(12): p. 1135-1142.
143. Mirvish, S.S., Nickols, J., Weisenburger, D.D., and Smyrk, T., Carcinogenicity Tests of Methyl-N-Amylnitrosamine (MNAN) Administered to Newborn and Adult Rats and Hamsters and Adult Mice and of 2-Oxo-MNAN Administered to Adult Rats. *Cancer Lett*, 1996. 107(2): p. 171-177.
144. Mathew, P., Sanger, W.G., Weisenburger, D.D., Valentine, M., Valentine, V., Pickering, D., Higgins, C., Hess, M., Cui, X., Srivastava, D.K., and Morris, S.W., Detection of the t(2;5)(p23;q35) and NPM-ALK Fusion in Non-Hodgkin's Lymphoma by Two-Color Fluorescence in Situ Hybridization. *Blood*, 1997. 89(5): p. 1678-1685.
145. Ward, M.H., Sinha, R., Heineman, E.F., Rothman, N., Markin, R., Weisenburger, D.D., Correa, P., and Zahm, S.H., Risk of Adenocarcinoma of the Stomach and Esophagus with Meat Cooking Method and Doneness Preference. *Int J Cancer*, 1997. 71(1): p. 14-19.
146. Mann, S.L., Joshi, S.S., Crouse, D.A., Armitage, J.O., Kessinger, A., Weisenburger, D.D., Vaughan, W.P., and Sharp, J.G., Increased Hematopoietic Progenitor Cell Maintenance in Long-Term Bone Marrow Cultures Containing Minimal Numbers of Contaminating Breast Cancer Cells. *Breast Cancer Res Treat*, 1997. 44(2): p. 115-121.
147. Zahm, S.H., Weisenburger, D.D., Holmes, F.F., Cantor, K.P., and Blair, A., Tobacco and Non-Hodgkin's Lymphoma: Combined Analysis of Three Case-Control Studies (United States). *Cancer Causes Control*, 1997. 8(2): p. 159-166.
148. Armitage JO, Anderson JR, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*, 1997. 89(11): p. 3909-3918.
149. Ohno, T., Stribley, J.A., Wu, G., Hinrichs, S.H., Weisenburger, D.D., and Chan, W.C., Clonality in Nodular Lymphocyte-Predominant Hodgkin's Disease. *N Engl J Med*, 1997. 337(7): p. 459-465.
150. Coiffier B, Armitage JO, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. Effect of Age on the Characteristics and Clinical Behavior of Non-Hodgkin's Lymphoma Patients. The Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol*, 1997. 8(10): p. 973-978.
151. Ohno, T., Smir, B.N., Weisenburger, D.D., Gascoyne, R.D., Hinrichs, S.D., and Chan, W.C., Origin of the Hodgkin/Reed-Sternberg Cells in Chronic Lymphocytic Leukemia with "Hodgkin's Transformation". *Blood*, 1998. 91(5): p. 1757-1761.

Dennis Weisenburger, MD - MC

152. Vose, J.M., Bierman, P.J., Lynch, J.C., Weisenburger, D.D., Kessinger, A., Chan, W.C., Greiner, T.C., and Armitage, J.O., Effect of Follicularity on Autologous Transplantation for Large-Cell Non-Hodgkin's Lymphoma. *J Clin Oncol*, 1998. 16(3): p. 844-849.
153. Anderson, J.R., Armitage, J.O., and Weisenburger, D.D., Epidemiology of the Non-Hodgkin's Lymphomas: Distributions of the Major Subtypes Differ by Geographic Locations. Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol*, 1998. 9(7): p. 717-720.
154. Armitage, J.O. and Weisenburger, D.D., New Approach to Classifying Non-Hodgkin's Lymphomas: Clinical Features of the Major Histologic Subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol*, 1998. 16(8): p. 2780-2795.
155. Pavletic, Z.S., Bierman, P.J., Vose, J.M., Bishop, M.R., Wu, C.D., Pierson, J.L., Kollath, J.P., Weisenburger, D.D., Kessinger, A., and Armitage, J.O., High Incidence of Relapse after Autologous Stem-Cell Transplantation for B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. *Ann Oncol*, 1998. 9(9): p. 1023-1026.
156. Diebold, J., Weisenburger, D., MacLennan, K.A., Müller-Hermelink, H.K., Nathwani, B.N., Harris, N.L., Anderson, J.R., Roy, P., and Armitage, J.O., Reproducibility and Prognostic Value of Histopathological Classifications of Malignant Lymphomas. Prolegomena for the 1st International Classification Proposed by WHO. Group of the Non-Hodgkin's Malignant Lymphoma Classification Project. *Bull Acad Natl Med*, 1998. 182(7): p. 1537-1548; discussion 1548-1539.
157. Dave, B.J., Pickering, D.L., Hess, M.M., Weisenburger, D.D., Armitage, J.O., and Sanger, W.G., Deletion of Cell Division Cycle 2-Like 1 Gene Locus on 1p36 in Non-Hodgkin Lymphoma. *Cancer Genet Cytogenet*, 1999. 108(2): p. 120-126.
158. Nathwani, B.N., Anderson, J.R., Armitage, J.O., Cavalli, F., Diebold, J., Drachenberg, M.R., Harris, N.L., MacLennan, K.A., Müller-Hermelink, H.K., Ullrich, F.A., and Weisenburger, D.D., Clinical Significance of Follicular Lymphoma with Monocytoid B Cells. Non-Hodgkin's Lymphoma Classification Project. *Hum Pathol*, 1999. 30(3): p. 263-268.
159. Abou-Elella, A.A., Weisenburger, D.D., Vose, J.M., Kollath, J.P., Lynch, J.C., Bast, M.A., Bierman, P.J., Greiner, T.C., Chan, W.C., and Armitage, J.O., Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients from the Nebraska Lymphoma Study Group. *J Clin Oncol*, 1999. 17(3): p. 784-790.
160. Dave, B.J., Hess, M.M., Pickering, D.L., Zaleski, D.H., Pfeifer, A.L., Weisenburger, D.D., Armitage, J.O., and Sanger, W.G., Rearrangements of Chromosome Band 1p36 in Non-Hodgkin's Lymphoma. *Clin Cancer Res*, 1999. 5(6): p. 1401-1409.
161. Gascoyne, R.D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B.F., Greiner, T.C., Morris, S.W., Connors, J.M., Vose, J.M., Viswanatha, D.S., Coldman, A., and Weisenburger, D.D., Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults with Anaplastic Large Cell Lymphoma. *Blood*, 1999. 93(11): p. 3913-3921.
162. Zhang, Q., Siebert, R., Yan, M., Hinzmann, B., Cui, X., Xue, L., Rakestraw, K.M., Naeve, C.W., Beckmann, G., Weisenburger, D.D., Sanger, W.G., Nowotny, H., Vesely, M., Callet-Bauchu, E., Salles, G., Dixit, V.M., Rosenthal, A., Schlegelberger, B., and Morris, S.W., Inactivating Mutations and Overexpression of BCL10, a Caspase Recruitment Domain-Containing Gene, in MALT Lymphoma with t(1;14)(p22;q32). *Nat Genet*, 1999. 22(1): p. 63-68.



Dennis Weisenburger, MD - MC

163. Nathwani, B.N., Anderson, J.R., Armitage, J.O., Cavalli, F., Diebold, J., Drachenberg, M.R., Harris, N.L., MacLennan, K.A., Müller-Hermelink, H.K., Ullrich, F.A., and Weisenburger, D.D., Marginal Zone B-Cell Lymphoma: A Clinical Comparison of Nodal and Mucosa-Associated Lymphoid Tissue Types. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol*, 1999. 17(8): p. 2486-2492.
164. Arcaroli, J.J., Dave, B.J., Pickering, D.L., Hess, M.M., Armitage, J.O., Weisenburger, D.D., and Sanger, W.G., Is a Duplication of 14q32 a New Recurrent Chromosomal Alteration in B-Cell Non-Hodgkin Lymphoma? *Cancer Genet Cytogenet*, 1999. 113(1): p. 19-24.
165. Morgan, J.A., Yin, Y., Borowsky, A.D., Kuo, F., Nourmand, N., Koontz, J.I., Reynolds, C., Soreng, L., Griffin, C.A., Graeme-Cook, F., Harris, N.L., Weisenburger, D., Pinkus, G.S., Fletcher, J.A., and Sklar, J., Breakpoints of the t(11;18)(q21;q21) in Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Lie within or near the Previously Undescribed Gene MALT1 in Chromosome 18. *Cancer Res*, 1999. 59(24): p. 6205-6213.
166. Weisenburger, D.D., Gascoyne, R.D., Bierman, P.J., Shenkier, T., Horsman, D.E., Lynch, J.C., Chan, W.C., Greiner, T.C., Connors, J.M., Vose, J.M., Armitage, J.O., and Sanger, W.G., Clinical Significance of the t(14;18) and BCL2 Overexpression in Follicular Large Cell Lymphoma. *Leuk Lymphoma*, 2000. 36(5-6): p. 513-523.
167. Alizadeh, A.A., Eisen, M.B., Davis, R.E., Ma, C., Lossos, I.S., Rosenwald, A., Boldrick, J.C., Sabet, H., Tran, T., Yu, X., Powell, J.I., Yang, L., Marti, G.E., Moore, T., Hudson, J., Jr., Lu, L., Lewis, D.B., Tibshirani, R., Sherlock, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Warnke, R., Levy, R., Wilson, W., Grever, M.R., Byrd, J.C., Botstein, D., Brown, P.O., and Staudt, L.M., Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. *Nature*, 2000. 403(6769): p. 503-511.
168. Pavletic, Z.S., Arrowsmith, E.R., Bierman, P.J., Goodman, S.A., Vose, J.M., Tarantolo, S.R., Stein, R.S., Bociek, G., Greer, J.P., Wu, C.D., Kollath, J.P., Weisenburger, D.D., Kessinger, A., Wolff, S.N., Armitage, J.O., and Bishop, M.R., Outcome of Allogeneic Stem Cell Transplantation for B Cell Chronic Lymphocytic Leukemia. *Bone Marrow Transplant*, 2000. 25(7): p. 717-722.
169. Abou-Elella, A., Shafer, M.T., Wan, X.Y., Velankar, M., Weisenburger, D.D., Nathwani, B.N., Gascoyne, R.D., Greiner, T.C., and Chan, W.C., Lymphomas with Follicular and Monocytoid B-Cell Components. Evidence for a Common Clonal Origin from Follicle Center Cells. *Am J Clin Pathol*, 2000. 114(4): p. 516-522.
170. Weisenburger, D.D., Vose, J.M., Greiner, T.C., Lynch, J.C., Chan, W.C., Bierman, P.J., Dave, B.J., Sanger, W.G., and Armitage, J.O., Mantle Cell Lymphoma. A Clinicopathologic Study of 68 Cases from the Nebraska Lymphoma Study Group. *Am J Hematol*, 2000. 64(3): p. 190-196.
171. Vose, J.M., Bierman, P.J., Weisenburger, D.D., Lynch, J.C., Bociek, Y., Chan, W.C., Greiner, T.C., and Armitage, J.O., Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma. *Biol Blood Marrow Transplant*, 2000. 6(6): p. 640-645.
172. Waddell, B.L., Zahm, S.H., Baris, D., Weisenburger, D.D., Holmes, F., Burmeister, L.F., Cantor, K.P., and Blair, A., Agricultural Use of Organophosphate Pesticides and the Risk of Non-Hodgkin's Lymphoma among Male Farmers (United States). *Cancer Causes Control*, 2001. 12(6): p. 509-517.
173. Zheng, T., Zahm, S.H., Cantor, K.P., Weisenburger, D.D., Zhang, Y., and Blair, A., Agricultural Exposure to Carbamate Pesticides and Risk of Non-Hodgkin Lymphoma. *J Occup Environ Med*, 2001. 43(7): p. 641-649.



Dennis Weisenburger, MD - MC

174. Weisenburger, D.D., Anderson, J.R., Diebold, J., Gascoyne, R.D., MacLennan, K.A., Müller-Hermelink, H.K., Nathwani, B.N., Ullrich, F., and Armitage, J.O., Systemic Anaplastic Large-Cell Lymphoma: Results from the Non-Hodgkin's Lymphoma Classification Project. *Am J Hematol*, 2001. 67(3): p. 172-178.
175. Hunt, J.P., Chan, J.A., Samoszuk, M., Brynes, R.K., Hernandez, A.M., Bass, R., Weisenburger, D.D., Müller-Hermelink, K., and Nathwani, B.N., Hyperplasia of Mantle/Marginal Zone B Cells with Clear Cytoplasm in Peripheral Lymph Nodes. A Clinicopathologic Study of 35 Cases. *Am J Clin Pathol*, 2001. 116(4): p. 550-559.
176. Ohno, T., Huang, J.Z., Wu, G., Park, K.H., Weisenburger, D.D., and Chan, W.C., The Tumor Cells in Nodular Lymphocyte-Predominant Hodgkin Disease Are Clonally Related to the Large Cell Lymphoma Occurring in the Same Individual. Direct Demonstration by Single Cell Analysis. *Am J Clin Pathol*, 2001. 116(4): p. 506-511.
177. Lynch, H.T., Sanger, W.G., Pirruccello, S., Quinn-Laquer, B., and Weisenburger, D.D., Familial Multiple Myeloma: A Family Study and Review of the Literature. *J Natl Cancer Inst*, 2001. 93(19): p. 1479-1483.
178. Diebold, J., Anderson, J.R., Armitage, J.O., Connors, J.M., MacLennan, K.A., Müller-Hermelink, H.K., Nathwani, B.N., Ullrich, F., and Weisenburger, D.D., Diffuse Large B-Cell Lymphoma: A Clinicopathologic Analysis of 444 Cases Classified According to the Updated Kiel Classification. *Leuk Lymphoma*, 2002. 43(1): p. 97-104.
179. Rudiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F., Müller-Hermelink, H.K., and Non-Hodgkin's Lymphoma Classification, P., Peripheral T-Cell Lymphoma (Excluding Anaplastic Large-Cell Lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. *Ann Oncol*, 2002. 13(1): p. 140-149.
180. Chen, H., Ward, M.H., Graubard, B.I., Heineman, E.F., Markin, R.M., Potischman, N.A., Russell, R.M., Weisenburger, D.D., and Tucker, K.L., Dietary Patterns and Adenocarcinoma of the Esophagus and Distal Stomach. *Am J Clin Nutr*, 2002. 75(1): p. 137-144.
181. Palanisamy, N., Abou-Elella, A.A., Chaganti, S.R., Houldsworth, J., Offit, K., Louie, D.C., Terayu-Feldstein, J., Cigudosa, J.C., Rao, P.H., Sanger, W.G., Weisenburger, D.D., and Chaganti, R.S., Similar Patterns of Genomic Alterations Characterize Primary Mediastinal Large-B-Cell Lymphoma and Diffuse Large-B-Cell Lymphoma. *Genes Chromosomes Cancer*, 2002. 33(2): p. 114-122.
182. Dave, B.J., Nelson, M., Pickering, D.L., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., and Sanger, W.G., Cytogenetic Characterization of Diffuse Large Cell Lymphoma Using Multi-Color Fluorescence in Situ Hybridization. *Cancer Genet Cytogenet*, 2002. 132(2): p. 125-132.
183. Weekes, C.D., Vose, J.M., Lynch, J.C., Weisenburger, D.D., Bierman, P.J., Greiner, T., Bociek, G., Enke, C., Bast, M., Chan, W.C., Armitage, J.O., and Nebraska Lymphoma Study, G., Hodgkin's Disease in the Elderly: Improved Treatment Outcome with a Doxorubicin-Containing Regimen. *J Clin Oncol*, 2002. 20(4): p. 1087-1093.
184. Vose, J.M., Weisenburger, D.D., Lynch, J.C., Bierman, P.J., Chan, J.C., Bast, M., Aoun, P., Bociek, G., Greiner, T., Armitage, J.O., and Nebraska Lymphomas Study, G., CNOP for Diffuse Aggressive Non-Hodgkin's Lymphoma: The Nebraska Lymphoma Study Group Experience. *Leuk Lymphoma*, 2002. 43(4): p. 799-804.

Dennis Weisenburger, MD - MC

185. Chiu, B.C., Weisenburger, D.D., Cantor, K.P., Zahm, S.H., Holmes, F., Burmeister, L.F., and Blair, A., Alcohol Consumption, Family History of Hematolymphoproliferative Cancer, and the Risk of Non-Hodgkin's Lymphoma in Men. *Ann Epidemiol*, 2002. 12(5): p. 309-315.
186. Huang, J.Z., Sanger, W.G., Greiner, T.C., Staudt, L.M., Weisenburger, D.D., Pickering, D.L., Lynch, J.C., Armitage, J.O., Warnke, R.A., Alizadeh, A.A., Lossos, I.S., Levy, R., and Chan, W.C., The t(14;18) Defines a Unique Subset of Diffuse Large B-Cell Lymphoma with a Germinal Center B-Cell Gene Expression Profile. *Blood*, 2002. 99(7): p. 2285-2290.
187. Vose, J.M., Sharp, G., Chan, W.C., Nichols, C., Loh, K., Inwards, D., Rifkin, R., Bierman, P.J., Lynch, J.C., Weisenburger, D.D., Kessinger, A., and Armitage, J.O., Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease. *J Clin Oncol*, 2002. 20(9): p. 2344-2352.
188. Chen, H., Ward, M.H., Tucker, K.L., Graubard, B.I., McComb, R.D., Potischman, N.A., Weisenburger, D.D., and Heineman, E.F., Diet and Risk of Adult Glioma in Eastern Nebraska, United States. *Cancer Causes Control*, 2002. 13(7): p. 647-655.
189. Rosenwald, A., Wright, G., Chan, W.C., Connors, J.M., Campo, E., Fisher, R.I., Gascoyne, R.D., Müller-Hermelink, H.K., Smeland, E.B., Giltner, J.M., Hurt, E.M., Zhao, H., Averett, L., Yang, L., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Powell, J., Duffey, P.L., Longo, D.L., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Montserrat, E., Lopez-Guillermo, A., Grogan, T.M., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Delabie, J., Holte, H., Krajci, P., Stokke, T., Staudt, L.M., and Lymphoma/Leukemia Molecular Profiling, P., The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. *N Engl J Med*, 2002. 346(25): p. 1937-1947.
190. Zheng, T., Blair, A., Zhang, Y., Weisenburger, D.D., and Zahm, S.H., Occupation and Risk of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. *J Occup Environ Med*, 2002. 44(5): p. 469-474.
191. Weisenburger, D.D. and Chiu, B.C., Does Asbestos Exposure Cause Non-Hodgkin's Lymphoma or Related Hematolymphoid Cancers? A Review of the Epidemiologic Literature. *Clin Lymphoma*, 2002. 3(1): p. 36-40.
192. Lynch, H.T., Weisenburger, D.D., Quinn-Laquer, B., Snyder, C.L., Lynch, J.F., Lipkin, S.M., and Sanger, W.G., Family with Acute Myelocytic Leukemia, Breast, Ovarian, and Gastrointestinal Cancer. *Cancer Genet Cytogenet*, 2002. 137(1): p. 8-14.
193. Chen, H., Tucker, K.L., Graubard, B.I., Heineman, E.F., Markin, R.S., Potischman, N.A., Russell, R.M., Weisenburger, D.D., and Ward, M.H., Nutrient Intakes and Adenocarcinoma of the Esophagus and Distal Stomach. *Nutr Cancer*, 2002. 42(1): p. 33-40.
194. Lawnicki, L.C., Weisenburger, D.D., Aoun, P., Chan, W.C., Wickert, R.S., and Greiner, T.C., The t(14;18) and BCL-2 Expression Are Present in a Subset of Primary Cutaneous Follicular Lymphoma: Association with Lower Grade. *Am J Clin Pathol*, 2002. 118(5): p. 765-772.
195. Lynch, H.T., Weisenburger, D.D., Quinn-Laquer, B., Watson, P., Lynch, J.F., and Sanger, W.G., Hereditary Chronic Lymphocytic Leukemia: An Extended Family Study and Literature Review. *Am J Med Genet*, 2002. 115(3): p. 113-117.



Dennis Weisenburger, MD - MC

196. Rosenwald, A., Wright, G., Wiestner, A., Chan, W.C., Connors, J.M., Campo, E., Gascoyne, R.D., Grogan, T.M., Müller-Hermelink, H.K., Smeland, E.B., Chiorazzi, M., Giltman, J.M., Hurt, E.M., Zhao, H., Averett, L., Henrikson, S., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., Montserrat, E., Bosch, F., Greiner, T.C., Weisenburger, D.D., Sanger, W.G., Dave, B.J., Lynch, J.C., Vose, J., Armitage, J.O., Fisher, R.I., Miller, T.P., LeBlanc, M., Ott, G., Kvaloy, S., Holte, H., Delabie, J., and Staudt, L.M., The Proliferation Gene Expression Signature Is a Quantitative Integrator of Oncogenic Events That Predicts Survival in Mantle Cell Lymphoma. *Cancer Cell*, 2003. 3(2): p. 185-197.
197. Hans, C.P., Weisenburger, D.D., Vose, J.M., Hock, L.M., Lynch, J.C., Aoun, P., Greiner, T.C., Chan, W.C., Bociek, R.G., Bierman, P.J., and Armitage, J.O., A Significant Diffuse Component Predicts for Inferior Survival in Grade 3 Follicular Lymphoma, but Cytologic Subtypes Do Not Predict Survival. *Blood*, 2003. 101(6): p. 2363-2367.
198. Vandenberghe, E., Ruiz de Elvira, C., Loberiza, F.R., Conde, E., Lopez-Guillermo, A., Gisselbrecht, C., Guilhot, F., Vose, J.M., van Biesen, K., Rizzo, J.D., Weisenburger, D.D., Isaacson, P., Horowitz, M.M., Goldstone, A.H., Lazarus, H.M., and Schmitz, N., Outcome of Autologous Transplantation for Mantle Cell Lymphoma: A Study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. *Br J Haematol*, 2003. 120(5): p. 793-800.
199. Fang, N.Y., Greiner, T.C., Weisenburger, D.D., Chan, W.C., Vose, J.M., Smith, L.M., Armitage, J.O., Mayer, R.A., Pike, B.L., Collins, F.S., and Hacia, J.G., Oligonucleotide Microarrays Demonstrate the Highest Frequency of ATM Mutations in the Mantle Cell Subtype of Lymphoma. *Proc Natl Acad Sci U S A*, 2003. 100(9): p. 5372-5377.
200. De Roos, A.J., Zahm, S.H., Cantor, K.P., Weisenburger, D.D., Holmes, F.F., Burmeister, L.F., and Blair, A., Integrative Assessment of Multiple Pesticides as Risk Factors for Non-Hodgkin's Lymphoma among Men. *Occup Environ Med*, 2003. 60(9): p. E11.
201. Huang, J.Z., Weisenburger, D.D., Vose, J.M., Greiner, T.C., Aoun, P., Chan, W.C., Lynch, J.C., Bierman, P.J., Armitage, J.O., and Nebraska Lymphoma Study, G., Diffuse Large B-Cell Lymphoma Arising in Nodular Lymphocyte Predominant Hodgkin Lymphoma. A Report of 21 Cases from the Nebraska Lymphoma Study Group. *Leuk Lymphoma*, 2003. 44(11): p. 1903-1910.
202. Chiu, B.C. and Weisenburger, D.D., An Update of the Epidemiology of Non-Hodgkin's Lymphoma. *Clin Lymphoma*, 2003. 4(3): p. 161-168.
203. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Müller-Hermelink, H.K., Connors, J.M., Braziel, R., Grogan, T.M., Fisher, R.I., Miller, T.P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W.H., Jaffe, E.S., Simon, R., Klausner, R.D., and Staudt, L.M., Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. *J Exp Med*, 2003. 198(6): p. 851-862.
204. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., Müller-Hermelink, H.K., Campo, E., Braziel, R.M., Jaffe, E.S., Pan, Z., Farinha, P., Smith, L.M., Falini, B., Banham, A.H., Rosenwald, A., Staudt, L.M., Connors, J.M., Armitage, J.O., and Chan, W.C., Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. *Blood*, 2004. 103(1): p. 275-282.



Dennis Weisenburger, MD - MC

205. Aoun, P., Blair, H.E., Smith, L.M., Dave, B.J., Lynch, J., Weisenburger, D.D., Pavletic, S.Z., and Sanger, W.G., Fluorescence in Situ Hybridization Detection of Cytogenetic Abnormalities in B-Cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. *Leuk Lymphoma*, 2004. 45(8): p. 1595-1603.
206. Chiu, B.C., Weisenburger, D.D., Zahm, S.H., Cantor, K.P., Gapstur, S.M., Holmes, F., Burmeister, L.F., and Blair, A., Agricultural Pesticide Use, Familial Cancer, and Risk of Non-Hodgkin Lymphoma. *Cancer Epidemiol Biomarkers Prev*, 2004. 13(4): p. 525-531.
207. Nola, M., Pavletic, S.Z., Weisenburger, D.D., Smith, L.M., Bast, M.A., Vose, J.M., and Armitage, J.O., Prognostic Factors Influencing Survival in Patients with B-Cell Small Lymphocytic Lymphoma. *Am J Hematol*, 2004. 77(1): p. 31-35.
208. Rimsza, L.M., Roberts, R.A., Miller, T.P., Unger, J.M., LeBlanc, M., Braziel, R.M., Weisenburger, D.D., Chan, W.C., Müller-Hermelink, H.K., Jaffe, E.S., Gascoyne, R.D., Campo, E., Fuchs, D.A., Spier, C.M., Fisher, R.I., Delabie, J., Rosenwald, A., Staudt, L.M., and Grogan, T.M., Loss of MHC Class II Gene and Protein Expression in Diffuse Large B-Cell Lymphoma Is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival Regardless of Other Prognostic Factors: A Follow-up Study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*, 2004. 103(11): p. 4251-4258.
209. Dave, B.J., Weisenburger, D.D., Higgins, C.M., Pickering, D.L., Hess, M.M., Chan, W.C., and Sanger, W.G., Cytogenetics and Fluorescence in Situ Hybridization Studies of Diffuse Large B-Cell Lymphoma in Children and Young Adults. *Cancer Genet Cytogenet*, 2004. 153(2): p. 115-121.
210. Naresh, K.N., Agarwal, B., Nathwani, B.N., Diebold, J., McLennan, K.A., Müller-Hermelink, K.H., Armitage, J.O., and Weisenburger, D.D., Use of the World Health Organization (WHO) Classification of Non-Hodgkin's Lymphoma in Mumbai, India: A Review of 200 Consecutive Cases by a Panel of Five Expert Hematopathologists. *Leuk Lymphoma*, 2004. 45(8): p. 1569-1577.
211. Iqbal, J., Sanger, W.G., Horsman, D.E., Rosenwald, A., Pickering, D.L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., Sherman, S., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Ott, G., Müller-Hermelink, H.K., Delabie, J., Braziel, R.M., Jaffe, E.S., Campo, E., Lynch, J.C., Connors, J.M., Vose, J.M., Armitage, J.O., Grogan, T.M., Staudt, L.M., and Chan, W.C., BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. *Am J Pathol*, 2004. 165(1): p. 159-166.
212. Lee, W.J., Lijinsky, W., Heineman, E.F., Markin, R.S., Weisenburger, D.D., and Ward, M.H., Agricultural Pesticide Use and Adenocarcinomas of the Stomach and Oesophagus. *Occup Environ Med*, 2004. 61(9): p. 743-749.
213. Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Müller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M., and Staudt, L.M., Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. *N Engl J Med*, 2004. 351(21): p. 2159-2169.

Dennis Weisenburger, MD - MC

214. Lynch, H.T., Watson, P., Tarantolo, S., Wiernik, P.H., Quinn-Laquer, B., Isgur Bergsagel, K., Huiart, L., Olopade, O.I., Sobol, H., Sanger, W., Hogg, D., and Weisenburger, D., Phenotypic Heterogeneity in Multiple Myeloma Families. *J Clin Oncol*, 2005. 23(4): p. 685-693.
215. Chiu, B.C., Kolar, C., Gapstur, S.M., Lawson, T., Anderson, J.R., and Weisenburger, D.D., Association of NAT and GST Polymorphisms with Non-Hodgkin's Lymphoma: A Population-Based Case-Control Study. *Br J Haematol*, 2005. 128(5): p. 610-615.
216. Zu, Y., Steinberg, S.M., Campo, E., Hans, C.P., Weisenburger, D.D., Braziel, R.M., Delabie, J., Gascoyne, R.D., Müller-Hermelink, K., Pittaluga, S., Raffeld, M., Chan, W.C., Jaffe, E.S., and Pathology Panel of the Lymphoma/Leukemia Molecular Profiling, P., Validation of Tissue Microarray Immunohistochemistry Staining and Interpretation in Diffuse Large B-Cell Lymphoma. *Leuk Lymphoma*, 2005. 46(5): p. 693-701.
217. Heineman, E.F., Ward, M.H., McComb, R.D., Weisenburger, D.D., and Zahm, S.H., Hair Dyes and Risk of Glioma among Nebraska Women. *Cancer Causes Control*, 2005. 16(7): p. 857-864.
218. Hans, C.P., Weisenburger, D.D., Greiner, T.C., Chan, W.C., Aoun, P., Cochran, G.T., Pan, Z., Smith, L.M., Lynch, J.C., Bociek, R.G., Bierman, P.J., Vose, J.M., and Armitage, J.O., Expression of PKC-Beta or Cyclin D2 Predicts for Inferior Survival in Diffuse Large B-Cell Lymphoma. *Mod Pathol*, 2005. 18(10): p. 1377-1384.
219. Ward, M.H., Heineman, E.F., McComb, R.D., and Weisenburger, D.D., Drinking Water and Dietary Sources of Nitrate and Nitrite and Risk of Glioma. *J Occup Environ Med*, 2005. 47(12): p. 1260-1267.
220. Lee, W.J., Colt, J.S., Heineman, E.F., McComb, R., Weisenburger, D.D., Lijinsky, W., and Ward, M.H., Agricultural Pesticide Use and Risk of Glioma in Nebraska, United States. *Occup Environ Med*, 2005. 62(11): p. 786-792.
221. Fu, K., Weisenburger, D.D., Greiner, T.C., Dave, S., Wright, G., Rosenwald, A., Chiorazzi, M., Iqbal, J., Gesk, S., Siebert, R., De Jong, D., Jaffe, E.S., Wilson, W.H., Delabie, J., Ott, G., Dave, B.J., Sanger, W.G., Smith, L.M., Rimsza, L., Braziel, R.M., Müller-Hermelink, H.K., Campo, E., Gascoyne, R.D., Staudt, L.M., Chan, W.C., and Lymphoma/Leukemia Molecular Profiling, P., Cyclin D1-Negative Mantle Cell Lymphoma: A Clinicopathologic Study Based on Gene Expression Profiling. *Blood*, 2005. 106(13): p. 4315-4321.
222. Bea, S., Zettl, A., Wright, G., Salaverria, I., Jehn, P., Moreno, V., Burek, C., Ott, G., Puig, X., Yang, L., Lopez-Guillermo, A., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Grogan, T.M., Braziel, R., Fisher, R.I., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Simon, R., Powell, J., Wilson, W.H., Jaffe, E.S., Montserrat, E., Müller-Hermelink, H.K., Staudt, L.M., Campo, E., Rosenwald, A., and Lymphoma/Leukemia Molecular Profiling, P., Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles That Influence Tumor Biology and Improve Gene-Expression-Based Survival Prediction. *Blood*, 2005. 106(9): p. 3183-3190.
223. Rimsza, L.M., Roberts, R.A., Campo, E., Grogan, T.M., Bea, S., Salaverria, I., Zettl, A., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Delabie, J., Fisher, R.I., Unger, J.M., Leblanc, M., Staudt, L.M., Jaffe, E.S., Gascoyne, R.D., Chan, W.C., Weisenburger, D.D., Greiner, T., Braziel, R.M., and Miller, T.P., Loss of Major Histocompatibility Class II Expression in Non-Immune-Privileged Site Diffuse Large B-Cell Lymphoma Is Highly Coordinated and Not Due to Chromosomal Deletions. *Blood*, 2006. 107(3): p. 1101-1107.



Dennis Weisenburger, MD – MC

224. Morton, L.M., Wang, S.S., Devesa, S.S., Hartge, P., Weisenburger, D.D., and Linet, M.S., Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001. *Blood*, 2006. 107(1): p. 265-276.
225. Greiner, T.C., Dasgupta, C., Ho, V.V., Weisenburger, D.D., Smith, L.M., Lynch, J.C., Vose, J.M., Fu, K., Armitage, J.O., Braziel, R.M., Campo, E., Delabie, J., Gascoyne, R.D., Jaffe, E.S., Müller-Hermelink, H.K., Ott, G., Rosenwald, A., Staudt, L.M., Im, M.Y., Karaman, M.W., Pike, B.L., Chan, W.C., and Hacia, J.G., Mutation and Genomic Deletion Status of Ataxia Telangiectasia Mutated (ATM) and P53 Confer Specific Gene Expression Profiles in Mantle Cell Lymphoma. *Proc Natl Acad Sci U S A*, 2006. 103(7): p. 2352-2357.
226. Iqbal, J., Neppalli, V.T., Wright, G., Dave, B.J., Horsman, D.E., Rosenwald, A., Lynch, J., Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Campo, E., Ott, G., Müller-Hermelink, H.K., Delabie, J., Jaffe, E.S., Grogan, T.M., Connors, J.M., Vose, J.M., Armitage, J.O., Staudt, L.M., and Chan, W.C., BCL2 Expression Is a Prognostic Marker for the Activated B-Cell-Like Type of Diffuse Large B-Cell Lymphoma. *J Clin Oncol*, 2006. 24(6): p. 961-968.
227. Young, K.H., Chan, W.C., Fu, K., Iqbal, J., Sanger, W.G., Ratashak, A., Greiner, T.C., and Weisenburger, D.D., Mantle Cell Lymphoma with Plasma Cell Differentiation. *Am J Surg Pathol*, 2006. 30(8): p. 954-961.
228. Ganti, A.K., Weisenburger, D.D., Smith, L.M., Hans, C.P., Bociek, R.G., Bierman, P.J., Vose, J.M., and Armitage, J.O., Patients with Grade 3 Follicular Lymphoma Have Prolonged Relapse-Free Survival Following Anthracycline-Based Chemotherapy: The Nebraska Lymphoma Study Group Experience. *Ann Oncol*, 2006. 17(6): p. 920-927.
229. Dave, S.S., Fu, K., Wright, G.W., Lam, L.T., Kluin, P., Boerma, E.J., Greiner, T.C., Weisenburger, D.D., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Grogan, T.M., Campo, E., Jaffe, E.S., Dave, B.J., Sanger, W., Bast, M., Vose, J.M., Armitage, J.O., Connors, J.M., Smeland, E.B., Kvaloy, S., Holte, H., Fisher, R.I., Miller, T.P., Montserrat, E., Wilson, W.H., Bahl, M., Zhao, H., Yang, L., Powell, J., Simon, R., Chan, W.C., Staudt, L.M., and Lymphoma/Leukemia Molecular Profiling, P., Molecular Diagnosis of Burkitt's Lymphoma. *N Engl J Med*, 2006. 354(23): p. 2431-2442.
230. Davies, A.J., Rosenwald, A., Wright, G., Lee, A., Last, K.W., Weisenburger, D.D., Chan, W.C., Delabie, J., Braziel, R.M., Campo, E., Gascoyne, R.D., Jaffe, E.S., Müller-Hermelink, K., Ott, G., Calaminici, M., Norton, A.J., Goff, L.K., Fitzgibbon, J., Staudt, L.M., and Andrew Lister, T., Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Proceeds by Distinct Oncogenic Mechanisms. *Br J Haematol*, 2007. 136(2): p. 286-293.
231. Chiu, B.C., Dave, B.J., Blair, A., Gapstur, S.M., Zahm, S.H., and Weisenburger, D.D., Agricultural Pesticide Use and Risk of t(14;18)-Defined Subtypes of Non-Hodgkin Lymphoma. *Blood*, 2006. 108(4): p. 1363-1369.
232. Chakravarti, D., Zahid, M., Backora, M., Myers, E.M., Gaikwad, N., Weisenburger, D.D., Cavalieri, E.L., Rogan, E.G., and Joshi, S.S., Ortho-Quinones of Benzene and Estrogens Induce Hyperproliferation of Human Peripheral Blood Mononuclear Cells. *Leuk Lymphoma*, 2006. 47(12): p. 2635-2644.



Dennis Weisenburger, MD - MC

233. Aoun, P., Zhou, G., Chan, W.C., Page, C., Neth, K., Pickering, D., Sanger, W., Quinn-Laquer, B., Watson, P., Lynch, J.F., Lynch, H.T., and Weisenburger, D.D., Familial B-Cell Chronic Lymphocytic Leukemia: Analysis of Cytogenetic Abnormalities, Immunophenotypic Profiles, and Immunoglobulin Heavy Chain Gene Usage. *Am J Clin Pathol*, 2007. 127(1): p. 31-38.
234. Chiu, B.C., Dave, B.J., Blair, A., Gapstur, S.M., Chmiel, J.S., Fought, A.J., Zahm, S.H., and Weisenburger, D.D., Cigarette Smoking, Familial Hematopoietic Cancer, Hair Dye Use, and Risk of t(14;18)-Defined Subtypes of Non-Hodgkin's Lymphoma. *Am J Epidemiol*, 2007. 165(6): p. 652-659.
235. Wang, S.S., Slager, S.L., Brennan, P., Holly, E.A., De Sanjose, S., Bernstein, L., Boffetta, P., Cerhan, J.R., Maynadie, M., Spinelli, J.J., Chiu, B.C., Cocco, P.L., Mensah, F., Zhang, Y., Nieters, A., Dal Maso, L., Bracci, P.M., Costantini, A.S., Vineis, P., Severson, R.K., Roman, E., Cozen, W., Weisenburger, D., Davis, S., Franceschi, S., La Vecchia, C., Foretova, L., Becker, N., Staines, A., Vornanen, M., Zheng, T., and Hartge, P., Family History of Hematopoietic Malignancies and Risk of Non-Hodgkin Lymphoma (NHL): A Pooled Analysis of 10 211 Cases and 11 905 Controls from the International Lymphoma Epidemiology Consortium (Interlymph). *Blood*, 2007. 109(8): p. 3479-3488.
236. Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Müller-Hermelink, H.K., Ott, G., Chan, W.C., Greiner, T.C., Weisenburger, D.D., Vose, J., Armitage, J.O., Gascoyne, R.D., Connors, J.M., Campo, E., Montserrat, E., Bosch, F., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Fisher, R.I., Grogan, T.M., Miller, T.P., Wilson, W.H., Jaffe, E.S., and Staudt, L.M., Point Mutations and Genomic Deletions in CCND1 Create Stable Truncated Cyclin D1 mRNAs That Are Associated with Increased Proliferation Rate and Shorter Survival. *Blood*, 2007. 109(11): p. 4599-4606.
237. Salaverria, I., Zettl, A., Bea, S., Moreno, V., Valls, J., Hartmann, E., Ott, G., Wright, G., Lopez-Guillermo, A., Chan, W.C., Weisenburger, D.D., Gascoyne, R.D., Grogan, T.M., Delabie, J., Jaffe, E.S., Montserrat, E., Müller-Hermelink, H.K., Staudt, L.M., Rosenwald, A., and Campo, E., Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expression-Based Proliferation Signature. *J Clin Oncol*, 2007. 25(10): p. 1216-1222.
238. Raval, A., Tanner, S.M., Byrd, J.C., Angerman, E.B., Perko, J.D., Chen, S.S., Hackanson, B., Grever, M.R., Lucas, D.M., Matkovic, J.J., Lin, T.S., Kipps, T.J., Murray, F., Weisenburger, D., Sanger, W., Lynch, J., Watson, P., Jansen, M., Yoshinaga, Y., Rosenquist, R., de Jong, P.J., Coggill, P., Beck, S., Lynch, H., de la Chapelle, A., and Plass, C., Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia. *Cell*, 2007. 129(5): p. 879-890.
239. Morton, L.M., Turner, J.J., Cerhan, J.R., Linet, M.S., Treseler, P.A., Clarke, C.A., Jack, A., Cozen, W., Maynadie, M., Spinelli, J.J., Costantini, A.S., Rudiger, T., Scarpa, A., Zheng, T., and Weisenburger, D.D., Proposed Classification of Lymphoid Neoplasms for Epidemiologic Research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (Interlymph). *Blood*, 2007. 110(2): p. 695-708.
240. Mittal, A.K., Hegde, G.V., Aoun, P., Bociek, R.G., Dave, B.J., Joshi, A.D., Sanger, W.G., Weisenburger, D.D., and Joshi, S.S., Molecular Basis of Aggressive Disease in Chronic Lymphocytic Leukemia Patients with 11q Deletion and Trisomy 12 Chromosomal Abnormalities. *Int J Mol Med*, 2007. 20(4): p. 461-469.

Dennis Weisenburger, MD - MC

241. Linet, M.S., Schubauer-Berigan, M.K., Weisenburger, D.D., Richardson, D.B., Landgren, O., Blair, A., Silver, S., Field, R.W., Caldwell, G., Hatch, M., and Dores, G.M., Chronic Lymphocytic Leukaemia: An Overview of Aetiology in Light of Recent Developments in Classification and Pathogenesis. *Br J Haematol*, 2007. 139(5): p. 672-686.
242. Blair, A., Purdue, M.P., Weisenburger, D.D., and Baris, D., Chemical Exposures and Risk of Chronic Lymphocytic Leukaemia. *Br J Haematol*, 2007. 139(5): p. 753-761.
243. Young, K.H., Weisenburger, D.D., Dave, B.J., Smith, L., Sanger, W., Iqbal, J., Campo, E., Delabie, J., Gascoyne, R.D., Ott, G., Rimsza, L., Müller-Hermelink, H.K., Jaffe, E.S., Rosenwald, A., Staudt, L.M., Chan, W.C., and Greiner, T.C., Mutations in the DNA-Binding Codons of TP53, Which Are Associated with Decreased Expression of TRAIL Receptor-2, Predict for Poor Survival in Diffuse Large B-Cell Lymphoma. *Blood*, 2007. 110(13): p. 4396-4405.
244. Soni, L.K., Hou, L., Gapstur, S.M., Evens, A.M., Weisenburger, D.D., and Chiu, B.C., Sun Exposure and Non-Hodgkin Lymphoma: A Population-Based, Case-Control Study. *Eur J Cancer*, 2007. 43(16): p. 2388-2395.
245. Kimm, L.R., deLeeuw, R.J., Savage, K.J., Rosenwald, A., Campo, E., Delabie, J., Ott, G., Müller-Hermelink, H.K., Jaffe, E.S., Rimsza, L.M., Weisenburger, D.D., Chan, W.C., Staudt, L.M., Connors, J.M., Gascoyne, R.D., and Lam, W.L., Frequent Occurrence of Deletions in Primary Mediastinal B-Cell Lymphoma. *Genes Chromosomes Cancer*, 2007. 46(12): p. 1090-1097.
246. Chiu, B.C., Soni, L., Gapstur, S.M., Fought, A.J., Evens, A.M., and Weisenburger, D.D., Obesity and Risk of Non-Hodgkin Lymphoma (United States). *Cancer Causes Control*, 2007. 18(6): p. 677-685.
247. Iqbal, J., Greiner, T.C., Patel, K., Dave, B.J., Smith, L., Ji, J., Wright, G., Sanger, W.G., Pickering, D.L., Jain, S., Horsman, D.E., Shen, Y., Fu, K., Weisenburger, D.D., Hans, C.P., Campo, E., Gascoyne, R.D., Rosenwald, A., Jaffe, E.S., Delabie, J., Rimsza, L., Ott, G., Müller-Hermelink, H.K., Connors, J.M., Vose, J.M., McKeithan, T., Staudt, L.M., Chan, W.C., and Leukemia/Lymphoma Molecular Profiling, P., Distinctive Patterns of BCL6 Molecular Alterations and Their Functional Consequences in Different Subgroups of Diffuse Large B-Cell Lymphoma. *Leukemia*, 2007. 21(11): p. 2332-2343.
248. Balague, O., Martinez, A., Colomo, L., Rosello, E., Garcia, A., Martinez-Bernal, M., Palacin, A., Fu, K., Weisenburger, D., Colomer, D., Burke, J.S., Warnke, R.A., and Campo, E., Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-Cell Lymphomas: A Phenomenon with Distinctive Clinicopathologic Features. *Am J Surg Pathol*, 2007. 31(9): p. 1310-1322.
249. Jaye, D.L., Iqbal, J., Fujita, N., Geigerman, C.M., Li, S., Karanam, S., Fu, K., Weisenburger, D.D., Chan, W.C., Moreno, C.S., and Wade, P.A., The BCL6-Associated Transcriptional Co-Repressor, MTA3, Is Selectively Expressed by Germinal Centre B Cells and Lymphomas of Putative Germinal Centre Derivation. *J Pathol*, 2007. 213(1): p. 106-115.
250. Willett, E.V., Morton, L.M., Hartge, P., Becker, N., Bernstein, L., Boffetta, P., Bracci, P., Cerhan, J., Chiu, B.C., Cocco, P., Dal Maso, L., Davis, S., De Sanjose, S., Smedby, K.E., Ennas, M.G., Foretova, L., Holly, E.A., La Vecchia, C., Matsuo, K., Maynadie, M., Melbye, M., Negri, E., Nieters, A., Severson, R., Slager, S.L., Spinelli, J.J., Staines, A., Talamini, R., Vornanen, M., Weisenburger, D.D., Roman, E., and Interlymph, C., Non-Hodgkin Lymphoma and Obesity: A Pooled Analysis from the Interlymph Consortium. *Int J Cancer*, 2008. 122(9): p. 2062-2070.



Dennis Weisenburger, MD - MC

251. Vose, J.M., Bierman, P.J., Loberiza, F.R., Lynch, J.C., Bociek, G.R., Weisenburger, D.D., and Armitage, J.O., Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index. *Biol Blood Marrow Transplant*, 2008. 14(1): p. 36-42.
252. Pike, B.L., Greiner, T.C., Wang, X., Weisenburger, D.D., Hsu, Y.H., Renaud, G., Wolfsberg, T.G., Kim, M., Weisenberger, D.J., Siegmund, K.D., Ye, W., Groshen, S., Mehrian-Shai, R., Delabie, J., Chan, W.C., Laird, P.W., and Hacia, J.G., DNA Methylation Profiles in Diffuse Large B-Cell Lymphoma and Their Relationship to Gene Expression Status. *Leukemia*, 2008. 22(5): p. 1035-1043.
253. Nelson, M., Horsman, D.E., Weisenburger, D.D., Gascoyne, R.D., Dave, B.J., Loberiza, F.R., Ludkovski, O., Savage, K.J., Armitage, J.O., and Sanger, W.G., Cytogenetic Abnormalities and Clinical Correlations in Peripheral T-Cell Lymphoma. *Br J Haematol*, 2008. 141(4): p. 461-469.
254. Chiu, B.C., Lan, Q., Dave, B.J., Blair, A., Zahm, S.H., and Weisenburger, D.D., The Utility of t(14;18) in Understanding Risk Factors for Non-Hodgkin Lymphoma. *J Natl Cancer Inst Monogr*, 2008(39): p. 69-73.
255. Chiu, B.C., Dave, B.J., Ward, M.H., Fought, A.J., Hou, L., Jain, S., Gapstur, S., Evens, A.M., Zahm, S.H., Blair, A., and Weisenburger, D.D., Dietary Factors and Risk of t(14;18)-Defined Subgroups of Non-Hodgkin Lymphoma. *Cancer Causes Control*, 2008. 19(8): p. 859-867.
256. Fu, K., Weisenburger, D.D., Choi, W.W., Perry, K.D., Smith, L.M., Shi, X., Hans, C.P., Greiner, T.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Chan, W.C., and Vose, J.M., Addition of Rituximab to Standard Chemotherapy Improves the Survival of Both the Germinal Center B-Cell-Like and Non-Germinal Center B-Cell-Like Subtypes of Diffuse Large B-Cell Lymphoma. *J Clin Oncol*, 2008. 26(28): p. 4587-4594.
257. Savage, K.J., Harris, N.L., Vose, J.M., Ullrich, F., Jaffe, E.S., Connors, J.M., Rimsza, L., Pileri, S.A., Chhanabhai, M., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D., and International Peripheral, T-Cell Lymphoma Project, ALK-Negative Anaplastic Large-Cell Lymphoma Is Clinically and Immunophenotypically Different from Both ALK-Positive ALCL and Peripheral T-Cell Lymphoma, Not Otherwise Specified: Report from the International Peripheral T-Cell Lymphoma Project. *Blood*, 2008. 111(12): p. 5496-5504.
258. Vose, J., Armitage, J., Weisenburger, D., and International, T.C.L.P., International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. *J Clin Oncol*, 2008. 26(25): p. 4124-4130.
259. Lynch, H.T., Ferrara, K., Barlogie, B., Coleman, E.A., Lynch, J.F., Weisenburger, D., Sanger, W., Watson, P., Nipper, H., Witt, V., and Thome, S., Familial Myeloma. *N Engl J Med*, 2008. 359(2): p. 152-157.
260. Hegde, G.V., Munger, C.M., Emanuel, K., Joshi, A.D., Greiner, T.C., Weisenburger, D.D., Vose, J.M., and Joshi, S.S., Targeting of Sonic Hedgehog-Gli Signaling: A Potential Strategy to Improve Therapy for Mantle Cell Lymphoma. *Mol Cancer Ther*, 2008. 7(6): p. 1450-1460.
261. Ward, M.H., Heineman, E.F., Markin, R.S., and Weisenburger, D.D., Adenocarcinoma of the Stomach and Esophagus and Drinking Water and Dietary Sources of Nitrate and Nitrite. *Int J Occup Environ Health*, 2008. 14(3): p. 193-197.

Dennis Weisenburger, MD - MC

262. Salaverria, I., Zettl, A., Bea, S., Hartmann, E.M., Dave, S.S., Wright, G.W., Boerma, E.J., Kluin, P.M., Ott, G., Chan, W.C., Weisenburger, D.D., Lopez-Guillermo, A., Gascoyne, R.D., Delabie, J., Rimsza, L.M., Braziel, R.M., Jaffe, E.S., Staudt, L.M., Müller-Hermelink, H.K., Campo, E., Rosenwald, A., Leukemia, and Lymphoma Molecular Profiling, P., Chromosomal Alterations Detected by Comparative Genomic Hybridization in Subgroups of Gene Expression-Defined Burkitt's Lymphoma. *Haematologica*, 2008. 93(9): p. 1327-1334.
263. Hegde, G.V., Peterson, K.J., Emanuel, K., Mittal, A.K., Joshi, A.D., Dickinson, J.D., Kollessery, G.J., Bociek, R.G., Bierman, P., Vose, J.M., Weisenburger, D.D., and Joshi, S.S., Hedgehog-Induced Survival of B-Cell Chronic Lymphocytic Leukemia Cells in a Stromal Cell Microenvironment: A Potential New Therapeutic Target. *Mol Cancer Res*, 2008. 6(12): p. 1928-1936.
264. Young, K.H., Leroy, K., Moller, M.B., Colleoni, G.W., Sanchez-Beato, M., Kerbaux, F.R., Haion, C., Eickhoff, J.C., Young, A.H., Gaulard, P., Piris, M.A., Oberley, T.D., Rehrauer, W.M., Kahl, B.S., Malter, J.S., Campo, E., Delabie, J., Gascoyne, R.D., Rosenwald, A., Rimsza, L., Huang, J., Braziel, R.M., Jaffe, E.S., Wilson, W.H., Staudt, L.M., Vose, J.M., Chan, W.C., Weisenburger, D.D., and Greiner, T.C., Structural Profiles of TP53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-Cell Lymphoma: An International Collaborative Study. *Blood*, 2008. 112(8): p. 3088-3098.
265. Lenz, G., Wright, G.W., Emre, N.C., Kohlhammer, H., Dave, S.S., Davis, R.E., Carty, S., Lam, L.T., Shaffer, A.L., Xiao, W., Powell, J., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Rimsza, L.M., Fisher, R.I., Weisenburger, D.D., Chan, W.C., and Staudt, L.M., Molecular Subtypes of Diffuse Large B-Cell Lymphoma Arise by Distinct Genetic Pathways. *Proc Natl Acad Sci U S A*, 2008. 105(36): p. 13520-13525.
266. Lenz, G., Wright, G., Dave, S.S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., Vose, J., Bast, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Armitage, J.O., Kyle, A., May, L., Gascoyne, R.D., Connors, J.M., Troen, G., Holte, H., Kvaloy, S., Dierickx, D., Verhoef, G., Delabie, J., Smeland, E.B., Jares, P., Martinez, A., Lopez-Guillermo, A., Montserrat, E., Campo, E., Braziel, R.M., Miller, T.P., Rimsza, L.M., Cook, J.R., Pohlman, B., Sweetenham, J., Tubbs, R.R., Fisher, R.I., Hartmann, E., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Wrench, D., Lister, T.A., Jaffe, E.S., Wilson, W.H., Chan, W.C., Staudt, L.M., and Lymphoma/Leukemia Molecular Profiling, P., Stromal Gene Signatures in Large-B-Cell Lymphomas. *N Engl J Med*, 2008. 359(22): p. 2313-2323.
267. Aldoss, I.T., Weisenburger, D.D., Fu, K., Chan, W.C., Vose, J.M., Bierman, P.J., Bociek, R.G., and Armitage, J.O., Adult Burkitt Lymphoma: Advances in Diagnosis and Treatment. *Oncology (Williston Park)*, 2008. 22(13): p. 1508-1517.
268. Lynch, H.T., Ferrara, K.M., Weisenburger, D.D., Sanger, W.G., Lynch, J.F., and Thome, S.D., Genetic Counseling for DAPK1 Mutation in a Chronic Lymphocytic Leukemia Family. *Cancer Genet Cytogenet*, 2008. 186(2): p. 95-102.
269. Dores, G.M., Matsuno, R.K., Weisenburger, D.D., Rosenberg, P.S., and Anderson, W.F., Hairy Cell Leukaemia: A Heterogeneous Disease? *Br J Haematol*, 2008. 142(1): p. 45-51.
270. Abuzetun, J.Y., Loberiza, F., Vose, J., Bierman, P., Bociek, R.G., Enke, C., Bast, M., Weisenburger, D., Armitage, J.O., and Nebraska Lymphoma Study, G., The Stanford V Regimen Is Effective in Patients with Good Risk Hodgkin Lymphoma but Radiotherapy Is a Necessary Component. *Br J Haematol*, 2009. 144(4): p. 531-537.



Dennis Weisenburger, MD - MC

271. Suzumiya, J., Ohshima, K., Tamura, K., Karube, K., Uike, N., Tobinai, K., Gascoyne, R.D., Vose, J.M., Armitage, J.O., Weisenburger, D.D., and International Peripheral, T.C.L.P., The International Prognostic Index Predicts Outcome in Aggressive Adult T-Cell Leukemia/Lymphoma: Analysis of 126 Patients from the International Peripheral T-Cell Lymphoma Project. *Ann Oncol*, 2009. 20(4): p. 715-721.
272. Au, W.Y., Weisenburger, D.D., Intragumtornchai, T., Nakamura, S., Kim, W.S., Sng, I., Vose, J., Armitage, J.O., Liang, R., and International Peripheral, T.C.L.P., Clinical Differences between Nasal and Extranasal Natural Killer/T-Cell Lymphoma: A Study of 136 Cases from the International Peripheral T-Cell Lymphoma Project. *Blood*, 2009. 113(17): p. 3931-3937.
273. Lankes, H.A., Fought, A.J., Evens, A.M., Weisenburger, D.D., and Chiu, B.C., Vaccination History and Risk of Non-Hodgkin Lymphoma: A Population-Based, Case-Control Study. *Cancer Causes Control*, 2009. 20(5): p. 517-523.
274. Naushad, H., Choi, W.W., Page, C.J., Sanger, W.G., Weisenburger, D.D., and Aoun, P., Mantle Cell Lymphoma with Flow Cytometric Evidence of Clonal Plasmacytic Differentiation: A Case Report. *Cytometry B Clin Cytom*, 2009. 76(3): p. 218-224.
275. Choi, W.W., Weisenburger, D.D., Greiner, T.C., Piris, M.A., Banham, A.H., Delabie, J., Brazier, R.M., Geng, H., Iqbal, J., Lenz, G., Vose, J.M., Hans, C.P., Fu, K., Smith, L.M., Li, M., Liu, Z., Gascoyne, R.D., Rosenwald, A., Ott, G., Rimsza, L.M., Campo, E., Jaffe, E.S., Jaye, D.L., Staudt, L.M., and Chan, W.C., A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. *Clin Cancer Res*, 2009. 15(17): p. 5494-5502.
276. Loberiza, F.R., Jr., Cannon, A.J., Weisenburger, D.D., Vose, J.M., Moehr, M.J., Bast, M.A., Bierman, P.J., Bociek, R.G., and Armitage, J.O., Survival Disparities in Patients with Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study. *J Clin Oncol*, 2009. 27(32): p. 5376-5382.
277. Bhagavathi, S., Gu, K., Loberiza, F.R., Bast, M., Vose, J.M., and Weisenburger, D.D., Does a Diffuse Growth Pattern Predict for Survival in Patients with Low-Grade Follicular Lymphoma? *Leuk Lymphoma*, 2009. 50(6): p. 900-903.
278. Gu, K., Fu, K., Jain, S., Liu, Z., Iqbal, J., Li, M., Sanger, W.G., Weisenburger, D.D., Greiner, T.C., Aoun, P., Dave, B.J., and Chan, W.C., t(14;18)-Negative Follicular Lymphomas Are Associated with a High Frequency of BCL6 Rearrangement at the Alternative Breakpoint Region. *Mod Pathol*, 2009. 22(9): p. 1251-1257.
279. Leich, E., Salaverria, I., Bea, S., Zettl, A., Wright, G., Moreno, V., Gascoyne, R.D., Chan, W.C., Brazier, R.M., Rimsza, L.M., Weisenburger, D.D., Delabie, J., Jaffe, E.S., Lister, A., Fitzgibbon, J., Staudt, L.M., Hartmann, E.M., Mueller-Hermelink, H.K., Campo, E., Ott, G., and Rosenwald, A., Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations. *Blood*, 2009. 114(4): p. 826-834.
280. Gaikwad, N.W., Yang, L., Weisenburger, D.D., Vose, J., Beseler, C., Rogan, E.G., and Cavalieri, E.L., Urinary Biomarkers Suggest That Estrogen-DNA Adducts May Play a Role in the Aetiology of Non-Hodgkin Lymphoma. *Biomarkers*, 2009. 14(7): p. 502-512.

Dennis Weisenburger, MD - MC

281. Mozos, A., Royo, C., Hartmann, E., De Jong, D., Baro, C., Valera, A., Fu, K., Weisenburger, D.D., Delabie, J., Chuang, S.S., Jaffe, E.S., Ruiz-Marcellan, C., Dave, S., Rimsza, L., Brazier, R., Gascoyne, R.D., Sole, F., Lopez-Guillermo, A., Colomer, D., Staudt, L.M., Rosenwald, A., Ott, G., Jares, P., and Campo, E., SOX11 Expression Is Highly Specific for Mantle Cell Lymphoma and Identifies the Cyclin D1-Negative Subtype. *Haematologica*, 2009. 94(11): p. 1555-1562.
282. Federico, M., Bellei, M., Pesce, E., Zucca, E., Pileri, S., Montoto, S., Weisenburger, D.D., Ruediger, T., Ko, Y.H., Liang, R., Zinzani, P.L., Connors, J.M., Foss, F.M., Horwitz, S.M., Polliack, A., and Vose, J.M., T-Cell Project: An International, Longitudinal, Observational Study of Patients with Aggressive Peripheral T-Cell Lymphoma. *Revista Brasileira de Hematologia e Hemoterapia*, 2009. 31: p. 21-25.
283. Iqbal, J., Weisenburger, D.D., Greiner, T.C., Vose, J.M., McKeithan, T., Kucuk, C., Geng, H., Deffenbacher, K., Smith, L., Dybkaer, K., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Au, W.Y., Ko, Y.H., Sng, I., Armitage, J.O., Chan, W.C., and International Peripheral T-Cell Lymphoma Project, Molecular Signatures to Improve Diagnosis in Peripheral T-Cell Lymphoma and Prognostication in Angioimmunoblastic T-Cell Lymphoma. *Blood*, 2010. 115(5): p. 1026-1036.
284. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Müller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Brazier, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C., and Gascoyne, R.D., Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. *N Engl J Med*, 2010. 362(10): p. 875-885.
285. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Brazier, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K., and Staudt, L.M., Chronic Active B-Cell-Receptor Signalling in Diffuse Large B-Cell Lymphoma. *Nature*, 2010. 463(7277): p. 88-92.
286. Wang, X.M., Greiner, T.C., Bibikova, M., Pike, B.L., Siegmund, K.D., Sinha, U.K., Muschen, M., Jaeger, E.B., Weisenburger, D.D., Chan, W.C., Shibata, D., Fan, J.B., and Hacia, J.G., Identification and Functional Relevance of De Novo DNA Methylation in Cancerous B-Cell Populations. *J Cell Biochem*, 2010. 109(4): p. 818-827.
287. Morovic, A., Aurer, I., Dotlic, S., Weisenburger, D.D., and Nola, M., NK Cell Lymphoma, Nasal Type, with Massive Lung Involvement: A Case Report. *J Hematop*, 2010. 3(1): p. 19-22.
288. Arevalo, A., Caponetti, G.C., Hu, Q., Greiner, T.C., and Weisenburger, D.D., Cytotoxic Peripheral T Cell Lymphoma Arising in a Patient with Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Case Report. *J Hematop*, 2010. 3(1): p. 23-28.
289. Audouin, J., Diebold, J., Nathwani, B., Ishak, E., MacLennan, K., Mueller-Hermelink, H.K., Armitage, J.O., and Weisenburger, D.D., Epstein-Barr Virus and Hodgkin's Lymphoma in Cairo, Egypt. *J Hematop*, 2010. 3(1): p. 11-18.



Dennis Weisenburger, MD - MC

290. Hartmann, E.M., Campo, E., Wright, G., Lenz, G., Salaverria, I., Jares, P., Xiao, W., Brazier, R.M., Rimsza, L.M., Chan, W.C., Weisenburger, D.D., Delabie, J., Jaffe, E.S., Gascoyne, R.D., Dave, S.S., Mueller-Hermelink, H.K., Staudt, L.M., Ott, G., Bea, S., and Rosenwald, A., Pathway Discovery in Mantle Cell Lymphoma by Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling. *Blood*, 2010. 116(6): p. 953-961.
291. Turner, J.J., Morton, L.M., Linet, M.S., Clarke, C.A., Kadin, M.E., Vajdic, C.M., Monnereau, A., Maynadie, M., Chiu, B.C., Marcos-Gragera, R., Costantini, A.S., Cerhan, J.R., and Weisenburger, D.D., Interlymph Hierarchical Classification of Lymphoid Neoplasms for Epidemiologic Research Based on the WHO Classification (2008): Update and Future Directions. *Blood*, 2010. 116(20): p. e90-98.
292. Rui, L., Emre, N.C., Kruhlak, M.J., Chung, H.J., Steidl, C., Slack, G., Wright, G.W., Lenz, G., Ngo, V.N., Shaffer, A.L., Xu, W., Zhao, H., Yang, Y., Lamy, L., Davis, R.E., Xiao, W., Powell, J., Maloney, D., Thomas, C.J., Moller, P., Rosenwald, A., Ott, G., Müller-Hermelink, H.K., Savage, K., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Weisenburger, D.D., Chan, W.C., Gascoyne, R.D., Levens, D., and Staudt, L.M., Cooperative Epigenetic Modulation by Cancer Amplicon Genes. *Cancer Cell*, 2010. 18(6): p. 590-605.
293. Vose, J.M., Weisenburger, D.D., Loberiza, F.R., Arevalo, A., Bast, M., Armitage, J., Bierman, P.J., Bociek, R.G., and Armitage, J.O., Late Relapse in Patients with Diffuse Large B-Cell Lymphoma. *Br J Haematol*, 2010. 151(4): p. 354-358.
294. Meyer, P.N., Fu, K., Greiner, T., Smith, L., Delabie, J., Gascoyne, R., Ott, G., Rosenwald, A., Brazier, R., Campo, E., Vose, J., Lenz, G., Staudt, L., Chan, W., and Weisenburger, D.D., The Stromal Cell Marker SPARC Predicts for Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab. *Am J Clin Pathol*, 2011. 135(1): p. 54-61.
295. Iqbal, J., Weisenburger, D.D., Chowdhury, A., Tsai, M.Y., Srivastava, G., Greiner, T.C., Kucuk, C., Deffenbacher, K., Vose, J., Smith, L., Au, W.Y., Nakamura, S., Seto, M., Delabie, J., Berger, F., Loong, F., Ko, Y.H., Sng, I., Liu, X., Loughran, T.P., Armitage, J., Chan, W.C., and International Peripheral, T-Cell Lymphoma Project, Natural Killer Cell Lymphoma Shares Strikingly Similar Molecular Features with a Group of Non-Hepatosplenic  $\gamma\delta$  T-Cell Lymphoma and Is Highly Sensitive to a Novel Aurora Kinase a Inhibitor in Vitro. *Leukemia*, 2011. 25(2): p. 348-358.
296. Meyer, P.N., Fu, K., Greiner, T.C., Smith, L.M., Delabie, J., Gascoyne, R.D., Ott, G., Rosenwald, A., Brazier, R.M., Campo, E., Vose, J.M., Lenz, G., Staudt, L.M., Chan, W.C., and Weisenburger, D.D., Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab. *J Clin Oncol*, 2011. 29(2): p. 200-207.
297. Ngo, V.N., Young, R.M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., Shaffer, A.L., Romesser, P., Wright, G., Powell, J., Rosenwald, A., Müller-Hermelink, H.K., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Fisher, R.I., Brazier, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., and Staudt, L.M., Oncogenically Active MYD88 Mutations in Human Lymphoma. *Nature*, 2011. 470(7332): p. 115-119.
298. Chang, C.M., Wang, S.S., Dave, B.J., Jain, S., Vasef, M.A., Weisenburger, D.D., Cozen, W., Davis, S., Severson, R.K., Lynch, C.F., Rothman, N., Cerhan, J.R., Hartge, P., and Morton, L.M., Risk Factors for Non-Hodgkin Lymphoma Subtypes Defined by Histology and t(14;18) in a Population-Based Case-Control Study. *Int J Cancer*, 2011. 129(4): p. 938-947.

Dennis Weisenburger, MD - MC

299. Cardesa-Salzmänn, T.M., Colomo, L., Gutierrez, G., Chan, W.C., Weisenburger, D., Climent, F., Gonzalez-Barca, E., Mercadal, S., Arenillas, L., Serrano, S., Tubbs, R., Delabie, J., Gascoyne, R.D., Connors, J.M., Mate, J.L., Rimsza, L., Brazier, R., Rosenwald, A., Lenz, G., Wright, G., Jaffe, E.S., Staudt, L., Jares, P., Lopez-Guillermo, A., and Campo, E., High Microvessel Density Determines a Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Chemotherapy. *Haematologica*, 2011. 96(7): p. 996-1001.
300. Chiu, B.C., Kwon, S., Evens, A.M., Surawicz, T., Smith, S.M., and Weisenburger, D.D., Dietary Intake of Fruit and Vegetables and Risk of Non-Hodgkin Lymphoma. *Cancer Causes Control*, 2011. 22(8): p. 1183-1195.
301. Weisenburger, D.D., Savage, K.J., Harris, N.L., Gascoyne, R.D., Jaffe, E.S., MacLennan, K.A., Rudiger, T., Pileri, S., Nakamura, S., Nathwani, B., Campo, E., Berger, F., Coiffier, B., Kim, W.S., Holte, H., Federico, M., Au, W.Y., Tobinai, K., Armitage, J.O., Vose, J.M., and International Peripheral T-cell L.P., Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Report of 340 Cases from the International Peripheral T-Cell Lymphoma Project. *Blood*, 2011. 117(12): p. 3402-3408.
302. Delabie, J., Holte, H., Vose, J.M., Ullrich, F., Jaffe, E.S., Savage, K.J., Connors, J.M., Rimsza, L., Harris, N.L., Müller-Hermelink, K., Rudiger, T., Coiffier, B., Gascoyne, R.D., Berger, F., Tobinai, K., Au, W.Y., Liang, R., Montserrat, E., Hochberg, E.P., Pileri, S., Federico, M., Nathwani, B., Armitage, J.O., and Weisenburger, D.D., Enteropathy-Associated T-Cell Lymphoma: Clinical and Histological Findings from the International Peripheral T-Cell Lymphoma Project. *Blood*, 2011. 118(1): p. 148-155.
303. Grass, S., Preuss, K.D., Thome, S., Weisenburger, D.D., Witt, V., Lynch, J., Zettl, F., Trumper, L., Fadle, N., Regitz, E., Lynch, H., and Pfreundschuh, M., Paraproteins of Familial MGUS/Multiple Myeloma Target Family-Typical Antigens: Hyperphosphorylation of Autoantigens Is a Consistent Finding in Familial and Sporadic MGUS/MM. *Blood*, 2011. 118(3): p. 635-637.
304. Perry, A.M., Molina-Kirsch, H., Nathwani, B.N., Diebold, J., MacLennan, K.A., Müller-Hermelink, H.K., Armitage, J.O., and Weisenburger, D.D., Classification of Non-Hodgkin Lymphomas in Guatemala According to the World Health Organization System. *Leuk Lymphoma*, 2011. 52(9): p. 1681-1688.
305. Morton, L.M., Cerhan, J.R., Hartge, P., Vasef, M.A., Neppalli, V.T., Natkunam, Y., Dogan, A., Dave, B.J., Jain, S., Levy, R., Lossos, I.S., Cozen, W., Davis, S., Schenk, M.J., Maurer, M.J., Lynch, C.F., Rothman, N., Chatterjee, N., Yu, K., Staudt, L.M., Weisenburger, D.D., and Wang, S.S., Immunostaining to Identify Molecular Subtypes of Diffuse Large B-Cell Lymphoma in a Population-Based Epidemiologic Study in the Pre-Rituximab Era. *Int J Mol Epidemiol Genet*, 2011. 2(3): p. 245-252.
306. Iqbal, J., Meyer, P.N., Smith, L.M., Johnson, N.A., Vose, J.M., Greiner, T.C., Connors, J.M., Staudt, L.M., Rimsza, L., Jaffe, E., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Brazier, R.M., Cook, J.R., Tubbs, R.R., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D., and Chan, W.C., BCL2 Predicts Survival in Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Treated with CHOP-Like Therapy and Rituximab. *Clin Cancer Res*, 2011. 17(24): p. 7785-7795.
307. Steuter, J., Weisenburger, D.D., Bociek, R.G., Bierman, P., Vose, J., Bast, M., Loberiza, F., and Armitage, J.O., Non-Hodgkin Lymphoma of the Prostate. *Am J Hematol*, 2011. 86(11): p. 952-954.



Dennis Weisenburger, MD - MC

308. Leich, E., Zamo, A., Horn, H., Haralambieva, E., Puppe, B., Gascoyne, R.D., Chan, W.C., Braziel, R.M., Rimsza, L.M., Weisenburger, D.D., Delabie, J., Jaffe, E.S., Fitzgibbon, J., Staudt, L.M., Mueller-Hermelink, H.K., Calaminici, M., Campo, E., Ott, G., Hernandez, L., and Rosenwald, A., MicroRNA Profiles of t(14;18)-Negative Follicular Lymphoma Support a Late Germinal Center B-Cell Phenotype. *Blood*, 2011. 118(20): p. 5550-5558.
309. Ai, W.Z., Chang, E.T., Fish, K., Fu, K., Weisenburger, D.D., and Keegan, T.H., Racial Patterns of Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, in California: A Population-Based Study. *Br J Haematol*, 2012. 156(5): p. 626-632.
310. Papathomas, T.G., Venizelos, I., Dunphy, C.H., Said, J.W., Wang, M.L., Campo, E., Swerdlow, S.H., Chan, J.C., Bueso-Ramos, C.E., Weisenburger, D.D., Medeiros, L.J., and Young, K.H., Mantle Cell Lymphoma as a Component of Composite Lymphoma: Clinicopathologic Parameters and Biologic Implications. *Hum Pathol*, 2012. 43(4): p. 467-480.
311. Ward, M.H., Cross, A.J., Abnet, C.C., Sinha, R., Markin, R.S., and Weisenburger, D.D., Heme Iron from Meat and Risk of Adenocarcinoma of the Esophagus and Stomach. *Eur J Cancer Prev*, 2012. 21(2): p. 134-138.
312. Cabrera, M.E., Martinez, V., Nathwani, B.N., Müller-Hermelink, H.K., Diebold, J., MacLennan, K.A., Armitage, J., and Weisenburger, D.D., Non-Hodgkin Lymphoma in Chile: A Review of 207 Consecutive Adult Cases by a Panel of Five Expert Hematopathologists. *Leuk Lymphoma*, 2012. 53(7): p. 1311-1317.
313. Gilling, C.E., Mittal, A.K., Chaturvedi, N.K., Iqbal, J., Aoun, P., Bierman, P.J., Bociek, R.G., Weisenburger, D.D., and Joshi, S.S., Lymph Node-Induced Immune Tolerance in Chronic Lymphocytic Leukaemia: A Role for Caveolin-1. *Br J Haematol*, 2012. 158(2): p. 216-231.
314. Deffenbacher, K.E., Iqbal, J., Sanger, W., Shen, Y., Lachel, C., Liu, Z., Liu, Y., Lim, M.S., Perkins, S.L., Fu, K., Smith, L., Lynch, J., Staudt, L.M., Rimsza, L.M., Jaffe, E., Rosenwald, A., Ott, G.K., Delabie, J., Campo, E., Gascoyne, R.D., Cairo, M.S., Weisenburger, D.D., Greiner, T.C., Gross, T.G., and Chan, W.C., Molecular Distinctions between Pediatric and Adult Mature B-Cell Non-Hodgkin Lymphomas Identified through Genomic Profiling. *Blood*, 2012. 119(16): p. 3757-3766.
315. Iqbal, J., Shen, Y., Liu, Y., Fu, K., Jaffe, E.S., Liu, C., Liu, Z., Lachel, C.M., Deffenbacher, K., Greiner, T.C., Vose, J.M., Bhagavathi, S., Staudt, L.M., Rimsza, L., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Cook, J.R., Tubbs, R.R., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D., McKeithan, T.W., and Chan, W.C., Genome-Wide MicroRNA Profiling of Mantle Cell Lymphoma Reveals a Distinct Subgroup with Poor Prognosis. *Blood*, 2012. 119(21): p. 4939-4948.
316. Mitrovic, Z., Perry, A.M., Suzumiya, J., Armitage, J.O., Au, W.Y., Coiffier, B., Holte, H., Jaffe, E.S., Monserrat, E., Rajan, S.K., Savage, K.J., Tobinai, K., Vose, J.M., and Weisenburger, D.D., The Prognostic Significance of Lymphopenia in Peripheral T-Cell and Natural Killer/T-Cell Lymphomas: A Study of 826 Cases from the International Peripheral T-Cell Lymphoma Project. *Am J Hematol*, 2012. 87(8): p. 790-794.
317. Gu, K., Weisenburger, D.D., Fu, K., Chan, W.C., Greiner, T.C., Aoun, P., Smith, L.M., Bast, M., Liu, Z., Bociek, R.G., Bierman, P.J., Armitage, J.O., and Vose, J.M., Cell of Origin Fails to Predict Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Autologous Hematopoietic Stem Cell Transplantation. *Hematol Oncol*, 2012. 30(3): p. 143-149.

Dennis Weisenburger, MD - MC

318. Prodduturi, P., Perry, A.M., Aoun, P., Weisenburger, D.D., and Akhtari, M., Recurrent Bone Marrow Aplasia Secondary to Nilotinib in a Patient with Chronic Myeloid Leukemia: A Case Report. *J Oncol Pharm Pract*, 2012. 18(4): p. 440-444.
319. Hegde, G.V., Nordgren, T.M., Munger, C.M., Mittal, A.K., Bierman, P.J., Weisenburger, D.D., Vose, J.M., Sharp, J.G., and Joshi, S.S., Novel Therapy for Therapy-Resistant Mantle Cell Lymphoma: Multipronged Approach with Targeting of Hedgehog Signaling. *Int J Cancer*, 2012. 131(12): p. 2951-2960.
320. Munger, C.M., Hegde, G.V., Weisenburger, D.D., Vose, J.M., and Joshi, S.S., Optimized Adoptive T-Cell Therapy for the Treatment of Residual Mantle Cell Lymphoma. *Cancer Immunol Immunother*, 2012. 61(10): p. 1819-1832.
321. Caponetti, G.C., Miranda, R.N., Althof, P.A., Dobesh, R.C., Sanger, W.G., Medeiros, L.J., Greiner, T.C., and Weisenburger, D.D., Immunohistochemical and Molecular Cytogenetic Evaluation of Potential Targets for Tyrosine Kinase Inhibitors in Langerhans Cell Histiocytosis. *Hum Pathol*, 2012. 43(12): p. 2223-2228.
322. Perry, A.M., Cardesa-Salzmann, T.M., Meyer, P.N., Colomo, L., Smith, L.M., Fu, K., Greiner, T.C., Delabie, J., Gascoyne, R.D., Rimsza, L., Jaffe, E.S., Ott, G., Rosenwald, A., Brazier, R.M., Tubbs, R., Cook, J.R., Staudt, L.M., Connors, J.M., Sehn, L.H., Vose, J.M., Lopez-Guillermo, A., Campo, E., Chan, W.C., and Weisenburger, D.D., A New Biologic Prognostic Model Based on Immunohistochemistry Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma. *Blood*, 2012. 120(11): p. 2290-2296.
323. Johnson, N.A., Slack, G.W., Savage, K.J., Connors, J.M., Ben-Neriah, S., Rogic, S., Scott, D.W., Tan, K.L., Steidl, C., Sehn, L.H., Chan, W.C., Iqbal, J., Meyer, P.N., Lenz, G., Wright, G., Rimsza, L.M., Valentino, C., Brunnhoeber, P., Grogan, T.M., Brazier, R.M., Cook, J.R., Tubbs, R.R., Weisenburger, D.D., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Holcroft, C., Jaffe, E.S., Staudt, L.M., and Gascoyne, R.D., Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. *J Clin Oncol*, 2012. 30(28): p. 3452-3459.
324. Aschebrook-Kilfoy, B., Ollberding, N.J., Kolar, C., Lawson, T.A., Smith, S.M., Weisenburger, D.D., and Chiu, B.C., Meat Intake and Risk of Non-Hodgkin Lymphoma. *Cancer Causes Control*, 2012. 23(10): p. 1681-1692.
325. Guitart, J., Weisenburger, D.D., Subtil, A., Kim, E., Wood, G., Duvic, M., Olsen, E., Junkins-Hopkins, J., Rosen, S., Sundram, U., Ivan, D., Selim, M.A., Pincus, L., Deonizio, J.M., Kwasny, M., and Kim, Y.H., Cutaneous  $\gamma\delta$  T-Cell Lymphomas: A Spectrum of Presentations with Overlap with Other Cytotoxic Lymphomas. *Am J Surg Pathol*, 2012. 36(11): p. 1656-1665.
326. Dispenzieri, A., Armitage, J.O., Loe, M.J., Geyer, S.M., Allred, J., Camoriano, J.K., Menke, D.M., Weisenburger, D.D., Ristow, K., Dogan, A., and Habermann, T.M., The Clinical Spectrum of Castleman's Disease. *Am J Hematol*, 2012. 87(11): p. 997-1002.



Dennis Weisenburger, MD - MC

327. Schmitz, R., Young, R.M., Ceribelli, M., Jhavar, S., Xiao, W., Zhang, M., Wright, G., Shaffer, A.L., Hodson, D.J., Buras, E., Liu, X., Powell, J., Yang, Y., Xu, W., Zhao, H., Kohlhammer, H., Rosenwald, A., Kluin, P., Müller-Hermelink, H.K., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Olgwang, M.D., Reynolds, S.J., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pittaluga, S., Wilson, W., Waldmann, T.A., Rowe, M., Mbulaiteye, S.M., Rickinson, A.B., and Staudt, L.M., Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics. *Nature*, 2012. 490(7418): p. 116-120.
328. Muringampurath-John, D., Jaye, D.L., Flowers, C.R., Saxe, D., Chen, Z., Lechowicz, M.J., Weisenburger, D.D., Bast, M., Arellano, M.L., Bernal-Mizrachi, L., Heffner, L.T., McLemore, M., Kaufman, J.L., Winton, E.F., Lonial, S., Armitage, J.O., and Khoury, H.J., Characteristics and Outcomes of Diffuse Large B-Cell Lymphoma Presenting in Leukaemic Phase. *Br J Haematol*, 2012. 158(5): p. 608-614.
329. Laurini, J.A., Perry, A.M., Boilesen, E., Diebold, J., MacLennan, K.A., Müller-Hermelink, H.K., Nathwani, B.N., Armitage, J.O., and Weisenburger, D.D., Classification of Non-Hodgkin Lymphoma in Central and South America: A Review of 1028 Cases. *Blood*, 2012. 120(24): p. 4795-4801.
330. Federico, M., Rudiger, T., Bellei, M., Nathwani, B.N., Luminari, S., Coiffier, B., Harris, N.L., Jaffe, E.S., Pileri, S.A., Savage, K.J., Weisenburger, D.D., Armitage, J.O., Mounier, N., and Vose, J.M., Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. *J Clin Oncol*, 2013. 31(2): p. 240-246.
331. Vose, J.M., Bierman, P.J., Loberiza, F.R., Enke, C., Hankins, J., Bociek, R.G., Chan, W.C., Weisenburger, D.D., and Armitage, J.O., Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma. *Biol Blood Marrow Transplant*, 2013. 19(1): p. 123-128.
332. Gibson, T.M., Smedby, K.E., Skibola, C.F., Hein, D.W., Slager, S.L., de Sanjose, S., Vajdic, C.M., Zhang, Y., Chiu, B.C., Wang, S.S., Hjalgrim, H., Nieters, A., Bracci, P.M., Krickler, A., Zheng, T., Kolar, C., Cerhan, J.R., Darabi, H., Becker, N., Conde, L., Holford, T.R., Weisenburger, D.D., De Roos, A.J., Butterbach, K., Riby, J., Cozen, W., Benavente, Y., Palmers, C., Holly, E.A., Sampson, J.N., Rothman, N., Armstrong, B.K., and Morton, L.M., Smoking, Variation in N-Acetyltransferase 1 (NAT1) and 2 (NAT2), and Risk of Non-Hodgkin Lymphoma: A Pooled Analysis within the Interlymph Consortium. *Cancer Causes Control*, 2013. 24(1): p. 125-134.
333. Ollberding, N.J., Aschebrook-Kilfoy, B., Caces, D.B., Wright, M.E., Weisenburger, D.D., Smith, S.M., and Chiu, B.C., Phytanic Acid and the Risk of Non-Hodgkin Lymphoma. *Carcinogenesis*, 2013. 34(1): p. 170-175.
334. Valentino, C., Kendrick, S., Johnson, N., Gascoyne, R., Chan, W.C., Weisenburger, D., Braziel, R., Cook, J.R., Tubbs, R., Campo, E., Rosenwald, A., Ott, G., Delabie, J., Jaffe, E., Zhang, W., Brunhoeber, P., Nitta, H., Grogan, T., and Rimsza, L., Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating with Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. *Am J Clin Pathol*, 2013. 139(2): p. 242-254.
335. Aschebrook-Kilfoy, B., Ward, M.H., Dave, B.J., Smith, S.M., Weisenburger, D.D., and Chiu, B.C., Dietary Nitrate and Nitrite Intake and Risk of Non-Hodgkin Lymphoma. *Leuk Lymphoma*, 2013. 54(5): p. 945-950.

Dennis Weisenburger, MD - MC

336. Mbulaiteye, S.M., Clarke, C.A., Morton, L.M., Gibson, T.M., Pawlish, K., Weisenburger, D.D., Lynch, C.F., Goodman, M.T., and Engels, E.A., Burkitt Lymphoma Risk in U.S. Solid Organ Transplant Recipients. *Am J Hematol*, 2013. 88(4): p. 245-250.
337. Piccaluga, P.P., Fuligni, F., De Leo, A., Bertuzzi, C., Rossi, M., Bacci, F., Sabattini, E., Agostinelli, C., Gazzola, A., Laginestra, M.A., Mannu, C., Sapienza, M.R., Hartmann, S., Hansmann, M.L., Piva, R., Iqbal, J., Chan, J.C., Weisenburger, D., Vose, J.M., Bellei, M., Federico, M., Inghirami, G., Zinzani, P.L., and Pileri, S.A., Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase 3 Diagnostic Accuracy Study. *J Clin Oncol*, 2013. 31(24): p. 3019-3025.
338. Engels, E.A., Clarke, C.A., Pfeiffer, R.M., Lynch, C.F., Weisenburger, D.D., Gibson, T.M., Landgren, O., and Morton, L.M., Plasma Cell Neoplasms in US Solid Organ Transplant Recipients. *Am J Transplant*, 2013. 13(6): p. 1523-1532.
339. Mitrovic, Z., Iqbal, J., Fu, K., Smith, L.M., Bast, M., Greiner, T.C., Aoun, P., Armitage, J.O., Vose, J.M., Weisenburger, D.D., and Chan, W.C., CD43 Expression Is Associated with Inferior Survival in the Non-Germinal Centre B-Cell Subgroup of Diffuse Large B-Cell Lymphoma. *Br J Haematol*, 2013. 162(1): p. 87-92.
340. Wasik, M.A., Jimenez, G.S., and Weisenburger, D.D., Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications. *Pathobiology*, 2013. 80(5): p. 252-258.
341. Ollberding, N.J., Aschebrook-Kilfoy, B., Caces, D.B., Smith, S.M., Weisenburger, D.D., and Chiu, B.C., Dietary Patterns and the Risk of Non-Hodgkin Lymphoma. *Public Health Nutr*, 2014. 17(7): p. 1531-1537.
342. Liu, C., Iqbal, J., Teruya-Feldstein, J., Shen, Y., Dabrowska, M.J., Dybkaer, K., Lim, M.S., Piva, R., Barreca, A., Pellegrino, E., Spaccarotella, E., Lachel, C.M., Kucuk, C., Jiang, C.S., Hu, X., Bhagavathi, S., Greiner, T.C., Weisenburger, D.D., Aoun, P., Perkins, S.L., McKeithan, T.W., Inghirami, G., and Chan, W.C., MicroRNA Expression Profiling Identifies Molecular Signatures Associated with Anaplastic Large Cell Lymphoma. *Blood*, 2013. 122(12): p. 2083-2092.
343. Liu, L., Perry, A.M., Cao, W., Smith, L.M., Hsi, E.D., Liu, X., Mo, J.Q., Dotlic, S., Mosunjac, M., Talmon, G., Weisenburger, D.D., and Fu, K., Relationship between Rosai-Dorfman Disease and IgG4-Related Disease: Study of 32 Cases. *Am J Clin Pathol*, 2013. 140(3): p. 395-402.
344. Ollberding, N.J., Aschebrook-Kilfoy, B., Caces, D.B., Smith, S.M., Weisenburger, D.D., and Chiu, B.C., Dietary Intake of Fruits and Vegetables and Overall Survival in Non-Hodgkin Lymphoma. *Leuk Lymphoma*, 2013. 54(12): p. 2613-2619.
345. Enjuanes, A., Albero, R., Clot, G., Navarro, A., Bea, S., Pinyol, M., Martin-Subero, J.I., Klapper, W., Staudt, L.M., Jaffe, E.S., Rimsza, L., Braziel, R.M., Delabie, J., Cook, J.R., Tubbs, R.R., Gascoyne, R., Connors, J.M., Weisenburger, D.D., Greiner, T.C., Chan, W.C., Lopez-Guillermo, A., Rosenwald, A., Ott, G., Campo, E., and Jares, P., Genome-Wide Methylation Analyses Identify a Subset of Mantle Cell Lymphoma with a High Number of Methylated CpGs and Aggressive Clinicopathological Features. *Int J Cancer*, 2013. 133(12): p. 2852-2863.



Dennis Weisenburger, MD – MC

346. Barber, N.A., Loberiza, F.R., Jr., Perry, A.M., Bast, M., Holdeman, K.P., Esfahane, A.B., Weisenburger, D.D., Vose, J., Bierman, P., Armitage, J.O., and Bociek, R.G., Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma from T-Cell/Histiocyte-Rich Large B-Cell Lymphoma? *Clin Lymphoma Myeloma Leuk*, 2013. 13(4): p. 392-397.
347. Ollberding, N.J., Evens, A.M., Aschebrook-Kilfoy, B., Caces, D.B., Weisenburger, D.D., Smith, S.M., and Chiu, B.C., Pre-Diagnosis Cigarette Smoking and Overall Survival in Non-Hodgkin Lymphoma. *Br J Haematol*, 2013. 163(3): p. 352-356.
348. Hielscher, A., McGuire, T., Weisenburger, D., and Sharp, J.G., Matrigel Modulates a Stem Cell Phenotype and Promotes Tumor Formation in a Mantle Cell Lymphoma Cell Line. *Stem Cell Discovery*, 2013. Vol.03No.03: p. 13.
349. Andreotti, G., Birmann, B., De Roos, A.J., Spinelli, J., Cozen, W., Camp, N.J., Moysich, K., Chiu, B., Steplowski, E., Krzystan, J., Boffetta, P., Benhaim-Luzon, V., Brennan, P., de Sanjose, S., Costas, L., Costantini, A.S., Miligi, L., Cocco, P., Becker, N., Foretova, L., Maynadie, M., Nieters, A., Staines, A., Tricot, G., Milliken, K., Weisenburger, D., Zheng, T., Baris, D., and Purdue, M.P., A Pooled Analysis of Alcohol Consumption and Risk of Multiple Myeloma in the International Multiple Myeloma Consortium. *Cancer Epidemiol Biomarkers Prev*, 2013. 22(9): p. 1620-1627.
350. Pullarkat, S.T., Pullarkat, V., Lagoo, A., Brynes, R., Weiss, L.M., Bedell, V., Chen, W., Huang, Q., Gaal, K., Weisenburger, D.D., and Kim, Y.S., Characterization of Bone Marrow Mast Cells in Acute Myeloid Leukemia with t(8;21)(q22;q22); RUNX1-RUNX1T1. *Leuk Res*, 2013. 37(11): p. 1572-1575.
351. Clarke, C.A., Morton, L.M., Lynch, C., Pfeiffer, R.M., Hall, E.C., Gibson, T.M., Weisenburger, D.D., Martinez-Maza, O., Hussain, S.K., Yang, J., Chang, E.T., and Engels, E.A., Risk of Lymphoma Subtypes after Solid Organ Transplantation in the United States. *Br J Cancer*, 2013. 109(1): p. 280-288.
352. Perry, A.M., Crockett, D., Dave, B.J., Althof, P., Winkler, L., Smith, L.M., Aoun, P., Chan, W.C., Fu, K., Greiner, T.C., Bierman, P., Gregory Bociek, R., Vose, J.M., Armitage, J.O., and Weisenburger, D.D., B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: Study of 39 Cases. *Br J Haematol*, 2013. 162(1): p. 40-49.
353. Huang, X., Meng, B., Iqbal, J., Ding, B.B., Perry, A.M., Cao, W., Smith, L.M., Bi, C., Jiang, C., Greiner, T.C., Weisenburger, D.D., Rimsza, L., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Gascoyne, R.D., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Armitage, J.O., Vose, J.M., Staudt, L.M., McKeithan, T.W., Chan, W.C., Ye, B.H., and Fu, K., Activation of the STAT3 Signaling Pathway Is Associated with Poor Survival in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. *J Clin Oncol*, 2013. 31(36): p. 4520-4528.
354. Perry, A.M., Warnke, R.A., Hu, Q., Gaulard, P., Copie-Bergman, C., Alkan, S., Wang, H.Y., Cheng, J.X., Bacon, C.M., Delabie, J., Ranheim, E., Kucuk, C., Hu, X., Weisenburger, D.D., Jaffe, E.S., and Chan, W.C., Indolent T-Cell Lymphoproliferative Disease of the Gastrointestinal Tract. *Blood*, 2013. 122(22): p. 3599-3606.
355. Bautista-Quach, M.A., Nademane, A., Weisenburger, D.D., Chen, W., and Kim, Y.S., Implant-Associated Primary Anaplastic Large-Cell Lymphoma with Simultaneous Involvement of Bilateral Breast Capsules. *Clin Breast Cancer*, 2013. 13(6): p. 492-495.

Dennis Weisenburger, MD - MC

356. Cutucache, C.E., Iqbal, J., Bierman, P.J., Bociek, R.G., Weisenburger, D.D., and Joshi, S.S., Polycomb Response Element-Binding Sites in the MDR of CLL: Potential Tumor Suppressor Regulation. *Advances in Bioscience and Biotechnology*, 2013. Vol.04No.01: p. 7.
357. Chihara, D., Ito, H., Matsuda, T., Shibata, A., Katsumi, A., Nakamura, S., Tomotaka, S., Morton, L.M., Weisenburger, D.D., and Matsuo, K., Differences in Incidence and Trends of Haematological Malignancies in Japan and the United States. *Br J Haematol*, 2014. 164(4): p. 536-545.
358. Bouska, A., McKeithan, T.W., Deffenbacher, K.E., Lachel, C., Wright, G.W., Iqbal, J., Smith, L.M., Zhang, W., Kucuk, C., Rinaldi, A., Bertoni, F., Fitzgibbon, J., Fu, K., Weisenburger, D.D., Greiner, T.C., Dave, B.J., Gascoyne, R.D., Rosenwald, A., Ott, G., Campo, E., Rimsza, L.M., Delabie, J., Jaffe, E.S., Braziel, R.M., Connors, J.M., Staudt, L.M., and Chan, W.C., Genome-Wide Copy-Number Analyses Reveal Genomic Abnormalities Involved in Transformation of Follicular Lymphoma. *Blood*, 2014. 123(11): p. 1681-1690.
359. Perry, A.M., Alvarado-Bernal, Y., Laurini, J.A., Smith, L.M., Slack, G.W., Tan, K.L., Schn, L.H., Fu, K., Aoun, P., Greiner, T.C., Chan, W.C., Bierman, P.J., Bociek, R.G., Armitage, J.O., Vose, J.M., Gascoyne, R.D., and Weisenburger, D.D., MYC and BCL2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with Rituximab. *Br J Haematol*, 2014. 165(3): p. 382-391.
360. Yang, Y., Schmitz, R., Mitala, J., Whiting, A., Xiao, W., Ceribelli, M., Wright, G.W., Zhao, H., Yang, Y., Xu, W., Rosenwald, A., Ott, G., Gascoyne, R.D., Connors, J.M., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Wiestner, A., Kruhlak, M.J., Iwai, K., Bernal, F., and Staudt, L.M., Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. *Cancer Discov*, 2014. 4(4): p. 480-493.
361. Scott, D.W., Wright, G.W., Williams, P.M., Lih, C.J., Walsh, W., Jaffe, E.S., Rosenwald, A., Campo, E., Chan, W.C., Connors, J.M., Smeland, E.B., Mottok, A., Braziel, R.M., Ott, G., Delabie, J., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Greiner, T.C., Glinsmann-Gibson, B.J., Fu, K., Staudt, L.M., Gascoyne, R.D., and Rimsza, L.M., Determining Cell-of-Origin Subtypes of Diffuse Large B-Cell Lymphoma Using Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue. *Blood*, 2014. 123(8): p. 1214-1217.
362. Khalil, M.O., Morton, L.M., Devesa, S.S., Check, D.P., Curtis, R.E., Weisenburger, D.D., and Dores, G.M., Incidence of Marginal Zone Lymphoma in the United States, 2001-2009 with a Focus on Primary Anatomic Site. *Br J Haematol*, 2014. 165(1): p. 67-77.
363. Gibson, T.M., Engels, E.A., Clarke, C.A., Lynch, C.F., Weisenburger, D.D., and Morton, L.M., Risk of Diffuse Large B-Cell Lymphoma after Solid Organ Transplantation in the United States. *Am J Hematol*, 2014. 89(7): p. 714-720.
364. Morton, L.M., Gibson, T.M., Clarke, C.A., Lynch, C.F., Weisenburger, D.D., and Engels, E.A., Hepatitis B or C Virus Infection and Risk of Non-Hodgkin Lymphoma among Solid Organ Transplant Recipients. *Haematologica*, 2014. 99(5): p. 70-73.
365. Bowen, J.M., Perry, A.M., Laurini, J.A., Smith, L.M., Klinetobe, K., Bast, M., Vose, J.M., Aoun, P., Fu, K., Greiner, T.C., Chan, W.C., Armitage, J.O., and Weisenburger, D.D., Lymphoma Diagnosis at an Academic Centre: Rate of Revision and Impact on Patient Care. *Br J Haematol*, 2014. 166(2): p. 202-208.



Dennis Weisenburger, MD - MC

366. Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R.D., Weisenburger, D.D., Greiner, T.C., Smith, L., Guo, S., Wilcox, R.A., Teh, B.T., Lim, S.T., Tan, S.Y., Rimsza, L.M., Jaffe, E.S., Campo, E., Martinez, A., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Ott, G., Geissinger, E., Gaulard, P., Piccaluga, P.P., Pileri, S.A., Au, W.Y., Nakamura, S., Seto, M., Berger, F., de Leval, L., Connors, J.M., Armitage, J., Vose, J., Chan, W.C., Staudt, L.M., Lymphoma Leukemia Molecular Profiling, P., and the International Peripheral, T.c.L.P., Gene Expression Signatures Delineate Biological and Prognostic Subgroups in Peripheral T-Cell Lymphoma. *Blood*, 2014. 123(19): p. 2915-2923.
367. Morton, L.M., Sampson, J.N., Cerhan, J.R., Turner, J.J., Vajdic, C.M., Wang, S.S., Smedby, K.E., de Sanjose, S., Monnereau, A., Benavente, Y., Bracci, P.M., Chiu, B.C., Skibola, C.F., Zhang, Y., Mbulaiteye, S.M., Spriggs, M., Robinson, D., Norman, A.D., Kane, E.V., Spinelli, J.J., Kelly, J.L., La Vecchia, C., Dal Maso, L., Maynadie, M., Kadin, M.E., Cocco, P., Costantini, A.S., Clarke, C.A., Roman, E., Miligi, L., Colt, J.S., Berndt, S.I., Mannetje, A., de Roos, A.J., Kricker, A., Nieters, A., Franceschi, S., Melbye, M., Boffetta, P., Clavel, J., Linet, M.S., Weisenburger, D.D., and Slager, S.L., Rationale and Design of the International Lymphoma Epidemiology Consortium (Interlymph) Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 1-14.
368. Smedby, K.E., Sampson, J.N., Turner, J.J., Slager, S.L., Maynadie, M., Roman, E., Habermann, T.M., Flowers, C.R., Berndt, S.I., Bracci, P.M., Hjalgrim, H., Weisenburger, D.D., and Morton, L.M., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Mantle Cell Lymphoma: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 76-86.
369. Mbulaiteye, S.M., Morton, L.M., Sampson, J.N., Chang, E.T., Costas, L., de Sanjose, S., Lightfoot, T., Kelly, J., Friedberg, J.W., Cozen, W., Marcos-Gragera, R., Slager, S.L., Birmann, B.M., and Weisenburger, D.D., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Sporadic Burkitt Lymphoma/Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 106-114.
370. Wang, S.S., Flowers, C.R., Kadin, M.E., Chang, E.T., Hughes, A.M., Ansell, S.M., Feldman, A.L., Lightfoot, T., Boffetta, P., Melbye, M., Lan, Q., Sampson, J.N., Morton, L.M., Zhang, Y., and Weisenburger, D.D., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Peripheral T-Cell Lymphomas: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 66-75.
371. Linet, M.S., Vajdic, C.M., Morton, L.M., de Roos, A.J., Skibola, C.F., Boffetta, P., Cerhan, J.R., Flowers, C.R., de Sanjose, S., Monnereau, A., Cocco, P., Kelly, J.L., Smith, A.G., Weisenburger, D.D., Clarke, C.A., Blair, A., Bernstein, L., Zheng, T., Miligi, L., Clavel, J., Benavente, Y., and Chiu, B.C., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Follicular Lymphoma: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 26-40.
372. Skibola, C.F., Slager, S.L., Berndt, S.I., Lightfoot, T., Sampson, J.N., Morton, L.M., and Weisenburger, D.D., Medical History, Lifestyle, Family History, and Occupational Risk Factors for Adult Acute Lymphocytic Leukemia: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 125-129.

Dennis Weisenburger, MD – MC

373. Morton, L.M., Slager, S.L., Cerhan, J.R., Wang, S.S., Vajdic, C.M., Skibola, C.F., Bracci, P.M., de Sanjose, S., Smedby, K.E., Chiu, B.C., Zhang, Y., Mbulaiteye, S.M., Monnereau, A., Turner, J.J., Clavel, J., Adami, H.O., Chang, E.T., Glimelius, B., Hjalgrim, H., Melbye, M., Crosignani, P., di Lollo, S., Miligi, L., Nanni, O., Ramazzotti, V., Rodella, S., Costantini, A.S., Stagnaro, E., Tumino, R., Vindigni, C., Vineis, P., Becker, N., Benavente, Y., Boffetta, P., Brennan, P., Cocco, P., Foretova, L., Maynadie, M., Nieters, A., Staines, A., Colt, J.S., Cozen, W., Davis, S., de Roos, A.J., Hartge, P., Rothman, N., Severson, R.K., Holly, E.A., Call, T.G., Feldman, A.L., Habermann, T.M., Liebow, M., Blair, A., Cantor, K.P., Kane, E.V., Lightfoot, T., Roman, E., Smith, A., Brooks-Wilson, A., Connors, J.M., Gascoyne, R.D., Spinelli, J.J., Armstrong, B.K., Krickler, A., Holford, T.R., Lan, Q., Zheng, T., Orsi, L., Dal Maso, L., Franceschi, S., La Vecchia, C., Negri, E., Serraino, D., Bernstein, L., Levine, A., Friedberg, J.W., Kelly, J.L., Berndt, S.I., Birmann, B.M., Clarke, C.A., Flowers, C.R., Foran, J.M., Kadin, M.E., Paltiel, O., Weisenburger, D.D., Linet, M.S., and Sampson, J.N., Etiologic Heterogeneity among Non-Hodgkin Lymphoma Subtypes: The Interlymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monogr*, 2014. 2014(48): p. 130-144.
374. Mittal, A.K., Chaturvedi, N.K., Rai, K.J., Gilling-Cutucache, C.E., Nordgren, T.M., Moragues, M., Lu, R., Opavsky, R., Bociek, G.R., Weisenburger, D.D., Iqbal, J., and Joshi, S.S., Chronic Lymphocytic Leukemia Cells in a Lymph Node Microenvironment Depict Molecular Signature Associated with an Aggressive Disease. *Mol Med*, 2014. 20: p. 290-301.
375. Cerhan, J.R., Berndt, S.I., Vijai, J., Ghesquieres, H., McKay, J., Wang, S.S., Wang, Z., Yeager, M., Conde, L., de Bakker, P.I., Nieters, A., Cox, D., Burdett, L., Monnereau, A., Flowers, C.R., De Roos, A.J., Brooks-Wilson, A.R., Lan, Q., Severi, G., Melbye, M., Gu, J., Jackson, R.D., Kane, E., Teras, L.R., Purdue, M.P., Vajdic, C.M., Spinelli, J.J., Giles, G.G., Albanes, D., Kelly, R.S., Zucca, M., Bertrand, K.A., Zeleniuch-Jacquotte, A., Lawrence, C., Hutchinson, A., Zhi, D., Habermann, T.M., Link, B.K., Novak, A.J., Dogan, A., Asmann, Y.W., Liebow, M., Thompson, C.A., Ansell, S.M., Witzig, T.E., Weiner, G.J., Veron, A.S., Zelenika, D., Tilly, H., Haioun, C., Molina, T.J., Hjalgrim, H., Glimelius, B., Adami, H.O., Bracci, P.M., Riby, J., Smith, M.T., Holly, E.A., Cozen, W., Hartge, P., Morton, L.M., Severson, R.K., Tinker, L.F., North, K.E., Becker, N., Benavente, Y., Boffetta, P., Brennan, P., Foretova, L., Maynadie, M., Staines, A., Lightfoot, T., Crouch, S., Smith, A., Roman, E., Diver, W.R., Offit, K., Zelenetz, A., Klein, R.J., Villano, D.J., Zheng, T., Zhang, Y., Holford, T.R., Krickler, A., Turner, J., Southey, M.C., Clavel, J., Virtamo, J., Weinstein, S., Riboli, E., Vineis, P., Kaaks, R., Trichopoulos, D., Vermeulen, R.C., Boeing, H., Tjonneland, A., Angelucci, E., Di Lollo, S., Rais, M., Birmann, B.M., Laden, F., Giovannucci, E., Kraft, P., Huang, J., Ma, B., Ye, Y., Chiu, B.C., Sampson, J., Liang, L., Park, J.H., Chung, C.C., Weisenburger, D.D., Chatterjee, N., Fraumeni, J.F., Jr., Slager, S.L., Wu, X., de Sanjose, S., Smedby, K.E., Salles, G., Skibola, C.F., Rothman, N. and Chanock, S.J., Genome-Wide Association Study Identifies Multiple Susceptibility Loci for Diffuse Large B Cell Lymphoma. *Nat Genet*, 2014. 46(11): p. 1233-1238.
376. Kendrick, S.L., Redd, L., Muranyi, A., Henricksen, L.A., Stanislaw, S., Smith, L.M., Perry, A.M., Fu, K., Weisenburger, D.D., Rosenwald, A., Ott, G., Gascoyne, R.D., Jaffe, E.S., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Staudt, L.M., Chan, W.C., Steidl, C., Grogan, T.M., and Rimsza, L.M., BCL2 Antibodies Targeted at Different Epitopes Detect Varying Levels of Protein Expression and Correlate with Frequent Gene Amplification in Diffuse Large B-Cell Lymphoma. *Hum Pathol*, 2014. 45(10): p. 2144-2153.
377. Hassan, H.M., Varney, M.L., Jain, S., Weisenburger, D.D., Singh, R.K., and Dave, B.J., Disruption of Chromosomal Locus 1p36 Differentially Modulates TAp73 and  $\Delta$ Np73 Expression in Follicular Lymphoma. *Leuk Lymphoma*, 2014. 55(12): p. 2924-2931.



Dennis Weisenburger, MD - MC

378. Morton, L.M., Gibson, T.M., Clarke, C.A., Lynch, C.F., Anderson, L.A., Pfeiffer, R., Landgren, O., Weisenburger, D.D., and Engels, E.A., Risk of Myeloid Neoplasms after Solid Organ Transplantation. *Leukemia*, 2014. 28(12): p. 2317-2323.
379. Muppidi, J.R., Schmitz, R., Green, J.A., Xiao, W., Larsen, A.B., Braun, S.E., An, J., Xu, Y., Rosenwald, A., Ott, G., Gascoyne, R.D., Rimsza, L.M., Campo, E., Jaffe, E.S., Delabie, J., Smeland, E.B., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Vaidehi, N., Staudt, L.M., and Cyster, J.G., Loss of Signalling Via Gα13 in Germinal Centre B-Cell-Derived Lymphoma. *Nature*, 2014. 516(7530): p. 254-258.
380. Huang, Q., Reddi, D., Chu, P., Snyder, D.S., and Weisenburger, D.D., Clinical and Pathologic Analysis of Extramedullary Tumors after Hematopoietic Stem Cell Transplantation. *Hum Pathol*, 2014. 45(12): p. 2404-2410.
381. Wang, S.S., Vajdic, C.M., Linet, M.S., Slager, S.L., Voutsinas, J., Nieters, A., de Sanjose, S., Cozen, W., Alarcon, G.S., Martinez-Maza, O., Brown, E.E., Bracci, P.M., Lightfoot, T., Turner, J., Hjalgrim, H., Spinelli, J.J., Zheng, T., Morton, L.M., Birmann, B.M., Flowers, C.R., Paltiel, O., Becker, N., Holly, E.A., Kane, E., Weisenburger, D., Maynadie, M., Cocco, P., Foretova, L., Staines, A., Davis, S., Severson, R., Cerhan, J.R., Breen, E.C., Lan, Q., Brooks-Wilson, A., De Roos, A.J., Smith, M.T., Roman, E., Boffetta, P., Krickler, A., Zhang, Y., Skibola, C., Chanock, S.J., Rothman, N., Benavente, Y., Hartge, P., and Smedby, K.E., Associations of Non-Hodgkin Lymphoma (NHL) Risk with Autoimmune Conditions According to Putative NHL Loci. *Am J Epidemiol*, 2015. 181(6): p. 406-421.
382. Boudjerra, N., Perry, A.M., Audouin, J., Diebold, J., Nathwani, B.N., MacLennan, K.A., Müller-Hermelink, H.K., Bast, M., Boilesen, E., Armitage, J.O., and Weisenburger, D.D., Classification of Non-Hodgkin Lymphoma in Algeria According to the World Health Organization Classification. *Leuk Lymphoma*, 2015. 56(4): p. 965-970.
383. Iqbal, J., Shen, Y., Huang, X., Liu, Y., Wake, L., Liu, C., Deffenbacher, K., Lachel, C.M., Wang, C., Rohr, J., Guo, S., Smith, L.M., Wright, G., Bhagavathi, S., Dybkaer, K., Fu, K., Greiner, T.C., Vose, J.M., Jaffe, E., Rimsza, L., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Cook, J.R., Tubbs, R.R., Armitage, J.O., Weisenburger, D.D., Staudt, L.M., Gascoyne, R.D., McKeithan, T.W., and Chan, W.C., Global MicroRNA Expression Profiling Uncovers Molecular Markers for Classification and Prognosis in Aggressive B-Cell Lymphoma. *Blood*, 2015. 125(7): p. 1137-1145.
384. Andreotti, G., Birmann, B.M., Cozen, W., De Roos, A.J., Chiu, B.C., Costas, L., de Sanjose, S., Moysich, K., Camp, N.J., Spinelli, J.J., Pahwa, P., Dosman, J.A., McLaughlin, J.R., Boffetta, P., Staines, A., Weisenburger, D., Benhaim-Luzon, V., Brennan, P., Costantini, A.S., Miligi, L., Campagna, M., Nieters, A., Becker, N., Maynadie, M., Foretova, L., Zheng, T., Tricot, G., Milliken, K., Krzystan, J., Stepkowski, E., Baris, D., and Purdue, M.P., A Pooled Analysis of Cigarette Smoking and Risk of Multiple Myeloma from the International Multiple Myeloma Consortium. *Cancer Epidemiol Biomarkers Prev*, 2015. 24(3): p. 631-634.
385. Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Ercole, E., Todaro, M., Boi, M., Acquaviva, A., Ficarra, E., Novero, D., Rinaldi, A., Tousseyn, T., Rosenwald, A., Kenner, L., Cerroni, L., Tzankov, A., Ponzoni, M., Paulli, M., Weisenburger, D., Chan, W.C., Iqbal, J., Piris, M.A., Zamo, A., Ciardullo, C., Rossi, D., Gaidano, G., Pileri, S., Tiacci, E., Falini, B., Shultz, L.D., Mevellec, L., Vialard, J.E., Piva, R., Bertoni, F., Rabadan, R., Inghirami, G., European T-Cell Lymphoma Study Group, Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. *Cancer Cell*, 2015. 27(4): p. 516-532.

Dennis Weisenburger, MD – MC

386. Pearce, N.E., Blair, A., Vineis, P., Ahrens, W., Andersen, A., Anto, J.M., Armstrong, B.K., Baccarelli, A.A., Beland, F.A., Berrington, A., Bertazzi, P.A., Birnbaum, L.S., Brownson, R.C., Bucher, J.R., Cantor, K.P., Cardis, E., Cherrie, J.W., Christiani, D.C., Cocco, P., Coggon, D., Comba, P., Demers, P.A., Dement, J.M., Douwes, J., Eisen, E.A., Engel, L.S., Fenske, R.A., Fleming, L.E., Fletcher, T., Fontham, E., Forastiere, F., Frentzel-Beyme, R., Fritsch, L., Gerin, M., Goldberg, M., Grandjean, P., Grimsrud, T.K., Gustavsson, P., Haines, A., Hartge, P., Hansen, J., Hauptmann, M., Heederik, D., Hemminki, K., Hemon, D., Hertz-Picciotto, I., Hoppin, J.A., Huff, J., Jarvholm, B., Kang, D., Karagas, M.R., Kjaerheim, K., Kjuus, H., Kogevinas, M., Kriebel, D., Kristensen, P., Kromhout, H., Laden, F., Lebaillly, P., LeMasters, G., Lubin, J.H., Lynch, C.F., Lynge, E., t Mannelte, A., McMichael, A.J., McLaughlin, J.R., Marrett, L., Martuzzi, M., Merchant, J.A., Merler, E., Merletti, F., Miller, A., Mirer, F.E., Monson, R., Nordby, K.K., Olshan, A.F., Parent, M.E., Perera, F.P., Perry, M.J., Pesatori, A.C., Pirastu, R., Porta, M., Pukkala, E., Rice, C., Richardson, D.B., Ritter, L., Ritz, B., Ronckers, C.M., Rushton, L., Rusiecki, J.A., Rusyn, I., Samet, J.M., Sandler, D.P., de Sanjose, S., Schernhammer, E., Seniori Constantini, A., Seixas, N., Shy, C., Siemiatycki, J., Silvermann, D.T., Simonato, L., Smith, A.H., Smith, M.T., Spinelli, J.J., Spitz, M.R., Stallones, L., Stayner, L.T., Steenland, K., Stenzel, M., Stewart, B.W., Stewart, P.A., Symanski, E., Terracini, B., Tolbert, P.E., Vainio, H., Vena, J., Vermeulen, R., Victora, C.G., Ward, E.M., Weinberg, C.R., Weisenburger, D., Wesseling, C., Weiderpass, E. and Zahm, S.H., IARC Monographs: 40 Years of Evaluating Carcinogenic Hazards to Humans. *Environ Health Perspect*, 2015. 123(6): p. 507-514.
387. Caponetti, G.C., Dave, B.J., Perry, A.M., Smith, L.M., Jain, S., Meyer, P.N., Bast, M., Bierman, P.J., Bociek, R.G., Vose, J.M., Armitage, J.O., Aoun, P., Fu, K., Greiner, T.C., Chan, W.C., Sanger, W.G., and Weisenburger, D.D., Isolated MYC Cytogenetic Abnormalities In Diffuse Large B-Cell Lymphoma Do Not Predict An Adverse Clinical Outcome. *Leuk Lymphoma*, 2015. 56(11): p.3082-3089.
388. Yuan, J., Wright, G., Rosenwald, A., Steidl, C., Gascoyne, R.D., Connors, J.M., Mottok, A., Weisenburger, D.D., Greiner, T.C., Fu, K., Smith, L., Rimsza, L.M., Jaffe, E.S., Campo, E., Martinez, A., Delabie, J., Braziel, R.M., Cook, J.R., Ott, G., Vose, J.M., Staudt, L.M., Chan, W.C., and Lymphoma Leukemia Molecular Profiling, P., Identification of Primary Mediastinal Large B-Cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. *Am J Surg Pathol*, 2015. 39(10): p. 1322-1330.
389. Wang, C., McKeithan, T.W., Gong, Q., Zhang, W., Bouska, A., Rosenwald, A., Gascoyne, R.D., Wu, X., Wang, J., Muhammad, Z., Jiang, B., Rohr, J., Cannon, A., Steidl, C., Fu, K., Li, Y., Hung, S., Weisenburger, D.D., Greiner, T.C., Smith, L., Ott, G., Rogan, E.G., Staudt, L.M., Vose, J., Iqbal, J., and Chan, W.C., IDH2R172 Mutations Define a Unique Subgroup of Patients with Angioimmunoblastic T-Cell Lymphoma. *Blood*, 2015. 126(15): p. 1741-1752.
390. Glaser, S.L., Clarke, C.A., Keegan, T.H., Chang, E.T., and Weisenburger, D.D., Time Trends in Rates of Hodgkin Lymphoma Histologic Subtypes: True Incidence Changes or Evolving Diagnostic Practice? *Cancer Epidemiol Biomarkers Prev*, 2015. 24(10): p. 1474-1488.
391. Dotlic, S., Perry, A.M., Petrusevska, G., Fetica, B., Diebold, J., MacLennan, K.A., Muller-Hermelink, H.K., Nathwani, B.N., Boilesen, E., Bast, M., Armitage, J.O., and Weisenburger, D.D., Classification of Non-Hodgkin Lymphoma in South-Eastern Europe: Review of 632 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Br J Haematol*, 2015. 171(3): p. 366-372.
392. Song, J.Y., Venkataraman, G., Fedoriw, Y., Herrera, A.F., Siddiqi, T., Alikhan, M.B., Kim, Y.S., Murata-Collins, J., Weisenburger, D.D., Liu, X., and Duffield, A.S., Burkitt Leukemia Limited to the Bone Marrow Has a Better Prognosis Than Burkitt Lymphoma with Bone Marrow Involvement in Adults. *Leuk Lymphoma*, 2016. 57(4): p. 866-871.



Dennis Weisenburger, MD - MC

393. Kendrick, S., Tus, K., Wright, G., Jaffe, E.S., Rosenwald, A., Campo, E., Chan, W.C., Connors, J.M., Braziel, R.M., Ott, G., Delabie, J., Cook, J.R., Weisenburger, D.D., Greiner, T.C., Fu, K., Staudt, L.M., Gascoyne, R.D., Scott, D.W., and Rimsza, L.M., Diffuse Large B-Cell Lymphoma Cell-of-Origin Classification Using the Lymph2cx Assay in the Context of Bcl2 and Myc Expression Status. *Leuk Lymphoma*, 2016. 57(3): p. 717-720.
394. Rohr, J., Guo, S., Huo, J., Bouska, A., Lachel, C., Li, Y., Simone, P.D., Zhang, W., Gong, Q., Wang, C., Cannon, A., Heavican, T., Mottok, A., Hung, S., Rosenwald, A., Gascoyne, R., Fu, K., Greiner, T.C., Weisenburger, D.D., Vose, J.M., Staudt, L.M., Xiao, W., Borgstahl, G.E., Davis, S., Steidl, C., McKeithan, T., Iqbal, J., and Chan, W.C., Recurrent Activating Mutations of CD28 in Peripheral T-Cell Lymphomas. *Leukemia*, 2016. 30(5): p. 1062-1070.
395. Clemens, M.W., Medeiros, L.J., Butler, C.E., Hunt, K.K., Fanale, M.A., Horwitz, S., Weisenburger, D.D., Liu, J., Morgan, E.A., Kanagal-Shamanna, R., Parkash, V., Ning, J., Sohani, A.R., Ferry, J.A., Mehta-Shah, N., Dogan, A., Liu, H., Thormann, N., DiNapoli, A., Lade, S., Piccolini, J., Reyes, R., Williams, T., McCarthy, C.M., Hanson, S.E., Nastoupil, L.J., Gaur, R., Oki, Y., Young, K.H., and Miranda, R.N., Complete Surgical Excision Is Essential for the Management of Patients with Breast Implant-associated Anaplastic Large-cell Lymphoma. *J Clin Oncol*, 2016. 34(2): p. 160-168.
396. Perry, A.M., Diebold, J., Nathwani, B.N., MacLennan, K.A., Muller-Hermelink, H.K., Bast, M., Boilesen, E., Armitage, J.O., and Weisenburger, D.D., Non-Hodgkin Lymphoma in the Far East: Review of 730 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Ann Hematol*, 2016. 95(2): p. 245-251.
397. Perry, A.M., Diebold, J., Nathwani, B.N., MacLennan, K.A., Muller-Hermelink, H.K., Bast, M., Boilesen, E., Armitage, J.O., and Weisenburger, D.D., Relative Frequency of Non-Hodgkin Lymphoma Subtypes in Selected Centres in North Africa, the Middle East and India: A Review of 971 Cases. *Br J Haematol*, 2016. 172(5): p. 699-708.
398. Perry, A.M., Perner, Y., Diebold, J., Nathwani, B.N., MacLennan, K.A., Muller-Hermelink, H.K., Bast, M., Boilesen, E., Armitage, J.O., and Weisenburger, D.D., Non-Hodgkin Lymphoma in Southern Africa: Review of 487 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Br J Haematol*, 2016. 172(5): p. 716-723.
399. Machiela, M.J., Lan, Q., Slager, S.L., Vermeulen, R.C., Teras, L.R., Camp, N.J., Cerhan, J.R., Spinelli, J.J., Wang, S.S., Nieters, A., Vijai, J., Yeager, M., Wang, Z., Ghesquieres, H., McKay, J., Conde, L., de Bakker, P.I., Cox, D.G., Burdett, L., Monnereau, A., Flowers, C.R., De Roos, A.J., Brooks-Wilson, A.R., Giles, G.G., Melbye, M., Gu, J., Jackson, R.D., Kane, E., Purdue, M.P., Vajdic, C.M., Albanes, D., Kelly, R.S., Zucca, M., Bertrand, K.A., Zeleniuch-Jacquotte, A., Lawrence, C., Hutchinson, A., Zhi, D., Habermann, T.M., Link, B.K., Novak, A.J., Dogan, A., Asmann, Y.W., Liebow, M., Thompson, C.A., Ansell, S.M., Witzig, T.E., Tilly, H., Haioun, C., Molina, T.J., Hjalgrim, H., Glimelius, B., Adami, H.O., Roos, G., Bracci, P.M., Riby, J., Smith, M.T., Holly, E.A., Cozen, W., Hartge, P., Morton, L.M., Severson, R.K., Tinker, L.F., North, K.E., Becker, N., Benavente, Y., Boffetta, P., Brennan, P., Foretova, L., Maynadie, M., Staines, A., Lightfoot, T., Crouch, S., Smith, A., Roman, E., Diver, W.R., Offit, K., Zelenetz, A., Klein, R.J., Villano, D.J., Zheng, T., Zhang, Y., Holford, T.R., Turner, J., Southey, M.C., Clavel, J., Virtamo, J., Weinstein, S., Riboli, E., Vineis, P., Kaaks, R., Boeing, H., Tjonneland, A., Angelucci, E., Di Lollo, S., Rais, M., De Vivo, I., Giovannucci, E., Kraft, P., Huang, J., Ma, B., Ye, Y., Chiu, B.C., Liang, L., Park, J.H., Chung, C.C., Weisenburger, D.D., Fraumeni, J.F., Jr., Salles, G., Glenn, M., Cannon-Albright, L., Curtin, K., Wu, X., Smedby, K.E., de Sanjose, S., Skibola, C.F., Berndt, S.I., Birmann, B.M., Chanock, S.J. and Rothman, N., Genetically Predicted Longer Telomere Length Is Associated with Increased Risk of B-Cell Lymphoma Subtypes. *Hum Mol Genet*, 2016. 25(8): p. 1663-1676.

Dennis Weisenburger, MD - MC

400. Bowen, E.M., Pfeiffer, R.M., Linet, M.S., Liu, W.T., Weisenburger, D.D., Freedman, D.M., and Cahoon, E.K., Relationship between Ambient Ultraviolet Radiation and Hodgkin Lymphoma Subtypes in the United States. *Br J Cancer*, 2016. 114(7): p. 826-831.
401. Wang, S.S., Deapen, D., Voutsinas, J., Lacey, J.V., Jr., Lu, Y., Ma, H., Clarke, C.A., Weisenburger, D., Forman, S.J., and Bernstein, L., Breast Implants and Anaplastic Large Cell Lymphomas among Females in the California Teachers Study Cohort. *Br J Haematol*, 2016. 174(3): p. 480-483.
402. Hassan, H.M., Varney, M.L., Chaturvedi, N.K., Joshi, S.S., Weisenburger, D.D., Singh, R.K., and Dave, B.J., Modulation of P73 Isoforms Expression Induces Anti-Proliferative and Pro-Apoptotic Activity in Mantle Cell Lymphoma Independent of P53 Status. *Leuk Lymphoma*, 2016. 57(12): p. 2874-2889.
403. Nardi, E.A., Wolfson, J.A., Rosen, S.T., Diasio, R.B., Gerson, S.L., Parker, B.A., Alvarnas, J.C., Levine, H.A., Fong, Y., Weisenburger, D.D., Fitzgerald, C.L., Egan, M., Stranford, S., Carlson, R.W., and Benz, E.J., Jr., Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. *J Natl Compr Cancer Netw*, 2016. 14(7): p. 837-847.
404. Presutti, R., Harris, S.A., Kachuri, L., Spinelli, J.J., Pahwa, M., Blair, A., Zahm, S.H., Cantor, K.P., Weisenburger, D.D., Pahwa, P., McLaughlin, J.R., Dosman, J.A., and Freeman, L.B., Pesticide Exposures and the Risk of Multiple Myeloma in Men: An Analysis of the North American Pooled Project. *Int J Cancer*, 2016. 139(8): p. 1703-1714.
405. Perry, A.M., Diebold, J., Nathwani, B.N., MacLennan, K.A., Muller-Hermelink, H.K., Bast, M., Boilesen, E., Armitage, J.O., and Weisenburger, D.D., Non-Hodgkin Lymphoma in the Developing World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Haematologica*, 2016. 101(10): p. 1244-1250.
406. Portier, C.J., Armstrong, B.K., Baguley, B.C., Baur, X., Belyaev, I., Belle, R., Belpoggi, F., Biggeri, A., Bosland, M.C., Bruzzi, P., Budnik, L.T., Bugge, M.D., Burns, K., Calaf, G.M., Carpenter, D.O., Carpenter, H.M., Lopez-Carrillo, L., Clapp, R., Cocco, P., Consonni, D., Comba, P., Craft, E., Dalvie, M.A., Davis, D., Demers, P.A., De Roos, A.J., DeWitt, J., Forastiere, F., Freedman, J.H., Fritsch, L., Gaus, C., Gohlke, J.M., Goldberg, M., Greiser, E., Hansen, J., Hardell, L., Hauptmann, M., Huang, W., Huff, J., James, M.O., Jameson, C.W., Kortenkamp, A., Kopp-Schneider, A., Kromhout, H., Larramendy, M.L., Landrigan, P.J., Lash, L.H., Leszczynski, D., Lynch, C.F., Magnani, C., Mandrioli, D., Martin, F.L., Merler, E., Michelozzi, P., Miligi, L., Miller, A.B., Mirabelli, D., Mirer, F.E., Naidoo, S., Perry, M.J., Petronio, M.G., Pirastu, R., Portier, R.J., Ramos, K.S., Robertson, L.W., Rodriguez, T., Roosli, M., Ross, M.K., Roy, D., Rusyn, I., Saldiva, P., Sass, J., Savolainen, K., Scheepers, P.T., Sergi, C., Silbergeld, E.K., Smith, M.T., Stewart, B.W., Sutton, P., Tateo, F., Terracini, B., Thielmann, H.W., Thomas, D.B., Vainio, H., Vena, J.E., Vineis, P., Weiderpass, E., Weisenburger, D.D., Woodruff, T.J., Yorifuji, T., Yu, I.J., Zambon, P., Zeeb, H., and Zhou, S.F., Differences in the Carcinogenic Evaluation of Glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (Efsa). *J Epidemiol Community Health*, 2016. 70(8): p. 741-745.
407. Mohanty, A., Sandoval, N., Das, M., Pillai, R., Chen, L., Chen, R.W., Amin, H.M., Wang, M., Marcucci, G., Weisenburger, D.D., Rosen, S.T., Pham, L.V., and Ngo, V.N., CCND1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma. *Oncotarget*, 2016. 7(45): p. 73558-73572.



Dennis Weisenburger, MD - MC

408. Song, J.Y., Song, L., Herrera, A.F., Venkataraman, G., Murata-Collins, J.L., Bedell, V.H., Chen, Y.Y., Kim, Y.S., Tadros, R., Nathwani, B.N., Weisenburger, D.D., and Feldman, A.L., Cyclin D1 Expression in Peripheral T-Cell Lymphomas. *Mod Pathol*, 2016. 29(11): p. 1306-1312.
409. Mohanty, S., Mohanty, A., Sandoval, N., Tran, T., Bedell, V., Wu, J., Scuto, A., Murata-Collins, J., Weisenburger, D.D., and Ngo, V.N., Cyclin D1 Depletion Induces DNA Damage in Mantle Cell Lymphoma Lines. *Leukemia & Lymphoma*, 2017. 58(3): p. 676-688.
410. Bouska, A., Zhang, W., Gong, Q., Iqbal, J., Scuto, A., Vose, J., Ludvigsen, M., Fu, K., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Rosenwald, A., Ott, G., Campo, E., Rimsza, L.M., Delabie, J., Jaffe, E.S., Braziel, R.M., Connors, J.M., Wu, C.I., Staudt, L.M., D'Amore, F., McKeithan, T.W., and Chan, W.C., Combined Copy Number and Mutation Analysis Identifies Oncogenic Pathways Associated with Transformation of Follicular Lymphoma. *Leukemia*, 2017. 31(1): p. 83-91.
411. McKinney, M., Moffitt, A.B., Gaulard, P., Travert, M., De Leval, L., Nicolae, A., Raffeld, M., Jaffe, E.S., Pittaluga, S., Xi, L., Heavican, T., Iqbal, J., Belhadj, K., Delfau-Larue, M.H., Fatacccioli, V., Czader, M.B., Lossos, I.S., Chapman-Fredricks, J.R., Richards, K.L., Fedoriw, Y., Ondrejka, S.L., Hsi, E.D., Low, L., Weisenburger, D., Chan, W.C., Mehta-Shah, N., Horwitz, S., Bernal-Mizrachi, L., Flowers, C.R., Beaven, A.W., Parihar, M., Baseggio, L., Parrens, M., Moreau, A., Sujobert, P., Pilichowska, M., Evens, A.M., Chadburn, A., Au-Yeung, R.K., Srivastava, G., Choi, W.W., Goodlad, J.R., Aurer, I., Basic-Kinda, S., Gascoyne, R.D., Davis, N.S., Li, G., Zhang, J., Rajagopalan, D., Reddy, A., Love, C., Levy, S., Zhuang, Y., Datta, J., Dunson, D.B., and Dave, S.S., The Genetic Basis of Hepatosplenic T-Cell Lymphoma. *Cancer Discov*, 2017. 7(4): p. 369-379.
412. Tennesse, A., Skrabek, P.J., Nasr, M.R., Sekiguchi, D.R., Morales, C., Brown, T.C., Weisenburger, D.D., and Perry, A.M., Four Lymphomas in 1 Patient: A Unique Case of Triple Composite Non-Hodgkin Lymphoma Followed by Classical Hodgkin Lymphoma. *Int J Surg Pathol*, 2017. 25(3): p. 276-280.
413. Herrera, A.F., Mei, M., Low, L., Kim, H.T., Griffin, G.K., Song, J.Y., Merryman, R.W., Bedell, V., Pak, C., Sun, H., Paris, T., Stiller, T., Brown, J.R., Budde, L.E., Chan, W.C., Chen, R., Davids, M.S., Freedman, A.S., Fisher, D.C., Jacobsen, E.D., Jacobson, C.A., LaCasce, A.S., Murata-Collins, J., Nademane, A.P., Palmer, J.M., Pihan, G.A., Pillai, R., Popplewell, L., Siddiqi, T., Sohani, A.R., Zain, J., Rosen, S.T., Kwak, L.W., Weinstock, D.M., Forman, S.J., Weisenburger, D.D., Kim, Y., Rodig, S.J., Krishnan, A., and Armand, P., Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival after Autologous Stem-Cell Transplantation. *J Clin Oncol*, 2017. 35(1): p. 24-31.
414. Fetica, B., Achimas-Cadariu, P., Pop, B., Dima, D., Petrov, L., Perry, A.M., Nathwani, B.N., Muller-Hermelink, H.K., Diebold, J., MacLennan, K.A., Fulop, A., Blaga, M.L., Coza, D., Nicula, F.A., Irimie, A., and Weisenburger, D.D., Non-Hodgkin Lymphoma in Romania: A Single-Centre Experience. *Hematol Oncol*. (in press)
415. Shukla A, Chaturvedi NK, Ahrens AK, Cutucache EC, Mittal AK, Bierman P, Weisenburger DD, Lu R, Joshi SS. Stromal Tumor Microenvironment in Chronic Lymphocytic Leukemia: Regulation of Leukemic Progression. *Leukemia*. (in press)
416. Mittal AK, Iqbal J, Gillig CE, Nordgren T, Moragues M, Bociek GR, Aoun P, Weisenburger DD, Joshi SS. Regulation of Survival, Proliferation, and Migration of Chronic Lymphocytic Leukemia Cells by the Tumor Microenvironment. *Mol Med*. (in press)

Dennis Weisenburger, MD - MC

417. Song JY, Maghami E, Wu H, Kim YS, Weisenburger DD, Levine A, Nademanee A. Rapid Development of Oral Squamous Cell Carcinoma after Autologous Stem Cell Transplantation for Hodgkin Lymphoma. *Hum Pathol Case Rep.* (in press)
418. Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rudiger T, Federico M, Pileri S. Pitfalls and Major Issues in the Histologic Diagnosis of Peripheral T-cell Lymphomas: Results of the Central Review of 573 Cases from the T-cell Project, an International Cooperative Study. *Hematol Oncol.* (in press)
419. Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BC, Spinelli JJ, Becker N, Benhaim-Luzon V, Bhatti P, Boffetta P, Brennan P, Brown EE, Cocco P, Costas L, Cozen W, de Sanjosé S, Foretová L, Giles GG, Maynadié M, Moysich KB, Nieters A, Staines A, Tricot G, Weisenburger D, Zhang Y, Baris D, Purdue MP. Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC). *Cancer Epidemiol Biomarkers Prev.* (in press)
420. Scott DW, Abrisqueta P, Wright GW, Slack GW, Mottok A, Villa D, Jares P, Rauert-Wunderlich H, Royo C, Clot G, Pinyol M, Boyle M, Braziel RM, Chan WC, Weisenburger DD, et al. A New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formation-fixed Paraffin-embedded Biopsies. *J Clin Oncol.* (in press)
421. Bouska A, Changfeng B, Lone W, Zhang W, Kidwai A, Heavican T, Lachel CM, Yu J, Fu K, Ferro R, Eldorhamy N, Greiner TC, Vose J, Weisenburger DD, et al. Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies a Potential Therapeutic Target. *Blood.* (in press)
422. Yuan J, Greiner TC, Fu K, Smith LM, Aoun P, Chan WC, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Weisenburger DD. Rituximab Improves the Outcome of Patients with Grade 3 Follicular Lymphoma Receiving Anthracycline-based Therapy. (submitted)
423. El Behery R, Laurini JA, Weisenburger DD, et al. Follicular Large Cleaved Cell (Centrocytic) Lymphoma is a Distinctive Morphological and Clinical Variant of Follicular Lymphoma. (submitted)
424. Aldoss I, Pham A, Li SM, et al. Therapy-related Myelodysplasia: Molecular Features and Allogenic Hematopoietic Cell Transplantation Outcomes. (submitted)
425. Wang S, Carrington M, Bendt S, et al. HLA Zygosity and Non-Hodgkin Lymphoma Etiology. (submitted)

**Publications (review articles), 15 Total**

1. Coleman, M., Armitage, J.O., Gaynor, M., McDermott, D., Weisenburger, D.D., Adler, K., Beshevkin, M., Silver, R.T., Reisman, A.M., and Pasmantier, M.W., The Cop-Blam Programs: Evolving Chemotherapy Concepts in Large Cell Lymphoma. *Semin Hematol*, 1988. 25(2 Suppl 2): p. 23-33.
2. Harrington, D.S., Weisenburger, D.D., and Purtilo, D.T., Epstein-Barr Virus--Associated Lymphoproliferative Lesions. *Clin Lab Med*, 1988. 8(1): p. 97-118.
3. Vose, J.M., Weisenburger, D.D., Sanger, W.G., Bierman, P.J., and Armitage, J.O., Peripheral T-Cell Lymphoma-a Brief Review. *Leuk Lymphoma*, 1990, 3(2): p. 77-86.



Dennis Weisenburger, MD - MC

4. Weisenburger, D.D., Non-Hodgkin's Lymphomas of Primary Follicle/Mantle Zone Origin. *Leukemia*, 1991. 5 Suppl 1: p. 26-29.
5. Weisenburger DD. Pathological Classification of Non-Hodgkin's Lymphoma for Epidemiological Studies. *Cancer Res*, 1992. 52:5456s-5464s.
6. Weisenburger, D.D. and Chan, W.C., Lymphomas of Follicles. Mantle Cell and Follicle Center Cell Lymphomas. *Am J Clin Pathol*, 1993. 99(4): p. 409-420.
7. Weisenburger, D.D., Potential Health Consequences of Ground-Water Contamination by Nitrates in Nebraska. *Nebr Med J*, 1993. 78(1): p. 7-12.
8. Weisenburger, D.D., Human Health Effects of Agrichemical Use. *Hum Pathol*, 1993. 24(6): p. 571-576.
9. Weisenburger, D.D., Epidemiology of Non-Hodgkin's Lymphoma: Recent Findings Regarding an Emerging Epidemic. *Ann Oncol*, 1994. 5 Suppl 1: p. 19-24.
10. Vose, J.M., Anderson, J.R., Bierman, P.J., Bast, M., Weisenburger, D., Chan, W.C., Bishop, M.R., and Armitage, J.O., Comparison of Front-Line Chemotherapy for Aggressive Non-Hodgkin's Lymphoma Using the Cap-Bop Regimens. The Nebraska Lymphoma Study Group. *Semin Hematol*, 1994. 31(2 Suppl 3): p. 4-8.
11. Delabie, J., Chan, W.C., Weisenburger, D.D., and De Wolf-Peeters, C., The Antigen-Presenting Cell Function of Reed-Sternberg Cells. *Leuk Lymphoma*, 1995. 18(1-2): p. 35-40.
12. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WC, Tarantolo SR, Weisenburger, DD, Kessinger A, Armitage JO. Incidence and Characterization of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia Following High-dose Chemotherapy and Autologous Stem-cell Transplantation for Lymphoid Malignancies. *Classic Papers and Current Comments*, 1996. 1:406-414.
13. Weisenburger, D.D. and Armitage, J.O., Mantle Cell Lymphoma-- an Entity Comes of Age. *Blood*, 1996. 87(11): p. 4483-4494.
14. Armitage, J.O. and Weisenburger, D.D., New Approach to Classifying Non-Hodgkin's Lymphomas: Clinical Features of the Major Histologic Subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol*, 1998. 16(8): p. 2780-2795.
15. Weisenburger DD. The Importance of Accurate Diagnosis in T-cell Lymphoma: A Pathologist's Perspective. *Clin Adv Hematol Oncol*, 2011. 9:5-8.

#### **Editorials and Letters, 25 Total**

##### **Editorials:**

1. Weisenburger DD. An Epidemic of Non-Hodgkin's Lymphoma: Comments on Time Trends, Possible Etiologies, and the Role of Pathology. *Mod Pathol*, 1992. 5:481-482.
2. Weisenburger DD. Progress in the Classification of Non-Hodgkin's Lymphoma. *Am J Clin Pathol*, 1993. 100:367-368.

Dennis Weisenburger, MD - MC

3. Delabie J, Weisenburger DD, Chan WC. Hodgkin's Disease: A Monoclonal Lymphoproliferative Disorder? *Histopathol*, 1995. 27:93-96.
4. Armitage JO, Vose JM, Weisenburger DD. Towards Understanding the Peripheral T-cell Lymphomas. *Ann Oncol*, 2004. 15:1447-1449.

Published Letters:

1. Weisenburger DD, Helms CM, Viner JP, Renner E. Demonstration of the Legionnaires' Bacillus in Hilar Lymph Nodes. *Arch Pathol Lab Med*, 1979. 103:153.
2. Weisenburger DD, Fry GL, Hoak JC. Thrombotic Thrombocytopenic Purpura: Conflicting Results of In-Vitro Studies. *Lancet*, 1980. 1:99-100.
3. Weisenburger DD, Purtilo DT. Registry for Angiofollicular Lymph Node Hyperplasia. *Ann Int Med*, 1984. 102:132.
4. Weisenburger DD, Bierman PJ. Specificity of Leu-M1 Antibody for Reed-Sternberg Cells. *Am J Clin Pathol*, 1985. 84:408.
5. Williams TL, Weisenburger DD, Gnarr DG. Cell Surface and Serum Monoclonal Immunoglobulin in Burkitt's Lymphoma. *Arch Pathol Lab Med*, 1985. 109:389.
6. Weisenburger DD. Mantle-Zone Lymphoma: Another Opinion. *Am J Surg Pathol*, 1986. 10:733-734.
7. Armitage JO, Weisenburger DD. Chemotherapy of Diffuse Large Cell Lymphoma. *J Clin Oncol*, 1986. 4:1420-1421.
8. Zahm SH, Blair A, Weisenburger DD. Sex Differences in the Risk of Multiple Myeloma Associated with Agriculture. *Br J Indust Med*, 1992. 49:815-816.
9. Weisenburger DD. Mantle Cell Lymphoma. *Am J Surg Pathol*, 1993. 17:639-640.
10. Anderson JR, Armitage JO, Weisenburger DD. More on Follicular Lymphoma. *J Clin Oncol* 1993. 11:1834-1835.
11. Weisenburger DD. The Health Effects of Agrichemicals: Herbicides and Soft Tissue Sarcomas. *Human Pathol*, 1994. 24:1384-1385.
12. Chan WC, Elmberger G, Lozano MD, Sanger W, Weisenburger DD. Large-Cell Anaplastic Lymphoma-specific Translocation in Hodgkin's Disease. *Lancet*, 1995. 345:921.
13. Weisenburger DD, Armitage JO. Serum Ig Abnormalities in Mantle Cell Lymphoma - Response. *Blood*, 1997. 90:895-896.
14. Weisenburger DD. Nodal Marginal Zone Lymphoma. *Am J Surg Pathol*, 2000. 24:315.
15. Ward MH, Mark SD, Cantor KP, Weisenburger DD, Correa-Villasenor A. Non-Hodgkin's Lymphoma and Nitrate in Drinking Water. *J Epidemiol Commun Health*, 2000. 54:772-773.



Dennis Weisenburger, MD – MC

16. Gesk S, Klapper W, Martin-Subero JI, Nagel I, Harder L, Fu K, Bernd HW, Weisenburger DD, Parwaresch R, Siebert R. Activation of Cyclin D2 by Chromosomal Translocations in Cyclin D1-negative Mantle Cell Lymphoma. *Blood*, 2006. 108: 1109-1110.
17. Thieblemont C, Rolland D, Baseggio L, Felman P, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Houlgatte R, Fu K, Weisenburger D, et al. Comprehensive Analysis of GST- $\pi$  Expression in B-cell Lymphomas: Correlation with Histological Subtypes and Survival. *Leuk*, 2008. 7:1403-1406.
18. Kendrick S, Tus K, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, Scott DW, and Rimsza LM, Diffuse Large B-Cell Lymphoma Cell-of-Origin Classification Using the Lymph2cx Assay in the Context of Bcl2 and Myc Expression Status. *Leuk Lymphoma*, 2016. 57(3): p. 717-720.
19. Weisenburger, D.D. and Gross, T.G., Post-Transplant Lymphoproliferative Disorder: A Heterogeneous Conundrum. *Br J Haematol*, 2016.
20. Fetica B, Pop B, Blaga ML, Fulop A, Dima D, Zdrenghia MT, Vlad CI, Bojan AS, Achimas-Cadariu P, Lisencu CI, Irimie A, and Weisenburger DD, High Prevalence of Viral Hepatitis in a Series of Splenic Marginal Zone Lymphomas from Romania. *Blood Cancer J*, 2016. 6(11): p. e498.
21. Wang SS, Luo J, Cozen W, Lu Y, Halley-Sullivan J, Voutsinas J, Zhong C, Song J, Lacey JV, Jr, Weisenburger D, and Bernstein L, Sun Sensitivity, Indoor Tanning and B-Cell Non-Hodgkin Lymphoma Risk among Caucasian Women in Los Angeles County. *Br J Haematol*, 2017. 177(1): p. 153-156.

#### **Book Chapters, 36 Total**

1. Smith FG, Weisenburger DD, Matson JR. Renal Response to Immunologic Injury. In *Pediatrics Update: Reviews for Physicians* (AJ Moss, Ed.), Elsevier North-Holland, Inc., New York, 1981:249-263.
2. Weisenburger DD, Purtilo DT. Failure in Immunologic Control of Epstein-Barr Virus Infection: Fatal Infectious Mononucleosis. In *The Epstein-Barr Virus: Recent Advances* (MA Epstein and BG Achong, Eds.), William Heinemann Medical books Ltd., London, 1986:127-161.
3. Vaughan WP, Weisenburger DD, Sanger WG, Gale RP, Armitage JO. Early Leukemic Recurrence of Non-Hodgkin's Lymphoma After High Dose Anti-Neoplastic Therapy with Autologous Marrow Rescue. In *Recent Advances in Bone Marrow Transplantation* (RP Gale, R Champlin, Eds.), Alan R. Liss, Inc., New York, 1987:787-796.
4. Linder J, Ye JL, Armitage JO, Weisenburger DD. Monoclonal Antibodies Marking T- and B-Lymphocytes in Paraffin Embedded Tissue. In *Leukocyte Typing III: White Cell Differentiation Antigens* (AJ McMichael, Ed.), Oxford University Press, Oxford, 1987:297-301.
5. Weisenburger DD, Harrington DS, Armitage JO. B-Cell Neoplasia Recapitulates the Normal Humoral Immune Response. In *Recent Advances in Leukemia and Lymphoma* (RP Gale, DW Golde, Eds.), Alan R. Liss, Inc., New York, 1987:535-543.

Dennis Weisenburger, MD - MC

6. Harrington DS, Weisenburger DD, Purtilo DT. Lymphoproliferative Disorders Associated with Epstein-Barr Virus. In *Clinics in Laboratory Medicine: Classification, Diagnosis, and Molecular Biology of Lymphoproliferative Disorders* (FR Davey, Ed.), W.B. Saunders Co., Philadelphia, 1988:97-118.
7. Duggan MJ, Weisenburger DD, Sun NCJ, Purtilo DT. Bone Marrow Findings in Immunodeficiency Syndromes. In: *Hematology/Oncology Clinics of North America* (B Hyun, Ed.), W.B. Saunders Co., Philadelphia, 1988:637-656.
8. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Restoration of Hematopoietic Function with Autologous Cryopreserved Peripheral Stem Cells. In *Autologous Bone Marrow Transplantation III* (K Dicke, G Spitzer, S Jagannath, Eds.), University of Texas Press, Houston, 1987:681-685.
9. Sharp JG, Mann SL, Kessinger A, Joshi SS, Crouse DA, Weisenburger DD. Detection of Occult Breast Cancer Cells in Cultured Pre-Transplantation Bone Marrow. In *Autologous Bone Marrow Transplantation III* (K Dicke, G Spitzer, S Jagannath, Eds.), University of Texas Press, Houston, 1987:497-502.
10. Smith DM, Kessinger A, Lobo F, Schouten HC, Landmark JD, Weisenburger DD, Armitage JO. Peripheral Blood Stem Cell Collection and Toxicity. In *Autologous Bone Marrow Transplantation III* (K Dicke, G Spitzer, S Jagannath, Eds.), University of Texas Press, Houston, 1989:697-701.
11. Sharp JG, Armitage JO, Crouse D, Joshi SS, Kessinger A, Mann S, Vaughan WP, Weisenburger DD. Recent Progress in the Detection of Metastatic Tumor in Bone Marrow by Culture Techniques. In *Autologous Bone Marrow Transplantation IV* (K Dicke, G Spitzer, S Jagannath, Eds.), MD Anderson Press, Houston, 1989:421-425.
12. Sharp JG, Armitage JO, Crouse D, DeBoer J, Joshi S, Mann S, Weisenburger DD, Kessinger A. Are Occult Tumor Cells Present in Peripheral Stem Cell Harvests of Candidates for Autologous Transplantation? In *Autologous Bone Marrow Transplantation IV* (K Dicke, G Spitzer, S Jagannath, Eds.), MD Anderson Press, Houston, 1989:693-696.
13. Weisenburger DD, Harrington DS, Armitage JO. B-Cell Neoplasia. A Conceptual Understanding Based on the Normal Humoral Immune Response. In *Pathology Annual* (PP Rosen, RE Fechner, Eds.), Appleton & Lange, East Norwalk, 1990:99-115.
14. Weisenburger DD, Duggan MJ, Perry DA, Sanger WG, Armitage JO. Non-Hodgkin's Lymphomas of Mantle Zone Origin. In *Pathology Annual* (PP Rosen, RE Fechner, Eds.), Appleton & Lange, East Norwalk, 1991:139-158.
15. Vose JM, Bierman PJ, Weisenburger DD, Armitage JO. The Therapy of Non-Hodgkin's Lymphomas. Introduction and Overview. In *Hematology/Oncology Clinics of North America* (JO Armitage, Ed.) 5; 1991:845-852.
16. Sharp JG, Kessinger MA, Pirruccello SJ, Masih AS, Mann SL, DeBoer J, Sanger WG, Weisenburger DD. Frequency of Detection of Suspected Lymphoma Cells in Peripheral Blood Stem Cell Collections. In *Autologous Bone Marrow Transplantation V* (KA Dicke, JO Armitage, Eds.), University of Nebraska Press, Lincoln, 1991:801-810.



Dennis Weisenburger, MD - MC

17. Sharp JG, Vaughan WP, Kessinger A, Mann SL, DeBoer J, Sanger WG, Weisenburger DD. Significance of Detection of Tumor Cells in Hematopoietic Stem Cell Harvests of Patients with Breast Cancer. In *Autologous Bone Marrow Transplantation V* (K Dicke, J Armitage, Eds.), University of Nebraska Press, Lincoln, 1991:385-392.
18. Weisenburger DD. Potential Health Consequences of Groundwater Contamination by Nitrates in Nebraska. In *Proceedings of NATO Advanced Research Workshop on Nitrate Contamination: Exposure, Consequences, and Control* (I Bogardi, Ed.), Springer-Verlag, Berlin and Heidelberg, 1991:309-315.
19. Weisenburger DD, Crespi M, Forman D, Hotchkiss JH, Leach SA, Møller H, Mirvish SS. Medical Panel Consensus Statement on the Potential Health Consequences of Elevated Nitrate Levels in Drinking Water. In *Proceedings of NATO Advanced Research Workshop on Nitrate Contamination: Exposure, Consequences, and Control* (I Bogardi, Ed.), Springer-Verlag, Berlin and Heidelberg, 1991:327-329.
20. Weisenburger DD. Mantle Cell Lymphoma. In *Neoplastic Hematopathology* (DM Knowles, Ed.), Williams and Wilkins, Baltimore, 1992:617-628.
21. Sharp JG, Kessinger A, Armitage JO, Bierman P, Crouse D, Mann S, Pirruccello S, Vose J, Weisenburger DD. Clinical Significance of Occult Tumor Cell Contamination of Hematopoietic Harvests in Non-Hodgkin's Lymphoma and Hodgkin's Disease. In *Proceedings of International Symposium on Autologous Bone Marrow Transplantation for Lymphomas, Hodgkin's Disease and Multiple Myeloma* (A. Zander, B. Barlogie, Eds.), Springer-Verlag, Berlin, 1993:123-132.
22. Sharp JG, Kessinger A, Armitage JO, Bierman PJ, Mann SL, Reed EC, Weisenburger DD. Influence of Minimal Tumor Contamination of Hematopoietic Harvests on Clinical Outcome of Patients Undergoing High Dose Therapy and Transplantation. In *Autologous Bone Marrow Transplantation VI* (KA Dicke, Ed.), 1993:223-226.
23. Weisenburger DD. Human Health Effects of Agrichemical Use. In *Monograph of Environmental and Occupational Disease* (JE Craighead, Ed.), Universities Associated for Research and Education in Pathology:1993:59-66.
24. Zahm SH, Weisenburger DD, Saal RC, Vaught JB, Babbitt PA, Blair A. Pesticides and Multiple Myeloma in Men and Women in Nebraska. In *Supplement to Agricultural Health and Safety: Workplace, Environment, Sustainability*. (HH McDuffie, JA Dosman, KM Semchuk, SA Olenchock, A Santhilselvan, Eds.), University of Saskatchewan, Saskatoon, 1994:75-81.
25. Zahm SH, Weisenburger DD, Saal RC, Vaught JB, Babbitt PA, Blair A. Pesticide Use, Genetic Susceptibility, and Non-Hodgkin's Lymphoma in Women. In *Agricultural Health and Safety: Workplace, Environment, Sustainability*. (HH McDuffie, JA Dosman, KM Semchuk, SA Olenchock, A Santhilselvan, Eds.), CRC Press Inc., Lewis Publishers, Boca Raton, FL, 1995:127-133.
26. Zahm SH, Weisenburger DD, Cantor KP, Holmes FF, Blair A. Non-Hodgkin's Lymphoma and the Use of Atrazine: Results from Three Case-Control Studies. In *Agricultural Health and Safety: Workplace, Environment, Sustainability*. (HH McDuffie, JA Dosman, KM Semchuk, SA Olenchock, A Santhilselvan, Eds.), CRC Press Inc., Lewis Publishers, Boca Raton, FL, 1995:151-156.

Dennis Weisenburger, MD - MC

27. Ward MH, Zahm SH, Weisenburger DD, Cantor KP, Saal RC, Blair A. Diet and Drinking Water Source: Association with Non-Hodgkin's Lymphoma in Eastern Nebraska. In *Agricultural Health and Safety: Workplace, Environment, Sustainability*. (HH McDuffie, JA Dosman, KM Semchuk, SA Olenchock, A Santhilselvan, Eds.), CRC Press Inc., Lewis Publishers, Boca Raton, FL, 1995:143-150.
28. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Truc T, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. The Lymphochip: A Specialized cDNA Microarray for the Genomic-scale Analysis of Gene Expression in Normal and Malignant Lymphocytes. In *Proceedings of the Cold Spring Harbor Symposium on Quantitative Biology*. Cold Spring Harbor Laboratory Press, LXIV: 71-78, 1999.
29. Weisenburger DD, Armitage JO. Mantle Cell Lymphoma. In *Malignant Lymphomas* (BW Hancock, PJ Selby, K MacLennan, JO Armitage, Eds.), Arnold, London, 2000:27-41.
30. Weisenburger DD. Mantle Cell Lymphoma. In *Neoplastic Hematopathology* (DM Knowles, Ed.), Lippincott Williams and Wilkins, Philadelphia, PA, 2001:789-803.
31. Nathwani BN, Harris NL, Weisenburger DD, Isaacson PG, Pileri MA, Berger F, Müller-Hermelink HK, Swerdlow SH. Follicular Lymphoma. In *Pathology and Genetics of Tumors of the Haematopoietic and Lymphoid Tissues* (ES Jaffe, NL Harris, H Stein, JW Vardiman, Eds), World Health Organization Classification of Tumours, IARC Press, Lyon, 2001:162-167.
32. Hiddemann W, Lenz G, Weisenburger DD, Dreyling MH. Mantle Cell Lymphoma. In *Non-Hodgkin's Lymphomas* (PM Mauch, JO Armitage, B Coiffier, R Dalla-Favera, NL Harris, Eds.), Lippincott Williams & Wilkins, Philadelphia, PA, 2004:461-476.
33. Pileri SA, Weisenburger DD, Sng I, Jaffe ES, Ralfkiaer E, Nakamura S, Müller-Hermelink HK. Peripheral T-cell Lymphoma, Not Otherwise Specified. In *WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues* (SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, JW Vardiman, Eds). IARC Press, Lyon, 2008:306-308.
34. d'Amore F, de Nulley Brown P, Weisenburger DD. Epidemiology of Extranodal Lymphomas. In *Textbook of Extranodal Lymphomas. Pathology and Management* (F Cavalli, H Stein, E Zucca, Eds), Informa Healthcare, London, 2008:14-23.
35. Song JY, Weisenburger DD. Classification of Hodgkin and Non-Hodgkin Lymphomas. In *Management of Lymphomas: A Case-Based Approach* (J Zain, LW Kwak, Eds). Adis Press, Cham, Switzerland, 2017: 33-44.
36. Pileri SA, Weisenburger DD, Sng I, Jaffe ES, Ralfkiaer E, Nakamura S, Müller-Hermelink HK. Peripheral T-cell Lymphoma, Not Otherwise Specified. In *WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues* (SH Swerdlow, E Campo, NL Harris, ES Jaffe, SA Pileri, H Stein, JW Vardiman, Eds). IARC Press, Lyon. (in press)

#### **Published Abstracts, 597 Total**

1. Weisenburger DD, Armitage JO, Dick F. Immunoblastic Lymphadenopathy with Pulmonary Infiltrates, Hypocomplementemia, and Vasculitis. A Hyperimmune Syndrome. In *The Year Book of Medicine* (DE Rogers, Ed.), Year Book Medical Publishers Inc., Chicago, 1980:147-148.



Dennis Weisenburger, MD - MC

2. Weisenburger DD. Interstitial Pneumonitis Associated with Azathioprine Therapy. In *The Year Book of Diagnostic Radiology* (WM Whitehouse, Ed.), Year Book Medical Publishers Inc., Chicago, 1980:208-209.
3. Weisenburger DD, Helms CM, Renner ED. Sporadic Legionnaires' Disease. A Clinicopathologic Study of Twenty-Three Cases. *Am J Clin Pathol* 74:504, 1980.
4. Weisenburger DD, Helms CM, Renner ED. Sporadic Legionnaires' Disease. A Study of 23 Fatal Cases. In *Internal Medicine Digest* (AB Bergman, Ed.), International Synopses, 1981:11.
5. Weisenburger DD, Nathwani BN, Diamond LW, Winberg CD, Rappaport H. Malignant Lymphoma, Intermediate Lymphocytic Type: A Clinicopathologic Study of 42 Cases. *Lab Invest* 44:74A-75A, 1981.
6. Weisenburger DD, Kim H, Rappaport H. Mantle-Zone Lymphoma. *Lab Invest* 46:89A, 1982.
7. Helms C, Viner J, Weisenburger DD, Chiu L, Renner E, Johnson W. Clinical and Epidemiologic Observations in 87 Cases of Legionnaires' Disease. Symposium on Legionella, Center for Disease Control, 1983.
8. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric Angiofollicular Lymph Node Hyperplasia. A Clinicopathologic Study of 16 Cases with Evolution to Malignant Lymphoma in Four. *Lab Invest* 50:66A, 1984.
9. Weisenburger DD, Astorino RN, Glassy FJ, Miller CM, MacKenzie MR, Caggiano V. Peripheral T-Cell Lymphoma. A Clinicopathologic Study of a Morphologically Diverse Entity. *International Congress of the International Academy of Pathology Proceedings*, 1984.
10. Armitage JO, Weisenburger DD, Linder J, et al. Response of Diffuse Aggressive Lymphoma to Intensive Chemotherapy: The Effect of Histologic Subtype. *Blood* 64:178A, 1984.
11. Armitage JO, Weisenburger DD, Linder J, Purtilo DT. Histologic Transformation in Non-Hodgkin's Lymphomas (NHL): Progression to a More Aggressive Histologic Type Versus Second Neoplasm? *Blood* 64:152A, 1984.
12. Weisenburger DD, Daley DT, Armitage JO, Linder J. Intermediate Lymphocytic Lymphoma: An Immunohistologic Study with Comparison to Other Lymphocytic Lymphomas. *Lab Invest* 52:74A, 1985.
13. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric Angiofollicular Lymph Node Hyperplasia: Pathology of the Spleen. *Lab Invest* 52:74A, 1985.
14. Linder J, Daley DT, Armitage JO, Kay DH, Klassen LW, Weisenburger DD. Interleukin-2 Receptor (TAC) Expression in Non-Hodgkin's Lymphoma. *Lab Invest* 52:39A, 1985.
15. Linder J, Wilson RB, Armitage JO, Weisenburger DD. B Lymphocyte Monoclonal Antibody Reactivity with Neuroendocrine Tumors. *Lab Invest* 52:39A, 1985.
16. Sanger WG, Armitage JO, Weisenburger DD, Linder J, Purtilo DT. Serial Cytogenetic Studies in Malignant Lymphoma. *Proc AACR* 26:183, 1985.

Dennis Weisenburger, MD - MC

17. Sanger WG, Weisenburger DD, Armitage JO, Fordyce R, Speaks S, Purtilo DT. Cytogenetics of Noncutaneous Peripheral T-Cell Lymphoma. *Am J Hum Genet* 37:A37, 1985.
18. Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT. Intermediate Lymphocytic Lymphoma. An Immunophenotypic and Cytogenetic Analysis of 12 Cases. *Blood* 66:246A, 1985.
19. Weisenburger DD, Jackson JD, Gnarr DJ, Crouse DA, Sharp JG. Characterization of the Specific Defect in a Patient with Congenital Agranulocytosis (Kostman's Syndrome). *Blood* 66:81A, 1985.
20. Vaughan WP, Sanger WG, Weisenburger DD, Armitage JO. Early Leukemic Recurrence of Malignant Lymphoma (ML) After High Dose Therapy Supported by Infusion of Histologically Negative Autologous Marrow. *Blood* 66:192A, 1985.
21. Armitage JO, Weisenburger DD, Hutchens M, et al. Rapidly Responding Patients with Diffuse Large Cell Lymphoma (DLCL) have More Durable Remissions. *Blood* 66:212A, 1985.
22. Vaughan WP, Sanger WG, Weisenburger DD, Armitage JO. Leukemic Recurrence of Malignant Lymphoma (ML) after High Dose Therapy Supported by Infusion of Histologically Negative Autologous Marrow. *Clin Res* 33:891A, 1985.
23. Lipscomb Grierson HL, Armitage JO, Weisenburger DD, Purtilo DT. Epstein-Barr Virus (EBV) Serology in Patients with Non-Hodgkin's Lymphoma. Associations of Sex of Patients with Histologic Grade and Stage of Disease, and Response to Therapy. Second International Conference on Immunobiology and Prophylaxis of Human Herpesvirus Infections, 1985.
24. Meyers S, Weisenburger DD, Crouse D. Influence of Peripheral Blood Mononuclear Cells on the Quantitative Assessment of Bone Marrow Fibroblastoid Stromal Cells. UNMC Student Research Forum, 1985.
25. Weisenburger DD, Lipscomb Grierson HL, Purtilo DT. Immunologic Studies of Multicentric (M) and Unicentric (U) Angiofollicular Lymphoid Hyperplasia (AFH). *Lab Invest* 54:68A, 1986.
26. Weisenburger DD, Lipscomb Grierson HL, Daley DT, Purtilo DT, Linder J. Immunologic Studies of Sinus Histiocytosis with Massive Lymphadenopathy (SHML). *Lab Invest* 54:68A, 1986.
27. Harrington DS, Weisenburger DD, Daley DT, Linder J, Armitage JO. Monoclonal Antibody Analysis of B-Cell Lymphoma. *Lab Invest* 54:24A, 1986.
28. Harrington DS, Weisenburger DD, Purtilo DT. Malignant Lymphomas (ML) in X-Linked Lymphoproliferative Syndrome (XLP). *Lab Invest* 54:24A, 1986.
29. Mroczek EC, Weisenburger DD, Lipscomb Grierson HL, Purtilo DT. Fatal Epstein-Barr Virus-Associated Hemophagocytic Syndrome. *Lab Invest* 54:45A, 1986.
30. Linder J, Armitage JO, Weisenburger DD. B-Cell Monoclonal Antibodies in Paraffin and Frozen Tissue. *Lab Invest* 54:37A, 1986.
31. Purtilo DT, Lipscomb Grierson HL, Mroczek EC, Weisenburger DD. Fatal Infectious Mononucleosis (FIM). Failure in Immunological Control of Epstein-Barr Virus. *Fed Proc* 45:252, 1986.



Dennis Weisenburger, MD - MC

32. Mackeen L, Brown M, Ip SH, Kung PC, Yasuda N, Harrington DS, Hinuma Y, Weisenburger DD, Lai P, Purtilo DT. Serum Interleukin-2 Receptors as a Marker for Active T-Cell Malignancies. *Fed Proc* 45:454, 1986.
33. Weisenburger DD, Armitage JO, Purtilo DT. Environmental Epidemiology of Non-Hodgkin's Lymphoma (NHL) in Eastern Nebraska. *Fed Proc* 45:640, 1986.
34. Armitage JO, Linder J, Weisenburger DD, Purtilo DT. Clinical Significance of Immunologic Phenotype in Uniformly Treated Patients (PTS) with Diffuse Aggressive Lymphoma. *Proc ASCO* 5:191, 1986.
35. Purtilo DT, Lipscomb Grierson HL, Harrington DS, Weisenburger DD. Non-Hodgkin's Lymphomas (NHL) in the X-Linked Lymphoproliferative Syndrome (XLP) Registry. *Proc AACR* 27:161, 1986.
36. Weisenburger DD, Joshi SS, Mirvish SS. Induction of B-Cell Lymphoma/Leukemia in Wistar Rats by 2-Hydroxyethylnitrosourea (HENU). *Proc AACR* 27:98, 1986.
37. Weisenburger DD, Linder J, Armitage JO. Peripheral T-Cell Lymphoma (PTCL): A Clinicopathologic Study of 42 Cases. *Proc AACR* 27:199, 1986.
38. Smith DM, Weisenburger DD, Bierman P, Kessinger A, Vaughan WP, Armitage JO. Acute Renal Failure Associated with Autologous Bone Marrow Transplantation. *J Cell Biochem* 10D:221, 1986.
39. Mann SL, Joshi SS, Weisenburger DD, Armitage JO, Kessinger A, Vaughan WP, Sharp JG. Detection of Tumor Cells in Histologically Normal Bone Marrow of Autologous Transplant Patients Using Culture Techniques. *Exp Hematol* 14:541, 1986.
40. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD, Anderson R. Is There a Correlation Between the Number of Autologous Peripheral Mononuclear Cells and Peripheral Stem Cells Infused and the Rate of Marrow Recovery? *Exp Hematol* 14:541, 1986.
41. Stahl MG, Armitage JO, Pierson JL, Weisenburger DD, Rennard SI. Sub-acute Fatal Lung Disease Associated with Intensive Chemotherapy for Non-Hodgkin's Lymphoma. *Clin Res* 34:570A, 1986.
42. Weisenburger DD, Sanger WG, Armitage JO, Purtilo DT. Intermediate Lymphocytic Lymphoma: An Immunologic and Cytogenetic Study. *International Congress of the International Academy of Pathology Proceedings*, 1986.
43. Harrington DS, Ye YL, Weisenburger DD. Non-Hodgkin's Lymphoma in Nebraska and Guangzhou, China: A Comparative Study. *International Congress of the International Academy of Pathology Proceedings*, 1986.
44. Harrington DS, Ye JL, Weisenburger DD. Non-Hodgkin's Lymphoma in Nebraska and Guangzhou, China: A Comparative Study. *American Society of Clinical Pathologists Proceedings*, 1986.
45. Keller DJ, Alter R, Joshi SS, Kessinger A, Landmark JD, Weisenburger DD. Decreased Yield of Peripheral Blood Progenitor Cells Harvested at Longer Time Intervals During Leukapheresis. *UNMC Student Research Forum*, 1986.

Dennis Weisenburger, MD - MC

46. O'Connor SJ, Joshi SS, Weisenburger DD. Immunosuppression by Metastasis Associated Cell Surface Molecules. UNMC Student Research Forum, 1986.
47. Wooldridge TN, Grierson HL, Collins M, Pauza M, Armitage JO, Weisenburger DD, Purtilo DT. Flow Cytometric Analysis of DNA Content of Paraffin-Embedded Tissues from Patients with Aggressive Non-Hodgkin's Lymphoma. UNMC Student Research Forum, 1986.
48. Weisenburger DD, Schmidt H, Steele SJ, Babbitt PR, Armitage JO. Environmental Epidemiology of Non-Hodgkin's Lymphoma (NHL) in Eastern Nebraska. Nebraska Symposium on Cancer and Smoking Related Diseases, 1986.
49. Joshi SS, Weisenburger DD, Sharp JG. The Role of Cell Surface Glycosylation on RAW117 Murine Metastatic Lymphoma Cells. Nebraska Symposium on Cancer and Smoking Related Diseases, 1986.
50. Joshi SS, Glenn L, Vaughan WP, Stevenson M, Sanger WG, Sharp JG, Weisenburger DD. Correlation of In-vitro cultured and In-vivo Selected Clones in Acute Lymphoblastic Leukemia. Nebraska Symposium on Cancer and Smoking Related Diseases, 1986.
51. Sharp JG, Mann SL, Joshi SS, Kessinger A, Crouse DA, Weisenburger DD, Sanger WG. Culture of Human Bone Marrow Stem Cells and Stroma Leads to Detection of Tumor Cells Contaminating Histologically Normal Bone Marrow. Nebraska Symposium on Cancer and Smoking Related Diseases, 1986.
52. Mirvish SS, Weisenburger DD, Joshi SS, Nickols J. Promoting Agents for Leukemia/Lymphoma Induction in Rats. Nebraska Symposium on Cancer and Smoking Related Diseases, 1986.
53. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Restoration of Hematopoietic Function with Autologous Cryopreserved Peripheral Stem Cells. Third International Symposium on Autologous Bone Marrow Transplantation, 1986.
54. Sharp JG, Mann SL, Kessinger A, Joshi SS, Crouse DA, Weisenburger DD. Detection of Occult Breast Cancer Cells in Cultured Pre-transplantation Bone Marrow. Third International Symposium on Autologous Bone Marrow Transplantation, 1986.
55. Armitage JO, Greer JP, Levine AM, Weisenburger DD, Formenti SC, Bast M, Conley S, Pierson J, Linder J, Cousar J, Nathwani B. Peripheral T-Cell Lymphoma (PTCL). Blood 68:208a, 1986.
56. Joshi SS, Glenn L, Vaughan WP, Stevenson M, Sanger WG, Sharp JG, Weisenburger DD. Correlation of In-vitro Cultured and In-vivo Selected Clones in Acute Lymphoblastic Leukemia Validates Detection of Occult Malignant Cells. Blood 68:247A, 1986.
57. Smith DM, Rogers K, Vaughan WP, Civin CI, Weisenburger DD, Kessinger A, Armitage JO. A Correlation of My-10 Positive Cells in Human Bone Marrow with Bone Marrow Culture Results. Blood 68:292A, 1986.
58. Alter R, Joshi SS, Verdirame JD, Weisenburger DD. Pure Red Cell Aplasia Associated with B-Cell Non-Hodgkin's Lymphoma: Demonstration of Bone Marrow Colony Inhibition by Serum Immunoglobulin. Blood 68:102A, 1986.



Dennis Weisenburger, MD – MC

59. Vaughan WP, Weisenburger DD, Grierson HL, Joshi SS, Sanger WG, Crvin CI. Acute Leukemia with Homogeneous Expression of the Pluripotent Stem Cell Surface Antigen My-10 has an Otherwise Variable Phenotype but Uniformly Poor Prognosis. *Blood* 68:206A, 1986.
60. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Cryopreserved Autologous Peripheral Stem Cell Infusions Following High Dose Therapy Result in Complete Restoration of Hematopoietic Function for Patients with Non-Leukemic Malignancies. *Blood* 68:290A, 1986.
61. Joshi SS, Weisenburger DD, O'Connor SJ, Sharp JG. Metastatic Lymphoma Induced Immunosuppression. Midwest Autumn Immunology Conference, 1986.
62. Smith DM, Dooley DC, Kessinger A, Law P, Vaughan WP, Armitage JO, Weisenburger DD. A Simple Method for the Bulk Isolation of Low Density Cells From Bone Marrow. First International Conference on Bone Marrow Purging, 1986.
63. Dooley DC, Smith DM, Kessinger A, Law P, Landmark JD, Armitage JO, Weisenburger DD. Collection of T-Cell Depleted Peripheral Blood Mononuclear Cells from Bone Marrow. First International Conference on Bone Marrow Purging, 1986.
64. Joshi SS, Weisenburger DD, Sharp JG. Role of Cell Surface Glycosylation in Metastasis of RAW117 Murine Metastatic Lymphoma Cells. *J Cell Biochem* 14D:214, 1987.
65. Weisenburger DD, Harrington DS, Armitage JO. B-Cell Leukemia/Lymphoma Recapitulates the Normal Humoral Immune Response. *J Cell Biochem* 11A:233, 1987.
66. Weisenburger DD, Hapke MR, Nathwani BN, Levine AM, Armitage JO. Histologic Type and Immunotype Predict Clinical Outcome in Peripheral T-Cell Lymphoma. *Lab Invest* 56:85A, 1987.
67. Weisenburger DD, Schmidt H, Steele SJ, Babbitt PR, Armitage JO. Environmental Epidemiology of Non-Hodgkin's Lymphoma (NHL) in Eastern Nebraska. *Lab Invest* 56:85A, 1987.
68. Harrington DS, Linder J, Weisenburger DD, Daley D, Armitage JO. Peripheral T-Cell Lymphoma (PTCL): An Immunophenotypic and Clinical Analysis. *Lab Invest* 56:29A, 1987.
69. Vago JF, Weisenburger DD, Armitage JO. Do Pathologic Features in Diffuse Large B-Cell Lymphoma Predict Prognosis? *Lab Invest* 56:82A, 1987.
70. Weisenburger DD, Markin RS, Langdon SM, Page JA, Winsten D, Butterfield RJ. Financial Justification of a Laboratory Information System. *Am J Clin Pathol* 87:420, 1987.
71. Joshi SS, O'Connor SJ, Weisenburger DD, Sharp JG. Metastatic Lymphoma Induced Immunosuppression. *Proc AACR* 28:73, 1987.
72. Weisenburger DD, Joshi SS, Hickman TI, Babcook DM, Walker BA, Mirvish SS. N-nitrosoatrazine (NNAT). Synthesis, Chemical Properties, Acute Toxicity, and Mutagenicity. *Proc AACR* 28:103, 1987.

Dennis Weisenburger, MD - MC

73. Wooldridge TN, Grierson HL, Pierson JL, Pauza M, Collins MM, Armitage JO, Weisenburger DD, Purtilo DT. DNA Aneuploidy and Low Proliferative Activity (PA) Predict a Favorable Clinical Outcome in Diffuse Large Cell and Mixed Cell Non-Hodgkin's Lymphoma (NHL). Proc AACR 28:33, 1987.
74. Peterson C, Armitage JO, Linder J, Weisenburger DD. Autologous Bone Marrow Transplantation (ABMT) in Peripheral T-Cell Lymphoma (PTCL). Proc AACR 28:213, 1987.
75. Armitage JO, Vose J, Weisenburger DD, Moravec D, Hutchins M, Howe D, Sorensen S, Dowling M, Okerbloom J, Pevnick W, Packard W, Thompson J. ChlVPP: An Effective and Well Tolerated Alternative to MOPP. Proc ASCO 6:196, 1987.
76. Severson GS, Harrington DS, Weisenburger DD, McComb RD, Casey J, Rappaport H. Castleman's Disease of the Leptomeninges: Three Cases Mimicking Meningiomas. XIV World Congress of Anatomic and Clinical Pathology Proceedings, 1987.
77. Weisenburger DD, Harrington DS, Armitage JO. B-Cell Neoplasia Recapitulates the Normal Humoral Immune Response. Proceedings of the Third International Conference on Malignant Lymphoma, 1987.
78. Keller DJ, Alter R, Joshi SS, Kessinger A, Landmark JD, Weisenburger DD. Decreased Yield of Peripheral Blood Progenitor Cells Harvested During Leukopheresis. Proceedings of the Nebraska Academy of Sciences, 1987.
79. Bolte LJ, Joshi SS, Weisenburger DD. Increased Production of Granulocytic Colony Stimulating Factor(s) by Normal Human Bone Marrow is Induced with Retinoic Acid. Proceedings of the 5th International Meeting on Differentiation of Normal and Neoplastic Cells, 1987.
80. Vaughan WP, Civin CI, Weisenburger DD, Karp JE, Graham ML, Sanger WG, Grierson HL, Joshi SS, Benke PJ. Acute Leukemia with > 70% of Blasts Expressing the Human Hematopoietic Stem Cell Membrane Antigen MY10. Proceedings of the World Congress of Haematology, 1987.
81. Vaughan WP, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Breast Cancer in Histologically Negative Bone Marrow Detected by Cell Culture Techniques - Clinical Correlations. Breast Cancer Res Treat 10:110, 1987.
82. Vaughan WP, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Malignant Cells in Histologically Negative Bone Marrow Detected by Cell Culture Techniques - Clinical Correlations. Clin Res 35:901A, 1987.
83. Bolte LJ, Joshi SS, Weisenburger DD. Increased Production of Granulocytic Colony Stimulating Factors by Normal Human Bone Marrow is Induced with Retinoic Acid. UNMC Student Research Forum, 1987.
84. Bolte LJ, Joshi SS, Sharp JG, Armitage JO, Weisenburger DD. Detection of Occult Lymphoma Cells in Bone Marrow Harvested for Autologous Transplantation. UNMC Student Research Forum, 1987.



Dennis Weisenburger, MD - MC

85. Wooldridge TN, Grierson HL, Sanger W, Armitage JO, Weisenburger DD, Fordyce R, Purtilo DT. Correlation of Cytogenetic and Flow Cytometric Analysis of DNA Content in Non-Hodgkin's Lymphoma. UNMC Student Research Forum, 1987.
86. Keller DJ, Alter R, Landmark JD, Kessinger A, Weisenburger DD. Harvested Normal Peripheral Blood CFU-GEMM Decrease During Leukapheresis. UNMC Student Research Forum, 1987.
87. Ward B, Smith DM, Joshi SS, Weisenburger DD. Comparison of Feeder Layer and Giant Cell Tumor Conditioned Media in the CFU-GM Assay. UNMC Student Research Forum, 1987.
88. Mroczek EC, Weisenburger DD, Grierson HL, Markin RM, Purtilo DT. Fatal Infectious Mononucleosis and Virus-Associated Hemophagocytic Syndrome. International Synopses, 1987.
89. Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Wigton RS, Armitage JO. Harvesting Peripheral Blood Stem Cells for Autologous Transplantation. Blood 70:321A, 1987.
90. Armitage JO, Sanger W, Weisenburger DD, Harrington DS, Linder J, Purtilo DT. Secondary Cytogenetic Abnormalities Correlate with Histologic Appearance in Non-Hodgkin's Lymphomas with the t(14;18)(q32;q21). Blood 70:274A, 1987.
91. Smith DM, Lobo F, Kessinger A, Law P, Dooley DC, Landmark JD, Weisenburger DD, Armitage JO. The Use of Peripheral Blood Mononuclear Cells Isolated by Density Gradient Centrifugation to Restore Hematopoiesis in an Effort to Reduce Transfusion Related Toxicity. Blood 70:324A, 1987.
92. Keller DJ, Alter R, Landmark JD, Kessinger A, Weisenburger DD. Harvested Normal Peripheral Blood CFU-GEMM Decrease During Leukapheresis. Blood 70:321A, 1987.
93. Ward B, Smith DM, Joshi SS, Weisenburger DD. Comparison of Feeder Layer and Giant Cell Tumor Conditioned Media in the CFU-GM Assay. Blood 70:164A, 1987.
94. Bolte LJ, Joshi SS, Sharp JG, Armitage JO, Weisenburger DD. Detection of Occult Lymphoma Cell in Bone Marrow Harvested for Autologous Transplantation. Blood 70:317A, 1987.
95. Weisenburger DD, Vinh TN, Levinson B. Malakoplakia of Bone. An Unusual Cause of Pathologic Fracture in an Immunosuppressed Patient. Calcified Tissue Abstracts 19:58, 1987.
96. Harrington DS, Wickert R, Waldman M, Babbitt C, Weisenburger DD, Linder J, Purtilo DT, Armitage JO. T-Cell Receptor and Immunoglobulin Gene Rearrangements in 145 Consecutive Cases Submitted to the Nebraska Lymphoma Registry. Mod Pathol 1:37A, 1988.
97. Harrington DS, Wickert R, Babbitt C, Waldman M, Weisenburger DD, Purtilo DT, Armitage JO. T-Cell Receptor and Immunoglobulin Gene Rearrangements in Hodgkin's Disease. Mod Pathol 1:37A, 1988.
98. Marcus J, Weisenburger DD, Watson P, Fitzsimmons M, Grierson HL, Smith D, Lynch J, Purtilo DT, Lynch H. Pathology and Laboratory Studies in a Lymphoma Family. Mod Pathol 1:60A, 1988.
99. Linder J, Ye JL, Armitage JO, Weisenburger DD. Comprehensive Immunohistochemical Analysis of Paraffin-Embedded Non-Hodgkin's Lymphoma. Mod Pathol 1:55A, 1988.
100. Ye YL, Weisenburger DD, Armitage JO, Linder J. Immunohistochemical Characterization of Intermediate Lymphocytic Lymphoma in Paraffin-Embedded Tissue. Mod Pathol 1:106A, 1988.

Dennis Weisenburger, MD - MC

101. Duggan MJ, Weisenburger DD, Linder J, Ye YL, Bast MA, Pierson JL, Armitage JO. Mantle- Zone Lymphoma: A Clinicopathologic Study of 25 Cases. *Mod Pathol* 1:26A, 1988.
102. Bolte LJ, Joshi SS, Sharp JG, Armitage JO, Weisenburger DD. Detection of Occult Lymphoma Cells in Bone Marrow Harvested for Autologous Transplantation. *Mod Pathol* 1:11A, 1988.
103. Weisenburger DD, Hickman TI, Babcock DM, Walker BA, Lawson TA, Mirvish SS. N-nitrosoatrazine (NNAT). Synthesis, Chemical Properties, and Mutagenesis. Eppley Institute Conference on Advances in the Biology and Chemistry of N-Nitroso and Related Compounds, 1988.
104. Weisenburger DD, Harrington DS, Armitage JO. B-Cell Lymphoma Recapitulates the Normal Humoral Immune Response. *Proc ASCO* 7:909, 1988.
105. Vaughan WP, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Breast Cancer in Histologically Uninvolved Bone Marrow Detected by Cell Culture Techniques - Clinical Correlations. *Proc ASCO* 7:35, 1988.
106. Weisenburger DD, Joshi SS, Hickman TI, Walker BA, Lawson TA. Mutagenesis Tests of Atrazine and Nitrosoatrazine: Compounds of Special Interest to the Midwest. *Proc AACR* 29:421, 1988.
107. Marcus J, Weisenburger DD, Watson P, Fitzsimmons M, Grierson H, Smith D, Lynch J, Purtilo DT, Lynch H. Epidemiological and Laboratory Findings in a Lymphoma Kindred. *Proc AACR* 29:860, 1988.
108. Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Moravec D, Hutchins M, Howe D, Sorensen S, Dowling M, Okerbloom J, Pevnick W, Packard W, Thompson J. Effect of Age on Cause of Death in Patients Treated with Chemotherapy for Aggressive Non-Hodgkin's Lymphoma (NHL). *Proc AACR* 29:838, 1988.
109. Joshi SS, Bolte LJ, Ketels DJ, Maitreya V, Weisenburger DD, Sharp JG. Levels of Detection of Tumor Cells in Human Bone Marrow. *Proc AACR* 29:697, 1988.
110. Sharp JG, Joshi SS, Armitage JO, Bolte J, Kessinger A, Mann S, Vaughan WP, Weisenburger DD. Tumor Cells Cultured from Histopathologically Normal Marrow of Patients with Lymphomas and Solid Tumors. *UCLA Symposium on Bone Marrow Transplantation. J Cell Biochem* 12C:123, 1988.
111. Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Armitage JO. Autologous Peripheral Stem Cell Transplantation Following High Dose Chemotherapy - An Update. *UCLA Symposium on Bone Marrow Transplantation. J Cell Biochem* 12C:121, 1988.
112. Smith DM, Lobo F, Kessinger A, Law P, Dooley DC, Landmark JD, Weisenburger DD, Armitage JO. The Use of Peripheral Blood Mononuclear Cells Isolated by Density Gradient Centrifugation to Restore Hematopoiesis in an Effort to Reduce Transfusion Related Toxicity. *World Apheresis Association 2nd International Congress*, 1988.
113. Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Armitage JO. Transplantation of Autologous Peripheral Stem Cells Following High Dose Therapy for Malignancies. *Meeting of the European Cooperative Group for Bone Marrow Transplantation*, 1988.



Dennis Weisenburger, MD - MC

114. Wooldridge TN, Grierson HL, Sanger W, Armitage JO, Weisenburger DD, Fordyce R, Purtilo DT. Correlation of Cytogenetic and Flow Cytometric Analysis of DNA Content in Non-Hodgkin's Lymphoma. *Proc FASEB* 2:A1408, 1988.
115. Zahm SH, Weisenburger DD, Babbitt PA, Saal RC, Cantor KP, Blair A. A Case-Control Study of Non-Hodgkin's Lymphoma and Agricultural Factors in Eastern Nebraska. Society for Epidemiologic Research Meeting, 1988.
116. Weisenburger DD. Environmental Epidemiology of Non-Hodgkin's Lymphoma in Eastern Nebraska. Iowa Symposium on Agricultural Occupational and Environmental Health, 1988.
117. Weisenburger DD. Lymphoid Malignancies and Agricultural Practices. NIEHS Workshop on the Quantification of Risk in Immunotoxicology, 1988.
118. Ward WG, Weisenburger DD, Kessinger A. An Improved Method for CFU-GM Culture of Peripheral Blood Stem Cell Collections. UNMC Student Research Forum, 1988.
119. Alter R, Landmark JD, Weisenburger DD, Wigton R, Kessinger A. Does the Efficiency of Peripheral Blood Hematopoietic Stem Cell Collection Change During a Four Hour Apheresis Procedure? UNMC Student Research Forum, 1988.
120. Smith DM, Kessinger A, Landmark JD, Armitage JO, Weisenburger DD. Recovery of Peripheral Blood Stem Cells (PBSC) and Depletion of Erythrocytes by Elutriation or Density Gradient Separation. *Blood* 72:408A, 1988.
121. Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Weisenburger DD, Armitage JO. Autologous Bone Marrow Transplantation in Follicular Non-Hodgkin's Lymphoma. *Blood* 72:405A, 1988.
122. Vose J, Armitage JO, Bierman P, Linder J, Weisenburger DD. Clinical Significance of Immunophenotype in Aggressive Non-Hodgkin's Lymphoma. *Blood* 72:259A, 1988.
123. Schouten HC, Sanger WG, Duggan M, Weisenburger DD, McLennan KA, Armitage JO. Chromosomal Abnormalities in Hodgkin's Disease. *Blood* 72:256A, 1988.
124. Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Weisenburger DD, Armitage JO. Autologous Bone Marrow Transplantation in Follicular Non-Hodgkin's Lymphoma. *Blood* 72:405A, 1988.
125. Alter R, Landmark JM, Weisenburger DD, Wigton R, Kessinger A. Does the Efficiency of Peripheral Blood Hematopoietic Stem Cell Collection Change During a Four Hour Apheresis Procedure? *Exp Hematol* 16:478, 1988.
126. Schouten HC, Smith DM, Weisenburger DD, Landmark JD, Wigton R, Armitage JO, Kessinger A. Comparison of the Standard Versus the Lymphocyte Surge Procedure for Collection of Stem Cells from Peripheral Blood. *Exp Hematol* 16:486, 1988.
127. Smith DM, Kessinger A, Landmark JD, Weisenburger DD, Armitage JO. Collection of Peripheral Blood Stem Cells Using a Modified Elutriation Protocol. *Exp Hematol* 16:486, 1988.
128. Kessinger A, Smith DM, Strandjord SE, Landmark JD, Dooley DC, Coccia PF, Warkentin PI, Weisenburger DD, Armitage JO. Allogeneic Peripheral Stem Cell Transplantation. *Exp Hematol* 16:493, 1988.

Dennis Weisenburger, MD - MC

129. Ward WG, Weisenburger DD, Kessinger A. An Improved Method for CFU-GM Culture of Peripheral Blood Stem Cell Collections. *Exp Hematol* 16:538, 1988.
130. Weisenburger DD, Babbitt PA, Zahm SH, Saal RC, Cantor KP, Blair A. Lymphoid Malignancies and Agricultural Practices. American Association for the Advancement of Science Meeting, 1989.
131. O'Connor SJ, Daley DT, Weisenburger DD. Pseudofollicular Proliferation Centers in Small Lymphocytic Lymphoma Lack Dendritic Reticulum Cells. *Midwest Student Medical Research Forum*, 1989.
132. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Hematologic Abnormalities in Non-Hodgkin's Lymphoma at Presentation Predict Outcome. American Federation for Clinical Research Meeting, 1989.
133. Mirvish SS, Nickols J, Weisenburger DD, Joshi SS, Gross ML, Tana H. B-cell Lymphoma/Leukemia (BCL) in Rats and Mice Treated with 2-Hydroxyethylnitrosourea (HENU) and Effects of Coadministration of 2,4,5-Trichlorophenoxyacetic Acid (245T) and Pentachlorophenol (PCP). *J Toxicol* 9:210, 1989.
134. Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Armitage JO. Autologous Transplantation with Peripheral Blood Stem Cells: Clinical Results. *J Clin Apheresis* 5:43, 1989.
135. O'Connor SJ, Daley DT, Weisenburger DD. Pseudofollicular Proliferation Centers in Small Lymphocytic Lymphoma Lack Dendritic Reticulum Cells. *Mod Pathol* 2:67A, 1989.
136. Linder J, Ye JL, Harrington DS, Armitage JO, Weisenburger DD. Immunohistochemistry in the Differential Diagnosis of Hodgkin's Disease (HD) Versus Non-Hodgkin's Lymphoma (NHL) in Paraffin Embedded Tissue. *Mod Pathol* 2:53A, 1989.
137. Harrington DS, Waldman M, Masih A, Wickert B, Hakenson S, Weisenburger DD, Armitage JO. Correlation of Immunophenotype and Genotype in 106 B-Cell Lymphomas. *Mod Pathol* 2:39A, 1989.
138. Masih AS, Weisenburger DD, Vose JM, Bast MA, Armitage JO. Histologic Grade in Nodular Sclerosing Hodgkin's Disease Does Not Predict Clinical Outcome. *Mod Pathol* 2:59A, 1989.
139. Weisenburger DD, Harrington DH, Linder J, Perry DA, Bast MA, Armitage JO. Pathologic Features Predict Clinical Outcome in Peripheral T-Cell Lymphoma. *Mod Pathol* 2:104A, 1989.
140. Weisenburger DD, Hickman TI, Babcock DM, Walker BA, Lawson TA, Mirvish SS. N-Nitrosoatrazine (NNAT). Synthesis, Chemical Properties, Mutagenicity and Carcinogenicity. Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
141. Weisenburger DD, Babbitt PA, Zahm SH, Saal RC, Cantor KP, Blair A. Environmental Epidemiology of Non-Hodgkin's Lymphoma in Eastern Nebraska. Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
142. Wooldridge TN, Grierson HL, Sanger WG, Weisenburger DD, Armitage JO, Pierson JL, Fordyce R, Purtilo DT. Analysis and Correlation of DNA Content in Non-Hodgkin's Lymphomas (NHL) by Cytogenetics and Flow Cytometry. Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.



Dennis Weisenburger, MD - MC

143. Grierson HL, Wooldridge TN, Weisenburger DD, Armitage JO, Sanger WG, Pierson J, Fordyce R, Purtilo DT. DNA Analysis by Flow Cytometry of Paraffin-Embedded Biopsy Samples from Patients with Non-Hodgkin's Lymphomas (NHL). Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
144. Mirvish SS, Nickols J, Weisenburger DD, Joshi SS, Gross ML, Tana H. B-cell Lymphoma/Leukemia (BCL) in Rats and Mice Treated with 2-Hydroxyethylnitrosourea (HENU) and Effects of Coadministration of 2,4,5-Trichlorophenoxyacetic Acid (245T) and Pentachlorophenol (PCP). Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
145. Smith DM, Kessinger A, Landmark JD, Armitage JO, Weisenburger DD. Recovery of Peripheral Blood Stem Cells (PBSC) and Depletion of Erythrocytes by Elutriation or Density Gradient Separation. Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
146. Smith DM, Kessinger A, Law P, Dooley DC, Strandjord SE, Coccia PF, Weisenburger DD, Warkentin PI, Landmark JD, Meryman HT, Armitage JO. Collection and Successful Allogeneic Transplantation of Human Peripheral Blood Stem Cells. Third Nebraska Symposium on Cancer and Smoking Related Diseases, 1989.
147. Perry DA, Weisenburger DD, Bast MA, Armitage JO. Diffuse Intermediate Lymphocytic Lymphoma: A Clinicopathologic Study of 39 Cases. *Proc AACR* 30:263, 1989.
148. Lobo F, Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Wigton RS, Armitage JO. Does the Addition of Peripheral Blood Stem Cells Shorten the Period of Aplasia in Patients Receiving Myeloablative Therapy and Autologous Bone Marrow Transplantation? *Proc AACR* 30:234, 1989.
149. Conlan MG, Armitage JO, Bast M, Weisenburger DD. Clinical Significance of Bone Marrow Involvement by Non-Hodgkin's Lymphoma. *Proc AACR* 30:220, 1989.
150. Kessinger A, Armitage JO, Landmark JD, Schmit-Pokorny KA, Smith DM, Weisenburger DD. Augmentation of Hypocellular Autologous Bone Marrow Collection with Autologous Peripheral Stem Cells for Transplantation Following Marrow-Ablative Therapy. *Proc AACR* 30:234, 1989.
151. Sharp JG, Mann SL, DeBoer J, Messbarger L, Joshi SS, Crouse DA, Kessinger MA, Vaughan WP, Armitage JO, Weisenburger DD. Long Term Culture as a Method of Detection of Occult Tumor Cells in Bone Marrow and Blood. *In Vitro* 25:16A, 1989.
152. Sharp JG, Kessinger MA, DeBoer J, Mann S, Weisenburger DD. Occult Tumor Cells in Peripheral Blood Stem Cell and Bone Marrow Harvests of Candidates for Autologous Transplantation. *Exp Hematol* 17:650, 1989.
153. DeBoer JM, Hess M, Joshi SS, Sanger WG, Strandjord SE, Weisenburger DD, Sharp JG. Atypical Chromosomal Abnormalities and Aggressive In Vitro Tumorigenicity of a Newly Established Burkitt's Lymphoma Cell Line. *Karyogram* 15:79, 1989.
154. Alter R, Ward WG, Welniak L, Weisenburger DD. Improving Sensitivity of the Colony Forming Unit Granulocyte/Monocyte Assay using Recombinant Growth Factors. UNMC Student Research Forum, 1989.
155. Welniak L, Ward WG, Alter R, Rehder B, Smith DM, Weisenburger DD. Methods to Optimize the Recovery of CFU-GM Following Cryopreservation of Bone Marrow in 10% DMSO. UNMC Student Research Forum, 1989.

Dennis Weisenburger, MD - MC

156. Wooldridge T, Grierson H, Purtilo D, Pierson J, Bast M, Wooldridge L, Armitage J, Weisenburger D. Low Proliferative Activity is Associated with a Favorable Prognosis in Peripheral T-Cell Lymphoma. UNMC Student Research Forum, 1989.
157. Vaughan WP, Mann SL, Garvey J, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Breast Cancer in Histologically Negative Bone Marrow Detected by Cell Culture Techniques Predicts Systemic Relapse in Patients with Stage I, II, III and Locally Recurrent Disease. 12th Annual Breast Cancer Symposium, 1989.
158. Vaughan WP, Mann SL, Garvey J, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Breast Cancer in Histologically Negative Bone Marrow Detected by Cell Culture Techniques Predicts Systemic Relapse in Patients with Stage I,II,III and Locally Recurrent Disease. Central Society for Clinical Research, 1989.
159. Grierson H, Sanger W, Weisenburger D, Armitage J, Wooldridge T, Fordyce R, Wooldridge L, Purtilo D. The Significance of Ploidy in Non-Hodgkin's Lymphoma (NHL): Analysis by Flow Cytometry and Cytogenetics. Symposium on DNA Flow Cytometry: Status and Controversies, 1989.
160. Sharp JG, Joshi SS, Armitage JO, Coccia PF, Crouse DA, Harrington DS, Kessinger A, Mann SL, Pirruccello SJ, Vaughan WP. Weisenburger DD. Clinical Significance of Tumor Cells in Long Term Cultures of Bone Marrow from Patients with Leukemia and Non-Hodgkin's Lymphoma. XIVth International Symposium for Comparative Research on Leukemia and Related Disorders, 1989.
161. Joshi SS, DeBoer JM, Strandjard SE, Pirruccello SJ, Harrington DS, Sanger WG, Weisenburger DD, Sharp JG. Characterization of a Newly Established Burkitt's Lymphoma Cell Line, OMA-BL-1. XIVth International Symposium for Comparative Research on Leukemia and Related Disorders, 1989.
162. Welniak LA, Ward WG, Alter R, Rehder E, Smith DM, Weisenburger DD. Methods to Optimize the Recovery of CFU-GM Following Cryopreservation of Bone Marrow in 10% DMSO. Blood 74:425A, 1989.
163. Perry DA, Bast MA, Armitage JO, Weisenburger DD. Diffuse Intermediate Lymphocytic Lymphoma: A Clinicopathologic Study with Comparison to Small Lymphocytic Lymphoma and Diffuse Small Cleaved Cell Lymphoma. Blood 74:378A, 1989.
164. Sharp JG, Joshi SS, Armitage JO, Bierman PJ, Kessinger A, Coccia PF, Crouse DA, Harrington DS, Mann SL, Weisenburger DD. Prognostic Significance of Occult Tumor Cells in Bone Marrow of Patients with Intermediate and High Grade Non-Hodgkin's Lymphoma. UCLA Symposium on New Strategies in Bone Marrow Transplantation. J Cell Biochem 14A:313, 1990.
165. Smith DM, Weisenburger DD, Kessinger A. A Comparison of Myeloid Engraftment Rates Using Three Methods of Processing Peripheral Blood Stem Cells (PBSC). UCLA Symposium on New Strategies in Bone Marrow Transplantation. J Cell Biochem 14A:324, 1990.
166. Weisenburger DD, Armitage JO, Kessinger A, Mann S, DeBoer JM, Sharp JG. Culture of Ber-H2 (CD30) Positive Reed-Sternberg-Like Cells from Peripheral Blood Stem Cell and Bone Marrow Harvests of Patients with Hodgkin's Disease. UCLA Symposium on New Strategies in Bone Marrow Transplantation. J Cell Biochem 14A, 315, 1990.



Dennis Weisenburger, MD - MC

167. Nakamine H, Masih A, Duggan M, Armitage J, Weisenburger D. Clear-cell variant of immunoblastic lymphoma with a B-cell phenotype. *Mod Pathol* 3:71A, 1990.
168. Weisenburger D, Zahm S, Ward M, Babbitt P, Holmes F, Boysen C, Robel R, Saal R, Vaught J, Cantor K, Blair A. Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic Type. *Mod Pathol* 3:105A, 1990.
169. Harrington D, Grogan T, Miller T, Weisenburger D, Spier C, Duggan M, Masih A, Bast M, Armitage J. Correlation of Immunophenotype and Prognosis in T-Cell Lymphomas. *Mod Pathol* 3:42A, 1990.
170. Weisenburger D, Bast M, Perry D, Duggan M, Armitage J. Diffuse Intermediate Lymphocytic Lymphoma: A Refined Definition Based on Comparative Clinical Studies. *Mod Pathol* 3:105A, 1990.
171. Grierson H, Wooldridge T, Purtilo D, Pierson J, Bast M, Wooldridge L, Armitage J, Weisenburger D. Low Proliferative Activity is Associated with a Favorable Prognosis in Peripheral T-Cell Lymphoma. *Mod Pathol* 3:39A, 1990.
172. Vose JM, Bierman PJ, Weisenburger DD, Armitage JO. The Importance of Early Autologous Bone Marrow Transplantation (ABMT) in the Management of Patients (PTS) with Hodgkin's Disease. *Proc ASCO* 9:256, 1990.
173. Zahm S, Weisenburger D, Babbitt P, Saal R, Vaught J, Blair A. An Increased Risk of Developing Non-Hodgkin's Lymphoma and Multiple Myeloma is Associated with Hair Coloring Product Use. *Proc ASCO* 9:264, 1990.
174. Vaughan WP, Mann SL, Garvey J, Joshi SS, Sharp JG, Kessinger A, Weisenburger DD. Breast Cancer Detected in Cell Culture of Histologically Negative Bone Marrow Predicts Systemic Relapse in Patients with Stage I, II, III and Locally Recurrent Disease. *Proc ASCO* 9:9, 1990.
175. Weisenburger DD, Hickman TI, Patil KD, Lawson TA, Mirvish SS. Carcinogenesis Tests of Atrazine and N-Nitrosoatrazine - Compounds of Special Interest to the Midwest. *Proc AACR* 31:103, 1990.
176. Grierson H, Wooldridge T, Purtilo D, Armitage J, Weisenburger D. Prognostic Significance of Proliferative Activity in Non-Hodgkin's Lymphoma. Fourth International Conference on Malignant Lymphoma, 1990.
177. Globe DA, Ward WG, Weisenburger DD. Standardization of the Burst Forming Unit Erythroid (BFU-E) Assay. *Allied Health Student Research Forum*, 1990.
178. Ward WG, Welniak LA, Smith DM, Kessinger MA, Weisenburger DD. Optimizing the Peripheral Blood Colony Forming Unit - Granulocyte/Monocyte (CFU-GM) Assay Using Colony Stimulating Factors (CSF's). *Exp Hematol* 18:611, 1990.
179. Weisenburger DD, Armitage JO, Kessinger A, Mann S, DeBoer JM, Sharp JG. Culture of Reed-Sternberg-like Cells from Peripheral Blood Stem Cell and Bone Marrow Harvests of Patients with Hodgkin's Disease. *Exp Hematol* 18:651, 1990.
180. Weisenburger DD, Babbitt P, Mirvish S, et al. Potential Health Consequences of Groundwater Contamination by Agrichemicals in Nebraska. *Proceedings of NATO Advanced Research Workshop on Nitrate Contamination: Exposure, Consequences, and Control*, 1990.

Dennis Weisenburger, MD - MC

181. Sharp JG, Weisenburger DD, Bierman PJ, Armitage JO, Mann S, Kessinger MA. Frequency of Detection of Suspected Lymphoma Cells in Peripheral Stem Cell Collections. Fifth International Symposium on Autologous Bone Marrow Transplantation, 1990.
182. Sharp JG, Vaughan WP, Kessinger MA, Mann SL, DeBoer J, Sanger WG, Weisenburger DD. Significance of Detection of Tumor Cells in Hematopoietic Stem Cell Harvests of Patients with Breast Cancer. Fifth International Symposium on Autologous Bone Marrow Transplantation, 1990.
183. Smith DM, Weisenburger DD, Kessinger A. A Comparison of Myeloid Engraftment Rates Using Three Methods of Processing Peripheral Blood Stem Cells (PBSC). Fifth International Symposium on Autologous Bone Marrow Transplantation, 1990.
184. Sharp JG, Pirruccello SJ, DeBoer JM, Mann SL, Welniak LA, Vaughan WP, Dicke KA, Sanger WG, Weisenburger DD. Differentiation of Human Acute Myelogenous Leukemia Cells in Long Term Culture. AACR Special Conference on Chromosomal and Growth Factor Abnormalities in Leukemia, 1990.
185. Weisenburger DD, Zahm S, Ward M, Babbitt P, Holmes F, Boysen C, Robel R, Saal R, Vaught J, Cantor K, Blair A. Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic Type. Proceedings of the Third Meeting of the European Association for Haematopathology, 1990.
186. Weisenburger DD, Bast M, Perry D, Duggan M, Armitage J. Diffuse Intermediate Lymphocytic Lymphoma: A Refined Definition Based on Comparative Clinical Studies. Proceedings of the Third Meeting of the European Association for Haematopathology, 1990.
187. Mann KK, Welniak LA, Jackson JD, Weisenburger DD. Effects of Interleukin-4 (IL-4), Interleukin-6 (IL-6) and Erythropoietin (EPO) on Colony Forming Cells In Vitro. Blood 76:153A, 1990.
188. Alter RA, Welniak LA, Jackson JD, Garrison L, Weisenburger DD, Kessinger A. In Vitro Clonogenic Monitoring of Peripheral Blood Stem Cell Collections Following Interleukin-3 Administration. Blood 76:129A, 1990.
189. Masih A, Nakamine H, Mitchell D, Wickert R, Weisenburger D. Molecular Characteristics of Small Lymphocytic, Intermediate Lymphocytic, and Small Cleaved Cell Non-Hodgkin's Lymphomas. Mod Pathol 4:78A, 1991.
190. Weisenburger D, Bast M, Armitage J. When Does a Diffuse Component in Composite Follicular and Diffuse Non-Hodgkin's Lymphoma Affect Prognosis? Mod Pathol 4:85A, 1991.
191. Parks J, Synovec M, Masih A, Nakamine H, Harrington D, Braddock S, Weisenburger D. Immunophenotypic and Genotypic Characterization of Lymphomatoid Papulosis. Mod Pathol 4:80A, 1991.
192. Strobach S, Masih A, Bast M, Nakamine H, Armitage J, Weisenburger D. Lymphocyte Predominance Hodgkin's Disease and Transformation to Large Cell Lymphoma: An Immunohistochemical and Molecular Biologic Study of 42 Cases. Mod Pathol 4:85A, 1991.
193. Masih A, Nakamine H, Wickert R, Mitchell D, Weisenburger D. Molecular Genetic Analysis of Extranodal Non-Hodgkin's Lymphoma. Mod Pathol 4:77A, 1991.



Dennis Weisenburger, MD - MC

194. Masih A, Sun J, Dicke K, Weisenburger D, Armitage J, Wu K. Polymerase Chain Reaction Detection of t(14:18) Involving the Bcl-2 Major Breakpoint Region: Correlation with Southern Analysis. *Mod Pathol* 4:77A, 1991.
195. Ratashak A, Weisenburger D, Purtilo D, Armitage J, Grierson H. DNA Ploidy, But Not Proliferative Activity, is Associated with Decreased Disease-Free Survival in Follicular Non-Hodgkin's Lymphoma. *Mod Pathol* 4:82A, 1991.
196. Nakamine H, Bast M, Masih A, Strobach S, Armitage J, Weisenburger DD. Prognostic Significance of Clinical and Pathologic Features in Diffuse Large B-Cell Lymphoma. *Mod Pathol* 4:79A, 1991.
197. Poje E, Bierman P, Daley D, Hale C, Weisenburger D. Expression of P-Glycoprotein in B-Cell Non-Hodgkin's Lymphoma. *Proc AACR* 32:366, 1991.
198. Masih A, Nakamine H, Sanger W, Strobach S, Armitage J, Weisenburger D. Oncogene Rearrangement in Non-Hodgkin's Lymphomas with a 14q+ Chromosome of Unknown Origin. *Proc AACR* 32:30, 1991.
199. Vose JM, Bierman PJ, Anderson JR, Weisenburger DD, Armitage JO. CHLVPP Plus Involved Field Irradiation for Hodgkin's Disease: Comparable Results with Less Toxicity. *Proc ASCO* 10:272, 1991.
200. Masih A, Weisenburger D, Duggan M, Armitage J, Bashir R, Mitchell D, Wickert R, Purtilo D. Epstein-Barr Viral Genome in Hodgkin's Disease May be Within the Reactive Lymphoid Cells. *Proc FASEB* 5:A706, 1991.
201. Weisenburger DD, Zahm S, Ward M, Babbitt P, Holmes F, Boysen C, Robel R, Saal R, Vaught J, Cantor K, Blair A. Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic Type. Surgeon General's Conference on Agricultural Safety and Health, 1991.
202. Weisenburger DD. Non-Hodgkin's Lymphomas of Primary Follicle/Mantle Zone Origin. *Proc 2nd Vicenza International Workshop of Hematology*, 1991.
203. Weisenburger D, Bast M, Armitage J. When Does a Diffuse Component in Composite Follicular and Diffuse Non-Hodgkin's Lymphoma Affect Prognosis? *Proc Klein Symposium on Causes, Consequences, and Cures of Lymphoproliferative Diseases*, 1991.
204. Sharp JG, Kessinger A, Vaughan WP, Mann S, Crouse DA, Masih A, Weisenburger DD. Detection and Clinical Significance of Minimal Tumor Cell Contamination of Peripheral Stem Cell Harvests. *Proc 2nd International Symposium on Peripheral Blood Stem Cell Autografts*, 1991.
205. Sharp JG, Kessinger A, Armitage JO, Bierman P, Crouse D, Mann S, Vose J, Weisenburger DD. Clinical Significance of Occult Tumor Cell Contamination of Hematopoietic Harvests of Non-Hodgkin's Lymphoma and Hodgkin's Disease. *Proc of International Symposium on Autologous Bone Marrow Transplantation in Lymphomas, Hodgkin's Disease, and Multiple Myeloma*, 1991.
206. Weisenburger DD, Vose JM, Masih AS, Bast MA, Armitage JO. Is Histological Subclassification Useful in Hodgkin's Disease Treated with Curative Multidrug Chemotherapy? *Second International Symposium on Hodgkin's Disease*, 1991.

Dennis Weisenburger, MD - MC

207. Welniak LA, Alter R, Jackson JD, Vose JM, Garrison L, Weisenburger DD, Kessinger A. Interleukin-3 Enhances Collection of Peripheral Blood Mononuclear Cells and CFU-GM. UNMC Student Research Forum, 1991.
208. Weisenburger DD, Sanger WG, Armitage JO. Abnormalities of Chromosome 11q13 in Non-Hodgkin's Lymphoma (NHL). *Blood* 78:121A, 1991.
209. Gordon B, Weisenburger D, Warkentin P, Anderson J, Sanger W, Bast M, Gnarr D, Vose J, Bierman P, Armitage J, Coccia P. Peripheral T-Cell Lymphoma in Childhood: A Clinicopathologic Study of 22 Patients. *Blood* 78:175A, 1991.
210. Gordon B, Warkentin P, Weisenburger D, Vose J, Sanger W, Strandjord S, Anderson J, Verdirame J, Bierman P, Armitage J, Coccia P. Bone Marrow Transplantation for Relapsed Peripheral T-Cell Lymphoma in Children and Young Adults. *Blood* 78:237A, 1991.
211. Welniak LA, Alter R, Jackson JD, Vose JM, Garrison L, Weisenburger DD, Kessinger A. Interleukin-3 Enhances Collection of Peripheral Blood Mononuclear Cells and CFU-GM. *Blood* 78:224A, 1991.
212. Masih A, Weisenburger D, Nakamine H, Sanger W, Chan W, Armitage J. The t(14;18) Chromosome Abnormality Does Not Predict Response to Therapy or Survival in Uniformly Treated Patients with Diffuse Large B-Cell Lymphoma. *Mod Pathol* 5:82A, 1992.
213. McCarthy B, Vose J, Bast M, Bierman P, Armitage J, Weisenburger D. Prognostic Significance of Clinical and Immunopathologic Features in Follicular Large Cell Lymphoma: A Study of Uniformly Staged and Treated Patients. *Mod Pathol* 5:83A, 1992.
214. Weisenburger D, Zahm S, Babbitt P, Saal R, Vaught J, Blair A. An Increased Risk of Lymphoma and Multiple Myeloma in Women is Associated with Hair Coloring Product Use. *Mod Pathol* 5:89A, 1992.
215. Sharp JG, Mann SL, Crouse DA, Weisenburger DD, Kessinger A, Garrison L. Effects of Interleukin-3 on Long-Term Cultures of Human Bone Marrow and Apheresis Harvests from Lymphoma Patients. *J Cell Biochem (Suppl. 16A)*:205, 1992.
216. Alter R, Welniak LA, Jackson JD, Vose JM, Garrison L, Weisenburger DD, Kessinger A. In-Vitro Clonogenic Monitoring of Peripheral Stem Cell Growth Before and During Interleukin-3 Administration. *J Cell Biochem (Suppl. 16A)*:181, 1992.
217. Anderson JR, Vose JM, Bierman PJ, Weisenburger DD, Sanger W, Pierson JL, Bast MA, Armitage JO. Clinical Features and Prognosis of Follicular Large Cell Lymphoma (FLCL): A Report from the Nebraska Lymphoma Study Group (NLSG). *Proc ASCO* 11:1125, 1992.
218. Zahm SH, Weisenburger DD, Blair A. Agriculture and Multiple Myeloma in Men and Women in Nebraska. *Proceedings of the Third International Symposium on Issues in Health, Agriculture and the Environment*, 1992.
219. Zahm SH, Weisenburger DD, Blair A. The Role of Agricultural Pesticide Use in the Development of Non-Hodgkin's Lymphoma in Women. *Proceedings of the Third International Symposium on Issues in Health, Agriculture and the Environment*, 1992.



Dennis Weisenburger, MD - MC

220. Zahm SH, Weisenburger DD, Cantor KP, Holmes FF, Blair A. Non-Hodgkin's Lymphoma and the Use of Atrazine: Results from Three Case-Control Studies. *Proceedings of the Third International Symposium on Issues in Health, Agriculture and the Environment*, 1992.
221. Ward MH, Zahm SH, Weisenburger DD, Babbitt P, Cantor KP, Blair A. Animal Protein Consumption and Nitrate from Diet and Drinking Water: Association with Non-Hodgkin's Lymphoma in Nebraska. *Proceedings of the Third International Symposium on Issues in Health, Agriculture and the Environment*, 1992.
222. Weisenburger DD, Ullrich FA, Spalding ME, Spalding RF, Buehler BA, Anderson JR. Birth Defects and Well Water Contamination by Agrichemicals: An Ecologic Study. *Proceedings of the Third International Symposium on Issues in Health, Agriculture and the Environment*, 1992.
223. Hess MM, Nashelsky MB, Rebolloso FC, Mosier KS, Fordyce-Boyer R, Weisenburger DD, Sanger WG. Cytogenetic Abnormalities in B-Immunoblastic Lymphoma. *Proceedings of the American Association of Cytogenetic Technologists Meeting*, 1992.
224. Weisenburger DD, Zahm S, Babbitt P, Saal R, Vaught J, Blair A. An Increased Risk of Lymphoma and Multiple Myeloma in Women is Associated with Hair Coloring Product Use. *Proceedings of the Fifth Meeting of the European Association for Hematopathology*, 1992.
225. Sharp JG, Kessinger A, Armitage JO, Bierman PJ, Mann SL, Reed EC, Weisenburger DD. Influence of Minimal Disease on Clinical Outcome of Patients Undergoing High Dose Therapy and Transplantation. *Proceedings of the Sixth International Bone Marrow Transplantation Symposium*, 1992.
226. Chan WC, Hooper C, Wickert R, Benson JM, Vardiman J, Hinrichs S, Weisenburger D. HTLV-1 Sequences in Patients with Cutaneous T-Cell Lymphoma. *Blood*. 80:119A, 1992.
227. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, Armitage JO. Comparison of Front-Line Chemotherapy for Aggressive Non-Hodgkin's Lymphoma (NHL) Using CAP-BOP with Adriamycin (CB-A), Adriamycin and Infusional Bleomycin/Vincristine (CB-AI), or Mitoxantrone (CB-M). *Blood*. 80:43A, 1992.
228. Weisenburger DD, Strobach RS, Masih AS, Bast MA, Chan WC, Armitage JO. "Large Cell Lymphoma" Arising in Patients with Lymphocyte Predominant Hodgkin's Disease. *Mod Pathol* 6:103A, 1993.
229. Weisenburger DD, Vose JM, Gordon BG, Rison DL, Bast MA, Sanger WG, Chan WC. Is the 2;5 Chromosomal Translocation Specific for CD30-Positive Anaplastic Large Cell lymphoma? *Mod Pathol* 6:103A, 1993.
230. Chan WC, Hooper C, Wickert R, Benson JM, Hinrichs S, Weisenburger DD. HTLV-1 Sequences in Lymphoproliferative Disorders. *Mod Pathol* 6:87A, 1993.
231. Mirvish SS, Weisenburger D, Smyrk TC, Nickols J, Hinman CA. Carcinogenesis Tests of Methyl-n-amyl nitrosamine, Catechol and Ethanol. *Proc AACR* 34:132A, 1993.
232. Weisenburger DD. Epidemiology of Non-Hodgkin's Lymphoma. *J Cell Biochem* 17E:255, 1993.
233. Ward MH, Zahm SH, Weisenburger DD, Gridley G, Cantor KP, Blair A. Diet and Non-Hodgkin's Lymphoma. *Proceedings of the Society for Epidemiologic Research*, 1993.

Dennis Weisenburger, MD - MC

234. Weisenburger DD. Epidemiology of Non-Hodgkin's Lymphoma. Proceedings of the Fifth International Conference on Malignant Lymphoma, 1993.
235. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger DD, Chan WC, Armitage JO. Composition of Front-line Chemotherapy for Aggressive Non-Hodgkin's Lymphoma (NHL) using CAP-BOP with Adriamycin (CB-A), Adriamycin and Infusional Bleomycin/Vincristine (CB-AI), or Mitoxantrone (CB-M). Proceedings of the Fifth International Conference on Malignant Lymphoma, 1993.
236. Ward MN, Zahm SH, Weisenburger DD, Gridley G, Cantor KP, Blair A. Diet and Non-Hodgkin's Lymphoma. 26th Annual Meeting of the Society for Epidemiologic Research, 1993.
237. Vose JM, Weisenburger DD, Anderson JR, Bierman PJ, Bast M, Chan WC, Bishop MR, Armitage JO. Mantle Cell Lymphoma (MCL) has a Poorer Prognosis than Follicular Non-Hodgkin's Lymphoma (F-NHL); however, High-dose Therapy (HDC) and Autologous Stem Cell Transplantation (ASCT) may Overcome Treatment Resistance in MCL. Blood 82 (Suppl. 1):135A, 1993.
238. Masih A, Weisenburger D, Vose J, Bierman P, Nakamine H, Sanger W, Chan W, Anderson J, Armitage J. Clinicopathologic Analysis of the t(14;18) in Uniformly Treated De Novo Diffuse Large B-Cell Lymphoma. Blood 82 (Suppl. 1):133A, 1993.
239. Bashir R, Cheloha K, Weisenburger D, McManus B. Detection of EBER-1 Messenger RNA in AIDS and Non-AIDS Primary CNS Lymphoma Ann Neurol 34:313, 1993.
240. Yan Y, Chan WC, Weisenburger DD, Vose JM, Bierman PJ, Bast M, Armitage JO. Prognostic Significance of Bone Marrow Involvement in Patients with Diffuse Aggressive B-cell Lymphoma. Mod Pathol 7:124A, 1994.
241. Martin AR, Weisenburger DD, Vose JM, Anderson JR, Bierman PJ, Bast MA, Daley DT, Armitage JO, Chan WC. Prognostic Value of Cellular Proliferation in Follicular Lymphoma Studied by Image Analysis of Fixed Tissue Stained with Ki-67. Mod Pathol 7:115A, 1994.
242. Moynihan MJ, Bast MA, Chan WC, Wickert RS, Wu GQ, Weisenburger DD. Multiple Lymphomatous Polyposis: A Neoplasm of Follicular Mantle or Germinal Center Cell Origin. Mod Pathol 7:117A, 1994.
243. Casey JH, Vose JM, Chan WC, Bast MA, Bierman PJ, Armitage JO, Weisenburger DD. Primary Gastric Non-Hodgkin's Lymphoma. A Clinicopathologic Study of 29 Cases. Mod Pathol 7:104A, 1994.
244. Noel SM, Koo C, Marcus JN, Hsu SM, Weisenburger DD, Chan WC. Plasmacytoid Monocyte Proliferation: A Study of Cytokine Expression and Report of a Case with Extensive Marrow Infiltration. Mod Pathol 7:117A, 1994.
245. Ward MH, Cantor KP, Zahm SH, Weisenburger DD, Marks SD, Correa-Villasenor A, Blair A. Drinking Water Nitrate and Non-Hodgkin's Lymphoma: A Case-Control Study in Nebraska. Proceedings of the Joint Conference of the International Society of Environmental Epidemiology/International Society for Environmental Assessment, 1994.
246. Martin AR, Weisenburger DD, Ruby E. Ki-67 Proliferation Index in Follicular Lymphomas Determined by Image Analysis. Proceedings of the Meeting of the Clinical Cytometry Society, 1994.



Dennis Weisenburger, MD - MC

247. Morris SW, Shurtleff SA, Head D, Behm FG, Raimondi SC, Weisenburger DD, Kossakowska AE, Thorner P, Zielenski M, Lorenzana A, Ladanyi M, Downing JR. Molecular Detection of the t(2;5) of Non-Hodgkin's Lymphoma (NHL) by Reverse Transcriptase-Polymerase Chain Reaction. *Blood* 84 (Suppl 1):138A, 1994.
248. Delabie J, Tierens A, Weisenburger DD, Chan WC. Lymphocyte Predominance Hodgkin's Disease is a Polyclonal B Cell Disorder: Results of Single-Cell Studies. *Blood* 84 (Suppl 1):148A, 1994.
249. Vose J, Ruby E, Bierman P, Anderson J, Weisenburger DD, Armitage JO. Elderly Patients with Localized Diffuse Large Cell Non-Hodgkin's Lymphoma (NHL): Improved Results with Initial Chemotherapy. *Blood* 84 (Suppl 1): 1519A, 1994.
250. Tezcan H, Vose J, Bast M, Weisenburger D, Bierman P, Kessinger A, Armitage JO. Limited Stage Follicular Non-Hodgkin's Lymphoma: The Nebraska Lymphoma Study Group (NLSG) Experience. *Blood* 84 (Suppl 1): 1516A, 1994.
251. Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, Bierman PJ, Bast MA, Armitage JO. Value of Histologic Grade in Follicular Lymphoma: An Evaluation of Four Methods. *Mod Pathol* 8:115A, 1995.
252. Lozano MD, Tierens A, Greiner TC, Wickert RS, Weisenburger DD, Chan WC. Clonality Analysis of B-Lymphoid Proliferations Using PCR. *Mod Pathol* 8:115A, 1995.
253. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Weisenburger DD. p53 Mutations in Mantle Cell Lymphoma. *Mod Pathol* 8:111A, 1995.
254. Smir BN, Weisenburger DD. Multicentric Angiofollicular Lymph Node Hyperplasia in Children. *Mod Pathol* 8:120A, 1995.
255. Delabie J, Chan WC, Tierens A, Cuaing H, Weisenburger DD. Histiocyte-Rich B-Cell Lymphoma Occurring in Lymphocyte Predominance Hodgkin's Disease. *Mod Pathol* 8:108A, 1995.
256. Delabie J, Greiner TC, Chan WC, Weisenburger DD. Lymphocyte Predominance Hodgkin's Disease with Coexistent T-Cell Lymphoma. *Mod Pathol* 8:108A, 1995.
257. Moynihan MJ, Pederson AD, Chan WC, Kwok V, Bast MA, Greiner TC, Weisenburger DD. Mantle Cell Lymphoma: An Appraisal of its Morphologic, Immunophenotypic, and Genotypic Diversity. *Mod Pathol* 8:117A, 1995.
258. Downing J, Shurtleff S, Head D, Behm F, Raimondi S, Weisenburger D, Kossakowska A, Thorner P, Zielenski M, Lorenzana A, Morris S. Molecular Detection of the t(2;5) of Non-Hodgkin's Lymphoma (NHL) by Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). *Mod Pathol* 8:109A, 1995.
259. Chan WC, Delabie J, Tierens A, Wickert R, Weisenburger D. Lineage, Clonality and Evolution of Lymphocyte Predominance Subtype of Hodgkin's Disease. *FASEB* 9: 272 A, 1995.
260. Delabie J, Tierens A, Weisenburger DD, Chan WC. Nodular Sclerosis Hodgkin's Disease: Lineage and Clonality Analysis Using a Single-Cell Assay. *FASEB* 9: 272 A, 1995.
261. Ward MH, Mark SD, Cantor KP, Weisenburger D, Correa A, Zahm SH. Risk of Non-Hodgkin's Lymphoma and Drinking Water Nitrate. *Am J Epidemiol* 141:S32, 1995.

Dennis Weisenburger, MD - MC

262. Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Weisenburger DD. p53 Mutations in Mantle Cell Lymphoma. Proceedings of the Cancer Genetics and Tumor Suppressor Genes Meeting, 1995.
263. Delabie J, Tierens A, Gavril T, Weisenburger DD, Chan WC. Single Cell Study of the Lineage and Clonality of Reed-Sternberg Cells in Nodular Sclerosis Hodgkin's Disease. Proceedings of the Third International Symposium on Hodgkin's Lymphoma, 1995.
264. Chan WC, Delabie J, Tierens A, Wickert R, Weisenburger DD. Clonality and Evolution of Lymphocytic Predominance Hodgkin's Disease. Proceedings of the Third International Symposium on Hodgkin's Lymphoma, 1995.
265. d'Amore F, Johansen P, Mortensen LS, Weisenburger DD, Greiner TC, Anderson JR, Armitage JO. Epstein-Barr Virus Genome is a Predictor of Poor Clinical Outcome Independent of the International Prognostic Index in Aggressive T-cell Lymphoma. Blood 86 (Suppl 1):606a, 1995.
266. Mathew P, Valentine MB, Sanger WG, Weisenburger DD, Valentine V, Morris SW. Detection of the t(2;5)(p23;q35) of Non-Hodgkin's Lymphoma by Two-Color Fluorescence In Situ Hybridization (FISH). Blood 86 (Suppl 1):765A, 1995.
267. Weisenburger DD, Gascoyne RD, Bierman PJ, Shenkier T, Horsman D, Anderson JR, Chan WC, Greiner TC, Connors JM, Vose JM, Armitage JO, Sanger WG. Clinical Significance of the t(14;18)(q32;q21) in Follicular Large Cell Lymphoma (FLCL). Mod Pathol 9:126A, 1996.
268. Ward MH, Sinha R, Heineman EF, Markin RS, Rothman N, Weisenburger DD, Zahm SH. Risk of Adenocarcinoma of the Stomach and Esophagus with Intake of Well-Done and Barbecued Meats. American Society of Preventive Oncology, 1996.
269. Ward MH, Sinha R, Heineman EF, Rothman N, Markin RS, Weisenburger DD, Zahm SH. Risk of Stomach Cancer with Meat Doneness Level and Cooking Method. American Society of Cancer Research, 1996.
270. Ward MH, Sinha R, Heineman EF, Rothman N, Markin RS, Weisenburger DD, Zahm SH. Increased Risk of Stomach Cancer with the Level of Meat Doneness. Proc AACR 37:292, 1996.
271. d'Amore F, Johansen P, Mortensen LS, Weisenburger DD, Gascoyne R, Anderson JR, Armitage JO. Epstein-Barr Virus in T-cell Lymphomas: Frequency, Distribution and Prognostic Significance. Ann Oncol 7(Suppl 3):10, 1996.
272. Weisenburger DD, et al. Application of the International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma (NHL): Clinical Characteristics and Outcome of 1400 Patients from 8 Countries. Ann Oncol 7(Suppl 3):2, 1996.
273. Pickering DL, Morris SW, Mathew P, Hess MM, Weisenburger DD, Sanger WG. Detection of the t(2;5) in Non-Hodgkin's Lymphoma Utilizing Two-color FISH. Am J Hum Genet 59 (Suppl A): 78 A, 1996.
274. Ohno T, Stribley J, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in Lymphocyte Predominance Hodgkin's Disease: Report of Five Cases Studied by Single Cell Analysis. Blood 88 (Suppl 1):386A, 1996.



Dennis Weisenburger, MD - MC

275. Coiffier B, Anderson J, Armitage J, Berger F, Cavalli F, Chan W, Close P, Connors J, Diebold J, Gascoyne J, Harris N, Hiddemann W, Ho F, Jacobs P, Liang R, Lister A, MacClennan K, Müller-Hermelink H, Nathwani B, Norton A, Ott G, Pedrinis E, Rosenberg S, Roy P, Schauer A, Weisenburger D. Clinical Prognostic Factors are Stronger Predictors of Outcome in Non-Hodgkin's Lymphoma (NHL) than Pathologic Subtype. *Blood* 88 (Suppl 1):293A, 1996.
276. Weisenburger DD, for the International Non-Hodgkin's Lymphoma Classification Project. A Prospective Study of the International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma: Pathology Findings. *Proceedings of AACR/ASCO Joint Conference on Basic and Clinical Aspects of Lymphoma*, 1997.
277. Weisenburger DD, Greiner TC, Seto M, Chan WC. Mantle Cell Lymphoma: Molecular Analysis and Cyclin D1 Staining of 42 Cases. *Mod Pathol* 10:136A, 1997.
278. Abou-Elella AA, Vose JM, Anderson JR, Bierman PJ, Greiner TC, Chan WC, Armitage JO, Weisenburger DD. Primary Mediastinal Large B-cell Lymphoma: A Clinicopathologic Study of 50 Cases. *Mod Pathol* 10:119A, 1997.
279. Wu CD, Greiner TC, Vose JM, Gordon BG, Anderson JR, Chan WC, Morris SW, Weisenburger DD. Anaplastic Large Cell Lymphoma in Adults: A Clinicopathologic Study of 31 Cases. *Mod Pathol* 10:137A, 1997.
280. Weisenburger DD, for the International NHL Classification Project. The International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma (NHL): Pathologic Findings from a Large Multicenter Study. *Mod Pathol* 10:136A, 1997.
281. Weisenburger DD, for the International NHL Classification Project. The International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma (NHL): Clinical Findings from a Large Multicenter Study. *Mod Pathol* 10:136A, 1997.
282. Greiner TC, Lytle DM, Zahm SH, Weisenburger DD. P53 Mutations in Non-Hodgkin's Lymphoma of Patients with Pesticide Exposure. *Proc AACR* 38:628, 1997.
283. Palanisamy N, Rao PH, Abou-Elella A, Weisenburger DD, Chaganti RSK. Comparison of Primary Mediastinal Large B-Cell and Diffuse Large Cell Lymphomas: Genetic Anomalies Defined by CGH. *Blood* 90 (Suppl. 1):78A, 1997.
284. Müller-Hermelink HK, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Nathwani BN, Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Peripheral T-Cell Lymphoma (PTCL): A Clinicopathologic Analysis of 96 Cases. *Mod Pathol* 11:136A, 1998.
285. Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani B, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Grading of Follicular Lymphoma: Diagnostic Accuracy, Reproducibility, and Clinical Relevance. *Mod Pathol* 11:142A, 1998.
286. MacLennan KA, Anderson JR, Armitage JO, Diebold J, Müller-Hermelink HK, Nathwani BN, and Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Anaplastic large Cell Lymphoma (ALCL) of T/Null-Cell Type Is a Distinctive Clinicopathologic Entity. *Mod Pathol* 11:135A, 1998.

Dennis Weisenburger, MD - MC

287. Diebold J, Anderson JR, Armitage JO, MacLennan KA, Müller-Hermelink HK, Nathwani BN, and Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Diffuse Aggressive B-Cell Lymphoma (DABL): A Clinicopathologic Analysis of 480 Cases. *Mod Pathol* 11:128A, 1998.
288. Nathwani BN, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Müller-Hermelink HK, Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. A Clinicopathologic Comparison of 21 Patients with Nodal Marginal Zone B-Cell Lymphoma and 72 Patients with MALT Type Lymphoma. *Mod Pathol* 11:137A, 1998.
289. Nathwani BN, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Müller-Hermelink HK, Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Follicular Lymphoma with Benign and Malignant Monocytoid B-Cells. *Mod Pathol* 11:137A, 1998.
290. Gascoyne RD, Diebold J, Müller-Hermelink K, MacLennan KA, Nathwani BN, and Weisenburger DD, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Diffuse Small B-Cell Lymphomas. *Mod Pathol* 11:129A, 1998.
291. Gascoyne RD, Wu CD, Chhanabhai M, Morris SW, Pulford K, Mason D, Greiner TC, Connors JM, Vose JM, Coldman A, and Weisenburger DD. Prognostic Significance of ALK Oncogene Expression in Anaplastic Large Cell Lymphoma (ALCL). *Mod Pathol* 11:129A, 1998.
292. Aoun P, Greiner T, Vose J, Gordon B, Kollath J, Morris S, Chan W, Weisenburger D. Anaplastic Lymphoma Kinase (ALK): An Important Predictor of Survival in Peripheral T-Cell Lymphoma. *Mod Pathol* 11:125A, 1998.
293. Ohno T, Smir B, Weisenburger DD, Gascoyne R, Hinrichs SD, Chan WC. Clonal Relationship between H-RS Cells and CLL Cells in Richter's Syndrome with HD Characteristics. *Mod Pathol* 11:137A, 1998.
294. Ohno T, Park K, Weisenburger DD, Hinrichs S, Chan WC. Direct Demonstration by Single Cell Analysis that the Lymphocytic and Histiocytic (L&H) Cells in Nodular-Lymphocyte Predominant Hodgkin's Disease (NLPHD) are Clonally Related to the Large Cell Lymphoma (LCL) Developing in the Same Individual. *Mod Pathol* 11:138A, 1998.
295. Abou-Elella AA, Nathwani BN, Gascoyne R, Weisenburger DD, Velankar M, Greiner TC, Chan WC. The Relationship Between Monocytoid B-Cell (MBC) Lymphoma and Coexisting Follicular Lymphoma. *Mod Pathol* 11:124A, 1998.
296. Greiner TC, Zahm SH, Weisenburger DD. Molecular Epidemiology of P53 Mutations in Non-Hodgkin's Lymphomas Associated with Pesticide Exposures. *Mod Pathol* 11:130A, 1998.
297. Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani B, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Grading of Follicular Lymphoma: Diagnostic Accuracy, Reproducibility, and Clinical Relevance. *Proc of European Association of Hematopathology*, 1998.
298. Nathwani BN, Drachenberg MR, Anderson JR, Armitage JO, Diebold J, MacLennan KA, Müller-Hermelink HK, Weisenburger DD, for the Non-Hodgkin's Lymphoma Classification Project. Prognostic Factors in Marginal Zone B-cell Lymphoma, Extranodal, Mucosa-associated Lymphoid Tissue (MALT) Type. *Proc of European Association of Hematopathology*, 1998.



Dennis Weisenburger, MD - MC

299. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Rearrangements of Chromosome 1p36 in Non-Hodgkin's Lymphoma. *Proc AACR* 39:131, 1998.
300. Pavletic ZS, Weisenburger DD, Lynch JC, Bierman PJ, Vose JM, Bishop MR, Abou-Elella A, Bast MA, Armitage JO. Rai Classification and International Prognostic Index (IPI) in Small Lymphocytic Lymphoma. *Proc ASCO* 17:33A, 1998.
301. Chen NX, Vose JM, Bierman PJ, Weisenburger DD, Bast MA, Lynch JC, Armitage JO. Anthracycline-containing Combination Chemotherapy in Low-grade Follicular Lymphoma. *Proc ASCO* 17:22A, 1998.
302. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Rearrangements of Chromosome Band 1p36 and Loss of a Putative Tumor Suppressor Gene in Non-Hodgkin's Lymphoma. *Proc 17th International Cancer Congress*, 1998.
303. Weisenburger DD. New Classification for Non-Hodgkin's Lymphoma. *Proc 5th Seminar on New Trends in Treatment of Acute Leukemia*, 1998.
304. Weisenburger DD. Mantle Cell Lymphoma - Biological Characterization. *Proc 2nd International Symposium on Malignant Lymphomas*, 1998.
305. Weisenburger DD. Anderson J, Armitage J, Diebold J, MacLennan K, Müller-Hermelink K, Nathwani B, for the Non-Hodgkin's Lymphoma (NHL) Classification Project. Grading of Follicular Lymphoma: Diagnostic Accuracy, Reproducibility, and Clinical Relevance. *Proc 2nd International Symposium on Malignant Lymphomas*, 1998.
306. Aoun P, Greiner T, Vose J, Gordon B, Kollath J, Bast M, Morris S, Chan W, Bierman P, Armitage J, Weisenburger D. Is the Survival of Patients with Peripheral T-cell Lymphoma (PTCL) Different from Patients with Diffuse Aggressive B-cell Lymphoma (DABL)? *Blood* 92:84A, 1998.
307. Pavletic ZS, Weisenburger DD, Rai KR, Bast MA, Kollath JP, Bierman PJ, Vose JM, Bishop MR, Abou-Elella AA, Armitage JO. Factors Influencing Survival in Non-Leukemic B-cell Small Lymphocytic Lymphoma (B-SLL). *Blood* 92:85A, 1998.
308. Pavletic ZS, Arrowsmith ER, Bierman PJ, Goodman SA, Vose JM, Tarantolo SR, Stein RS, Greer JP, Kollath JP, Weisenburger DD, Wolff SN, Armitage JO, Bishop MR. Allogeneic Stem Cell Transplantation from Related or Unrelated Donors for B-cell Chronic Lymphocytic Leukemia (B-CLL). *Blood* 92:288A, 1998.
309. Zhang Q, Cui X, Siebert R, Rakestraw K, Naeve C, Hinzmann B, Weisenburger DD, Sanger WG, Nowotny H, Vesely M, Rosenthal A, Schlegelberger B, Morris SW. BCL10, a Novel Caspase Recruitment Domain (CARD) - containing Gene Overexpressed in MALT Lymphoma with t(1;14)(p22;q32). *Blood* 92:508A, 1998.
310. Weisenburger DD, Park K, Greiner T, Chan W, Pavletic S, Armitage J. Splenic "Marginal Zone" Lymphoma: A Clinicopathologic Study of 43 Cases. *Mod Pathol* 12:148A, 1999.
311. Chai C, Aoun P, Greiner T, Bishop J, Lynch J, Chan W, Bierman P, Gordon B, Vose J, Armitage J, Weisenburger D. BCL6 and P53 Gene Expression Predict Survival in the Small Noncleaved Cell Lymphomas. *Mod Pathol* 12:133A, 1999.

Dennis Weisenburger, MD - MC

312. Aoun P, Greiner T, Gascoyne R, Morris S, Pulford K, Mason D, Shiota M, Chan W, Weisenburger D. Detection of Anaplastic Lymphoma Kinase (ALK) by Immunostaining Varies with Antibody. *Mod Pathol* 12:131A, 1999.
313. Aoun P, Greiner T, Vose J, Kollath J, Morris S, Gordon B, Chan W, Weisenburger D. Prognostic Significance of Cytotoxic T-cell Intracellular Antigen (TIA-1) and Granzyme B (GR-B) in Peripheral T-cell Lymphoma (PTCL). *Mod Pathol* 12:131A, 1999.
314. Greiner T, Zahm S, Migliazza A, Weisenburger D. Molecular Epidemiology of BCL2 and BCL6 Mutations in Lymphomas Associated with Pesticide Exposure. *Mod Pathol* 12:137A, 1999.
315. Dave BJ, Singh RK, Varney ML, Bast MA, Weisenburger DD, Armitage JO, Sanger WG. Allelic Loss at Chromosome 1p36 and N-myc Amplification in Non-Hodgkin's Lymphoma. *Proc AACR* 40: 136, 1999.
316. Dave BJ, Arcaroli JJ, Trivedi AH, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG. Fluorescence In-situ Hybridization Reveals a New Recurrent Rearrangement in Non-Hodgkin's Lymphoma. *Proc AACR* 40: 541, 1999.
317. Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Morris SW, Greiner TC, Connors JM, Vose JM, Coldman A, Weisenburger DD. Prognostic Significance of ALK Oncogene Expression in Anaplastic Large Cell Lymphoma. *Ann Oncol* 10:118A, 1999.
318. Siebert R, Hinzmann B, Zhang Q, Cul X, Rakestraw K, Naeve C, Nowotney H, Vesely M, Weisenburger DD, Sanger WG, Morris SW, Rosenthal A, Schlegelberger B. Cloning of the Novel Caspase Recruitment Domain (CARD)-containing Gene BCL10 Affected by the t(1;14)(p22;q32) in MALT-lymphoma. *Medizinische Genetik* 11:W2-10, 1999.
319. Gordon B, Sanger W, Weisenburger D, Bast M, Pickering, D, Hess M, Bierman P, Vose J, Harper J, Abromowitch M, Armitage J, Coccia P. Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD) in Children: The Nebraska Lymphoma Study Group Experience. *J Pediatr Hematol Oncol* 21:331, 1999.
320. Gordon B, Weisenburger D, Lynch J, Bast M, Bierman P, Vose J, Bociek G, Armitage JO. Indolent Non-Hodgkin's Lymphoma (NHL) in Children and Young Adults: A Clinicopathologic Study of 19 Cases. *Blood* 94:94A, 1999.
321. Chan WC, Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JI, Yang L, Greiner TC, Weisenburger DD, Armitage JO, Marti GE, Moores T, Hudson J, Lossos I, Warnke R, Levy R, Botstein D, Brown PO, Staudt LM. Gene Expression in Large B-cell Lymphoma Using cDNA Microarray Technology. *Blood* 94:698A, 1999.
322. Vose JM, Bierman PJ, Lynch JC, Weisenburger DD, Chan JC, Greiner T, Bociek G, Armitage JO, for the Nebraska Lymphoma Study Group. Elderly Patients > 70 Years with Diffuse Aggressive Non-Hodgkin's Lymphoma (NHL): Clinical Prognostic Factor Analysis and Long-Term Results of CAP-BOP or CNOP Therapy. *Blood* 94:524A, 1999.
323. Weisenburger DD, Bociek RG, Lynch JC, Bierman PJ, Chan WC, Greiner TC, Vose JM, Armitage JO. Histologic Type Predicts Survival in Adults with Diffuse Aggressive B-cell Lymphoma (DABCL). *Mod Pathol* 13:165A, 2000.



Dennis Weisenburger, MD - MC

324. Aoun P, Pickering D, Greiner TC, Chan WC, Weisenburger DD, Morris SM, Sanger WG. Cytogenetic Analysis of the ALK Gene in Anaplastic Large Cell Lymphoma of B-cell Type by Interphase FISH on Paraffin-embedded Tissue. *Mod Pathol* 13:142A, 2000.
325. Aoun P, Greiner TC, Lynch JC, Vose JM, Gordon BG, Chan WC, Weisenburger DD. Clusterin Expression is Associated with Anaplastic Large Cell Lymphoma (ALCL) of T/null Cell Phenotype with ALK Expression. *Mod Pathol* 13:142A, 2000.
326. Chai C, Aoun P, Greiner TC, Lynch JC, Bishop J, Chan WC, Gordon BG, Armitage JO, Weisenburger DD. Diagnostic Accuracy and Clinical Relevance of the Subclassification of Small Noncleaved Cell Lymphoma. *Mod Pathol* 13:144A, 2000.
327. Chai C, Aoun P, Greiner TC, Lynch JC, Bishop J, Chan WC, Armitage JO, Weisenburger DD. Diffuse Large B-cell Lymphoma (DLBCL) With Burkitt-like Features - A Clinicopathologic Entity? *Mod Pathol* 13:144A, 2000.
328. Huang J, Chan WC, Greiner TC, Bast MA, Lynch JC, Armitage JO, Weisenburger DD. Diffuse Large B-cell Lymphoma (DLBCL) Arising in Lymphocyte Predominance Hodgkin's Disease (LPHD). *Mod Pathol* 13:150A, 2000.
329. Chan WC, Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T, Powell JJ, Yang L, Greiner TC, Weisenburger DD, Armitage JO, Marti GE, Moores T, Hudson J, Lossos I, Warnke R, Levy R, Botstein D, Brown PO, Staudt LM. Gene Expression in Large B-cell Lymphoma: cDNA Microarray Analysis. *Mod Pathol* 13:144A, 2000.
330. Simmons BH, Edelman M, Burke JS, Weisenburger DD, Evans L, Rataeh H. Primary Splenic Marginal Zone Lymphoma (PSMZL): Microanatomical Localization of B-lymphoma Cells Using a Combined Silver Nitrate and Immunoperoxidase Staining (SNIP) Technique. *Mod Pathol* 13:163A, 2000.
331. Weisenburger D, Anderson J, Armitage J, Diebold J, MacLennan K, Müller-Hermelink K, Nathwani B. Grading of Follicular Lymphoma: Diagnostic Accuracy, Reproducibility, and Clinical Relevance. *Proceedings of the 10th Meeting of the European Association for Haematopathology*, 2000.
332. Vose JM, Bierman PJ, Lynch JC, Weisenburger DD, Bociek G, Morris M, Greiner T, Chan J, Armitage JO. High-dose Chemotherapy (HDC) and Autologous Stem Cell Transplantation (ASCT) Overcomes Inferior Outcome of Patients (Pts) with T-cell Compared to B-cell Aggressive Non-Hodgkin's Lymphoma. *Proc ASCO* 19:17A, 2000.
333. Dave BJ, Hess MM, Weisenburger DD, Chan WC, Armitage JO, Sanger WG. Chromosomal Abnormalities in Hodgkin's Disease. *Proc AACR* 41:760, 2000.
334. Dave BJ, Singh RK, Joshee L, Weisenburger DD, Armitage JO, Sanger WG. CDC2L1 Gene Expression in Non-Hodgkin's Lymphoma. *Proc AACR* 41:776, 2000.
335. Chiu BCH, Weisenburger DD, Cantor KP, Zahm SH, Blair A. Alcohol Consumption, Familial Aggregation of Hematolymphoproliferative Cancer and Risk of Non-Hodgkin's Lymphoma. *Am J Epidemiol* 151:S76, 2000.

Dennis Weisenburger, MD - MC

336. Chen HL, Tucker KL, Heineman EF, Graubard BI, Potischman NA, Russell BM, McComb R, Weisenburger DD, Ward MH. Diet and Adult Glioma. *Am J Epidemiol* 151: S60, 2000.
337. Ward MH, Heinemann EF, Cantor KP, Chen H, McComb RD, Weisenburger DD, Merkle SK. Drinking Water Nitrate and Risk of Brain Cancer in Nebraska. *Epidemiol* 11:S141, 2000.
338. Hacia JG, Fang NY, Greiner TC, Armitage JO, Chan WC, Vose J, Weisenburger DD, Mayer RA, Collins FS. ATM Mutation Detection in Lymphoma using Oligonucleotide Microarrays. *Proceedings of the American Society of Human Genetics*, 2000.
339. Nelson M, Blair H, Carstens JM, Dave B, Hess M, Higgins C, Pickering D, Chan WC, Greiner TC, Weisenburger DD, Sanger WG. Utilization of M-FISH in Cases of Diffuse Large Cell Lymphoma to Further Delineate Chromosomal Abnormalities. *J Assoc Genet Technol* 26:133, 2000.
340. Aoun P, Greiner TC, Hock L, Vose JM, Gordon BG, Chan WC, Weisenburger DD. Expression of Linker for Activation of T-cells (LAT) Protein in Peripheral T-cell (PTCL) and T/null Anaplastic Large Cell (ALCL) Lymphoma. *Mod Pathol* 14:155A, 2001.
341. Greiner TC, Fang N, Weisenburger DD, Chan WC, Hock L, Collins F, Hacia J. ATM Mutations Do Not Predict Outcome or P53 Mutation Status in Mantle Cell Lymphoma. *Mod Pathol* 14:165A, 2001.
342. Huang JZ, Greiner TC, Lynch JC, Staudt LM, Weisenburger DD, Armitage JO, Chan WC. Gene Expression Profile Associated with T-cell Infiltration in Diffuse Large B-cell Lymphoma Analyzed by cDNA Microarray. *Mod Pathol* 14:167A, 2001.
343. Huang JZ, Sanger WG, Pickering DL, Greiner TC, Staudt LM, Lynch JC, Weisenburger DD, Armitage JO, Chan WC. CD10, BCL-2, and BCL-6 Protein Expression and t(14;18)(q32;q21) in Two Subtypes of Diffuse Large B-cell Lymphoma Defined by Gene Expression Profiles. *Mod Pathol* 14:167A, 2001.
344. Lawnicki LC, Aoun P, Chan WC, Weisenburger DD, Greiner TC. The t(14;18) and BCL-2 Expression are Present in a Subset of Primary Cutaneous Follicular Lymphomas (PCFL). *Mod Pathol* 14:170A, 2001.
345. Pickering DL, Dave BJ, Nelson M, Hess M, Weisenburger D, Chan WC, Armitage J, Sanger W. Interphase FISH Analysis of Selected Chromosomal Regions in Diffuse Large B-cell Lymphoma. *Proc AACR* 42: 632, 2001.
346. Greiner TC, Farrell BT, Weisenburger DD, Hock L, Armitage JO, Staudt L, Chan WC. P53 Mutations May Explain the Decreased Survival in the Activated B-like Subgroup of Diffuse Large B-cell Lymphomas. *Mod Pathol* 15:242A, 2002.
347. Hans CP, Weisenburger DD, Gascoyne RD, Greiner TC, Cochran GT, Pan X, Gao Z, Farinha P, Hock L, Lynch JC, Rosenwald A, Staudt LM, Connors J, Armitage JO, Chan WC. Classification of Diffuse Large B-cell Lymphoma into Prognostically Significant Subgroups by Immunohistochemistry Using a Tissue Microarray. *Mod Pathol* 15:243A, 2002.



Dennis Weisenburger, MD - MC

348. Hans CP, Weisenburger DD, Vose JM, Hock L, Lynch JC, Aoun P, Greiner TC, Chan WC, Bierman PJ, Armitage JO. Cytological Subdivision of Grade 3 Follicular Lymphoma is Not Important Prognostically, but a Significant Diffuse Component (>75%) Predicts for Inferior Survival. *Mod Pathol* 15:243A, 2002.
349. Huang JZ, Greiner TC, Weisenburger DD, Brazier RM, Chan WC. Analysis of Immunoglobulin Light Chain Gene Expression in B-cell Lymphomas by cDNA Microarray. *Mod Pathol* 15:245A, 2002.
350. Chiu BC, Weisenburger DD, Zahm S, Cantor KP, Blair A. Family History of Cancer, Agricultural Herbicide Use, and Risk for Non-Hodgkin's Lymphoma. *Proc AACR* 43:3813, 2002.
351. Dave BJ, Nelson MA, Pickering DL, Chan WC, Weisenburger DD, Greiner TC, Armitage JO, Sanger WG. Molecular Cytogenetic Characterization of Diffuse Large Cell Lymphoma Using M-FISH. *Proc AACR* 43:1472, 2002.
352. Aoun P, Blair H, Hock L, Lynch J, Sanger W, Weisenburger DD, Pavletic S. Clinicopathologic Study of Chromosomal Abnormalities Detected by Interphase FISH Cytogenetics in B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL). Proceedings of the 11th Meeting of the European Association for Haematopathology, 2002.
353. Dave BJ, Hess MM, Pickering DL, Weisenburger DD, Chan WC, Armitage JO, Sanger WG. Cytogenetic and M-FISH studies in Hodgkin's Disease. XVIII International Congress of the International Union Against Cancer, 2002.
354. Hans CP, Weisenburger DD, Greiner TC, Cochran GT, Pan Z, Lynch JC, Hock LM, Aoun P, Armitage JO, Chan WC. Expression of PKC-beta or Cyclin D2 Predicts for Inferior Survival in Diffuse Large B-cell Lymphoma. *Mod Pathol* 16:234A, 2003.
355. Hans CP, Dave BJ, Sanger WG, Aoun P, Greiner TC, Chan WC, Lynch JC, Armitage JO, Weisenburger DD. Cytogenetic Differences Between Grade 3A and Grade 3B Follicular Lymphoma. *Mod Pathol* 16:234A, 2003.
356. Weisenburger DD, Fu K, Pickering DJ, Aoun P, Greiner TC, Chan WC, Sanger WG. C-myc Rearrangement in Typical Burkitt and Atypical Burkitt Lymphoma. *Mod Pathol* 16:258A, 2003.
357. Fu K, Scanlan D, Aoun P, Chan J, Weisenburger D, Greiner T. Simian Virus 40 Sequences are Present at High Frequency, but Low Copy Number, in Both Lymphomas and Benign Tissues. *Mod Pathol* 16:232A, 2003.
358. Fu K, Palanisamy N, Sanger WG, Chan WC, Greiner TC, Aoun P, Chaganti RSK, Weisenburger DD. Recurrent Genomic Alterations in Splenic Marginal Zone B-cell Lymphoma. *Mod Pathol* 16:233A, 2003.
359. Fu K, Scodoris E, Chan WC, Pickering DL, Greiner TC, Aoun P, Sanger WG, Weisenburger DD. IgVH Gene Mutation and Chromosome 7q Deletion in Splenic Marginal Zone B-cell Lymphoma. *Mod Pathol* 16:233A, 2003.

Dennis Weisenburger, MD - MC

360. Greiner TC, Fu K, Scanlan D, Chan J, Weisenburger D. SV40 DNA Sequences Are Not Present at a Higher Frequency in B-cell and T-cell Lymphomas Compared to Benign Lymphoid Hyperplasias. *Proc AACR* 44:1407, 2003.
361. Dave BJ, Hess MM, Pickering DL, Weisenburger DD, Chan WC, Sanger WC. Mantle Cell Lymphoma, the Presence of t(11;14) (q13;q32) and Secondary Chromosomal Changes: a Combined Cytogenetic and FISH Analysis. *Proc AACR* 44:807, 2003.
362. Chiu BCH, Weisenburger DD, Zahm SH, Cantor KP, Blair A. Family History of Hematopoietic Cancer and Risk of Non-Hodgkin's Lymphoma Subtypes. *Proc AACR* 44:354, 2003.
363. Dave BJ, Hess MM, Pickering DL, Weisenburger DD, Chan WC, Sanger WG. Cytogenetic and M-FISH Studies in Pediatric and Adult Hodgkin's Disease. *Proc First International Symposium on Childhood and Adolescent Non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol* 25:S15, 2003.
364. Dave BJ, Jain S, Hess MM, Weisenburger DD, Sanger WG. The t(2;5) and Secondary Chromosome Abnormalities in Pediatric and Adult Anaplastic Large Cell Lymphoma. *Proc First International Symposium on Childhood and Adolescent Non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol* 25:S15, 2003.
365. Wiggins ML, Sanger WG, Pickering DL, Fu K, Weisenburger DD, Dave BJ. Incidence of C-MYC and BCL2 Rearrangements in Pediatric SNCL. *Proc First International Symposium on Childhood and Adolescent Non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol* 25:S14, 2003.
366. Pickering DL, Dave BJ, Chan WC, Weisenburger DD, Sanger WG. Combined Tissue Array and Interphase FISH Analyses in Diffuse Large B-cell Lymphoma. *Proc First International Symposium on Childhood and Adolescent Non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol* 25:S4, 2003.
367. Higgins CM, Dave BJ, Weisenburger DD, Chan WC, Hess MM, Sanger WG. Pediatric DLBCL: a Cytogenetic Analysis of Nebraska Cases. *Proc First International Symposium on Childhood and Adolescent Non-Hodgkin's Lymphoma. J Pediatr Hematol Oncol* 25:S14, 2003.
368. Watson P, Tarantolo S, Wiernik PH, Weisenburger DD, Hogg D, Quinn-Laquer B, Sanger WG, Lynch HT. Heredity Multiple Myeloma (MM): an International Consortium for MM Family Studies. *Proc of IX International Workshop on Multiple Myeloma*, 2003.
369. Greiner TC, Smith LM, Rosenwald A, Weisenburger DD, Gascoyne R, Connors J, Delabie J, Campo E, Ott G, Mueller-Hermelink K, Brazier RM, Jaffe ES, Armitage JO, Staudt LM, Chan WC. mRNA Expression Patterns in p53 Mutant vs WildType Subgroups of Diffuse Large B-cell Lymphoma. *Blood* 102:368A, 2003.
370. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose JM, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Müller-Hermelink HK, Connors JM, Brazier R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. *Blood* 102:62A, 2003.



Dennis Weisenburger, MD - MC

371. Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Gascoyne RD, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Brazier RM, Miller TP, Grogan TM, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Müller-Hermelink HK, Ott G, Davies AJ, Norton AJ, Lister TA, Campo E, Montserrat E, Wilson WH, Jaffe ES, Chiorazzi M, Zhao H, Staudt LM, the LLMPP. A Molecular Predictor of Survival Following Diagnosis of Follicular Lymphoma. *Blood* 102:177A, 2003.
372. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Brazier R, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. *Blood* 102:177-178A, 2003.
373. Zettl A, Bea S, Rosenwald A, Jehn P, Salaverria I, Ott G, Staudt LM, Chan WC, Jaffe ES, Weisenburger DD, Greiner TC, Gascoyne R, Grogan TM, Delabie J, Mueller-Hermelink HK, Campo E. Different Subtypes of Diffuse Large B-cell Lymphoma Defined by Gene Expression Profiling Are Genetically Distinct. *Blood* 102:178A, 2003.
374. Gascoyne RD, Dave S, Zettl A, Bea S, Chan WC, Rosenwald A, Jaffe ES, Campo E, Delabie J, Weisenburger DD, Greiner TC, Ott G, Müller-Hermelink HK, Rimsza L, Hans C, Connors JM, Wright G, Staudt LM. Gene Expression Microarray Analysis of De Novo CD5 + Diffuse Large B-cell Lymphoma (LLMPP Study): A Distinct Entity? *Blood* 102:178-179A, 2003.
375. Rimsza L, Roberts R, Miller T, Unger J, LeBlanc M, Brazier R, Weisenburger DD, Chan WC, Greiner T, Müller-Hermelink K, Jaffe E, Gascoyne RD, Campo E, Fuchs D, Spier C, Fisher R, Staudt L, Grogan T. Loss of MHC Class II Gene and Protein Expression in Diffuse Large B Cell Lymphoma Is Related to Decreased Tumor Immunosurveillance and Poor Patient Survival: A Follow-up Study to the Director's Challenge Leukemia and Lymphoma Molecular Profiling Project (LLMPP). *Blood* 102:390-391A, 2003.
376. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S, Cao K, Zhu Q, Xiao L, Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Ott G, Mueller-Hermelink HK, Delabie J, Brazier RM, Jaffe ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan T, Staudt LM, Chan WC. BCL2 Translocation Defines a Subset of DLBCL with Germinal Center B-cell-like Gene Expression Profiles and Preferential Expression of a Set of Genes. *Blood* 102:884A, 2003.
377. Arora A, Vose JM, Lynch J, Armitage JO, Bierman PJ, Bociek RG, Weisenburger DD. Localized Mantle Cell Lymphoma: High Initial Response, but a Short Duration of Remission with Poor Outcomes. *Blood* 102:889A, 2003.
378. Rimsza L, Roberts R, Campo E, Grogan T, Bea S, Salaverria I, Zettl A, Fisher R, Unger J, LeBlanc M, Staudt L, Gascoyne R, Chan W, Weisenburger DD, Greiner T, Jaffe E, Brazier R, Mueller-Hermelink K, Miller T. Loss of Major Histocompatibility Class II (MHCII) Expression in Nodal Diffuse Large B Cell Lymphoma (DLBCL) Is Highly Coordinated and Unlikely Related to Chromosomal Deletions. *Blood* 102:893A, 2003.
379. Tarantolo S, Watson P, Wiernik PH, Weisenburger DD, Hogg D, Quinn-Laquer B, Sanger WG, Bergsagel KI, Bergsagel L, Eisinger F, Sobol H, Huiart L, Ogmundsdottir H, Olopade OI, Thertulien R, Tlsty T, Kuehl M, Croce C, de la Chapelle A, Offit K, Lynch HT. Familial Multiple Myeloma (MM) Registry: An International Consortium for MM Family Studies. *Blood* 102:376B, 2003.

Dennis Weisenburger, MD – MC

380. Fu K, Weisenburger DD, Greiner TC, Ott G, Delabie J, Jaffe ES, Brazier RM, Gesk S, Siebert R, Pickering DL, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK, Campo E, Gascoyne RD, Rosenwald A, Chiorazzi M, Staudt LM, Chan WC. Cyclin D1-negative Mantle Cell Lymphoma: A Study of Nine Cases. *Mod Pathol* 17:248A, 2004.
381. Greiner TC, Rosenwald A, Chiorazzi M, Smith L, Lynch J, Chan WC Weisenburger DD, Sanger WG, Coad J, Gross T, Staudt L. Gene Expression Profiling by cDNA Microarray in Post-transplant Lymphoproliferative Disorders. *Mod Pathol* 17:250A, 2004.
382. Hans CP, Dave BJ, Sanger WG, Aoun P, Greiner TC, Chan WC, Pickering DL, Vose JM, Armitage JO, Weisenburger DD. Follicular Large Cleaved Cell Lymphoma: An Unrecognized Morphologic Variant of Grade 3 Follicular Lymphoma. *Mod Pathol* 17:250A, 2004.
383. Nola M, Pavletic SZ, Weisenburger DD, Smith LM, Bast MA, Vose JM, Armitage JO. Prognostic Factors Influencing Survival in Patients with B-cell Small Lymphocytic Lymphoma. *Mod Pathol* 17:263A, 2004.
384. Young KH, Pickering D, Dave B, Campo E, Delabie J, Gascoyne R, Mueller-Hermelink K, Jaffe ES, Weisenburger DD, Chan WC, Greiner TC. Chromosome 17p13 Deletions and Mutational Analysis of p53 in 116 Cases of Diffuse Large B-cell Lymphoma. *Mod Pathol* 17:277-278A, 2004.
385. Zu Y, Campo E, Hans CP, Weisenburger DD, Brazier R, Delabie J, Gascoyne R, Vivero A, Steinberg S, Pittaluga S, Chan WC, Jaffe ES. Validation of Tissue Microarray Immunohistochemistry Staining and Interpretation in Diffuse Large B-cell Lymphoma (DLBCL). *Mod Pathol* 17:349-350A, 2004.
386. Dave BJ, Weisenburger DD, Higgins CM, Hess MM, Pickering DL, Chan WC, Sanger WG. Cytogenetics of Diffuse Large B-cell Lymphoma in Children and Young Adults. *Cancer Genet Cytogenet* 153:115-121, 2004.
387. Nola M, Pavletic SZ, Weisenburger DD, Illic I, Sicaja M, Lukenda A, Smith LM, Bast MA, Vose JM, Armitage JO. Prognostic Factors Influencing Survival in Patients with B-cell Small Lymphocytic Lymphoma. XII Meeting of the European Association for Haematopathology, 2004.
388. Dave BJ, Chan WC, Weisenburger DD, Hess MM, Sanger WG. Early Secondary Cytogenetic Changes in t(14;18)-positive Follicular Lymphoma. Proceedings of the 54th Annual Meeting of the American Society of Human Genetics, 2004.
389. Dave BJ, Weisenburger DD, Higgins CM, Hess MM, Chan WC, Sanger WG. Cytogenetics of Diffuse Large B-cell Lymphoma in Children and Young Adults. *Proc AACR*, 2004.
390. Ganti AK, Weisenburger DD, Smith LM, Hans CP, Bociek RG, Bierman PJ, Vose JM, Armitage JO. Patients with Follicular Lymphoma, Grade 3, have a Prolonged Relapse-free Survival Following Aggressive Combination Chemotherapy. *Blood* 104:177A, 2004.
391. Zettl A, Bea S, Wright G, Salaverria I, Jenn P, Ott G, Chan WC, Jaffe E, Weisenburger DD, et al. Chromosomal Imbalances in Germinal Center B-cell-like and Activated B-cell-like Diffuse Large B-cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-based Survival Prediction. *Blood* 104:122A, 2004.



Dennis Weisenburger, MD - MC

392. Weistner A, Chiorazzi M, Lai R, Rosenwald A, Müller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, et al. High Cyclin D1 Expression is Associated with Increased Proliferation Rate and Decreased Survival in Mantle Cell Lymphoma (MCL) and is Caused by Genomic Deletions and Mutations that Enhance Stability of Cyclin D1 mRNA. *Blood* 104:200A, 2004.
393. Dave SS, Wright G, Tan B, Rosenwald A, Chan WC, Greiner TC, Weisenburger DD, et al. LymphDx: a Custom Microarray for Molecular Diagnosis and Prognosis in Non-Hodgkin Lymphoma. *Blood* 104:201A, 2004.
394. Abrahams NA, Johansson SL, Weisenburger DD. Non-Hodgkin's Lymphoma (NHL) of the Prostate: Emphasis on Useful Diagnostic Features. *Mod Pathol* 18:124A, 2005.
395. Robledo J, Weisenburger DD. Non-Hodgkin's Lymphoma of the Oral Cavity: a Retrospective Study of 37 Cases. *Mod Pathol* 18: 217A, 2005.
396. Aoun P, Zhou G, Chan WC, Quinn-Laquer B, Watson P, Lynch J, Sanger W, Lynch HT, Weisenburger DD. Immunoglobulin Heavy Chain Gene (IqVH) Usage and Immunophenotypic Profile in Familial B-cell Chronic Lymphocytic Leukemia (B-CLL) with Acquired del 13q14. *Mod Pathol* 18: 221A, 2005.
397. Fu K, Dave S, Wright G, Weisenburger DD, Greiner TC, Ott G, Müller-Hermelink HK, Rimsa LM, Braziel RM, Gascoyne RD, Delabie J, Campo E, Jaffe ES, Chiorazzi M, Zhao H, Chan WC, Staudt LM. Molecular Diagnosis of Burkitt Lymphoma Using Gene Expression Profiling. *Mod Pathol* 18: 230A, 2005.
398. Greiner T, Hacia J, Rosenwald A, Weisenburger DD, Smith L, Jaffe E, Gascoyne R, Campo E, Müller-Hermelink K, Ott G, Delabie J, Braziel R, Staudt L, Chan W. MRNA Expression Profile of p53 Mutant or ATM Mutant Cases of Mantle Cell Lymphoma. *Mod Pathol* 18: 232A, 2005.
399. Neppalli V, Iqbal J, Dave BJ, Pickering DL, Dave S, Hans CP, Weisenburger DD, et al. BCL2 Expression as a Prognostic Indicator in Subtypes of Diffuse Large B-cell Lymphoma. *Mod Pathol* 18: 243A, 2005.
400. Weisenburger DD, Aoun P, Greiner TC, Chan WC, Smith LM, Bociek RG, Bierman PJ, Vose JM, Armitage JO. Peripheral T-cell Lymphoma (PTCL): a Clinicopathologic Analysis with Comparison to Diffuse Large B-cell Lymphoma. *Mod Pathol* 18: 256A, 2005.
401. Dave BJ, Weisenburger DD, Chan WC, Jain S, Hess MM, Sanger WG. Cytogenetic Changes in Follicular Lymphoma with a Diffuse Large Cell Component. *Proc AACR* 46: 1151, 2005.
402. Chiu BCH, Dave BJ, Blair A, Gapstur SM, Zahm SH, Weisenburger DD. Association of Pesticides, Smoking, and Familial Cancer with Risk of t(14;18)-defined Subtypes of Non-Hodgkin Lymphoma. *Proc AACR* 46:304, 2005.
403. Weisenburger DD, Ullrich FA, MacLennan KA, Müller-Hermelink HK, Diebold J, Nathwani BN, Armitage JO. Non-Hodgkin Lymphoma (NHL) Around the World: Distribution of Major Subtypes Differs by Geographic Region. *Ann Oncol* 16 (suppl 5):28, 2005.
404. Weisenburger DD. Classification and Outcome in Peripheral T-cell lymphoma. *Proceedings of the Society for Hematopathology Workshop on Progress in T-cell and NK-cell Malignancies*, 2005.

Dennis Weisenburger, MD - MC

405. Iqbal J, Greiner TC, Patel K, Ji J, Dave BJ, Horsman DE, Shen Y, Weisenburger DD, et al. Distinctive Patterns of BCL6 Molecular Alterations in Different Subsets of Diffuse Large B-cell Lymphoma and Their Functional Consequences. *Blood* 106:50A, 2005.
406. Dave SS, Fu K, Wright G, Lam L, Greiner TC, Weisenburger DD, et al. Gene Expression Distinguishes Burkitt Lymphoma from Other Aggressive Lymphomas and Identifies Patients Who are Highly Curable with Intensive Chemotherapeutic Regimens. *Blood* 106:125A, 2005.
407. Vose JM, Weisenburger DD, et al. International Peripheral T-cell Lymphoma (PTCL) Clinical and Pathologic Review Project: Poor Outcome by Prognostic Indices and Lack of Efficacy with Anthracyclines. *Blood* 106:239A, 2005.
408. Fu K, Sanger WG, Weisenburger DD, Pickering DL, Dave B, Greiner TC, Chan WC. Identification of Recurrent Genomic Alterations in Burkitt and Burkitt-like Lymphoma Using Array-based Comparative Genomic Hybridization (GCH). *Mod Pathol* 19 (suppl 1):225A, 2006.
409. Greiner TC, Klinkebiel DL, Tang L, Weisenburger DD, Chan WC, Christman JK. Methylation Analysis in Mantle Cell Lymphoma. *Mod Pathol* 19 (suppl 1):228A, 2006.
410. Naushad H, Aoun P, Smith LM, Pan Z, Bierman P, Greiner TC, Chan WC, Weisenburger DD. Prognostic Significance of Bcl-2 and Bcl-6 Expression in Patients with Nodular Sclerosis Hodgkin Lymphoma. *Mod Pathol* 19 (suppl 1):239A, 2006.
411. Neppalli V, Fu K, Chan WC, Greiner TC, Weisenburger DD, Aoun P. Co-expression of CD15 and CD30 in Anaplastic Large Cell Lymphoma. *Mod Pathol* 19 (suppl 1): 239A, 2006.
412. Weisenburger DD. Peripheral T-cell and NK/T-cell Lymphomas: an International Study of 1,179 Cases. *Mod Pathol* 19 (suppl 1):251A, 2006.
413. Dave BJ, Weisenburger DD, Aoun P, Jain S, Hess MM, Pickering DL, Sanger WG. Secondary Genetic Abnormalities in Anaplastic Large Cell Lymphoma. *Proc AACR* 47:269, 2006.
414. Surawicz TS, Chiu BCH, Fought A, Gapstur S, Kolar C, Lawson T, Weisenburger DD. Association of Fruit and Vegetable Intake with Risk of Non-Hodgkin Lymphoma. *Proc AACR* 47:470, 2006.
415. Au W, Intragumtornchai T, Nakamura S, Armitage JO, Liang R, Weisenburger DD, et al. Clinical and Pathological Differences between Nasal and Nasal-type NK/T Cell Lymphomas: a Summary of 136 Cases from the International T-cell Lymphoma (ITCL) Project. *Blood* 108:292A, 2006.
416. Savage KJ, Vose JM, Harris NL, Weisenburger DD, et al. Survival Analysis of Anaplastic Large Cell Lymphoma, Systemic and Cutaneous Types: Report from the International T-cell Lymphoma Project. *Blood* 108:293A, 2006.
417. Young KH, Leory K, Moller MB, Sanchez-Beato M, Colleoni GWB, Kerbauf FR, Kodura PPK, Haioun C, Gaulard P, Piris MA, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Ott G, Huang J, Brazier R, Jaffe ES, Staudt LM, Wilson WH, Kanehira K, Rehrauer WM, Eickhoff JC, Kahl BS, Malter JS, Chan WC, Weisenburger DD, Greiner TC. Structural Profiles of P53 Gene Mutations Predict Clinical Outcome in Diffuse Large B-cell Lymphoma: An International Collaboration Study. *Blood* 108:811A, 2006.



Dennis Weisenburger, MD - MC

418. Bierman PJ, Loberiza F, Dave B, Sanger W, Bociek RG, Bast M, Vose JM, Armitage JO, Weisenburger DD. Significance of c-myc Rearrangements in Diffuse Large B-cell Lymphoma. *Blood* 108:2030A, 2006.
419. Hegde GV, Emanuel K, Joshi AD, Munger CM, Weisenburger DD. Sonic Hedgehog Signaling in Mantle Cell Lymphoma. *Blood* 108:2046A, 2006.
420. Ruediger T, Coiffier B, Weisenburger DD. International T-cell Lymphoma Classification Project: Angioimmunoblastic T-cell Lymphoma. *Blood* 108:2052A, 2006.
421. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Armitage JO, Weisenburger DD, et al. Adult T-cell Leukemia/Lymphoma: a Clinicopathologic Study of 126 Cases from the International T-Cell Lymphoma Project. *Blood* 108:2059A, 2006.
422. Delabie J, Holte H, Lister TA, Vose JM, Weisenburger DD, et al. Enteropathy-type T-cell Lymphoma: Clinical Features of a Series of 62 Cases. *Blood* 108:2459A, 2006.
423. Fu K, Chan WC, Pickering DL, Weisenburger DD, Greiner TC, Dave BJ, Sanger WG. Identification of Recurrent Genomic Alterations in Burkitt Lymphoma using Array-based Comparative Genomic Hybridization (CGH). *Proc of 2nd International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma*, 2006.
424. Young KH, Moller MB, Colleoni GWB, Sanchez-Beato M, Kerbaux FR, Leroy K, Piris MA, Eickhoff JC, Young AH, Kanehira K, Cook S, Ranheim EA, Kahl BS, Oliver M, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Chan WC, Weisenburger DD, Greiner TC. The Diversity of p53/p21 Transactivation Phenotype of p53 Signaling Pathway and their Relationship to TP53 Gene Mutation and Clinical Outcome in Diffuse Large B-cell Lymphoma (DLBCL). *Mod Pathol* 20:265A, 2007.
425. Zulficar MI, Hacia JG, Chan WC, Weisenburger DD, Greiner TC. Correlation of ATM Protein Expression with ATM Mutation Status and Overall Survival in Mantle Cell Lymphoma. *Mod Pathol* 20:267A, 2007.
426. Choi WWL, Fu K, Dave BJ, Sanger WG, Chan WC, Hans CP, Weisenburger DD, Greiner TC. Follicular Lymphomas with BCL6 Rearrangements but without a t(14;18): Frequent Deceptive Histological Features Leading to Diagnostic Pitfalls. *Mod Pathol* 20:237A, 2007.
427. Shi XL, Dave BJ, d'Amore F, Chan E, Jain S, Sanger W, Choi WWL, Greiner TC, Aoun P, Weisenburger DD, Chan WC, Fu K. T(14;18)-negative Non-cutaneous Follicular Lymphoma (FL): a Clinicopathologic Study of 59 cases. *Mod Pathol* 20:260A, 2007.
428. Hardjolutito ESR, Muthalib A, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Weisenburger DD. Indonesian Cases of Malignant Lymphoma Classified According to the World Health Organization Classification. *Proc of the 96th Annual Meeting of the Japanese Society of Pathology*, 2007.
429. Morton LM, Cerhan JR, Hartge P, Dave BJ, Vasef MA, Weisenburger DD, Jain S, Colt C, Staudt LM, Cozen W, Davis S, Severson RK, Rothman N, Chanock SJ, Wang SS. Environmental and Genetic Risk Factors for t(14;18)-defined Subtypes of Diffuse Large B-cell Lymphoma (DLBCL) in a Population-based, Case-control Study. *Proc AACR* 48:1713, 2007.

Dennis Weisenburger, MD - MC

430. Chiu BCH, Dave BJ, Ward MH, Blair A, Fought AJ, Gapstur SM, Jain S, Zahm SH, Weisenburger DD. Diet and Risk of t(14;18)-defined Subgroups of Non-Hodgkin Lymphoma. *Proc AACR* 48: 207, 2007.
431. Fu K, Perry KD, Smith LM, Hans CP, Greiner TC, Chan WC, Weisenburger DD, Bierman PJ, Bociek RG, Armitage JO, Vose JM. Effect of Addition of Rituximab to CHOP on Survival of Patients in both the GCB and Non-GCB Subgroups of Diffuse Large B-cell Lymphoma. *Proc ASCO* 5:451S, 2007.
432. Munger CM, Hedge G, Weisenburger DD, Vose J, Joshi S. Optimizing Dendritic Cell-based Therapy for Mantle Cell Lymphoma. *Clin Immunol* 123:S109, 2007.
433. Hegde GV, Munger CM, Emanuel K, Joshi A, Weisenburger DD, Vose JM, Joshi SS. Targeting Sonic Hedgehog-Gli Signaling for the Treatment of Mantle Cell Lymphoma. *Clin Immunol* 123: S109, 2007.
434. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BCH. Vaccination History and Non-Hodgkin Lymphoma: A Population-based, Case-control Study. *AACR Workshop on the Pathology of Cancer*, 2007.
435. Leich E, Salaverria I, Bea S, Zettl A, Gascoyne R, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al. Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations. *Blood* 110:113A, 2007.
436. Lenz G, Wright GW, Dave SS, Kohlmann A, Xiao W, Powell J, Zhao H, Xu W, Gascoyne R, Connors JM, May L, Weisenburger DD, et al. Gene Expression Signatures Predict Overall Survival in Diffuse Large B-cell Lymphoma Treated with Rituximab and CHOP-like Chemotherapy. *Blood* 110:109A, 2007.
437. Vose JM, Chan WC, Bierman PJ, Fu K, Loberiza F, Arevalo A, Weisenburger DD, Bociek RG, Bast M, Armitage JO. Relapse from Complete Remission More than 5 Years After Therapy for Diffuse Large B-cell Lymphoma (DLBCL): Relapse Histology Most Commonly DLBCL with a Germinal Center B-cell (GCB) Phenotype. *Blood* 110:1005A, 2007.
438. Bierman P, Vose JM, Bociek RG, Loberiza F, Bast M, Weisenburger DD, Armitage JO. Outcome of Limited-stage Peripheral T-cell Lymphoma: Results from the Nebraska Lymphoma Study Group. *Blood* 110:1011A, 2007.
439. Zulfigar MI, Weisenburger DD, Loberiza F, Vose JM, Bierman PJ, Bociek RG, Armitage JO. The Impact of Histological Subtypes on Outcome in Patients with Mantle Cell Lymphoma Treated with or without Autologous Stem Cell Transplant. *Blood* 110:565A, 2007.
440. Munger CM, Hegde GV, Weisenburger DD, Vose JM. Therapeutic Effectiveness of Adaptive T-cell Transfer for Minimal Residual Mantle Cell Lymphoma Following High Dose Therapy. *Blood* 110: 811A, 2007.
441. Raval A, Tanner S, Byrd J, Angerman E, Perko J, Chen S, Hackanson B, Grever M, Lucas D, Matkovic J, Lin T, Kipps T, Murray F, Weisenburger D, et al. Loss or Reduced Expression of DAPK1 Contributes to Heritable Predisposition to CLL. *Proc AACR*, 2007.



Dennis Weisenburger, MD - MC

442. Hegde GV, Peterson KJ, Emanuel K, Mittal AK, Bociek RG, Weisenburger DD, Joshi SS. GLI1 Transcription Factor: a Potential Therapeutic Target in B-CLL. *Blood* 110:912A, 2007.
443. Bhagavathi S, Gu K, Loberiza F, Vose JM, Weisenburger DD. Does a Diffuse Pattern Predict the Survival of Patients with Low-grade Follicle Center Cell Lymphoma (FCCL)? *Mod Pathol* 21:246A, 2008.
444. Choi WWL, Weisenburger DD, Greiner TC, et al. A New Immunostain Algorithm Improves the Classification of Diffuse Large B-cell Lymphoma into Prognostically Significant Subgroups. *Mod Pathol* 21:250A, 2008.
445. Young KH, Moller MB, Colleoni GWB, Sanchez-Beato M, Green TM, Thorborg T, Piris MA, Eickhoff C, Twohig M, Young AH, Oberley TD, Malter JC, Ferry JA, Chan WC, Weisenburger DD, Greiner C. Expression of MDM2 Oncoprotein Predicts for Poor Survival in Diffuse Large B-cell Lymphoma (DLBCL) with Wild-type TP53 Gene. *Mod Pathol* 21:283A, 2008.
446. Naushad H, Weisenburger DD, Chan WC, Smith L, Bast M, Armitage JO, Fu K. Ki-67 Proliferation Index (PI) Correlates with the Histologic Grade and Overall Survival in Follicular Lymphoma Treated with Rituximab. *Mod Pathol* 21:267A, 2008.
447. Gu K, Dave BJ, Fu K, Iqbal J, Jain S, Sanger WG, Weisenburger DD, Chan WC. BCL6 Translocation at the Alternative Breakpoint Region is Associated with t(14;18)- negative Follicular lymphoma. *Mod Pathol* 21:255A, 2008.
448. Loberiza FR, Armitage JO, Bierman PJ, Bociek GR, Darrington DL, Ganti AK, Vose JM, Weisenburger DD. 25-year Survival Trends of Patients with Lymphoma by Race/Ethnicity: as Reported to the Nebraska Lymphoma Study Group (NLSG). *Proc ASCO* 26:6547, 2008.
449. Greiner T, Klinkebiel D, Weisenburger D, Chan WC, Christman J. Genomic Hypermethylation Characterizes an Aggressive Subset of Mantle Cell Lymphoma. *Ann Oncol* 19 (suppl 4):10, 2008.
450. Lenz G, Wright G, Dave S, Kohlmann A, Xiao W, Powell J, Zhao H, Xu W, Gascoyne RD, Connors M, May L, Iqbal J, Vose J, Weisenburger DD, et al. Gene Expression Signatures Predict Survival in Diffuse Large B Cell Lymphoma Following Rituximab and CHOP-like Chemotherapy. *Ann Oncol* 19 (suppl 4):34, 2008.
451. Weisenburger DD, Vose JM, Armitage JO. Peripheral T-cell Lymphoma, Not Otherwise Specified: Clinicopathologic Study of 340 Cases from the International Peripheral T-cell Lymphoma Project. *Ann Oncol* 19 (suppl 4):113, 2008.
452. Rüdiger T, Weisenburger D, Coiffier B, Federico M, Armitage JO, Vose J. Angioimmunoblastic T-cell Lymphoma: a Report from the International Peripheral T-cell Lymphoma Project. *Ann Oncol* 9 (suppl 4):114, 2008.
453. Lenz G, Wright G, Dave S, Emre NT, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fischer RI, Weisenburger DD, et al. Gene Expression Subtypes of Diffuse Large B-cell Lymphoma Arise by Distinct Genetic Pathways. *Ann Oncol* 19(suppl 4):50, 2008.

Dennis Weisenburger, MD - MC

454. Weisenburger DD, for the Non-Hodgkin Lymphoma Classification Project. Non-Hodgkin Lymphoma Around the World. Proc InterLymph Symposium on New Insights into the Causes of Lymphoma, 2008.
455. Weisenburger DD. Peripheral T-cell Lymphoma: What We have Learned and New Classification Strategies. Proc Peripheral T-cell Lymphoma Forum, 2008.
456. Young KH, Moller MB, Colleoni GWB, Sanchez-Beato M, Green TM, Thorborg T, Piris MA, Eickhoff JC, Twohig M, Young AH, Oberley TD, Malter JS, Ferry JA, Chan WC, Weisenburger DD, Greiner TC. Expression of MDM2 Oncoprotein Predicts for Poor Survival in Diffuse Large B-cell Lymphoma (DLBCL) with Wild-type TP53 Gene. J Hematopath 1:LS 2, 2008.
457. Hartmann E, Salaverria I, Bea S, Zettl A, Jares P, Gascoyne RD, Chan WC, Weisenburger DD, et al. SNP Array Analysis Reveals Copy Number Alterations and Copy Neutral LOH in Mantle Cell Lymphoma at High Resolution. J Hematopath 1:LS 43, 2008.
458. Leich E, Salaverria I, Bea S, Zettl A, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al. Follicular Lymphomas with and without Translocation t(14:18) Differ in Gene Expression Profiles and Genetic Alterations. J Hematopath 1:LS 44, 2008.
459. Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, Wu W, Tan B, Goldschmidt N, Iqbal J, Vose JM, Bast MA, Fu K, Weisenburger DD, et al. Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment for Diffuse Large B-cell Lymphoma. Blood 112:475A, 2008.
460. Mittal AK, Iqbal J, Nordgren TM, Moragues M, Bociek RG, Aoun P, Weisenburger DD, Joshi SS. Molecular Basis of Proliferation/Survival and Migration of CLL in Peripheral Blood, Bone Marrow, and Lymph Nodes. Blood 112:546A, 2008.
461. Loberiza FR, Cannon AJ, Weisenburger DD, et al. Survival Disparities in Patients with Lymphoma According to Place of Residence and Treatment Provider: a Population-based Study. Blood 112: 874A, 2008.
462. Deffenbacher KE, Wright G, Iqbal J, Geng H, O'Shea D, Lister TA, Fitzgibbon J, Fu K, Liu Z, Weisenburger D, et al. Genetic Abnormalities Involved in the Development and Progression of Follicular Lymphoma. Blood 112: 2049A, 2008.
463. Hedge GV, Nordgren TM, Munger CM, Mittal AK, Bierman PJ, Weisenburger DD, Sharp G, Vose JM. Characterization and Novel Treatment for Therapy-resistant Mantle Cell Lymphoma Isolated from Liver and Kidney. Blood 112:2622A, 2008.
464. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular Signatures to Improve Diagnosis, Prognostication and Identification of Oncogenic Pathways in Peripheral T and NK Cell Lymphoma. Blood 112:339A, 2008.
465. Morovic A, Molina-Kirsch H, Diebold J, MacLennan K, Müller-Hermelink K, Nathwani B, Armitage J, Weisenburger DD. Comparison of Non-Hodgkin Lymphoma Subtypes in Guatemala and North America/Western Europe. Mod Pathol 22(Suppl 1):278A, 2009.



Dennis Weisenburger, MD - MC

466. Gu K, Fu K, Chan WC, Greiner TC, Aoun P, Smith LM, Liu Z, Meyer PN, Choi WW, Bociek G, Vose JM, Weisenburger DD. Neither Cell of Origin or LMO2 Expression Predict Survival in DLBCL Treated with Autologous Hematopoietic Stem Cell (HSC) Transplantation. *Mod Pathol* 22(Suppl 1):264A, 2009.
467. Meyer PN, Weisenburger DD, Choi WL, et al. LMO2 Expression and the Hans Algorithm in Predicting Germinal Center Phenotype and Survival in Diffuse Large B-cell Lymphoma Treated with Rituximab. *Mod Pathol* 22 (Suppl 1):277A, 2009.
468. Cheson BD, Vose JM, Bartlett NL, Lopez A, Vander Jagt RH, Tolcher AW, Weisenburger DD, et al. Safety and Efficacy of YM155 in Diffuse Large B-cell Lymphoma (DLBCL). *J Clin Oncol* 27:8502A, 2009.
469. Morton LM, Cerhan JR, Hartge P, Vasef MA, Nepalli V, Natkanam Y, Dogan A, Levy R, Lossos I, Cozen W, Davis S, Severson RK, Mauer MJ, Lynch CF, Rothman N, Chatterjee N, Yu K, Staudt LM, Weisenburger DD, Wang SS. Immunostaining for CD10, BCL6, MUM1, LM02, and BCL2 to Identify Molecular Subtypes of Diffuse Large B-cell Lymphoma in a Population-based Study During the Pre-Rituximab Era. *Proc of NCI Translational Science Meeting*, 2009.
470. Liang T, Conti DV, Clark C, Boffetta P, Weisenburger DD, Mack TM, Cozen W. International Variation in the Incidence of Lymphoid Neoplasms. *Proc InterLymph Consortium Annual Meeting*, 2009.
471. Cardesa T, Colomo L, Climent F, Gonzalez-Borca E, Gutierrez G, Mercadal S, Gascoyne RD, Connors JM, Rimsza L, Brazier R, Cook J, Tubbs R, Rosenwald A, Ott G, Mate JL, Ribera JM, Arenillas L, Serrano S, Combolia N, Delabie J, Lenz G, Wright G, Jaffe ES, Staudt L, Chan WC, Weisenburger D, Lopez-Guillermo A, Campo E. High Microvascular Density Correlates Independently with Poor Outcome in Patients with Diffuse Large B-cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT). *Blood* 114:1948A, 2009.
472. Iqbal J, Weisenburger DD, Chowdhury A, et al. NK-cell Lymphoma Shows Strikingly Similar Molecular Features with a Distinct Set of  $\square\square$  T-cell Lymphoma and Evaluation of Aurora Kinase A Inhibitor as a Novel Therapeutic Agent. *Blood* 114:313A, 2009.
473. Deffenbacher KE, Iqbal J, Liu Z, Perkins SL, Lim MS, Fu K, Shen Y, Staudt LM, Rimsza L, Jaffe ES, Rosenwald A, Ott G, Delabie J, Campo E, Gascoyne RD, Weisenburger DD, et al. Chromosomal Alterations in Gene Expression-defined Pediatric Aggressive B-cell Non-Hodgkin Lymphomas (B-NHL). *Blood* 114:2922A, 2009.
474. Johnson NA, Ben-Neriah S, Savage KJ, Lee T, Horsman DE, Connors JM, Chan WC, Lenz G, Wright G, Rimsza L, Brazier LR, Cook, Tubbs R, Weisenburger DD, et al. MYC Translocations and Expression are Clinically Important in R-CHOP Treated Patients with De Novo Diffuse Large B-cell Lymphoma (DLBCL). *Blood* 114:1100A, 2009.
475. Meyer PN, Smith LM, Fu K, Greiner TC, Aoun P, Delabie J, Gascoyne RD, Rosenwald A, Brazier R, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD. Comparing Immunohistochemical Methods for Predicting Gene Expression Profile and Survival of Diffuse Large B-cell Lymphoma Treated with Rituximab. *Mod Pathol* 23:311A, 2010.

Dennis Weisenburger, MD - MC

476. Meyer PN, Smith LM, Fu K, Greiner TC, Aoun P, Delabie J, Gascoyne RD, Rosenwald A, Braziel RM, Campo E, Vose JM, Lenz G, Staudt LM, Chan WC, Weisenburger DD. The Stromal Marker SPARC Predicts Survival of Patients with Diffuse Large B-cell lymphoma Treated with Rituximab. *Mod Pathol* 23:311A, 2010.
477. Caponetti GC, Streblow RC, Althof PA, Sanger WG, Greiner TC, Weisenburger DD. Immunohistochemical and Cytogenetic Evaluation of Potential Targets for Tyrosine Kinase Inhibitors in Langerhans Cell Histiocytosis, *Mod Pathol* 23:289A, 2010.
478. Grass S, Preuss KD, Wilkowitz A, Thome S, Weisenburger DD, et al. The Paraproteins of Patients with Familial MGUS/Multiple Myeloma (MM) Target Family-specific Antigens: Experience with Paratarg-7 and Paratarg-8. *Proc AACR*:1924A, 2010.
479. Leich E, Campo E, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, Weisenburger DD, et al. t(14;18) Negative Follicular Lymphoma is Characterized by Downregulation of MicroRNAs involved in Cell Cycle Control, Apoptosis and B-cell Differentiation. *Proc EAHF*: LS59, 2010.
480. Guitart J, Sundram U, Subtil A, Junkins-Hopkins J, Weisenburger DD, et al. Cutaneous Gamma-delta Lymphomas: Pathological Features of a Large Multicenter Study. *Proc Am Soc Dermatopathol*, 2010.
481. Guitart J, Subtil A, Kim E, Duvic M, Wood G, Weisenburger DD, et al. Cutaneous Gamma-delta Lymphomas: the US Experience. *Proc First World Congress on Cutaneous Lymphoma*, 2010.
482. Sammassimo S, Pruneri G, Pileri S, Staffanoni S, Negri M, Zinzani PL, Raderer M, Adam P, Armitage JO, Weisenburger DD, et al. Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Results of a Retrospective Analysis on behalf of IELSG. *Blood* 116:738A, 2010.
483. Johnson NA, Connors JM, Ben-Neriah S, Rojic S, Savage KJ, Steidl C, Horsman DE, Slack G, Sehn LH, Chan WC, Iqbal J, Meyer P, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, et al. Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome in DLBCL Patients Treated with R-CHOP. *Blood* 116:836A, 2010.
484. Savage KJ, O'Leary H, Connors JM, Chhanabhai M, Sehn LH, Campbell B, Gascoyne RD, Weisenburger DD, et al. The Prognosis of Limited Stage Peripheral T-cell Lymphoma (PTCL): a Population-based Analysis and Comparison to Diffuse Large B-cell Lymphoma (DLBCL). *Blood* 116:1680A, 2010.
485. Gilling C, Mittal A, Nganga V, Palmer V, Weisenburger DD, Bierman P, Bociek RG, Swanson P, Joshi SS. Molecular Determinants of Lymph Node Microenvironment Induced Host Immune Tolerance in CLL: Role for CAV1, PTPN6, and PKC in the Process. *Blood* 116:588A, 2010.
486. Perry A, Meyer P, Cardesa-Salzmann T, Smith L, Colomo L, Guillermo A, Campo E, Greiner T, Delabie J, Gascoyne R, Rimsza L, Jaffe E, Ott G, Rosenwald A, Braziel R, Tubbs R, Cook J, Staudt L, Connors J, Vose J, Chan W, Weisenburger D. A New Biological Model Based on Immunohistochemistry Predicts Survival in Patients with Diffuse Large B-cell lymphoma. *Mod Pathol* 24(Suppl 1):315A, 2011.



Dennis Weisenburger, MD - MC

487. Caponetti G, Dave B, Smith L, Meyer P, Bast M, Bierman P, Bociek G, Vose J, Armitage J, Aoun P, Fu K, Greiner T, Chan WC, Weisenburger D. Clinical Significance of CMYC Rearrangement in Diffuse Large B-Cell Lymphoma. *Mod Pathol* 24(Suppl 1):288A, 2011.
488. Hassan HM, Varney ML, Jain SS, Weisenburger DD, Singh RK, Dave BJ. Differential p73 Isoform Expression in Non-Hodgkin's Lymphoma with 1p36 Chromosomal Abnormality Modulates Aggressiveness and Angiogenic Phenotype. *Proc 42nd Midwest Student Biomedical Research Forum*, 2011.
489. Hassan HM, Varney ML, Jain SS, Weisenburger DD, Singh RK, Dave BJ. Disruption of Chromosomal Locus 1p36 Differentially Modulates TAp73 and  $\Delta$ Np73 Expression and Aggressiveness in Non-Hodgkin Lymphoma. *Cancer Res* 71:312A, 2011.
490. Ai W, Chang E, Fu K, Fish K, Weisenburger DD, Keegan T. Racial/Ethnic Patterns of NK/T-cell Lymphoma in California: a Population-based Study. *Ann Oncol* 22:167, 2011.
491. Cabrera ME, Martinez V, Nathwani B. Müller-Hermelink HK, Diebold J, MacLennan K, Weisenburger DD. Non-Hodgkin Lymphoma (NHL) in Chile. A Review of 207 Consecutive Cases by a Panel of Five Expert Hematopathologists. *Ann Oncol* 22:367, 2011.
492. Federico M, Bellei M, Pesce EA, Zucca E, Pileri SA, Montoto S, Weisenburger DD, Rudiger T, Ko YH, Liang R, Zinzani PL, Connors J, Horowitz S, Polliack A, Vose JM. T-cell Project: an International, Prospective, Observational Study of Patients with Aggressive Peripheral T-cell Lymphoma. Analysis of First 524 Patients. *Ann Oncol* 22:241, 2011.
493. Delabie J, Holte H, Vose J, Armitage JO, Weisenburger DD. Enteropathy-associated T-cell Lymphoma: Clinical and Histological Findings from the International Peripheral T-cell Lymphoma Project. *Ann Oncol* 22:129, 2011.
494. Birmann BM, Andreotti G, De Roos AJ, Spinelli JJ, Cozen, W, Camp N, Moysich K, Chiu B, Boffetta P, Benhaim-Luzon V, Brennen P, de Sanjose S, Costas Caudet L, Seniori Constantini A, Cocco P, Becker N, Foretova L, Maynadie M, Nieters A, Staines A, Weisenburger DD, Baris D, Purdue M. The International Multiple Myeloma Consortium (IMMC) Lifestyle Factors Pooling Project, Part One: a Pooled Analysis of Body Mass Index and Risk of Multiple Myeloma in Eight Case-control Studies. *Proc 10th InterLymph Meeting*, 2011.
495. Loberiza F, Armitage JO, Bierman PJ, Bociek GR, Darrington DL, Ganti AK, Vose JM, Weisenburger DD. 25-year Survival Trends for Patients with Lymphoma by Race/ethnicity: a Report from the Nebraska Lymphoma Study Group. *Proc Pan Pacific Lymphoma Conference*, 2011.
496. Sammassimo S, Pruneri G, Adam P, Pileri S, Rafaniello P, Steffanoni S, Gandini S, Negri M, Habermann TM, Li ZM, Zinzani PL, Raderer M, Armitage JO, Weisenburger DD, et al. Potential Pathogenic Role of *Achromobacter* (*Alcaligenes*) *Xylosoxidans* in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. *Blood* 118:880A, 2011.
497. Morton LM, Clarke CA, Chang ET, Hall EC, Lynch CF, Pfeiffer R, Weisenburger DD, Engels EA. Risk of Acute Myeloid Leukemia Among Solid Organ Transplant Recipients. *Blood* 118:2259A, 2011.

Dennis Weisenburger, MD - MC

498. Crockett DG, Perry AM, Armitage JO, Weisenburger DD, Bast M, Loberiza FR. Lymphoma with Features Intermediate Between DLBCL and Burkitt Lymphoma: Better Outcome with Intensive Chemotherapy Regimens. *Blood* 118:2710A, 2011.
499. Gupta P, Mittal AK, Weisenburger DD, Bierman PJ, Joshi SS. Heat-shock Protein Signature is Associated with Refractory Chronic Lymphocytic Leukemia Cells from Different In Vivo Microenvironments. *Blood* 118:3866A, 2011.
500. Mittal AK, Iqbal J, Gilling CE, Moragues M, Bociek RG, Aoun P, Weisenburger DD, Joshi SS. The Aggressive Molecular Signature of Peripheral Blood Chronic Lymphocytic Leukemia (CLL) Cells from Patients with Bulky Lymphadenopathy Closely Resembles that of CLL Cells from Lymph Nodes. *Blood* 118:3868A, 2011.
501. Guitart J, Sundram U, Subtil A, Junkins-Hopkins J, Weisenburger D, et al. Cutaneous Gamma-Delta Lymphomas: Pathological Features of a Multicenter Study. *Proc Am Soc Dermatopathol*, 2011.
502. Pirruccello S, Samson H, Dafferner A, Maas S, Julius H, Weisenburger D, et al. Myeloid Regulatory Cells in Cancer Patients. *Cancer Res* 71:453A, 2011.
503. Grass S, Preuss KD, Wikowicz A, Thome S, Weisenburger DD, et al. The Paraproteins of Patients with Familial MGUS/Multiple Myeloma (MM) Target Family-specific Antigens: Experience with Paratarg-7 and Paratarg-8. *Cancer Res* 70:1924A, 2011.
504. Perry A, Alvarado-Bernal Y, Laurini J, Smith L, Fu K, Aoun P, Greiner T, Chan W, Bierman P, Bociek G, Armitage J, Vose J, Weisenburger D. Immunostains for C-MYC and BCL2 Proteins Predict Survival in Patients with Diffuse Large B-cell Lymphoma Treated with Rituximab. *Mod Pathol* 5:361A, 2012.
505. Perry A, Dave B, Crockett D, Althof P, Smith L, Aoun P, Chan W, Fu K, Greiner T, Bierman P, Bociek G, Armitage J, Vose J, Weisenburger D. High-grade B-cell Lymphoma with Features Between Burkitt Lymphoma and Diffuse Large B-cell Lymphoma (Grey Zone Lymphoma): a Clinicopathologic Analysis of 39 Cases. *Mod Pathol* 5:361A, 2012.
506. Laurini JA, Perry AM, Boilesen E, Bast MA, Nathwani BN, Diebold J, MacLennan KA, Müller-Hermelink HK, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in South America: a Review of 1,028 cases. *Mod Pathol* 5:349A, 2012.
507. Liu L, Perry A, Cao W, Smith L, Hsi E, Mo J, Dotlic S, Damjanov I, Mosunjac M, Talmon G, Weisenburger DD, Fu K. Sinus Histocytosis with Massive Lymphadenopathy (Rosai-Dorfman Disease) is Not Part of IgG4-related Sclerosing Disease. *Mod Pathol* 5:352A, 2012.
508. Engels E, Clarke T, Landgren O, Lynch C, Weisenburger D, Gibson T, Hall E, Morton L. Plasma Cell Neoplasms Among Solid Organ Transplant Recipients. *Proc Am Transplant Congress*. 2012.
509. Gibson TM, Engels EA, Clarke CA, Pfeiffer RM, Lynch CF, Chang ET, Hall E, Weisenburger DD, Morton LM. Risk of Diffuse Large B-cell Lymphoma (DLBCL) in Solid Organ Transplant Recipients. *Proc AACR*, 2012.



Dennis Weisenburger, MD - MC

510. Andreotti G, Birmann B, De Roos A, Spinelli J, Cozen W, Camp N, Moysich K, Chiu B, Boffetta P, Benhaim-Luzon V, Brennan P, de Sanjose S, Costas Caudet L, Seniori Constantini A, Cocco P, Becker N, Foretova L, Maynadie M, Nieters A, Staines A, Milliken K, Weisenburger DD, Baris D, Purdue M. A Pooled Analysis of Smoking and Alcohol Drinking and Risk of Multiple Myeloma in the International Multiple Myeloma Consortium. *Proc AACR*, 2012.
511. Laurini JA, Perry AM, Bast MA, Biolesen E, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Armitage JO, Weisenburger DD. Classification of non-Hodgkin Lymphoma in Central and South America: a Review of 1028 Cases. *Proc 11th InterLymph Meeting*, 2012.
512. Chaturvedi NK, Ahrens AK, Shukla A, Gilling CE, Mittal AK, Bierman P, Weisenburger DD, et al. Stromal Tumor Environment in CLL: Regulation of Leukemic Progression. 54th ASH Annual Meeting, 1781A, 2012.
513. Evens AM, Chadburn A, Ollberding NJ, Dave SS, Aschebrook-Kilfoy B, Smith SM, Weisenburger DD, Chiu BCH. Influence of Lifestyle Factors on Expression of Tumor-related Microenvironment T-cells and Impact on Survival of Follicular Lymphoma (FL). 54th ASH Annual Meeting, 2694A, 2012.
514. Iqbal J, Wright G, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene Expression Signatures that Delineate Biologic and Prognostic Subgroups in Peripheral T-cell Lymphoma. 54th ASH Annual Meeting, 679A, 2012.
515. Bouska A, McKeithan T, Deffenbacher K, Lachel C, Wright GW, Iqbal J, Smith LM, Liu Z, Kucuk C, Bertoni F, Rinaldi A, Fitzgibbon J, Fu K, Weisenburger DD, et al. Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma. 54th ASH Annual Meeting, 2648A, 2012.
516. Ollberding NJ, Evens AM, Aschebrook-Kilfoy B, Caces DBD, Weisenburger DD, Smith SM, Chiu BCH. The Impact of Cigarette Smoking on Overall Survival in Non-Hodgkin Lymphoma. 54th ASH Annual Meeting, 5100A, 2012.
517. Beck JC, Bast M, Perry DA, Smith L, Weisenburger DD. Outcome of Adolescent and Young Adult (AYA) Patients with Diffuse Large B-cell Lymphoma (DLBCL). 54th ASH Annual Meeting, 1568A, 2012.
518. Vose JM, Loberiza FR, Bierman PJ, Bociek RG, Weisenburger DD, Armitage JO. The Role of Autologous Stem Cell Transplantation in First Complete Remission for Patients with Mantle Cell Lymphoma. *European Hematology Association Meeting*, 2012.
519. Perry A, Warnke R, Hu Q, Rosenwald A, Gaulard P, Copie-Bergman C, Geissinger E, Wang HY, Ranheim E, Weisenburger DD, Jaffe E, Chan W. Indolent T-cell Lymphoproliferative Disease of the Gastrointestinal Tract: Report of Seven Cases. *J Hematopathol* 5:224-225, 2012.
520. William BM, Kady N, Perry AM, Klinetobe K, Bociek RG, Bierman PJ, Vose JM, Armitage JO, Weisenburger DD, Busik JV. Impact of Bone Marrow Neuropathy on the Outcome of Autologous Stem Cell Transplantation (ASCT) for Lymphoma. *Bone Marrow Transplantation Tandem Meeting*, 156A, 2013.

Dennis Weisenburger, MD - MC

521. Bowen JM, Perry AM, Smith L, Klinetobe K, Bast M, Vose JM, Fu K, Greiner TC, Chan WC, Weisenburger DD, Aoun P. An Academic Medical Center's Experience with Lymphoma Diagnosis: Rate of Revision and Impact on Patient Care. *Mod Pathol* 26 (Suppl. 2): 321A, 2013.
522. El Behery R, Laurini JA, Weisenburger DD, et al. Follicular Large Cleaved Cell Lymphoma is a Distinctive Morphological and Clinical Variant of Follicular Lymphoma. *Mod Pathol* 26 (Suppl. 2): 1369A, 2013.
523. Liu C, Iqbal J, Teruya-Feldstein J, Shen Y, Dabrowska MJ, Dybkaer K, Lim MS, Piva R, Barreca A, Pellegrino E, Spaccarotella E, Lachel CM, Kucuk C, Jiang CS, Hu X, Bhagvati S, Greiner TC, Weisenburger DD, et al. MicroRNA Expression Profiling Identifies Molecular Diagnostic Signatures for Anaplastic Large Cell Lymphoma. *Mod Pathol* 26 (Suppl. 2): 242A, 2013.
524. Perry AM, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in Six Geographic Regions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Proc 12th International Conference on Malignant Lymphoma*, 2013.
525. Perry AM, Crockett D, Dave B, Althof P, Winkler L, Smith L, Aoun P, Chan W, Fu K, Greiner T, Bierman P, Bociek G, Armitage J, Vose J, Weisenburger D. Genetic Abnormalities in B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma (B-UCL): The Nebraska Experience. *Proc 12th International Conference on Malignant Lymphoma*, 2013.
526. Caponetti GC, Dave BJ, Smith L, Bast M, Meyer P, Bierman P, Bociek G, Vose J, Armitage J, Fu K, Aoun P, Greiner TC, Chan WC, Weisenburger DD. Clinical Relevance of MYC, BCL2 and BCL6 Rearrangements and Amplifications in Diffuse Large B-cell Lymphoma. *Proc 12th International Conference on Malignant Lymphoma*, 2013.
527. Perry AM, Skrubek P, Banerji V, Ahsanuddin A, Almiski M, Morales CM, Musuka C, Sekiguchi D, Sun P, Kumar R, Weisenburger DD, Nasr M. Relative Frequencies of Lymphoma Subtypes in the Province of Manitoba: a Population-based Study. *Proc. 12th InterLymph Meeting*, 2013.
528. Scott DW, Wright GS, Williams M, Lih J, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, et al. Determining Cell-of-origin Subtypes in Diffuse Large B-cell Lymphoma Using Gene Expression Profiling on Formalin-fixed Paraffin-embedded Tissue- an LLMPP Project. *55th ASH Annual Meeting*, 2013.
529. Mohanty S, Mohanty A, Sandoval N, Bedell V, Murata-Collins J, Wu J, Scuto A, Weisenburger DD, Ngo VN. Cyclin D1 Maintains Mantle Cell Lymphoma through CDK4-independent Regulation of RNA Replicative Checkpoints. *55th ASH Annual Meeting*, 2013.
530. Scotland P, Gaulard P, Love C, Fatacciolli V, Weisenburger DD, et al. Whole Genome and Exome Sequencing Defines the Genetic Landscape of Hepatosplenic T-cell Lymphoma. *55th ASH Annual Meeting*, 2013.
531. Yuan J, Wright G, Gascoyne RD, Connors JM, Rosenwald A, Weisenburger DD, et al. Gene Expression Signature Helps to Identify Primary Mediastinal Large B-cell Lymphoma at the Extra-mediastinal Sites without Mediastinal Involvement. *Mod Pathol* 27:387A, 2014.



Dennis Weisenburger, MD - MC

532. Batra R, Weisenburger D, Snyder D, Bedell V, Murata-Collins J, Gaal K. Prognostic Significance of Chromosomal Aberrations in Philadelphia Chromosome Negative Metaphases During Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia. *Mod Pathol* 27:335A, 2014.
533. Zhang N, Reddi DM, Weisenburger DD, Kim Y. Follicular Lymphoma with Marginal Zone Differentiation, an Institutional Experience. *Mod Pathol* 27:388A, 2014.
534. Perry AM, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in the Mediterranean/Middle East and Far East: Review of 1563 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Mod Pathol* 27:371A, 2014.
535. Dotlic S, Perry AM, Petrussevska G, Fetica B, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in Eastern Europe: Review of 595 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Mod Pathol* 27:346A, 2014.
536. Ottesen RA, Goldstein L, Olsen KK, Kilburn JA, Weisenburger DD, Chu P, Niland JC. Discrepancy-reducing Feedback Loops Based on Intra- and Inter-validation of Synoptic Pathology Data. *AMIA Joint Summits on Translational Science*, 2014.
537. Perry A, Diebold J, MacLennan K, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of NK/T-cell Non-Hodgkin Lymphoma (NHL) in Six Geographic Regions Around the World: Review of 569 Cases from the International NHL Classification Project. *Sixth Annual T-cell Forum*, 2014.
538. Wang SS, Zhang Y, Flowers C, .... Weisenburger DD. Epidemiologic Risk Factors for T-cell Lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *Sixth Annual T-cell Forum*, 2014.
539. Pahwa M, Beane Freeman L, Spinelli JJ, ..... Weisenburger DD, Harris SA. The North American Pooled Project (NAPP): Pooled Analyses of Case-control Studies of Pesticides and Agricultural Exposures, Lymphohematopoietic Cancers and Sarcoma. *EPICOH Conference on Challeges for Occupational Epidemiology in the 21st Century*, 2014.
540. Perry AM, Diebold J, MacLennan KA, Müller-Hermlink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in Six Geographic Reigions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Proc 13th InterLymph Meeting*, 2014.
541. Pahwa M, Beane Freeman L, Spinelli JJ, Blair A, Pahwa P, Dosman JA, McLaughlin JR, Demers PA, Hoar Zahm S, Cantor KP, Weisenburger DD, Harris SA. The North American Pooled Project (NAPP): a New Resource of Pooled Case-control Studies of Pesticides and Agricultural Exposures, Lymphatic and Hematopoietic Cancers, and Soft Tissue Sarcoma. *Occup Environ Med* 71:A116, 2014.

Dennis Weisenburger, MD - MC

542. Wang SS, Flowers CR, Kadin ME, Chang ET, Hughes AM, Ansell SM, Feldman AL, Lightfoot T, Boffetta P, Melbye M, Lan Q, Sampson JN, Morton LM, Zhang Y, and Weisenburger DD. Epidemiologic Risk Factors for T-cell Lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. Proc 13th InterLymph Meeting, 2014.
543. Evens AM, Ollberding NJ, Chadburn A, Smith SM, Weisenburger DD, Chiu BCH. The Influence of Lifestyle Habits on Tumor Markers and the Microenvironment in Follicular Lymphoma (FL): Novel Interactions and Impact on Survival. Proc 13th InterLymph Meeting, 2014.
544. Mohanty S, Mohanty A, Sandoval N, Bedell V, Murata-Collins J, Wu J, Scuto A, Weisenburger DD, Vu NG. Cyclin D1 Promotes Resistance to DNA Replication Inhibitors through an ATR-dependent Mechanism in Mantle Cell Lymphoma. ASH Meeting on Lymphoma Biology, 2014.
545. Telatar M, Hong H, Louie C, Sharma V, Fong C, Weisenburger DD, Chan J, Aoun P. Developing Multi-gene Mutational Profiling of Hematological Malignancies in a CLIA-licensed Laboratory. European Association of Haematopathology Meeting, 2014.
546. Petrusevska G, Jovanovic R, Basheska N, . . . Weisenburger D. Histological and Immunohistochemical Study of Malignant Lymphomas in Macedonia – Study of 222 Cases. European Association of Haematopathology Meeting, 2014.
547. Rohr J, Guo S, Hu D, Bouska A, Gascoyne RD, Rosenwald A, Simone P, Zhang W, Xiao W, Wang C, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Berger F, Borgstahl G, Davis S, McKeithan T, Iqbal J, and Chan WC, CD28 Mutations in Peripheral T-Cell Lymphomagenesis and Progression. 56th ASH Annual Meeting, 2014.
548. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S, Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG, Staudt LM, Vose J, Iqbal J, and Chan WC, IDH2R172 Mutations Define a Unique Subgroup of Patients with Angioimmunoblastic T-cell Lymphoma. 56th ASH Annual Meeting, 2014.
549. Kendrick SL, Tus K, Scott DW, Wright G, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Braziel RM, Ott G, Delabie J, Cook JR, Weisenburger DD, Greiner TC, Fu K, Staudt LM, Gascoyne RD, and Rimsza LM, Cell-of-origin Subtype Classification of Diffuse Large B-cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. 56th ASH Annual Meeting, 2014.
550. Cerhan JR, de Sanjosé S, Paige BM, Spinelli JJ, Vajdic CM, Monnereau A, Dal Maso L, Kane E, Chiu BCH, Bernstein L, Zhang Y, Weisenburger DD, and Slager SL, Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an InterLymph Pooled Study. 56th ASH Annual Meeting, 2014.
551. Song JY, Venkataraman G, Fedoriw YD, Alikhan M, Kim Y, Weisenburger DD, Collins J, Liu X, and Duffield AS, Burkitt Leukemia Involving Only the Bone Marrow has a Better Prognosis than Widespread Burkitt Lymphoma Involving the Bone Marrow in Adults. 56th ASH Annual Meeting, 2014.



Dennis Weisenburger, MD - MC

552. Scott DW, Wright GW, Williams M, Lih J, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland E, Braziel RM, Ott G, Delabie J, Weisenburger DD, Cook JR, Greiner TC, Fu K, Walsh W, Gascoyne RD, Staudt LM, and Rimsza LM, Accurate Diagnosis of Aggressive B-cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-fixed, Paraffin-embedded Tissues. 56th ASH Annual Meeting, 2014.
553. Scotland P, Gaulard P, Love CL, Fataccoli V, Travert M, De Leval L, Weisenburger DD, Czader M, Parihar M, Nair R, Sengar M, Beaven AW, Crow JH, Miles RR, Gordon LJ, Chadburn A, Evens AM, Gill J, Fedorin YD, Richards KL, Srivastava G, Choi WWL, Flowers CR, Bernal-Mizrachi L, Mann KP, Naresh K, Hsi ED, Horna P, Tao J, Sun Z, Long K, Zhang J, and Dave S, Whole Genome and Exome Sequencing Defines the Genetic Landscape of Hepatosplenic T-cell Lymphoma. 56th ASH Annual Meeting, 2014.
554. Ottesen RA, Goldstein L, Olsen KK, Kilburn JA, Weisenburger DD, Chu P, Niland JC. Discrepancy-reducing Feedback Loops Based on Intra- and Inter-validation of Synoptic Pathology Data. AMLA Joint Summits on Translational Science, 2014.
555. Yang L, Chen L, Wang Y, Jones J, Yen Y, Loera S, Pillai R, Chu P, Weisenburger DD. Characterization of Genetic Concordance Between Primary Tumor Cells, Circulating Tumor Cells, and Metastatic Tumor Cells from Patients with Prostate Cancer. Proc AACR, 2015.
556. Pahwa M, Spinelli JJ, Freeman LB, Demers PA, Blair A, Pahwa P, Dosman JA, McLaughlin JR, Zahm SH, Cantor KP, Weisenburger DD, Harris SA. An Evaluation of Glyphosate Use and the Risks of Non-Hodgkin Lymphoma Major Histological Subtypes in the North American Pooled Project (NAPP). Canadian Society for Epidemiology and Biostatistics Conference, 2015.
557. Glasser SL, Clarke CA, Keegan THM, Chang ET, Weisenburger DD. Changing Incidence of Hodgkin Lymphoma Histologic Subtypes: Risk Factor Trends or Evolving Diagnostic Practice? Annual NAACCR Conference, 2015.
558. Pahwa M, Spinelli JJ, Freeman LB, Demers PA, Blair A, Pahwa P, Dosman JA, McLaughlin JR, Zahm SH, Cantor KP, Weisenburger DD, Harris SA. An Evaluation of Glyphosate Use and the Risks of Non-Hodgkin Lymphoma Major Histological Subtypes in the North American Pooled Project (NAPP). International Society for Environmental Epidemiology Conference, 2015.
559. Lui H, Medeiros LJ, Weisenburger DD, et al. Breast Implant-associated Anaplastic Large Cell Lymphoma (BI-ALCL): a Comprehensive Histopathological Evaluation of 40 Cases with a Proposal for a Pathologic Staging System. Mod Pathol 28: 360A, 2015.
560. Caponetti G, Perry A, Smith LM, Bast M, Dave BJ, Fu K, Greiner T, Weisenburger DD. Immunohistochemical and Cytogenetic Evaluation of MYC in Diffuse Large B-cell Lymphoma. Mod Pathol 28: 338A, 2015.
561. Yuan J, Greiner TC, Fu K, Smith LM, Vose JM, Weisenburger DD. Rituximab Improves the Outcome of Patients with Grade 3 Follicular Lymphoma. Mod Pathol 28: 390A, 2015.
562. Song L, Feldman AL, Murata-Collins JL, Bedell V, Weisenburger DD, Nathwani BN, Song JY. Cyclin D1 Expression in T-cell Lymphomas. Mod Pathol 28: 379A, 2015.

Dennis Weisenburger, MD - MC

563. Low L, Song JY, Mei M, Krishnan A, Nademanee A, Popplewell L, Chen R, Spielberger R, Cai J, Chen YY, Gaal K, Aoun P, Weisenburger DD, Kim YS. Co-expression of MYC and BCL2 Protein in Diffuse Large B-cell Lymphoma Predicts a Poor Outcome in Patients Treated with Autologous Stem Cell Transplantation. *Mod Pathol* 28: 361A, 2015.
564. Perry AM, Perner Y, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma (NHL) in Southern Africa (SA): Review of 487 Cases from the International Non-Hodgkin Lymphoma Classification Project. *Mod Pathol* 28: 371A, 2015.
565. Gaulard P, DeLeval L, Czader M, Lossos I, Chapman-Fredericks J, Richards K, Chadburn A, Cheng R, Srivastava G, Ondrejka S, Hsi E, Fedoria Y, Weisenburger D, Flowers C, Bernal-Mizrachi L, Evens A, Pilichowska M, Gascoyne R, Dave S. The Genetic Landscape of Hepatosplenic T-cell Lymphoma Reveals Novel Strategies for Treatment and Risk-stratification. *Hematol Oncol* 33: 137, 2015.
566. Nathwani BN, Low L, Pillai R, Weisenburger D. EBV-positive Cells Present Exclusively within Clusters of Monocytoid B-cells Masquerading as a Nodal Marginal Zone B-cell Lymphoma. Society of Hematopathology Workshop on Immunodeficiency and Dysregulation, 2015.
567. Pillai R, Weisenburger D, Chan W, Nathwani B. Epstein-Barr Virus Positive Hodgkin Reed-Sternberg Type Cells Restricted within Clusters of Benign Monocytoid B-cells in a Patient with Bloom Syndrome. Society of Hematopathology Workshop on Immunodeficiency and Dysregulation, 2015.
568. Herrera AF, Mei MG, Low L, Merryman RW, Song JY, Paris T, Stiller T, Bedell V, Sun H, Brown JR, Budde LE, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, Kim HT, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer J, Pihan GA, Siddiqi T, Sohani AR, Popplewell LL, Zain J, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, and Armand P, Double Expressing (MYC/BCL2) and Double-hit Diffuse Large B-cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. 57th ASH Annual Meeting, 2015.
569. Siddiqi T, Scuto A, Beumer JH, Song JY, Frankel P, Ruel C, Cobb J, Kiesel BF, Weisenburger DD, Kelly KR, Tuscano J, Popplewell L, Forman SJ, Piekarz R, and Newman EM, Results From a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase A Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. 57th ASH Annual Meeting, 2015.
570. Perry AM, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in Seven Geographic Regions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. 57th ASH Annual Meeting, 2015.
571. Perry AM, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN, Boilesen E, Bast M, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma (NHL) in the Developing World: The International NHL Classification Project. *Mod Pathol* 29: 368A, 2016.
572. Low L, Song JY, Chen YY, Valle M, Weisenburger DD, Kim YS. Coexpression of MYC and BCL2 Proteins Identifies a Subset of Follicular Lymphoma that Undergoes Transformation to Diffuse Large B-cell Lymphoma and Correlates with Poor Survival. *Mod Pathol* 29: 360A, 2016.



Dennis Weisenburger, MD - MC

573. Ameri MD, Wong JT, Low L, Chen YY, Weisenburger DD, Pillai R, Kim YS, Song JY. CXCR4 Expression in Follicular Lymphoma. *Mod Pathol* 29: 334A, 2016.
574. Mohanty A, Sandoval N, Das M, Amin H, Marcucci G, Pillai R, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. Cyclin D1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma. *ASH Lymphoma Biology Meeting*, 2016.
575. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, Boilesen E, Armitage JO, Weisenburger DD. Classification of Non-Hodgkin Lymphoma in Seven Geographic Regions Around the World: Review of 4539 Cases from the International Non-Hodgkin Lymphoma Classification Project. *InterLymph Annual Conference*, 2016.
576. Herrera AF, Low A, Griffin GK, Mei M, Merryman R, Song J, Bedell V, Sun H, Paris T, Stiller T, Alyea E, Brown J, Budde E, Chen R, Chen YB, Chan WC, Cutler C, Davids M, Freeman A, Fisher D, Ho V, Jacobsen E, Jacobson C, Koreth J, LaCasce A, Murata-Collins J, Nademanee A, Nikiforow S, Palmer J, Pihan G, Pillai R, Siddiqi T, Sohani A, Popplewell L, Zain J, Kwak L, Weinstock D, Soiffer R, Antin J, Forman S, Weisenburger DD, Rodig S, Kim Y, Krishnan A, Armand P. Outcomes after Autologous and Allogeneic Stem Cell Transplantation (SCT) in Diffuse Large B-cell Lymphoma (DLBCL) Patients with MYC/BCL2 Co-expression, Double-hit Lymphoma, or MYC Copy Gain. *European Hematology Association Annual Meeting*, 2016.
577. Harris SA, Presutti R, Kachuri L, Spinelli JJ, Pahwa M, Blair A, Zham SH, Cantor KP, Weisenburger DD, Pahwa P, McLaughlin JR, Dosman JA, Freeman LB. Pesticide Exposures and the Risk of Multiple Myeloma in Men: An Analysis of the North American Pooled Project (NAPP). *50th IARC Global Cancer Occurance, Causes and Avenues to Prevention Conference*, 2016.
578. Pahwa M, Freeman LEB, Spinelli JJ, Blair A, Zahm SH, Cantor KP, Pahwa P, Dosman JA, McLaughlin JR, Weisenburger DD, Demers PA, Harris SA. A Detailed Assessment of Glyphosate Use and the Risks of Non-Hodgkin Lymphoma Overall and by Major Histological Subtypes: Findings from the North American Pooled Project (NAPP). *50th IARC Global Cancer Occurance, Causes and Avenues to Prevention Conference*, 2016.
579. Harris SA, Musa R, Pahwa M, Kachuri L, Spinelli JJ, Blair A, Pahwa P, McLaughlin JR, Dosman JA, Zahm SH, Cantor KP, Weisenburger DD, Freeman LEB. An Evaluation of Potentially Carcinogenic Pesticides and the Risks of Non-Hodgkin Lymphoma and its Histological Subtypes: An Analysis of the North American Pooled Project (NAPP). *50th IARC Global Cancer Occurance, Causes and Avenues to Prevention Conference*, 2016.
580. Kachuri L, Harris SA, Spinelli JJ, Blair A, Pahwa M, Zahm SH, Cantor KP, Weisenburger DD, Pahwa P, Dosman JA, McLaughlin JR, Demers PA, Freeman LEB. An Investigation of Organochlorine Insecticide Use and the Risks of Non-Hodgkin Lymphoma Subtypes: Findings from the North American Pooled Project (NAPP). *50th IARC Global Cancer Occurance, Causes and Avenues to Prevention Conference*, 2016.
581. Latifovic I, Freeman LB, Spinelli JJ, Pahwa M, Blair A, Pahwa P, McLaughlin JR, Dosman JA, Zahm SH, Cantor KP, Weisenburger DD, Demers PA, Harris SA. Pesticide Use and the Risk of Hodgkin Lymphoma: Results from the North American Pooled Project (NAPP). *50th IARC Global Cancer Occurance, Causes and Avenues to Prevention Conference*, 2016.

Dennis Weisenburger, MD - MC

582. Perry A, Diebold J, Nathwani B, MacLennan K, Müller-Hermelink HK, Bast M, Boilesen E, Armitage J, Weisenburger D. Non-Hodgkin Lymphoma in the Developing World: Review of 4539 Cases from the International Non-Hodgkin Classification Project. 18th Meeting of the European Association for Haematopathology, 2016.
583. Gonzalez BR, Song J, Weisenburger D, Palmer J, Zain J, Rosen ST, Querfeld C. The Immune Checkpoint Receptors ICOS and PD1 in Mycosis Fungoides and Sezary Syndrome: Correlation with Disease and Outcome. 3rd World Congress of Cutaneous Lymphomas, 2016.
584. Mohanty A, Sandoval N, Das M, Amin HM, Marcucci G, Pillai R, Weisenburger DD, Rosen ST, Pham LV, Ngo VN. CCND1 Mutations Increase Protein Stability and Promote Ibrutinib Resistance in Mantle Cell Lymphoma. 58th ASH Annual Meeting, 2016.
585. Herrera AF, Song JY, Griffin GK, Nikolaenko L, Mei M, Bedell V, Dal Cin P, Pak C, Stiller T, Sun H, Alyea EP, Budde LE, Chen RW, Chen Y-B, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer JM, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Nademanee AP, Weinstock DM, Soiffer RJ, Antin JH, Kim Y, Rodig SJ, Forman SJ, and Armand P, Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. 58th ASH Annual Meeting, 2016.
586. Bouska A, Bi C, Lone W, Zhang W, Kedwaï A, Heavican TB, Lachel CM, Yu J, Fu K, Ferro RA, Eldorhamy N, Greiner TC, Vose JM, Weisenburger DD, Gascoyne RD, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, Siebert R, Miles RR, Dave S, Reddy A, McKeithan TW, Staudt LM, Green MR, Chan WC, and Iqbal J, Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway as a Potential Therapeutic Target. 58th ASH Annual Meeting, 2016.
587. Heavican TB, Yu J, Bouska A, Greiner TC, Lachel CM, Wang C, Dave BJ, Amador CC, Fu K, Vose JM, Weisenburger DD, Gascoyne RD, Hartmann S, Pedersen MB, Wilcox R, Teh BT, Lim ST, Ong CK, Seto M, Berger F, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore FA, Inghirami G, Bertoni F, Staudt L, McKeithan TW, Pileri SA, Chan WC, and Iqbal J, Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve by Distinct Genetic Pathways. 58th ASH Annual Meeting, 2016.
588. Song J, Perry A, Pillai R, Herrera A, Ottensen R, Nikowitz J, Skrabek P, Goldstein L, McCarthy C, Najera L, Zain J, Wang J, Wu X, Nademanee A, Niland J, Chan WC, Weisenburger DD. Evaluation of de novo Diffuse Large B-cell Lymphoma Using a Targeted Next Generation Sequencing Assay. *Mod Pathol* 30: 1519A, 2017.
589. Perry AM, Skrabek P, Ahsanuddin A, Schroedter I, Menard C, Lambert P, Song J, Weisenburger DD, Nasr M. Prognostic Significance of Telomere Length in Diffuse Large B-cell Lymphoma. *Mod Pathol* 30: 1483A, 2017.
590. Siaghani P, Song JY, Wong J, Chen YY, Weisenburger DD, Kim YS. Tumor-associated Macrophages do Not Predict Survival in Relapsed/refractory Hodgkin Lymphoma Treated with Autologous Stem Cell Transplantation. *Mod Pathol* 30: 1515A, 2017.



Dennis Weisenburger, MD - MC

591. Song JY, Kim YS, Siaghani P, Cantu D, Chen YY, Pillai R, Chan WC, Weisenburger DD. CTLA-4 Expression in Hodgkin Lymphoma Confers a Worse Overall Survival in Relapsed/refractory Patients. *Mod Pathol* 30: 1518A, 2017.
592. Wong JT, Ameri MD, Cantu D, Siaghani P, Song J, Weisenburger DD, Kim Y. Defining True Cellularity in Age-matched Marrows. *Mod Pathol* 30: 2102A, 2017.
593. Wong JT, Ameri MD, Siaghani P, Cantu D, Chen YY, Song J, Weisenburger DD, Kim Y. Programmed Cell Death Ligand1 (PD-L1) Expression in the Follicular Lymphoma Microenvironment. *Mod Pathol* 30: 1545A, 2017.
594. Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Jais JP, Savage KJ. Prognostic Factors and Impact of Etoposide in Adults with Systemic ALK-Positive Anaplastic Large Cell Lymphoma: a Pooled Analysis of Six Studies. (submitted)
595. Weisenburger DD, El Behery R, Laurini JA, Smith LM, Dave BJ, Yuan J, Fu K, Chan WC, Nathwani BN, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Greiner TC, Aoun P. Follicular Large Cleaved Cell (Centrocytic) Lymphoma: a Distinctive but Unrecognized Variant of Follicular Lymphoma. (submitted)
596. Moltok A, Wright G, Rosewald A, Ott G, Ramsower C, Campo E, Braziel RM, Delabie J, Weisenburger DD, Song J, Chan WC, Cook J, Fu K, Greiner T, Smeland E, Holte H, Glinzmann-Gibson BJ, Gascoyne RD, Staudt LM, Jaffe E, Connors JM, Scott DW, Steidl C, Rimsza LM. Molecular Classification of Primary Mediastinal Large B-Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens – an LLMPP Project. (submitted)
597. Cantu D, Siaghani P, Aoun P, Weisenburger DD, Pillai R. Molecular Profiling in Chronic Myelomocytic Leukemia. (submitted)

#### **X. Invited Seminars/Lectures/Forums, 203 Total**

1. "Malignant Lymphoma, Intermediate Lymphocytic Type: A Clinicopathologic Study of 42 Cases." International Academy of Pathology Meeting, 1981.
2. "Mantle-Zone Lymphoma." International Academy of Pathology Meeting, 1982.
3. "Multicentric Angiofollicular Lymph Node Hyperplasia: A Clinicopathologic Study of 16 Cases." International Academy of Pathology Meeting, 1984.
4. "Intermediate Lymphocytic Lymphoma: An Immunohistologic Study with Comparison to Other Lymphocytic Lymphomas." International Academy of Pathology Meeting, 1985.
5. "Immunologic Studies of Multicentric and Unicentric Angiofollicular Lymphoid Hyperplasia." International Academy of Pathology Meeting, 1986.
6. "Induction of B-Cell Lymphoma/Leukemia in Wistar Rats by 2-Hydroxyethylnitrosourea." Proceedings of the American Association for Cancer Research, 1986.

Dennis Weisenburger, MD - MC

7. "Peripheral T-Cell Lymphoma: A Clinicopathologic Study of 42 Cases." Proceedings of the American Association for Cancer Research, 1986.
8. "Intermediate Lymphocytic Lymphoma: An Immunologic and Cytogenetic Study." International Congress of the International Academy of Pathology, 1986.
9. "Castleman's Disease: A Unified Concept." Eleventh Annual AFIP Course on Pathology of Lymph Nodes, 1987.
10. "B-Cell Neoplasia Recapitulates the Normal Humoral Immune Response." Third International Conference on Malignant Lymphoma, 1987.
11. "Detection of Occult Lymphoma Cells in Bone Marrow Harvested for Autologous Transplantation." International Academy of Pathology Meeting, 1988.
12. "Castleman's Disease: A Unified Concept." Twelfth Annual AFIP Course on Pathology of Lymph Nodes, 1988.
13. "Intermediate Lymphocytic and Mantle-Zone Lymphomas: Evolving Concepts." Twelfth Annual AFIP Course on Pathology of Lymph Nodes, 1988.
14. "Mantle-Zone Lymphoma: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1988.
15. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1988.
16. "Environmental Epidemiology of Non-Hodgkin's Lymphoma in Eastern Nebraska." Iowa Symposium on Agricultural Occupational and Environmental Health, 1988.
17. "Lymphoid Malignancies and Agricultural Practices." NIEHS Workshop on the Quantification of Risk in Immunotoxicology, 1988.
18. "Lymphoid Malignancies and Agricultural Practices." Symposium on Agricultural Impacts on Groundwater, American Association for the Advancement of Science Meeting, 1989.
19. "Castleman's Disease: A Unified Concept." Thirteenth Annual AFIP Course on Pathology of Lymph Nodes, 1989.
20. "Intermediate Lymphocytic and Mantle-Zone Lymphomas: Evolving Concepts." Thirteenth Annual AFIP Course on Pathology of Lymph Nodes, 1989.
21. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1989.
22. "Hematopoietic Neoplasia: A Conceptual Understanding." Environmental Epidemiology Branch, National Cancer Institute, 1989.
23. "Benign Diseases of Lymph Nodes: A Pattern Approach." Short Course for American Society of Clinical Pathologists Meeting, 1989.



Dennis Weisenburger, MD - MC

24. "Lymphoma Pathology in Epidemiologic Studies." Workshop on Cancer in Rural Areas, University of Saskatchewan, 1989.
25. "Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic type." International Academy of Pathology Meeting, 1990.
26. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1990.
27. "Benign Diseases of Lymph Nodes: A Pattern Approach." Short Course for American Society of Clinical Pathologists Meeting, 1990.
28. "Potential Health Consequences of Groundwater Contamination by Agrichemicals in Nebraska." NATO Advanced Research Workshop on Nitrate Contamination: Exposure, Consequences, and Control, 1990.
29. "Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic type." Third Meeting of the European Association for Haematopathology, 1990.
30. "Non-Hodgkin's Lymphoma Associated with the Agricultural Use of Herbicides: Analysis by Histologic Type." Klein Symposium on Causes, Consequences, and Cures Lymphoproliferative Diseases, 1991.
31. "Mantle Zone Lymphoma." International Academy of Pathology Meeting, 1991.
32. "Non-Hodgkin's Lymphomas of Primary Follicle/Mantle Zone Origin." 2nd Vicenza International Workshop of Hematology, 1991.
33. "Cancers of the Lymphohematopoietic System in Humans Exposed to 1,3-Butadiene." Occupational Safety and Health Administration, 1991.
34. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1991.
35. "Benign Diseases of Lymph Nodes: A Pattern Approach." Short Course for American Society of Clinical Pathologist Meeting, 1991.
36. "Intermediate Cell Lymphoma - Current Controversies." Society for Hematopathology Symposium, American Society of Clinical Pathologists Meeting, 1991.
37. "Human Health Effects of Agrichemical Use." Environmental and Occupational Disease - A State-of-the-Art Conference for Pathology Educators, 1991.
38. "Lymphoma Pathology in Epidemiologic Studies." National Cancer Institute Workshop on the Time Trends in Non-Hodgkin's Lymphoma - Current Knowledge and Recommendations for Research, 1991.
39. "Pesticides/Chemicals and Their Association with Non-Hodgkin's Lymphoma." National Cancer Institute Workshop on Mechanisms in B-Cell Neoplasia, 1992.

Dennis Weisenburger, MD - MC

40. "Birth Defects and Well Water Contamination by Agrichemicals." Third International Symposium on Issues in Health, Agriculture and the Environment, 1992.
41. "Benign Diseases of Lymph Nodes: A Systemic Approach". ASCP Course on Lymph Node Pathology, 1992.
42. "Strategies for Service Excellence in the Clinical Laboratory." Short Course for American Society of Clinical Pathologists Meeting, 1992.
43. "Benign Diseases of Lymph Nodes: A Pattern Approach." Short Course for American Society of Clinical Pathologists Meeting, 1992.
44. "Is the 2;5 Chromosomal Translocation Specific for CD30-Positive Anaplastic Large Cell Lymphoma? US/Canadian Academy of Pathology Meeting, 1993.
45. "Epidemiology of Non-Hodgkin's Lymphoma." Keystone Symposium on B- and T-Cell Lymphomas, 1993.
46. "Epidemiology of Non-Hodgkin's Lymphoma." Fifth International Conference on Malignant Lymphoma, 1993.
47. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 1993.
48. "Strategies for Service Excellence in the Clinical Laboratory." Short Course for American Society of Clinical Pathologists Meeting, 1993.
49. "Benign Diseases of Lymph Nodes: A Pattern Approach." Short Course for American Society of Clinical Pathologists Meeting, 1993.
50. "Mantle Cell Lymphoma - Pathologic Features". Society for Hematopathology Workshop on Disorders of Small B-Lymphocytes, 1993.
51. "Mantle Cell Lymphoma". Department of Pathology, Northwestern University Medical Center, 1993.
52. Lymphoma Slide Seminar, Kansas City Society of Pathologists Meeting, 1993.
53. "Mantle Cell Lymphoma - Clinical Features". European Task Force on Lymphoma Workshop on Mantle Cell Lymphoma, 1994.
54. "Epidemiology of Hodgkin's Disease". International Symposium on Hodgkin's Disease, 1994.
55. "Pathology of Hodgkin's Disease". International Symposium on Hodgkin's Disease, 1994.
56. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1994.
57. "Epidemiology of Non-Hodgkin's Lymphoma". Cancer Center, University of Virginia Medical Center, 1994.



Dennis Weisenburger, MD - MC

58. "New Views on Non-Hodgkin's Lymphoma Classification". Pan Pacific Lymphoma Conference, 1994.
59. "New Concepts in the Pathology of Hodgkin's Disease". Pan Pacific Lymphoma Conference, 1994.
60. "Health Effects of Contaminated Groundwater". Fall Symposium of the Groundwater Foundation, 1994.
61. "Strategies for Service Excellence in the Clinical Laboratory." Short Course for American Society of Clinical Pathologists Meeting, 1994.
62. "Classification of Non-Hodgkin's Lymphoma", Colorado Springs Memorial Hospital, 8th Annual Oncology Conference, 1995.
63. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1995.
64. "Benign Disorders of Lymph Nodes: A Pattern Approach". Society for Hematopathology Symposium on Diagnostic Issues and Advances in Hematopathology, 1995.
65. "International Non-Hodgkin's Lymphoma Classification Project", Department of Pathology Seminar, University of Hong Kong, 1995.
66. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1996.
67. "Clinical Significance of the t(14;18)(q32;q21) in Follicular Large Cell Lymphoma". US and Canadian Academy of Pathology Meeting, 1996.
68. "Application of the International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma (NHL). Study Design, Methods, and Pathology Results". Lugano Workshop on New Lymphoma Classification, 1996.
69. "The International Non-Hodgkin's Lymphoma Classification Project - Preliminary Findings". CALGB Lymphoma Committee Meeting, 1996.
70. "A Prospective Study of the International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma: Pathology Findings". AACR/ASCO Joint Conference on Basic and Clinical Aspects of Lymphoma, 1997.
71. "The International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma: Pathology Findings from a Large Multicenter Study". US/Canadian Academy of Pathology Meeting, 1997.
72. "The International Lymphoma Study Group (ILSG) Classification of Non-Hodgkin's Lymphoma: Clinical Findings from a Large Multicenter Study". US/Canadian Academy of Pathology Meeting, 1997.
73. "Non-Hodgkin's Lymphoma: A Practical and Cost-effective Approach to Diagnosis". US/Canadian Academy of Pathology Course, 1997.

Dennis Weisenburger, MD - MC

74. "Non-Hodgkin's Lymphoma: A Practical and Cost-Effective Approach to Diagnosis". ASCP Short Course, 1997.
75. "Overview of the Non-Hodgkin's Lymphoma Classification Project". Pan Pacific Lymphoma Conference, 1997.
76. "Mantle Cell Lymphoma - Pathology". Pan Pacific Lymphoma Conference, 1997.
77. "Follicular Lymphoma", International Non-Hodgkin's Lymphoma Classification Project Workshop, 1997.
78. "Grading of Follicular Lymphoma", WHO Clinical Advisory Committee Meeting on the Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Systems, 1997.
79. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1997.
80. "Non-Hodgkin's Lymphoma: A Practical and Cost-effective Approach to Diagnosis". US/Canadian Academy of Pathology Course, 1998.
81. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1998.
82. "New Classification for Non-Hodgkin's Lymphoma". Fifth Seminar on New Trends in Treatment for Acute Leukemia, 1998.
83. "Mantle Cell Lymphoma - Biological Characterization". 2nd International Symposium on Malignant Lymphomas, 1998.
84. "Evaluation of the New Lymphoma Classification". Medical College of Ohio, 1998.
85. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 1999.
86. "Results of the Non-Hodgkin's Lymphoma Classification Project". University of the Witwaterstrand, 1999.
87. "Burkitt-like Lymphoma". Pan Pacific Lymphoma Conference, 1999.
88. "Mantle Cell Lymphoma". ASCO-PANARAB Conference on Malignant Lymphoma, 1999.
89. "The Non-Hodgkin's Lymphoma Classification Project". ASCO-PANARAB Conference on Malignant Lymphoma, 1999.
90. "Histologic Type Predicts Survival in Adults with Diffuse Aggressive B-cell Lymphoma". US and Canadian Academy of Pathology Meeting, 2000.
91. "Gene Expression in Lymphoid Malignancies Using cDNA Microarray Technology". Workshop on the Comparative Pathology of HIV- and SIV-associated Lymphoma, 2000.
92. "Grading of Follicular Lymphoma: Diagnostic Accuracy, Reproducibility, and Clinical Relevance". Meeting of the European Association for Haematopathology, 2000.



Dennis Weisenburger, MD - MC

93. "The Non-Hodgkin's Lymphoma Classification Project". University of Texas M.D. Anderson Hospital, 2000.
94. "Benign Diseases of Lymph Nodes: A Systematic Approach". ASCP Course on Lymph Node Pathology, 2000.
95. "Classification and Staging of Non-Hodgkin's Lymphoma". 23rd Annual Nebraska Tumor Registry Workshop, 2000.
96. "The Non-Hodgkin's Lymphoma Classification – Clinical Relevance". International Symposium on New Trends in the Management of Lymphoma, 2000.
97. "Mantle Cell Lymphoma". International Symposium on New Trends in the Management of Lymphoma, 2000.
98. "The Non-Hodgkin's Lymphoma Classification Project". Thai Society of Pathologists, 2001.
99. "The Non-Hodgkin's Lymphoma Classification Project". Tata Memorial Hospital Lymphoma Study Group, 2001.
100. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 2001.
101. "The Non-Hodgkin's Lymphoma Classification Project." Beijing International Lymphoma Symposium, 2001.
102. "Mantle Cell Lymphoma." Beijing International Lymphoma Symposium, 2001.
103. "Low-Grade B-cell Lymphoma Slide Seminar." Beijing International Lymphoma Symposium, 2001.
104. "Incorporating Pathology into Epidemiologic Studies." International Consortium of Investigators Working on Lymphoma Epidemiologic Studies (InterLymph), 2001.
105. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 2002.
106. "Molecular Classification of Lymphoma – A Work in Progress." Roswell Park Cancer Institute, 2002.
107. "The REALity of Lymphoma Classification – Pathology Perspectives." Conference on Lymphoma & Myeloma, 2002.
108. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 2003.
109. "Update on Lymphoma Classification." Pan-Pacific Lymphoma Conference, 2003.
110. "Mantle Cell Lymphoma: From Discovery to 2003." Department of Pathology and Microbiology Grand Rounds, University of Nebraska Medical Center, 2003.

Dennis Weisenburger, MD - MC

111. "Cyclin D1-negative Mantle Cell Lymphoma." United States and Canadian Academy of Pathology Meeting, 2004.
112. "Follicular Lymphoma, Grade 3. Clinical and Biological Features." Lymphoma . . . the Next Questions International Conference, 2004.
113. "Benign Diseases of Lymph Nodes: A Systematic Approach." ASCP Course on Lymph Node Pathology, 2004.
114. "Follicular Lymphomas: Are They All the Same?" Conference in Lymphoma and Myeloma, 2004.
115. "Peripheral T-cell Lymphoma: a Clinicopathologic Analysis with Comparison to Diffuse Large B-cell Lymphoma." United States and Canadian Academy of Pathology Meeting, 2005.
116. "Peripheral T-cell Lymphoma: How Many Separate Disease Entities?" Lugano Workshop on T-cell Lymphoma, 2005.
117. "Non-Hodgkin Lymphoma (NHL) Around the World: Distribution of Major Subtypes Differs by Geographic Region." 9th International Conference on Malignant Lymphoma, 2005.
118. "Peripheral T-cell Lymphoma: the American View." Institute of Medical Hematology and Oncology, University of Bologna, 2005.
119. "Peripheral T-cell Lymphoma – International Classification and Clinical Project." Pan-Pacific Lymphoma Conference, 2005.
120. "Classification and Outcome in Peripheral T-cell Lymphoma." Society for Hematopathology Workshop on Progress in T-cell and NK-cell Malignancies, 2005.
121. "WHO Classification of Malignant Lymphoma." Wuhan First International Cancer Symposium, 2005.
122. "Mantle Cell Lymphoma." Wuhan First International Cancer Symposium, 2005.
123. "Peripheral T-cell Lymphoma – International Classification and Clinical Project." Wuhan First International Cancer Symposium, 2005.
124. "WHO Classification of Haematopoietic Malignancy – Clinical Relevance." Egyptian Society of Haematology Congress, 2005.
125. "T-cell Lymphoma." Egyptian Society of Haematology Congress, 2005.
126. "Mantle Cell Lymphoma." 2nd Annual Egyptian Oncology and Hematology Meeting, 2005.
127. "Classification and Outcome in Peripheral T-cell Lymphoma." Milton R. Hales Lecture in Pathology, West Virginia University School of Medicine, 2006.
128. "Peripheral T-cell and NK/T-cell Lymphomas: an International Study of 1320 Cases." United States and Canadian Academy of Pathology Meeting, 2006.



Dennis Weisenburger, MD - MC

129. "Classification and Outcome in Peripheral T-cell Lymphoma." 46th Annual Meeting of the Japanese Society of Lymphoreticular Tissue Research, 2006.
130. "Peripheral T-cell Lymphomas." Neoplastic Hematopathology Update: New Insights into Old Questions, 2006.
131. "Peripheral T-cell Lymphoma: Prognostic Factors." Bologna Workshop on T-cell Lymphomas, 2006.
132. "Non-Hodgkin Lymphoma Around the World." 13th Hong Kong International Cancer Congress, 2006.
133. "Peripheral T-cell Lymphoma, Unspecified." International T-cell Lymphoma Project Meeting, 2006.
134. "Peripheral T-cell Lymphoma – New Findings." Asia-Pacific T-cell Advisory Board Meeting, 2007.
135. "Geographic Variation in Non-Hodgkin Lymphoma Incidence." 7th International Network for Cancer Treatment and Research (INCTR) Meeting, 2007.
136. "Peripheral T-cell Lymphoma – New Findings." Department of Pathology, Fluminense Federal University of Brazil, 2007.
137. "Peripheral T-cell Lymphoma – New Findings." Hospital do Cancer, Sao Paulo, Brazil, 2007.
138. "Non-Hodgkin Lymphoma Around the World." International Non-Hodgkin Lymphoma Symposium, Society of Hematology in Chile, 2007.
139. "Pathology and Pathogenesis of B-cell Chronic Lymphocytic Leukemia." Monoclonal B-cell Lymphocytosis and Chronic Lymphocytic Leukemia: Environmental and Genetic Risk Factors Workshop, 2007.
140. "What Pathologic Prognostic Markers Can Be Helpful in Mantle Cell Lymphoma?" First Global Workshop on Mantle Cell Lymphoma, 2007.
141. "WHO Classification of Lymphoid Neoplasms: Update in 2008." Japanese Malignant Lymphoma Academy, 2008.
142. "How I Diagnose Lymphoma in Routine Practice and Consultation." Japanese Malignant Lymphoma Academy, 2008.
143. "Histopathologic and Molecular Diagnosis of Diffuse Large B-cell Lymphoma." Japanese Malignant Lymphoma Academy, 2008.
144. "Peripheral T-cell Lymphoma, Not Otherwise Specified: a Clinicopathologic Study of 340 Cases from the International Peripheral T-cell Project. 10th International Conference on Malignant Lymphoma, 2008.

Dennis Weisenburger, MD - MC

145. "WHO Classification of Non-Hodgkin Lymphoma in Developing Countries." Workshop in Epidemiology and Management of Lymphoma in Developing Countries: Challenges and Opportunities for International Collaborations. 10th International Conference on Malignant Lymphoma, 2008.
146. "Non-Hodgkin Lymphoma Around the World". InterLymph Symposium on New Insights into the Causes of Lymphoma, 2008.
147. "Update on the WHO Classification of Non-Hodgkin Lymphoma." InterLymph Symposium on New Insights into the Causes of Lymphoma, 2008.
148. "Why has the Incidence of Non-Hodgkin Lymphoma Plateaued in Recent Years?" InterLymph Consortium Annual Meeting, 2008.
149. "Peripheral T-cell Lymphoma: What We have Learned and New Classification Strategies. Peripheral T-cell Lymphoma Forum, 2008.
150. "Lymphoma Classification and Biology." North American Educational Forum on Lymphoma, 2008.
151. "Update on Mantle Cell Lymphoma." 27th International Congress of the International Academy of Pathology, 2008.
152. "Peripheral T-cell Lymphoma." Neoplastic Hematopathology Update: New Insights into Old Questions, 2008.
153. "Non-Hodgkin Lymphoma Around the World". Lymphoma Symposium in Brazil, 2009.
154. "Non-Hodgkin Lymphoma Around the World". Lymphoma Symposium in Argentina, 2009.
155. "Update on Mantle Cell Lymphoma". 22nd European Congress of Pathology, 2009.
156. "Non-Hodgkin Lymphoma Around the World". The 11th National Symposium on Lymphoma in China, 2009.
157. "Mantle Cell Lymphoma - Update and New Perspectives". Department of Pathology, Fudan University Shanghai Cancer Center, 2010.
158. "Non-Hodgkin Lymphoma in Relation to Environmental Contaminants In Nebraska." UNMC Center for Environmental Health and Toxicology, 2010.
159. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World". UNMC Center for Research in Leukemia and Lymphoma, 2010.
160. "Peripheral T-cell Lymphomas". 7th International Chicago Lymphoma Symposium, 2010.
161. "Epidemiology of Non-Hodgkin Lymphoma Around the World". Croatian Cooperative Group for Hematologic Diseases, 2010.



Dennis Weisenburger, MD - MC

162. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World." UNMC Hematologic Malignancies Research Meeting, 2010.
163. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World." Chinese Lymphoma Study Group, 2010.
164. "Peripheral T-cell Lymphomas." South Taiwan Lymphoma Club, 2010.
165. "Peripheral T-cell Lymphoma." Neoplastic Hematopathology Update: New Insights into Old Questions, 2010.
166. "Epidemiology of Non-Hodgkin Lymphoma Around the World". Peru National Institute of Cancer, 2011.
167. "Epidemiology of Non-Hodgkin Lymphoma Around the World". Pan Pacific Lymphoma Conference, 2011.
168. "CD30 Expression in Lymphoma". Seattle Genetics Advisory Board, 2011.
169. "Natural Killer/T-cell Lymphomas". Companion Meeting of American Society of Clinical Oncology, 2011.
170. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World". Bryan/Lincoln General Hospital Cancer Committee, 2011.
171. "Peripheral T-cell Lymphomas". City of Hope Medical Center, 2011.
172. "Epidemiology of Lymphomas". 8th Russian Conference on Malignant Lymphomas, 2011.
173. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World". Kansas City Society of Pathologists, 2011.
174. "Mantle Cell Lymphoma: Update and New Perspectives". Kansas City Society of Pathologists, 2011.
175. "Peripheral T-cell Lymphoma". Kansas City Society of Pathologists, 2011.
176. "CD30 Expression in Lymphoma". Seattle Genetics Pathology Round Table, 2011.
177. "Epidemiology of Non-Hodgkin Lymphoma in Nebraska and Around the World". UNMC Department of Pathology and Microbiology Grand Rounds, 2012.
178. "Hematologic Malignancy Tissue Banking and Research Applications". American Cancer Society Roundtable on Integrating Pathological Materials into Epidemiological Studies, 2012.
179. "Epidemiology of Non-Hodgkin Lymphoma Around the World". Algerian Society of Haematology, 2012.
180. "Follicular Lymphoma: Does Grading Really Predict Outcome?" Pan-Pacific Lymphoma Conference, 2012.

Dennis Weisenburger, MD - MC

181. "Peripheral T-cell Lymphoma." Neoplastic Hematopathology Update, 2012.
182. "Peripheral T-cell Lymphoma - an Update." Kaiser Pathology Group of Southern California, 2012.
183. "Molecular Prognostic Factors in Peripheral T-cell Lymphoma." 5th Annual T-cell Lymphoma Forum, 2013.
184. "Malignant Lymphomas Around the World with Special Regard to Lymphomas in South-East Europe." 1st Macedonian Inter-Congress Meeting, 2013.
185. "Peripheral T-cell Lymphoma." University of Macedonia School of Medicine, 2013.
186. "Nanostring Technology for Molecular Epidemiology Research." Pathology Working Group, 12th InterLymph Meeting, 2013.
187. "Peripheral T-cell Lymphoma." Japan Lymphoma Forum and Slide Seminar, 2013.
188. "Follicular Lymphoma Around the World." News Around Follicular Lymphoma Symposium, University of Munich, 2013.
189. "Non-Hodgkin Lymphoma Around the World." Ohio State University Pathology Update Course, 2013.
190. "Peripheral T-cell Lymphomas." Ohio State University Pathology Update Course, 2013.
191. "Considerations for Future Modifications of the WHO Classification of T-cell Lymphoma." 6th Annual T-cell Lymphoma Forum, 2014.
192. "Follicular Lymphoma: Environment and Lifestyle". 13th InterLymph Meeting, 2014.
193. "Peripheral T-cell Lymphoma". San Diego Society of Hematopathology Meeting, 2014.
194. "Peripheral T-cell Lymphoma". Department of Pathology Grand Rounds, Harbor-UCLA Medical Center, 2015.
195. "Epidemiology of Non-Hodgkin Lymphoma". Neoplastic Hematopathology Update: Lymphoma Symposium, 2015.
196. "Mantle Cell Lymphoma – Pathology and Biology". Postgraduate Athens Lymphoma Seminar, 2015.
197. "Considerations for Future Modifications of the WHO Classification of T-cell Lymphoma". Postgraduate Athens Lymphoma Seminar, 2015.
198. "Peripheral T-cell Lymphoma". Hematology Grand Rounds, University of Southern California, 2016.
199. "New Insights into Peripheral T-cell Lymphoma". Pan Pacific Lymphoma Conference, 2016.
200. "Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma – Same Disease? Same Approach?" Pan Pacific Lymphoma Conference, 2016.



Dennis Weisenburger, MD - MC

201. "Plasmablastic Lymphoma Arising in a Background of Small Lymphocytic Lymphoma". 18th Meeting of the European Association of Haematopathology, 2016.
202. "New Insights into Peripheral T-cell Lymphoma", University of Miami Medical Center, 2016.
203. "Mantle Cell Lymphoma – Pathology and Biology", Nebraska Association of Pathologists, 2016.

## **XI. PATENTS, INVENTIONS AND COPYRIGHTS**

### **PATENTS**

- No. 8,131,475 Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas
- No. 14/540,302 Survival Predictor for Diffuse Large B-Cell Lymphoma
- No. 61900553 Method for Selecting and Treating Lymphoma Types
- No. PCT/US14/64161 Methods for Selecting and Treating Lymphoma Patients
- No. 62/325,213 Evaluation of Mantle Cell Lymphoma and Methods Related Thereto
- No. 14803288.1 – 1403/3066215 Method for Subtyping Lymphoma Types by Means of Expression Profiling

### **TECHNOLOGIES LICENSED**

1. Methods for Identifying, Diagnosing, and Predicting Survival of Lymphomas, Nanostring

# EXHIBIT B



Dennis D. Weisenburger, MD – Case Testimony in last 4 years

1. Wendell vs. Johnson & Johnson, et al. United States District Court, Northern District of California, Oakland Division, 2014. Case No. 4:09-cv-04124-CW

Dennis D. Weisenburger, MD – Fees

\$500 per hour for work and \$5000 per day for deposition and trial, plus travel expenses.

# EXHIBIT C



## Other Literature Reviewed

1. Abass, K., Turpeinen, M., and Pelkonen, O., *An Evaluation of the Cytochrome P450 Inhibition Potential of Selected Pesticides in Human Hepatic Microsomes*. J Environ Sci Health B, 2009. 44(6): p. 553-563.
2. Acquavella, J.F., Alexander, B.H., Mandel, J.S., Burns, C.J., and Gustin, C., *Exposure Misclassification in Studies of Agricultural Pesticides: Insights from Biomonitoring*. Epidemiology, 2006. 17(1): p. 69-74.
3. Adam, A., Marzuki, A., Abdul Rahman, H., and Abdul Aziz, M., *The Oral and Intratracheal Toxicities of Roundup and Its Components to Rats*. Vet Hum Toxicol, 1997. 39(3): p. 147-151.
4. Alavanja, M.C., Sandler, D.P., McMaster, S.B., Zahm, S.H., McDonnell, C.J., Lynch, C.F., Pennybacker, M., Rothman, N., Dosemeci, M., Bond, A.E., and Blair, A., *The Agricultural Health Study*. Environ Health Perspect, 1996. 104(4): p. 362-369.
5. Amer, S., Aly, F., AA, F., and AAE, I., *In Vitro and in Vivo Evaluation of the Genotoxicity of the Herbicide Glyphosate in Mice*. Bull Natl Res Centre Egypt (Cairo), 2006. 31(5): p. 427-446.
6. Arbuckle, T.E., Burnett, R., Cole, D., Teschke, K., Dosemeci, M., Bancej, C., and Zhang, J., *Predictors of Herbicide Exposure in Farm Applicators*. Int Arch Occup Environ Health, 2002. 75(6): p. 406-414.
7. Astiz, M., de Alaniz, M.J., and Marra, C.A., *Antioxidant Defense System in Rats Simultaneously Intoxicated with Agrochemicals*. Environ Toxicol Pharmacol, 2009. 28(3): p. 465-473.
8. Bai, S.H. and Ogbourne, S.M., *Glyphosate: Environmental Contamination, Toxicity and Potential Risks to Human Health Via Food Contamination*. Environ Sci Pollut Res Int, 2016. 23(19): p. 18988-19001.
9. Bakry, F.A., Ismail, S.M., and Abd El-Atti, M.S., *Glyphosate Herbicide Induces Genotoxic Effect and Physiological Disturbances in Bulinus Truncatus Snails*. Pestic Biochem Physiol, 2015. 123: p. 24-30.

10. Benachour, N. and Seralini, G.E., *Glyphosate Formulations Induce Apoptosis and Necrosis in Human Umbilical, Embryonic, and Placental Cells*. Chem Res Toxicol, 2009. 22(1): p. 97-105.
11. Benedetti, A.L., Vituri Cde, L., Trentin, A.G., Domingues, M.A., and Alvarez-Silva, M., *The Effects of Sub-Chronic Exposure of Wistar Rats to the Herbicide Glyphosate-Biocarb*. Toxicol Lett, 2004. 153(2): p. 227-232.
12. Benedetti, D., Nunes, E., Sarmiento, M., Porto, C., Dos Santos, C.E., Dias, J.F., and da Silva, J., *Genetic Damage in Soybean Workers Exposed to Pesticides: Evaluation with the Comet and Buccal Micronucleus Cytome Assays*. Mutat Res, 2013. 752(1-2): p. 28-33.
13. Boccolini, P.M., Boccolini, C.S., Chrisman, J.R., Koifman, R.J., and Meyer, A., *Non-Hodgkin Lymphoma among Brazilian Agricultural Workers: A Death Certificate Case-Control Study*. Arch Environ Occup Health, 2016: p. 1-6.
14. Bolognesi, C., Creus, A., Ostrosky-Wegman, P., and Marcos, R., *Micronuclei and Pesticide Exposure*. Mutagenesis, 2011. 26(1): p. 19-26.
15. Brown, L.M., Blair, A., Gibson, R., Everett, G.D., Cantor, K.P., Schuman, L.M., Burmeister, L.F., Van Lier, S.F., and Dick, F., *Pesticide Exposures and Other Agricultural Risk Factors for Leukemia among Men in Iowa and Minnesota*. Cancer Res, 1990. 50(20): p. 6585-6591.
16. Brown, L.M., Burmeister, L.F., Everett, G.D., and Blair, A., *Pesticide Exposures and Multiple Myeloma in Iowa Men*. Cancer Causes Control, 1993. 4(2): p. 153-156.
17. Burstyn, I. and De Roos, A.J., *Visualizing the Heterogeneity of Effects in the Analysis of Associations of Multiple Myeloma with Glyphosate Use. Comments on Sorahan, T. Multiple Myeloma and Glyphosate Use: A Re-Analysis of Us Agricultural Health Study (Ahs) Data*. Int. J. Environ. Res. Public Health 2015, 12, 1548-1559. Int J Environ Res Public Health, 2016. 14(1).
18. Bus, J.S., *IARC Use of Oxidative Stress as Key Mode of Action Characteristic for Facilitating Cancer Classification: Glyphosate Case Example Illustrating a Lack of Robustness in Interpretative Implementation*. Regul Toxicol Pharmacol, 2017. 86: p. 157-166.



19. Caglar, S. and Kolankaya, D., *The Effect of Sub-Acute and Sub-Chronic Exposure of Rats to the Glyphosate-Based Herbicide Roundup*. Environ Toxicol Pharmacol, 2008. 25(1): p. 57-62.
20. Cantor, K.P., Blair, A., Everett, G., Gibson, R., Burmeister, L.F., Brown, L.M., Schuman, L., and Dick, F.R., *Pesticides and Other Agricultural Risk Factors for Non-Hodgkin's Lymphoma among Men in Iowa and Minnesota*. Cancer Res, 1992. 52(9): p. 2447-2455.
21. Chruscielska, K., Brzezinski, J., Kita, K., Kalhorn, D., Kita, I., Graffstein, B., and Korzeniowski, P., *Glyphosate. Evaluation of Chronic Activity and Possible Far - Reaching Effects Part 1. Studies on Chronic Toxicity*. Pestycydy -Warszawa-, 2000. (3-4): p. 11-20.
22. Clair, E., Mesnage, R., Traver, C., and Seralini, G.E., *A Glyphosate-Based Herbicide Induces Necrosis and Apoptosis in Mature Rat Testicular Cells in Vitro, and Testosterone Decrease at Lower Levels*. Toxicol In Vitro, 2012. 26(2): p. 269-279.
23. Conrad, A., Schroter-Kermani, C., Hoppe, H.W., Ruther, M., Pieper, S., and Kolossa-Gehring, M., *Glyphosate in German Adults - Time Trend (2001 to 2015) of Human Exposure to a Widely Used Herbicide*. Int J Hyg Environ Health, 2017. 220(1): p. 8-16.
24. Dallegre, E., Mantese, F.D., Oliveira, R.T., Andrade, A.J., Dalsenter, P.R., and Langeloh, A., *Pre- and Postnatal Toxicity of the Commercial Glyphosate Formulation in Wistar Rats*. Arch Toxicol, 2007. 81(9): p. 665-673.
25. de Brito Rodrigues, L., de Oliveira, R., Abe, F.R., Brito, L.B., Moura, D.S., Valadares, M.C., Grisolia, C.K., de Oliveira, D.P., and de Oliveira, G.A., *Ecotoxicological Assessment of Glyphosate-Based Herbicides: Effects on Different Organisms*. Environ Toxicol Chem, 2016.
26. El-Demerdash, F.M., Yousef, M.I., and Elagamy, E.I., *Influence of Paraquat, Glyphosate, and Cadmium on the Activity of Some Serum Enzymes and Protein Electrophoretic Behavior (in Vitro)*. J Environ Sci Health B, 2001. 36(1): p. 29-42.
27. El-Shenawy, N.S., *Oxidative Stress Responses of Rats Exposed to Roundup and Its Active Ingredient Glyphosate*. Environ Toxicol Pharmacol, 2009. 28(3): p. 379-385.

28. Engel, L.S., Seixas, N.S., Keifer, M.C., Longstreth, W.T., Jr., and Checkoway, H., *Validity Study of Self-Reported Pesticide Exposure among Orchardists*. J Expo Anal Environ Epidemiol, 2001. 11(5): p. 359-368.
29. Gehin, A., Guyon, C., and Nicod, L., *Glyphosate-Induced Antioxidant Imbalance in Hacat: The Protective Effect of Vitamins C and E*. Environ Toxicol Pharmacol, 2006. 22(1): p. 27-34.
30. George, J., Prasad, S., Mahmood, Z., and Shukla, Y., *Studies on Glyphosate-Induced Carcinogenicity in Mouse Skin: A Proteomic Approach*. J Proteomics, 2010. 73(5): p. 951-964.
31. Green, J.M., *The Rise and Future of Glyphosate and Glyphosate-Resistant Crops*. Pest Manag Sci, 2016.
32. Han, J., Moon, H., Hong, Y., Yang, S., Jeong, W.J., Lee, K.S., and Chung, H., *Determination of Glyphosate and Its Metabolite in Emergency Room in Korea*. Forensic Sci Int, 2016. 265: p. 41-46.
33. Hardell, L. and Eriksson, M., *A Case-Control Study of Non-Hodgkin Lymphoma and Exposure to Pesticides*. Cancer, 1999. 85(6): p. 1353-1360.
34. Helal, A. and Moussa, H., *Chromosomal Aberrations Induced by Glyphosate Isopropylamine Herbicide and Trials for Diminuting Its Toxicity Using Some Chemical Inactivators and Antioxidant*. Vet Med J Giza, 2005. 53(2): p. 169-187.
35. Heydens, W.F., Healy, C.E., Hotz, K.J., Kier, L.D., Martens, M.A., Wilson, A.G., and Farmer, D.R., *Genotoxic Potential of Glyphosate Formulations: Mode-of-Action Investigations*. J Agric Food Chem, 2008. 56(4): p. 1517-1523.
36. Hietanen, E., Linnainmaa, K., and Vainio, H., *Effects of Phenoxyherbicides and Glyphosate on the Hepatic and Intestinal Biotransformation Activities in the Rat*. Acta Pharmacol Toxicol (Copenh), 1983. 53(2): p. 103-112.
37. Hohenadel, K., Harris, S.A., McLaughlin, J.R., Spinelli, J.J., Pahwa, P., Dosman, J.A., Demers, P.A., and Blair, A., *Exposure to Multiple Pesticides and Risk of Non-Hodgkin Lymphoma in Men from Six Canadian Provinces*. Int J Environ Res Public Health, 2011. 8(6): p. 2320-2330.



38. Hoppin, J.A., Yucel, F., Dosemeci, M., and Sandler, D.P., *Accuracy of Self-Reported Pesticide Use Duration Information from Licensed Pesticide Applicators in the Agricultural Health Study*. J Expo Anal Environ Epidemiol, 2002. 12(5): p. 313-318.
39. Jasper, R., Locatelli, G.O., Pilati, C., and Locatelli, C., *Evaluation of Biochemical, Hematological and Oxidative Parameters in Mice Exposed to the Herbicide Glyphosate-Roundup((R))*. Interdiscip Toxicol, 2012. 5(3): p. 133-140.
40. Jauhiainen, A., Rasanen, K., Sarantila, R., Nuutinen, J., and Kangas, J., *Occupational Exposure of Forest Workers to Glyphosate During Brush Saw Spraying Work*. Am Ind Hyg Assoc J, 1991. 52(2): p. 61-64.
41. Jayasumana, C., Gunatilake, S., and Senanayake, P., *Glyphosate, Hard Water and Nephrotoxic Metals: Are They the Culprits Behind the Epidemic of Chronic Kidney Disease of Unknown Etiology in Sri Lanka?* Int J Environ Res Public Health, 2014. 11(2): p. 2125-2147.
42. Jayasumana, C., Paranagama, P., Agampodi, S., Wijewardane, C., Gunatilake, S., and Siribaddana, S., *Drinking Well Water and Occupational Exposure to Herbicides Is Associated with Chronic Kidney Disease, in Padavi-Sripura, Sri Lanka*. Environ Health, 2015. 14: p. 6.
43. Jensen, P.K., Wujcik, C.E., McGuire, M.K., and McGuire, M.A., *Validation of Reliable and Selective Methods for Direct Determination of Glyphosate and Aminomethylphosphonic Acid in Milk and Urine Using Lc-MS/MS*. J Environ Sci Health B, 2016. 51(4): p. 254-259.
44. Kachuri, L., Demers, P.A., Blair, A., Spinelli, J.J., Pahwa, M., McLaughlin, J.R., Pahwa, P., Dosman, J.A., and Harris, S.A., *Multiple Pesticide Exposures and the Risk of Multiple Myeloma in Canadian Men*. Int J Cancer, 2013. 133(8): p. 1846-1858.
45. Karunanayake, C.P., Spinelli, J.J., McLaughlin, J.R., Dosman, J.A., Pahwa, P., and McDuffie, H.H., *Hodgkin Lymphoma and Pesticides Exposure in Men: A Canadian Case-Control Study*. J Agromedicine, 2012. 17(1): p. 30-39.
46. Kim, Y.H., Lee, J.H., Cho, K.W., Lee, D.W., Kang, M.J., Lee, K.Y., Lee, Y.H., Hwang, S.Y., and Lee, N.K., *Prognostic Factors in Emergency Department Patients with Glyphosate*

- Surfactant Intoxication: Point-of-Care Lactate Testing*. Basic Clin Pharmacol Toxicol, 2016. 119(6): p. 604-610.
47. Kimmel, G.L., Kimmel, C.A., Williams, A.L., and DeSesso, J.M., *Evaluation of Developmental Toxicity Studies of Glyphosate with Attention to Cardiovascular Development*. Crit Rev Toxicol, 2013. 43(2): p. 79-95.
  48. Koller, V.J., Furhacker, M., Nersesyan, A., Misik, M., Eisenbauer, M., and Knasmueller, S., *Cytotoxic and DNA-Damaging Properties of Glyphosate and Roundup in Human-Derived Buccal Epithelial Cells*. Arch Toxicol, 2012. 86(5): p. 805-813.
  49. Koureas, M., Tsezou, A., Tsakalof, A., Orfanidou, T., and Hadjichristodoulou, C., *Increased Levels of Oxidative DNA Damage in Pesticide Sprayers in Thessaly Region (Greece). Implications of Pesticide Exposure*. Sci Total Environ, 2014. 496: p. 358-364.
  50. Kruger, M., Schrod, W., Pedersen, I., and Shehata, A.A., *Detection of Glyphosate in Malformed Piglets*. J Environ Anal Toxicol, 2014. 4(5): p. 230.
  51. Kwiatkowska, M., Huras, B., and Bukowska, B., *The Effect of Metabolites and Impurities of Glyphosate on Human Erythrocytes (in Vitro)*. Pestic Biochem Physiol, 2014. 109: p. 34-43.
  52. Kwiatkowska, M., Jarosiewicz, P., Michalowicz, J., Koter-Michalak, M., Huras, B., and Bukowska, B., *The Impact of Glyphosate, Its Metabolites and Impurities on Viability, Atp Level and Morphological Changes in Human Peripheral Blood Mononuclear Cells*. PLoS One, 2016. 11(6): p. e0156946.
  53. Lajmanovich, R.C., Sandoval, M.T., and Peltzer, P.M., *Induction of Mortality and Malformation in Scinax Nasicus Tadpoles Exposed to Glyphosate Formulations*. Bull Environ Contam Toxicol, 2003. 70(3): p. 612-618.
  54. Larsen, K., Najle, R., Lifschitz, A., and Virkel, G., *Effects of Sub-Lethal Exposure of Rats to the Herbicide Glyphosate in Drinking Water: Glutathione Transferase Enzyme Activities, Levels of Reduced Glutathione and Lipid Peroxidation in Liver, Kidneys and Small Intestine*. Environ Toxicol Pharmacol, 2012. 34(3): p. 811-818.



55. Lee, W.J., Cantor, K.P., Berzofsky, J.A., Zahm, S.H., and Blair, A., *Non-Hodgkin's Lymphoma among Asthmatics Exposed to Pesticides*. *Int J Cancer*, 2004. 111(2): p. 298-302.
56. Li, A.P. and Long, T.J., *An Evaluation of the Genotoxic Potential of Glyphosate*. *Fundam Appl Toxicol*, 1988. 10(3): p. 537-546.
57. Lioi, M.B., Scarfi, M.R., Santoro, A., Barbieri, R., Zeni, O., Di Berardino, D., and Ursini, M.V., *Genotoxicity and Oxidative Stress Induced by Pesticide Exposure in Bovine Lymphocyte Cultures in Vitro*. *Mutat Res*, 1998. 403(1-2): p. 13-20.
58. Lueken, A., Juhl-Strauss, U., Krieger, G., and Witte, I., *Synergistic DNA Damage by Oxidative Stress (Induced by H<sub>2</sub>O<sub>2</sub>) and Nongenotoxic Environmental Chemicals in Human Fibroblasts*. *Toxicol Lett*, 2004. 147(1): p. 35-43.
59. Luo, L., Wang, F., Zhang, Y., Zeng, M., Zhong, C., and Xiao, F., *In Vitro Cytotoxicity Assessment of Roundup (Glyphosate) in L-02 Hepatocytes*. *J Environ Sci Health B*, 2017: p. 1-8.
60. Manas, F., Peralta, L., Raviolo, J., Ovando, H.G., Weyers, A., Ugnia, L., Cid, M.G., Larripa, I., and Gorla, N., *Genotoxicity of Glyphosate Assessed by the Comet Assay and Cytogenetic Tests*. *Environ Toxicol Pharmacol*, 2009. 28(1): p. 37-41.
61. Mañas F., Peralta L., Ugnia L., Weyers A., García Ovando H., and Gorla N., *Oxidative Stress and Comet Assay in Tissues of Mice Administered Glyphosate and Ampa in Drinking Water for 14 Days*. *BAG, Journal of Basic and Applied Genetics* [online], 2013. 24(2): p. 67-75.
62. Mesnage, R., Arno, M., Costanzo, M., Malatesta, M., Seralini, G.E., and Antoniou, M.N., *Transcriptome Profile Analysis Reflects Rat Liver and Kidney Damage Following Chronic Ultra-Low Dose Roundup Exposure*. *Environ Health*, 2015. 14: p. 70.
63. Mesnage, R., Bernay, B., and Seralini, G.E., *Ethoxylated Adjuvants of Glyphosate-Based Herbicides Are Active Principles of Human Cell Toxicity*. *Toxicology*, 2013. 313(2-3): p. 122-128.

64. Mink, P.J., Mandel, J.S., Lundin, J.I., and Scurman, B.K., *Epidemiologic Studies of Glyphosate and Non-Cancer Health Outcomes: A Review*. Regul Toxicol Pharmacol, 2011. 61(2): p. 172-184.
65. Mink, P.J., Mandel, J.S., Scurman, B.K., and Lundin, J.I., *Epidemiologic Studies of Glyphosate and Cancer: A Review*. Regul Toxicol Pharmacol, 2012. 63(3): p. 440-452.
66. Mohamed, F., Endre, Z.H., Pickering, J.W., Jayamanne, S., Palangasinghe, C., Shahmy, S., Chathuranga, U., Wijerathna, T., Shihana, F., Gawarammana, I., and Buckley, N.A., *Mechanism-Specific Injury Biomarkers Predict Nephrotoxicity Early Following Glyphosate Surfactant Herbicide (Gpsh) Poisoning*. Toxicol Lett, 2016. 258: p. 1-10.
67. Nardi, J., Moras, P.B., Koeppe, C., Dallegrove, E., Leal, M.B., and Rossato-Grando, L.G., *Prepubertal Subchronic Exposure to Soy Milk and Glyphosate Leads to Endocrine Disruption*. Food Chem Toxicol, 2017. 100: p. 247-252.
68. Niemann, L., Sieke, C., Pfeil, R., and Solecki, R., *A Critical Review of Glyphosate Findings in Human Urine Samples and Comparison with the Exposure of Operators and Consumers*. Journal für Verbraucherschutz und Lebensmittelsicherheit, 2015. 10(1): p. 3-12.
69. Nordstrom, M., Hardell, L., Magnuson, A., Hagberg, H., and Rask-Andersen, A., *Occupational Exposures, Animal Exposure and Smoking as Risk Factors for Hairy Cell Leukaemia Evaluated in a Case-Control Study*. Br J Cancer, 1998. 77(11): p. 2048-2052.
70. Olorunsogo, O.O., *Modification of the Transport of Protons and Ca<sup>2+</sup> Ions across Mitochondrial Coupling Membrane by N-(Phosphonomethyl)Glycine*. Toxicology, 1990. 61(2): p. 205-209.
71. Olorunsogo, O.O., Bababunmi, E.A., and Bassir, O., *Effect of Glyphosate on Rat Liver Mitochondria in Vivo*. Bull Environ Contam Toxicol, 1979. 22(3): p. 357-364.
72. Paganelli, A., Gnazzo, V., Acosta, H., Lopez, S.L., and Carrasco, A.E., *Glyphosate-Based Herbicides Produce Teratogenic Effects on Vertebrates by Impairing Retinoic Acid Signaling*. Chem Res Toxicol, 2010. 23(10): p. 1586-1595.



73. Paz-y-Mino, C., Bustamante, G., Sanchez, M.E., and Leone, P.E., *Cytogenetic Monitoring in a Population Occupationally Exposed to Pesticides in Ecuador*. Environ Health Perspect, 2002. 110(11): p. 1077-1080.
74. Peixoto, F., *Comparative Effects of the Roundup and Glyphosate on Mitochondrial Oxidative Phosphorylation*. Chemosphere, 2005. 61(8): p. 1115-1122.
75. Peluso, M., Munnia, A., Bolognesi, C., and Parodi, S., *32p-Postlabeling Detection of DNA Adducts in Mice Treated with the Herbicide Roundup*. Environ Mol Mutagen, 1998. 31(1): p. 55-59.
76. Piesova, E., *The Influence of Different Treatment Length on the Induction of Micronuclei in Bovine Lymphocytes after Exposure to Glyphosate*. Folia Veterinaria, 2004. 48(3): p. 130-134.
77. Piesova, E., *The Effect of Glyphosate on the Frequency of Micronuclei in Bovine Lymphocytes in Vitro*. Acta Veterinaria (Beograd), 2005. 55(2-3): p. 101-109.
78. Poletta, G.L., Larriera, A., Kleinsorge, E., and Mudry, M.D., *Genotoxicity of the Herbicide Formulation Roundup (Glyphosate) in Broad-Snouted Caiman (Caiman Latirostris) Evidenced by the Comet Assay and the Micronucleus Test*. Mutat Res, 2009. 672(2): p. 95-102.
79. Portier, C.J., Armstrong, B.K., Baguley, B.C., Baur, X., Belyaev, I., Belle, R., Belpoggi, F., Biggeri, A., Bosland, M.C., Bruzzi, P., Budnik, L.T., Bugge, M.D., Burns, K., Calaf, G.M., Carpenter, D.O., Carpenter, H.M., Lopez-Carrillo, L., Clapp, R., Cocco, P., Consonni, D., Comba, P., Craft, E., Dalvie, M.A., Davis, D., Demers, P.A., De Roos, A.J., DeWitt, J., Forastiere, F., Freedman, J.H., Fritsch, L., Gaus, C., Gohlke, J.M., Goldberg, M., Greiser, E., Hansen, J., Hardell, L., Hauptmann, M., Huang, W., Huff, J., James, M.O., Jameson, C.W., Kortenkamp, A., Kopp-Schneider, A., Kromhout, H., Larramendy, M.L., Landrigan, P.J., Lash, L.H., Leszczynski, D., Lynch, C.F., Magnani, C., Mandrioli, D., Martin, F.L., Merler, E., Michelozzi, P., Miligi, L., Miller, A.B., Mirabelli, D., Mirer, F.E., Naidoo, S., Perry, M.J., Petronio, M.G., Pirastu, R., Portier, R.J., Ramos, K.S., Robertson, L.W., Rodriguez, T., Roosli, M., Ross, M.K., Roy, D., Rusyn, I., Saldiva, P., Sass, J., Savolainen, K., Scheepers, P.T., Sergi, C., Silbergeld, E.K., Smith, M.T., Stewart, B.W., Sutton, P., Tateo,

- F., Terracini, B., Thielmann, H.W., Thomas, D.B., Vainio, H., Vena, J.E., Vineis, P., Weiderpass, E., Weisenburger, D.D., Woodruff, T.J., Yorifuji, T., Yu, I.J., Zambon, P., Zeeb, H., and Zhou, S.F., *Differences in the Carcinogenic Evaluation of Glyphosate between the International Agency for Research on Cancer (IARC) and the European Food Safety Authority (Efsa)*. J Epidemiol Community Health, 2016. 70(8): p. 741-745.
80. Prasad, S., Srivastava, S., Singh, M., and Shukla, Y., *Clastogenic Effects of Glyphosate in Bone Marrow Cells of Swiss Albino Mice*. J Toxicol, 2009. 2009: p. 308985.
81. Richard, S., Moslemi, S., Sipahutar, H., Benachour, N., and Seralini, G.E., *Differential Effects of Glyphosate and Roundup on Human Placental Cells and Aromatase*. Environ Health Perspect, 2005. 113(6): p. 716-720.
82. Roustan, A., Aye, M., De Meo, M., and Di Giorgio, C., *Genotoxicity of Mixtures of Glyphosate and Atrazine and Their Environmental Transformation Products before and after Photoactivation*. Chemosphere, 2014. 108: p. 93-100.
83. Roy, N.M., Ochs, J., Zambrzycka, E., and Anderson, A., *Glyphosate Induces Cardiovascular Toxicity in Danio Rerio*. Environ Toxicol Pharmacol, 2016. 46: p. 292-300.
84. Schaumburg, L.G., Siroski, P.A., Poletta, G.L., and Mudry, M.D., *Genotoxicity Induced by Roundup(R) (Glyphosate) in Tegu Lizard (Salvator Merianae) Embryos*. Pestic Biochem Physiol, 2016. 130: p. 71-78.
85. Seralini, G.E., Mesnage, R., Defarge, N., Gress, S., Hennequin, D., Clair, E., Malatesta, M., and de Vendomois, J.S., *Answers to Critics: Why There Is a Long Term Toxicity Due to a Roundup-Tolerant Genetically Modified Maize and to a Roundup Herbicide*. Food Chem Toxicol, 2013. 53: p. 476-483.
86. Shaham, J., Kaufman, Z., Gurvich, R., and Levi, Z., *Frequency of Sister-Chromatid Exchange among Greenhouse Farmers Exposed to Pesticides*. Mutat Res, 2001. 491(1-2): p. 71-80.
87. Sivikova, K. and Dianovsky, J., *Cytogenetic Effect of Technical Glyphosate on Cultivated Bovine Peripheral Lymphocytes*. Int J Hyg Environ Health, 2006. 209(1): p. 15-20.
88. Solomon, K.R., Marshall, E.J., and Carrasquilla, G., *Human Health and Environmental Risks from the Use of Glyphosate Formulations to Control the Production of Coca in*



- Colombia: Overview and Conclusions*. J Toxicol Environ Health A, 2009. 72(15-16): p. 914-920.
89. Sorahan, T., *Visualising and Thinking and Interpreting. Response to the Burstyn and De Roos Comments on Sorahan, T. Multiple Myeloma and Glyphosate Use: A Re-Analysis of Us Agricultural Health Study (Ahs) Data*. Int. J. Environ. Res. Public Health 2015, 12, 1548-1559. Int J Environ Res Public Health, 2016. 14(1).
  90. Steinborn, A., Alder, L., Michalski, B., Zomer, P., Bendig, P., Martinez, S.A., Mol, H.G., Class, T.J., and Pinheiro, N.C., *Determination of Glyphosate Levels in Breast Milk Samples from Germany by Lc-Ms/Ms and Gc-Ms/Ms*. J Agric Food Chem, 2016. 64(6): p. 1414-1421.
  91. Townsend, M., Peck, C., Meng, W., Heaton, M., Robison, R., and O'Neill, K., *Evaluation of Various Glyphosate Concentrations on DNA Damage in Human Raji Cells and Its Impact on Cytotoxicity*. Regul Toxicol Pharmacol, 2017. 85: p. 79-85.
  92. Wester, R.C., Melendres, J., Sarason, R., McMaster, J., and Maibach, H.I., *Glyphosate Skin Binding, Absorption, Residual Tissue Distribution, and Skin Decontamination*. Fundam Appl Toxicol, 1991. 16(4): p. 725-732.
  93. Williams, G.M., Kroes, R., and Munro, I.C., *Safety Evaluation and Risk Assessment of the Herbicide Roundup and Its Active Ingredient, Glyphosate, for Humans*. Regul Toxicol Pharmacol, 2000. 31(2 Pt 1): p. 117-165.
  94. Yousef, M.I., Salem, M.H., Ibrahim, H.Z., Helmi, S., Seehy, M.A., and Bertheussen, K., *Toxic Effects of Carbofuran and Glyphosate on Semen Characteristics in Rabbits*. J Environ Sci Health B, 1995. 30(4): p. 513-534.
  95. Zyoud, S.H., Waring, W.S., Al-Jabi, S.W., and Sweileh, W.M., *Global Research Production in Glyphosate Intoxication from 1978 to 2015: A Bibliometric Analysis*. Hum Exp Toxicol, 2016.
  96. Deposition Transcript and Exhibits of Donna Farmer, taken 1/11/2017 and 1/12/2017.
  97. Deposition Transcript and Exhibits of Aaron Blair, Ph.D., taken on 3/20/2017.